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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Should the Hunt for Nonpalpable Breast Lesions
Be Called Off?

As a result of intuition and extensive pub
licity campaigns it is widely believed that
the earlier cancer is diagnosed the better,
and this is certainly justified in some
cancers such as the hematologic, lym
phatic and testicular types. Thus, there is
great interest in programs designed to
“ screen” people for cancers at the
preclinical stage. For any screening pro
gram to be worthwhile, two questions
must be answered in the affirmative.
First, does it work; that is, does the
screening technique succeed in diagnos
ing cancers earlier? Second, does the
patient benefit by having the cancer diag
nosed at an earlier stage? If the answer
to either of these questions is negative,
then one does not even have to go on to
analyse costs and benefits.
In the case of breast cancer there is
extensive evidence, including the paper by
Luoma and colleagues in this issue (pages
315 to 318), that the first question can
be answered positively. Using mammog
raphy as the screening technique, breast
cancer can be diagnosed at a preclinical
stage. In the Breast Cancer Detection
Demonstration Project (BCDDP),1 over
a quarter of a million women were
screened, and 0.54% or 1 in 185 were
found to have cancer at the first exami
nation. The data from the Health Insur
ance Plan of New York study (HIP)2
showed a detection rate for breast cancer
of 0.27%; in Luoma’s groups 1,2 and 3,
that is in women either randomly screened
or referred for screening because of highrisk factors, it was 0.25%. The BCDDP
and HIP data also demonstrated that
cancers found at mammography tend to
be smaller and are associated with a lower
rate of axillary lymph-node metastases.
Luoma and colleagues demonstrate
clearly and convincingly that their tech
nique of breast biopsy with fine-wire
localization for mammographic lesions is
both feasible and accurate. In summary,

we can be reasonably convinced that
mammography does point to breast
cancers and that the surgeon’s knife can
then be guided accurately to the lesion by
the fine-wire localization technique.
Now we must return to the second
question posed at the outset: does all of
this benefit the patient? Unfortunately,
the answer is by no means as clear.
Although it may seem obvious to some,
it is not generally understood that any
screening technique that successfully diag
noses cancer earlier autom atically
improves the “ prognosis” or the case sur
vival rate, even if no benefit is produced.
Earlier diagnosis simply gives an earlier
starting point for counting the years of
survival. To show benefit, screening must
result in a reduction in breast cancer
deaths using the screened population as
the denominator, not just the number of
cases found. To date there have been two
randomized prospective trials on the sub
ject, the HIP study2,3 and the Swedish
National Board of Health and Welfare
study (SNBH).4 The results of the two
studies are similar and are often summa
rized as showing a 25% relative reduction
in breast cancer deaths although the abso
lute reduction in breast cancer mortality
was 0.144% (i.e., the death rate in the
control and screened population was
0.602% and 0.458% respectively at 10
years in the HIP study). The alleged
benefit is confined to women over 50
years of age.
There is great difficulty in accepting
even this small difference as valid because
of methodologic problems, but it must be
said in the authors’ defence that design
ing a perfect trial to demonstrate such a
small difference between groups would be
extremely difficult. One of the major
problems of the data from these studies
is that the “ cancers” discovered at screen
ing include cases of carcinoma-in-situ
(CIS), with a preponderance of the lobu

lar type. The natural history of lobular
CIS is well known:5 in 20% of patients
invasive breast cancer will subsequently
develop, which means that in 80% it will
not, and when cancer does develop it is
of the invasive duct type involving both
breasts with equal frequency. Lobular
CIS, therefore, is not a cancer, and we
cannot even call it a precancerous lesion
because most such patients never have
breast cancer. It is nothing more than a
high-risk marker, carrying a risk of breast
cancer similar to a combination of a
family history, nulliparity and early
menarche.
The concept of “ minimal breast
cancer” is a dreadful example of how we
tend to systematize our delusions, and it
has no basis whatever in biologic reality.
Minimal breast cancer combines non
cancers (CIS) with invasive breast cancers
that happen to be found when the
primary is still small, and the evidence
that such cancers behave differently is
unconvincing. The claims for better
results in this group do not deserve seri
ous consideration because of the inclusion
of so many noncancers and the lead-time
bias that artificially improves case sur
vival rates. The term minimal breast
cancer is scientifically and intellectually
derelict and must be abandoned. (It is
interesting to note that in both the H IP
and SNBH studies, all-cause mortality
was increased in the screened groups, a
finding that is completely unexplained.)
If we assume, for the moment, that the
benefit from screening is real, we may
then assess how large that benefit is in
relation to the morbidity and costs, in
order to answer the most important ques
tion of all — should mass screening be
implemented? It is remarkable how the
morbidity caused by breast cancer screen
ing tends to be suppressed in the
enthusiasm for its implementation. A sus
picious lesion on a mammogram usually
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leads to biopsy, and even with the excel
lent technique described in this issue by
Luoma and his colleagues, the false
positive findings far outweigh the cancers
found. In other words, screening causes
a large number of unnecessary breast
operations. We must also recognize the
harm done by the false reassurance of a
negative mammogram in patients with
fast-growing “ interval” breast cancers,
and the raised level of anxiety caused by
the high profile of mammography and
breast cancer. Finally, the risk of
radiation-induced breast cancer may be
extremely small but is real. The financial
implications of an accessible nation-wide
screening program for breast cancer (such
as that suggested by the American Cancer
Society6) are staggering, and a major
redistribution of resources in radiology
would be required. Even in our wealthy
society where it might be financially pos
sible, we have to ask ourselves whether
net harm or net benefit is caused by the
intervention precipitated in relation to the
possible tiny reduction in mortality.
The fine-wire localization technique is
undoubtedly the best way of finding
breast lesions and nonlesions suggested by
mammography, but this begs the real
question, which is whether we should be
encouraging the use of mammography
which leads to the problem in the first

place. The hard evidence suggests
otherwise.
C harles J. Wright , mb , frcsc , frcs ,
FRCS(EDIN)
Professor of surgery,
University of Saskatchewan,
University Hospital,
Saskatoon, Sask.
S7N 0X0
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Arthroscopic Cost Containment
To the editors.— In arthroscopy of the
knee, most authors of major orthopedic
texts suggest that the joint be dis
tended before the arthroscope is inserted.
M. Watanabe, one of the founders of
operative arthroscopy, writes in his
text,1 “ injuries to the cartilagenous
surface can be prevented if the joint cavity
is amply distended with normal saline” .
Cam pbell’s Operative Orthopaedics2
instructs the reader to insert a large nee
dle laterally into the suprapatellar pouch
near the superior pole of the patella,
aspirate any joint fluid, distend the joint
and thoroughly lavage it with saline at
room temperature. In a more recent
book,3 the author states that, “ it is very
important to distend the knee with saline,
this minimizes the chances of impinging
the articular cartilage while inserting the
arthroscope” . Other texts4,5 agree with
the technique. For 8 years, one of us
(A.A.G.) has bypassed the preliminary step
of joint distension. The instruments are
directed towards the intercondylar notch
from either side of the patellar ligament,
thus avoiding damage to the femoral car
tilage.
We compared the costs of distending
the knee joint before inserting the arthro
scope and not distending the joint. The
method of distension at the Ottawa
General Hospital utilizes a 500-ml bag of
Ringer’s lactate solution ($1.03), “ bag a
jet” nozzle ($3.44), 50-ml syringe ($0.65)
and 18-gauge needle ($0.04). This is a
total of $5.16. Steri-strips ($1.25 per
package) have been used for wound
closure instead of a 4-0 suture ($1.58).
Use of this method resulted in a saving
of $5.47 per arthroscopic examination. At
the Ottawa General Hospital this would
mean a $2500 saving on the yearly
operating-room budget and translates
into a possible saving of $77 258 in
Ontario where in 1983-84 there were
14 124 arthroscopic examinations.
We believe that distension of the knee
joint before arthroscopy is unnecessary,

and that avoiding this step will cut
operating-room costs. In addition, no
complications could be attributed to this
omission.
Skin closure with Steri-strips has not
been associated with any complications
other than the rare skin reaction to tape.
The Steri-strips package is cheaper than
suture and requires no instruments for
removal.
A.W . P rofitt, md, frcsc
A.A. Giachino, md, frcsc
Department of Surgery,
Ottawa General Hospital,
501 Smyth Rd.,
Ottawa, Ont.,
K1H 8L6
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Chondromalacia Patellae —
Just Another Enthesopathy
To the editors.—The term chondromala
cia patellae,1 giving an apparent defini
tive, progressive and usually unhappy
prognosis to a frequently seen and selflimiting clinical syndrome, is unfortunate.
In recent years a number of clinicians and
researchers have substituted it for the
more general term, the patellofemoral
syndrome. In my view, medical literature
has placed too much emphasis on changes
in the articular cartilage and too little on
soft-tissue changes in an effort to give
cause for the discomfort felt in this con
dition.
In dealing with this syndrome through
a sports medicine clinic, I have been im
pressed by a number of important clinical

findings, including obvious overuse in
many cases, tenderness on palpation over
the lower patellar pole and unpredictable
changes seen at arthroscopy. In fact, in
a study I recently concluded, the main
finding at arthroscopy in 57 patients
under 30 years of age and 26 patients over
30 years was that of chronic inflamma
tion in the soft tissues at the bone-tendon
interface at the lower pole of the patella.
The changes noted at the bone-tendon
interface (enthesis) have prompted me to
interpret the patellofemoral syndrome as
a form of enthesopathy, a time-honoured
and recently rediscovered term describing
a benign, inflammatory reaction that is
localized and self-limiting, is initiated by
overuse and responds to rest and other
anti-inflammatory aids.2 Rarely, other
joints may be similarly affected in the
same patient and a rheumatologic work
up is indicated.

J ames D. Sullivan,

md, frcsc , facs

Orthopaedic surgeon,
Director,
Sports Medicine Clinic,
St. Mary’s Hospital,
Montreal, PQ
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Sclerotherapy for
Thyroid Cysts
To the editors.—We disagree with De
Young and colleagues (Can J Surg 1986;
29; 118-119) who advocate tetracycline
instillation for recurrent cystic thyroid
nodules. They classified thyroid nodules
into pure cystic and mixed cystic-solid
lesions according to the findings on
palpation of the thyroid after needle aspi
ration. This may not be correct. Conven
tional B-mode or grey-scale ultrasono
graphy accurately classifies thyroid
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nodules as solid, cystic or mixed cysticsolid lesions.1 In a survey of 16 series,
12% of the mixed lesions and 7% of the
cystic lesions were found to be malig
nant.2,3 DeYoung and colleagues stated
that the likelihood of thyroid cancer can
be ruled out by careful aspiration cyto
logic examination. However, this is not
so. Fine-needle aspiration biopsy may be
inaccurate when there is sampling error;
such errors can occur in lesions larger
than 4 cm, particularly if they are cystic,
because the fluid removed is not represen
tative of the epithelial component.2,3 The
three possible cytologic results are nega
tive, suggestive of or positive for malig
nant disease. No effective method has
been found to evaluate lesions that are
suggestive of a malignant mass; thus, sur
gical excision of all such nodules is recom
mended.4 Cysts larger than 4 cm in
dimension, those that do not decrease in
size or fail to disappear within 3 months
and reaccumulate after aspiration are all
indications for surgery.5 We believe that
the nodules reported by DeYoung and
colleagues should have been treated by
surgical excision.
V in a y K. K a p o o r , m b , b s , ms
T u s h a r K. C h a t t o p a d h y a y a , m b , b s ,
ms

L a l it K . S h a r m a , m b , b s , m s , fics
Department of Surgery,
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To the editors.—We agree with Kapoor
and associates that ultrasonography more
accurately classifies cystic thyroid nodules
as pure cysts or mixed cystic-solid lesions
and that this might have improved our
diagnostic accuracy.
However, we strongly disagree that the
recurrent cystic nodules successfully
treated by tetracycline instillation should
have been excised surgically. The true
occurrence rate of malignant cells in
thyroid cysts is closer to 1% ,‘-3 much
lower than the combined preselected sur
gical series that they have quoted. Recur
rent fluid accumulation and size greater
than 4 cm may bring the rate closer to that
of solid lesions,4 but in solid nodules,
aspiration cytology has been shown to be
an accurate predictor of malignancy.5
The possibility of sampling error in cystic
lesions can be reduced by repeated aspi
ration of both the fluid and solid com
ponent if present.6 All our samples were
negative before tetracycline instillation
was undertaken.
We have now followed up our original
10 patients for an additional 18 months,
making a mean follow-up of 33 months.
In none of the nine successfully treated
patients has there been any reaccumula

tion of fluid, and there have been no posi
tive cytologic findings in the five mixed
cystic-solid nodules on twice-yearly fineneedle aspiration of the solid component.
We therefore believe that recurrent cys
tic thyroid nodules can be successfully
managed by tetracycline instillation after
negative cytologic results on at least two
occasions, thus avoiding the risks of sur
gical intervention.
J. P a u l D e Y o u n g , md
A m no n K a h n , m d , fr c pc
S am L e r m a n , md
Division of Endocrinology
A lex F er en c zy , md
Department of Pathology
Sir Mortimer B. DavisJewish General Hospital,
3755 Cote Ste-Catherine,
Montreal, PQ
H3T 1E2
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BOOK REVIEWS
CARDIAC SURGERY: a Looseleaf Work
book and Update Service. Donald B. Doty.
Illust. Year Book Medical Publishers, Inc.,
Chicago, 1985. Price not stated, binder.
ISBN 0-8151-2760-X.

mend this book as a welcome addition to the
surgical library of any university hospital. It
would certainly be of interest as a reference text
for any active cardiac surgeon.

Doty has put together a looseleaf atlas of
cardiac surgical procedures in an excellent for
mat that permits insertion of updated material
every 6 months. This is a dimension that has
been lacking in books on cardiac surgery.
The illustrations by Christy Kranes are sim
ple but sufficiently detailed to demonstrate
clearly the various surgical procedures, and the
accompanying text is concise but comprehen
sive. The sections on congenital heart disease
are particularly well written. Each procedure
is followed by expert editorial comment and
a brief historical perspective. An added feature
is abstracts of recent articles, published in peerreviewed journals, that report the results of the
various surgical techniques. I would recom

Professor and chairman,
Department of Surgery,
University of Ottawa,
Ottawa, Ont.

W .J. K e o n , m d , frcsc
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FRACTURES OF THE PELVIS A N D
ACETABULUM. Marvin Tile. 256 pp.
Illust. Williams & Wilkins, Baltimore,
1984. $48.50 (US). ISBN 0-683-08249-3.

The management of fractures has evolved con
siderably in the last decade, mainly because of
an improved understanding of the patho
physiology of fractures and trauma, and the
critical assessment of the results of various
treatment methods.

In this textbook Marvin Tile presents a clear,
organized approach to the assessment and
management of pelvic fractures and disrup
tions. Unlike other textbooks on fractures, this
one provides the reader with a comprehensive
approach to the multifaceted problems affect
ing patients with pelvic disruptions. The author
capably guides the reader through the relevant
biomechanics and functional anatomy of the
pelvis before describing and classifying the var
ious injury patterns and their degree of inher
ent stability. These, together with his own
experience and a comprehensive review of the
literature, form the basis for his discussion of
treatment alternatives. The reader is frequently
reminded about the importance of setting
realistic goals and providing adequate, safe
treatment for the patient. These warnings,
directed at optimistic or aggressive surgeons,
continued on page 332
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.

MDs to Document Their Efforts to Save Organs
From Dying Patients
The Canadian Medical Association
(CMA) recommended last month that its
members routinely record whether dying
or brain-dead patients fulfil established
criteria for organ donation and, for those
who do, document whether the family has
been approached about the opportunity
to donate, stating either the reasons for
not approaching the family or the
outcome.
The concept, dubbed “ recorded con
sideration” , was supported in principle by
CMA’s governing body at the annual
meeting, Aug. 12, and the association’s
outgoing president, W illiam Vail,
FRCSC, requested that all who were
present and not opposed on religious
grounds “ serve as a personal and profes
sional example” by signing a donor con-

FIG. 1—Calvin Stiller, head of multiorgan
transplant service at University of Western
Ontario.

Contributions to this column are welcome.
Please send your material to: Mrs. Amy
Chouinard, Canadian Journal o f Surgery, PO
Box 8650, Ottawa, Ont. K1G 0G8.

sent card and relaying their wishes to
family members.
The recommendation came from the
CMA’s Council on Health Care in
response to statistics showing that more
than 85% of automobile-accident victims
who die in large hospitals (more than 400
beds) do not become organ donors mainly
because the attending physician fails to
approach the victim’s family.
The council drafted its recommenda
tion after hearing from Calvin Stiller,
FRCPC, head of the multiorgan trans
plant service in London, O nt., who co
chaired an Ontario task force to review
the province’s transplant network and
who commented: “ The limiting step in
transplantation is not now control of
rejection or lack of surgical expertise but
supply of donors.”
Physicians working in intensive care
units, and other hospital staff, have been
criticized for not acting promptly to
ensure th at organs of brain-dead
individuals are not wasted. The waste is
particularly frustrating to specialists who
have patients awaiting organ transplants,
and some have called for legislation to
force attending physicians to offer fami
lies the opportunity to donate organs of
the dying or dead person. Such legislation
has been adopted by a number of states
in the US and others will follow.
Dennis Modry, FRCSC, head of the
cardiac transplant team in Edmonton, is
one of those who sees such legislation as
justified by the increased donations.
Asked whether one could routinely —
say, at admission to hospital for any
problem — ask patients whether they
would be willing to donate their organs
in case of a fatal accident, Modry agreed
that it would be possible but noted that
the information, even if updated at sub
sequent admissions, would serve only to
alert physicians to potential consent.
“ In the final analysis, the physician has
to deal with the grieving family and he or

she has to pose the question. Routine
questions taken at admission are com
pletely forgotten when a loved one has
just died.” Nevertheless, physicians might
be less reticent if this information was in
the hospital records. The idea is to facili
tate the process of donation as much as
possible. For example, Quebec has
announced that, starting this fall, health
insurance cards will carry an option for
donor consent and by 1989 everyone in
the province should have received one of
the new cards.
In June this year, the Canadian Coun
cil on Hospital Accreditation (CCHA)
took a step toward ensuring hospitals
establish policies on organ donation: it
incorporated the subject in its Standards
fo r Accreditation o f Canadian Health
Care Facilities, which will be effective for
all surveys starting in January 1987. Sur
veyors will be noting hospitals’ policies
covering determination of brain death,
identification of potential donors, sup
port of the donor’s family, contact with
transplantation centres, consent for organ
donation, transportation of donor’s body

FIG. 2—Denis Modry who heads University
o f Alberta cardiac transplant team in
Edmonton.
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or organs and organ transplantation to
ensure they are appropriate, given the
mission and resources of the facility.

New CMA Guidelines
to Determine Brain Death
To dispel some of the uncertainty sur
rounding the patient’s transition to
beating-heart cadaver or nonliving donor,
the CMA has adopted new guidelines for
diagnosing when a patient is brain dead.
The guidelines, which were drafted by
a subcommittee of the Canadian Con
gress of Neurological Sciences and had
earlier been approved by the Canadian
Neurological Society, the Canadian
Neurosurgical Society, the Canadian
Association for Child Neurology and the
Canadian Society of Clinical Neuro
physiologists, were accepted by the CMA
at its annual meeting last month in
Winnipeg.
Said Peter Gorman, FRCSC, a neu
rosurgeon in Moncton, “ We hoped the
whole medical profession would adopt
the criteria because they clarify brain
death. Death can be said to occur when
there is no evidence of any brain function
— cerebral or brain stem. The lack of
activity can be confirmed by two flat elec
troencephalograms, produced at differ
ent times. In some instances angiograms
are used: dye is injected in the carotid
artery and none will enter the brain ves
sels if the patient is dead.
“ Clinically one has to confirm the
absence of all brain-stem reflexes: the
pupils must be dilated and unreactive to
light; there must be no evidence of gag
or cough reflex; no evidence of eye move
ment even after stimulation of the ves
tibular system — the balance mechanisms
— of the brain stem; no evidence of sen
sation; no movement (the exceptions
being movements that may simply reflect
residual function in the spinal cord) of
the extremities upon the deepest of pain
ful stimulation; and no evidence of
breathing after a fixed time — now 10
minutes — o ff the respirator. The last
criterion is applied after blood-gas meas
urements are determined to be normal.
“ The guidelines represent a thorough
review of the literature on the lack of
brain function and a solid base on which
physicians can comfortably rely. Of
course, in the presence of narcotics, all
bets are off. For example, when barbituates have been used to induce a thera
peutic coma, obviously they must be out
of the system — confirmed by blood
levels.
“ For virtually every potential donor
who meets these criteria in our hospital,
the family is asked about donation. Some
people just plain say no; we’ve had a
number of refusals this year. But I’m
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impressed that it’s much easier to obtain
donations than it was a few years ago.”
Statistics collected by the centre for
transplant studies in London, Ont.,
showed increases in absolute numbers of
donations in 1985 for most of the
provinces; the Maritimes and Saskatche
wan stayed the same and Ontario dropped
to 130 donors from 141 in 1984.
Said Michael Robinette, FRCSC,
Stiller’s counterpart on the Ontario task
force: “ A paradox developed in which
increased publicity was accompanied by
a drop in donors. We think the trend was
temporary and the publicity in the long
run will have positive effects. We have
done three things to make organ dona
tion medically easier: at Toronto General
one bed (and two if needed) in the ICU
has been set aside for donors, an organ
donor coordinator is available to handle
administrative details and clear-cut
instructions are being sent to hospitals to
eliminate confusion about whom to call,
what procedures to perform, and so on.”

Federal Initiatives
to Remove Barriers
to Organ Donation
Three federal/provincial working
groups are all entering the final stages of
their separate tasks to improve services
for organ donation and transplantation
in Canada; one group is drafting guide
lines for organ donation programs in
hospitals, another is designing an infor
mation system and the third is establish
ing standards for centres transplanting
vital organs.
Nancy LePitre, program and liaison
officer, Organ Donor Program, Health
and Welfare Canada, serves as secretary
for the three working groups. She spoke
with CJS and summarized the efforts of
the groups. “ We are trying to ensure pro
motion, coordination and sharing of
organs across the country. This means
dealing with the complexities brought
about, for example, by different billing
arrangements and legislation in the
provinces.”
The Working Group on Vital Organ
Transplant Centres is chaired by Alan
Thomson, MD, from the Nova Scotia
Department of Health; the Working
Group on Organ and Tissue Donation
Services in Hospitals is chaired by Harold
Colburn, MD, of Health and Welfare
Canada; and the Working Group on
Standards for Vital Organ Transplant
Centres is chaired by Derek Beckley, with
Alberta’s Department of Hospitals and
Medical Care.
The first group, which was constituted
in 1984, reported to the provincial
ministers of health a year later, noting
among other things deficiencies in inter

provincial arrangements for transport,
transfer payments, information collection
and dissemination. It documented differ
ences in provincial billing arrangements,
benefits, legislation covering human tis
sue donation and reviewed existing trans
plant services, recommending that two
centres no longer provide kidney trans
plant services. The report was accepted
and the working group was asked to sup
ply specifics for implementation of its
major recommendation: that an informa
tion system be developed.
“ The committee found that much of
the information it needed was not avail
able and the information available was of
little use” , said LePitre. The system
would be used by government but avail
able to clinicians for research — on a payas-you-use basis.
Working-group chairman Thomson
spoke briefly to CJS about his commit
tee’s proposals: “ The system would re
place the Canadian Renal Failure Register
and be expanded to include other organs.
It would include information on patients
waiting for transplants, since the focus of
the information system in on patients with
end-stage vital-organ failure not just
transplantation. We would like to have
information about sex, age, transplanta
tion date and outcome. Eventually the
data base could be expanded to make it
pertinent for organ exchange, but this is
in the future. We will be asking for
proposals from companies to design and
manufacture such a system. The centre at
University Hospital, London, Queen’s
University and Statistics Canada (cur
rently managing the data for the renal
register) may be interested. London may
have an advantage in that it is already col
lecting much of what we need.
“ We are not working in isolation; we
want our data base to be compatible with
registries elsewhere” , said Thomson.
The other two committees have not yet
released their reports.
LePitre, as the common element in all
the initiatives, acts as a traffic director,
ensuring forward progress by all the
groups. She coordinated the preparation
of an information kit to promote organ
donation; the kit launched “ Organ Donor
Awareness Week” last April. “ We sent
the information kit to all active treatment
hospitals with 25 beds or m ore.”
The kits provide brochures and teach
ing aids about donations of heart, lung,
liver, pancreas, bone, skin and eye; they
also include three articles dealing with the
psychologic trauma experienced by inten
sive care unit staff “ harvesting” organs
and provide lists of personnel involved in
organ donation and transplantation for
each of the provinces. They have been
used for in-service sessions and public
education.
A my C houinard
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STATE OF THE ART
Mark E. Boyd , md, frcog, frcsc

Dysfunctional Uterine Bleeding
Dysfunctional uterine bleeding is defined
as abnormal uterine bleeding in the
absence of organic disease. It is the
result of anovulation or the abnormal
local production of prostaglandins, and in
each case the primary fault is inappropri
ate hormone formation. There are two
approaches to diagnosis. The traditional
one is primarily concerned with the
exclusion of cancer of the endometrium;
this concern results in the frequent
resort to uterine curettage. The second
approach is to limit curettage to patients
whose symptoms are not ameliorated by
medical therapy.
The aim of medical treatment is either
to produce secretory change in the
endometrium or to decrease the forma
tion of uterine prostaglandins. Intermit
tent progesterone treatment is used to
cause secretory changes in the
endometrium. Decreased production of
the prostaglandins is achieved indirectly
by causing atrophy of the endometrium
or directly through the use of prostaglan
din synthetase inhibitors. Surgery in the
form of dilatation and curettage has no
long-term therapeutic effect; hysterec
tomy is definitive therapy.

La menometrorragie fonctionnelle se definit comme un saignement uterin anormal
en I'absence de toute maladie organique.
C'est le resultat d'une anovulation ou
d'une production locale anormale de
prostaglandines, et, dans les deux cas, la
cause primaire est un d^faut de produc
tion hormonale. Le diagnostic peut etre
aborde de deux facons. L'approche conventionnelle consiste avant tout a
exclure le cancer de I'endomfetre; elle
exige un frequent recours au curetage
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uterin. L'alternative consiste a reserver le
curetage aux patientes dont les symptomes ne sont pas ameliores par un traitement medical.
L'objectif du traitement medical est
soit de produire des changements secretoires dans I'endometre, soit de diminuer
la formation des prostaglandines ut6rines. Un traitement cyclique d la proges
terone est utilise pour causer des chan
gements secretaires dans I'endometre.
La production des prostaglandines peut
etre reduite indirectement en causant
une atrophie de I'endometre ou directement par I'emploi d'un inhibiteur de la
prostaglandine synthetase. La chirurgie
sous la forme d'une dilatation avec cure
tage n'a pas d'effet therapeutique a long
terme; I'hysterectomie guerit de facon
permanente.

Abnormal uterine bleeding that occurs in
the absence of organic disease (tumour,
infection, abnormal pregnancy or bleed
ing) is called dysfunctional uterine bleed
ing. It poses a considerable health
problem, as can be appreciated by an
examination of the indications for hys
terectomy in this country. During the
period 1980 to 1981 abdominal hysterec
tomy was the commonest major opera
tion performed on women in Canada,
being carried out 44 081 times; the
comparable figure for cholecystectomy is
38 402.1 Menstrual disorders account for
18% of hysterectomies done for benign
disease,2 and dysfunctional bleeding is a
major factor in such cases. Yet even this
figure does not reveal the complete pic
ture. In 40% of abdominal hysterecto
mies, the indication for surgery is a
fibroid uterus. The presenting symptom
in these cases is often abnormal vaginal
bleeding, which, in many instances, is
functional in nature. The fibroids are
incidental to and not the cause of
bleeding.
The diagnosis of and rationale for
treating dysfunctional uterine bleeding
depend on a clear understanding of the
pathophysiology of the menstrual cycle.

Pathophysiology

Hemostasis during the first 24 hours of
the menstrual period depends on platelet
function and the formation of thrombi.
In the following days, hemostasis is
achieved by vasospasm of the uterine
spiral arterioles. During this time, the
fibrinolytic system facilitates the slough
ing of endometrium by lysing clots that
do form. An upset in the fine hormonal
balance can affect the endometrium and
may result in dysfunctional uterine bleed
ing. There are two possible explanations
for the mechanism of this disruption;
anovulation or abnormal local production
of prostaglandins.
The classic endocrinologic explanation
ascribes the essential fault to anovulation.
As a result the endometrium is subject to
persistent estrogenic stimulation. The
endometrial surface becomes fragile,
thickened and prone to unpredictable and
uncontrolled hemorrhage. A problem in
the easy acceptance of this theory is the
frequency with which anovulation can be
documented. In many cases of dysfunc
tional uterine bleeding the patient shows
no clinical or laboratory evidence of
anovulation, the endometrium on histo
logic examination being normal for the
phase of the cycle.3-5 MacKenzie and
Bibby3 showed that equal numbers of
women had proliferative or secretory
endometrium when the indication for
dilatation and curettage was a menstrual
disturbance; Nedoss4 found that only
16% of endometrial specimens obtained
in the second half of the cycle were
proliferative. Anovulation is, however,
found more frequently in the juvenile or
the perimenopausal patient6 and in the
patient with acute vaginal bleeding not
associated with pregnancy.3 The diagno
sis of anovulation may be suggested by
irregular menses. However, the wide var
iety of histologic diagnoses demonstrated
with any menstrual disturbance make it
difficult to plan therapy on the basis of
menstrual pattern.
The second theory emphasizes the
active involvement of the endometrium
and myometrium in the menstrual
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process, through the abnormal secretion
of prostaglandins. The two prostaglan
dins involved are prostaglandin F2a and
prostaglandin E2, along with their
related metabolites, thromboxane and
prostacyclin. Prostaglandin F2„ causes
myometrial contraction, vasoconstriction
and platelet aggregation; prostaglandin
E2 acts in a contrary manner, causing
myometrial relaxation, vasodilation and
inhibition of platelet aggregation. Nor
mally a balance is struck between these
opposing factions, resulting in hemostatic
control of the menstrual process. Dys
functional uterine bleeding results from
an imbalance of these hormones and is
in effect an exaggeration of the normal
cycle.7'8 The quantitative increase and
disturbance of the ratio of one pro
staglandin to the other in dysfunc
tional uterine bleeding is shown in
Table I.9
This second theory emphasizes the
influence of sex hormones on the produc
tion of prostaglandins rather than the
changes in endometrial histology that
the hormones can cause. The fall in estro
gen concentration that precedes menstru
ation provokes the release of a prosta
glandin synthetase enzyme from the
endometrium. The formation of prosta
cyclin, thromboxane and the various
prostaglandins depends on prostaglandin
synthetase being present. Estrogen not
only controls the form ation of
prostaglandin but also affects the relative
amounts of prostaglandins F2a and E2
produced.10 The measure to which each
is formed will influence the menstrual
cycle.
Diagnosis

Patients are often able accurately to
describe a pattern of menstrual blood loss
but are unable to quantitate the amount
precisely.11 Half the patients who com
plain of heavy menses do not have a
measurable increased loss.12 Precise
measurement depends on the collection
and analysis of menstrual pads, a proce
dure that few patients or physicians are
prepared to do. On average, menstrual
loss is 30 ml per cycle. If the loss is more
than 60 to 80 ml, iron deficiency anemia
is common.13
The diagnosis of dysfunctional uterine
bleeding depends on the exclusion of
organic disease. This may be done in one
of two ways. The traditional approach is
concerned with the endometrial histology.
Thus, dilatation and curettage are done
in all instances, and, in selected cases, fur
ther investigations such as laparoscopy,
hysteroscopy, hysterosalpingography and
endocrinologic and hematologic studies
are carried out. The overriding concern
is to exclude malignant disease, in partic
ular endometrial cancer. This condition
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is uncommon except in patients who are
postmenopausal.3 MacKenzie and
Bibby,3 in their series of 1029 consecu
tive dilatation-and-curettage procedures
found only 15 cases (1.5%) of endo
metrial carcinoma and all women were
postmenopausal.
In the second approach the clinician is
more selective in resorting to curettage.
A diagnosis of dysfunctional uterine
bleeding is made from the patient’s his
tory and a finding of normal results on
pelvic examination, supplemented by
both vaginal and endometrial cytologic
studies. The patient is then treated.
Failure to respond to medical treatment
suggests the presence of uterine disease at
which time curettage and other special
investigations are undertaken. This
approach is cost-effective and often the
most appropriate.
Treatment

Treatment of dysfunctional uterine
bleeding may conveniently be divided
between patients who require immediate
therapy to control acute and threatening
hemorrhage and those whose needs are
less urgent.
Urgent Therapy
Dilatation and curettage has a tradi
tional place in both the diagnosis and
treatment of abnormal uterine bleeding.
It is a useful therapeutic measure in con
trolling acute hemorrhage; this is achieved
either by favouring thrombus formation
or by removing endometrial tissue rich in
substances that favour hemorrhage. It
should be noted that there is no evidence
of long-term benefit from this procedure.
Nilsson and Rybo14 showed that blood
loss was reduced by 69% in the first
period after curettage, but that the loss
increased in the second period and was
not significantly changed from the
preoperative state by the third and fourth
periods.
In some cases of acute blood loss,
when the histologic features of the
endometrium are known or surgery is
contraindicated, Premarin may be used
intravenously. DeVore and colleagues,15
in their double-blind series, showed that
in 72% of treated women the bleeding
stopped. In these cases Premarin acts in
a nonspecific manner on the coagulation
process and not through a change in the
endometrium itself. In order to effect
endometrial changes, oral contraceptives
are prescribed concurrently with the
Premarin.
Less-Urgent Therapy
The majority of patients with dysfunc
tional uterine bleeding are not acutely ill,

and in this group medical therapy is first
attempted.
Hormone therapy.— Since the basis of
the ailment is a dysfunction of the hor
mones controlling the mechanism of men
strual bleeding, control of the symptoms
should be possible through correct
manipulation of these same hormones.
The principles of this manipulation are,
I believe, most easily understood if we
consider two possible therapeutic aims.
In many circumstances, successful hor
mone therapy of dysfunctional bleeding
causes endometrial atrophy. A conse
quence of this “ down regulation” of
endometrial activity is the slowing of
prostaglandin production. Atrophy will
not occur unless estrogen activity is
diminished, and this is best achieved with
progesterone, which acts as an antiestro
genic substance. On a cellular level,
progesterone hastens the conversion of
estradiol to the less-potent estrone and
also decreases the numbers of estrogen
receptors in the endometrial cell. The
overall effect is a decrease in estrogen
activity. Thus, with continued progester
one use endometrial atrophy results.
In most circumstances endometrial
atrophy is easily achieved with oral con
traceptives, through the action of the
potent progestin they contain. Menstrual
blood loss decreases to 20 ml per cycle.
There is, however, a reluctance to
prescribe oral contraceptives to patients
over 35 years of age because of apparent
increased risks of stroke and myocardial
infarction. Documentation of the adverse
effects of oral contraceptives depends on
epidemiologic studies. These studies have
recently been subjected to critical
review.16 A therapeutic dilemma for the
clinician is the choice between the use of
oral contraceptives and other options that
may not be as effective or as risk-free.
Atrophy of the endometrium can be
obtained by continuous progesterone
medication. Magos and colleagues17 sug
gested a regimen of continuous
norethisterone (Micronor; Ortho Phar
maceutical [Canada] Ltd., Don Mills,
Ont.) and conjugated estrogens (Prema
rin; Ayerst Laboratories, Montreal, PQ)
Table 1-Ratio of Prostaglandins
Concentration,
ng/100 mg wet wt
Condition/
prostaglandin
Proliferative Secretory
Normal pelvis
9
19
ha
12
20
e2
Regular dysfunctional
bleeding
21
28
26
31
e2
Irregular dysfunctional
bleeding
47
62
e2«
78
87
e2
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as a means of producing endometrial
atrophy. The regimen is especially useful
in the postmenopausal patient.
D anazol (Cyclom en; W inthrop
Laboratories, Aurora, Ont.) and longacting luteinizing hormone-releasing hor
mone agonist may also be used to cause
endometrial atrophy.13'18 Side effects
and cost limit their clinical usefulness.
Progestin is not normally prescribed,
either alone or as a constituent of the
birth control pill, with the hope of
producing endometrial atrophy. For
many physicians the aim of treatment in
dysfunctional uterine bleeding is the con
version o f the proliferative endometrium
to endom etrium showing secretory
change. W ith norm al secretory
endometrium controlled menstruation is
possible. Thus, an oral progestin (often
prescribed as medroxyprogesterone ace
tate, Provera; The Upjohn Company of
Canada, Don Mills, Ont.) is given to the
patient for the last 10 days of each cycle.
However, progestin prescribed in this way
may be ineffective, for anovulation is
uncommon. The place of cyclic progestins as a therapeutic measure in dysfunc
tional uterine bleeding is uncertain.
Although Speroff and colleagues19 stated
that such therapy “ will suffice to control
the abnormality” , Smith20 pointed out
that “ there are few, if any, studies which
objectively assess the efficacy of this
treatment” .
Prostaglandin synthetase inhibitor ther
apy.—The use of prostaglandin synthe
tase inhibitors provides the clinician with
a new and worthwhile means of controll
ing dysfunctional uterine bleeding. The
formation of prostaglandin in this
instance is inhibited through its own
enzyme system rather than through estro
gen’s influence on the enzyme’s forma
tion. Prostaglandin synthetase inhibitors
can be seen as a direct rather than an
indirect means of achieving the same end.
The prostaglandin synthetase inhibitor,
mefenamic acid (Ponstan; Parke-Davis
Canada, Inc., T o ro n to , O nt.) or
naproxen sodium (Anaprox; Syntex, Inc.,
Mississauga, Ont.) is prescribed at the
time of heavy blood loss, often the first
3 days of the cycle.12 The result on the
menstrual flow is similar to that which
follows the use of oral contraceptives;
blood loss is decreased to 30% of its
previous level.9 These agents are espe
cially useful in patients with heavy dys
functional bleeding and bleeding
associated with an ovulatory menstrual
pattern.12 The long-term benefit of their
use has yet to be determined.21
Surgical Therapy.— In all cases of dys
functional uterine bleeding the therapeu
tic result of hysterectomy can be predicted
with certainty, at least as it affects bleed
ing. For this reason hysterectomies are
being performed in increasing numbers.
Selwood and Wood22 discussed the inci

dence of hysterectomy in Australia, where
nearly half the female population is
expected to have the operation. They
pointed out that menstrual disorders have
seemingly become more frequent in recent
years, and Australian women are appar
ently less tolerant to the disruption of
their life-styles from menstrual disorders.
Comments
Diagnosis of dysfunctional uterine
bleeding depends on the exclusion of
organic disease, and medical therapy
depends on a clear understanding of the
mechanism of menstruation.
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HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2*3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 744(5)
2) Johnson JD, et al (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
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Dalacin C Phosphate S.S.
(c lin d am yc in phosphate)

Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by

causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections

where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci. Clostridium
species and microaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when
the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindieitions: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in

patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride) has
not been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained. Dalacin C Phosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after therapy with

Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary,
continued only w ith close observation. Significant diarrhea occurring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration
or pseudomembrane formation, should be managed with fluid, electrolyte, and protein supplementa
tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis
should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 - 1 0 or more days, there was a rapid observed
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
Is should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals

“'hosphate must be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the
clinical situation.
As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients w ith impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not
effective means of removing the compound from the blood. Periodic serum levels should be determined
in patients w ith severe hepatic and renal insufficiency.
Adverse Reactions: Local.

(a) Intramuscular Injections: Of 404 patients treated w ith Dalacin C Phosphate (clindamycin phos
phate) intramuscularly (with a solution containing 150 mg/mL), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the
injection site and tw o developed sterile abscesses,
(b) Intravenous Infusions: Of 192 patients treated w ith Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjunction with the use of indwelling I V. catheters and it is difficult to know how much
the drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated w ith Dalacin C Phosphate (clindamycin

phosphate) by either the intramuscular or intravenous routes developed systemic side effects as
follows:
Number o f Patients
R ash.................................................................................................................................................................. 7
U rtic a ria ........................................................................................................................................................... 1
P ruritus............................................................................................................................................................. 1
Fever, Leucocytosis .................................................................................................................................... 1
Nausea, w ith or without v o m itin g .............................................................................................................. 1
Diarrhea (See also under "Warnings” ) ..................................................................................................... 4
Hypotension ................................................................................................................................................... 1
Hypertension................................................................................................................................................... 1
Shortness of Breath .................................................................................................................................... 1
S uperinfection*.............................................................................................................................................. 4
Cardiac arrest** ............................................................................................................................................ 1
Bad and bitter taste in m o u th ...................................................................................................................... 5
* Superinfection is a complication of antibiotic therapy in general and is not necessarily a true
side effect of clindamycin phosphate.
'* Due to underlying myocarditis in this patient.

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate

(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology,
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does not
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms md Trealmort ol Overdossge: No cases of overdosage have been reported. No specific antidote

is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been
given without adverse effects.
DOSAGE AND ADMINISTRATION
Adults

Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 ,3 or 4 equal doses. Intramuscular injections of more than
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to I.V.
administration to a dilution of 300 mg in 50 ml of diluent (6 m g/m l) or more, and infused in not less
than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recommended.
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.

Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each
infused over 20 minutes or longer.
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Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused over
20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip
or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:

Dose
300 mg
600 mg
900 mg
1200 mg

Diluent
50 ml
100 ml
150 ml
200 ml

•4 -

Time
10 min.
20 min.
30 min.
45 min.
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Alternatively, drug may be administered in the form of a single rapid infusion of thefirst dose followed
by continuous I.V, infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
Above 4 mcg/ml
10 mg/min. for 30 min.
0.75 mg/min.
Above 5 mcg/ml
15 mg/min. for 30 min.
1.00 mg/min.
Above 6 mcg/ml
20 mg/min. for 30 min.
1.25 mg/min.
Children: (Over one month of age)
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Intramuscular injection: 10 to 15 mg/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 m g/kg/day in 3 or 4 equal doses.
Intravenous Administration:

Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutesor longer. In severe infections, it is recommended that children be given no less
than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in the same
manner as for adults.)
Oilutlon and Compatibility:

4 ml (600 mg) Dalacin C Phosphate when diluted with 1000 ml of the following commonly used in
fusion solutions was found to be physically compatible and demonstrated no significant change in pH
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
Dextrose 5% in saline
Dextrose 5% in Ringer’s Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 21A% in Lactated Ringer's Solution (Hartmann's Solution)
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is
not recommended that Dalacin C Phosphate be mixed with any infusion solution containing B vitamins.
Supplied:

Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH
range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.1C
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Percutaneous Endoscopic Gastrostomy:
Indications and Results

Patients requiring feeding gastrostomies
are often poor risks for either laparotomy
or general anesthesia. Percutaneous
endoscopic gastrostomy can be per
formed at the bedside by a surgeonendoscopist and with minimal sedation.
The authors performed this procedure on
45 patients ranging in age from 17 to 88
years. The procedure was indicated for
neurologic disorders in 34 patients, head
and neck tumours in 2, failure to thrive
in 4, esophageal obstruction from lung
cancer in 1 and tracheostomy for mul
tisystem failure or trauma and sepsis in
4. In three cases the procedure could not
be performed because the stomach
could not be intubated. In 29 cases local
anesthesia and sedation (diazepam and
meperidine) were used, but in 16 cases
general anesthesia with hyperventilation
was preferred. The mean operative time
was 32 minutes, decreasing with
experience so that the current mean
operative time for the last nine cases
was 23 minutes. Feeding was begun on
day 1 after operation in most patients
and on day 2 in others. Complications
included tube displacement in three
patients, superficial infection at the site
of the tube insertion in three (not requir
ing drainage or tube removal) and
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asymptomatic pneumoperitoneum in one
patient. These complications all occurred
early in the series. No patient suffered
paralytic ileus, vomiting, aspiration or
significant leaking around the tube. In
the authors' opinion percutaneous
endoscopic gastrostomy is the preferred
method for placement of a feeding gas
trostomy. It can be performed rapidly
with minimal stress in high-risk patients.
Les patients qui necessitent une alimen
tation par gastrostomie sont souvent de
mauvais risques pour la laparotomie et
I'anesthesie generate. Une gastrostomie
endoscopique percutanee peut etre pratiqu6e au lit du malade par un chirurgienendoscopiste avec un minimum de seda
tion. Les auteurs ont pratique cette inter
vention chez 45 malades dont I'age
variait de 17 a 88 ans. L'operation a ete
rendue necessaire par des atteintes neurologiques chez 34 patients, des tumeurs
de la tete et du cou chez 2, I'absence de
developpement pondero-statural chez 4,
une obstruction oesophagienne consecu
tive & un cancer du poumon chez 1 et
une tracheostomie pour insuffisance plurifonctionnelle ou traumatisme et sepsie
chez 4. Dans trois cas, il fut impossible
de proceder a l'operation, ayant ete incapables d'intuber I'estomac. Dans 29 cas,
une anesthesie locale avec sedation (dia
zepam et meperidine) a ete utilis£e; dans
16 cas, on prefgra une anesthesie generale avec hyperventilation. Le temps operatoire moyen fut de 32 minutes. II a
diminue avec I'experience, de sorte que
pour les neuf derniers cas, il s'est etabli
a 23 minutes en moyenne. Pour la plupart des patients, I'alimentation a debute
le lendemain de l'operation, le surlendemain pour les autres. Les complications
observes comprennent un deplacement
du tube chez trois patients, une infection
superficielle au point d'insertion du tube

chez trois (ne necessitant pas de drai
nage ou I'enlevement du tube) et un
pneumoperitoine asymptomatique dans
un cas. Toutes les complications ont ete
vues au debut de la serie. Aucun patient
n'a souffert d'iieus paralytique, de
vomissement, d'aspiration ou d'une fuite
importante autour du tube. D'apres les
auteurs, la gastronomie endoscopique
percutande represente la methode de
premier choix d'etablir une alimentation
par gastronomie. Elle peut etre pratiquee
rapidement tout en imposant un mini
mum de stress aux patients a risque
eieve.
Enteral feeding is the preferred method
o f establishing and maintaining adequate
nutrition in patients with a functioning
gastrointestinal tract, when oral intake is
otherwise not possible.1-3 Candidates for
feeding gastrostomy, however, are often
poor risks fo r either laparotom y or
general anesthesia.4 In addition, gas
trostomy perform ed by laparotom y is
associated with substantial m orbidity.5,6
In 1981, G auderer and P o n s k y 7
described a technique fo r placing a gas
trostomy tube under endoscopic guidance
that could be perform ed with local
anesthesia and minimal sedation. Since its
introduction, this procedure has been
reported to be effective and safe with a
low incidence o f complications.8-10
This report details our experience with
45 cases o f percutaneous endoscopic gas
trostomy performed between March 1983
and July 1985 at The M ontreal General
Hospital.

Patients and Methods
In the study were 45 patients (27 men,
18 women) having a mean age o f 63 years
(range from 17 to 88 years). Patient
follow-up was from 4 to 780 days.
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Indications for percutaneous placement
of a gastrostomy tube were neurologic
disorders in 34 patients (cerebrovascular
accident 17, trauma 9, amyotrophic
lateral sclerosis 3, brain tumour 3, other
2), head and neck tumours in 2 patients,
failure to thrive in 4 patients, esophageal
obstruction from lung cancer in 1 patient,
and tracheostomy for multisystem failure
or trauma and sepsis in 4 patients.
Technique
The procedure requires two surgeons
— an abdominal surgeon and a surgeonendoscopist. The patient is placed in the
supine position and the abdomen pre
pared and draped. The endoscopist
sedates the patient and anesthetizes the
oropharynx with topical anesthetic. Then
the endoscopist passes the fiberoptic
endoscope and examines the esophagus,
stomach and duodenum to rule out
associated conditions. The stomach is
insufflated with air and the light of the
endoscope can be seen, transilluminated
through the abdominal wall in the left
upper quadrant. The abdominal surgeon
applies pressure with his finger over the
site of transillumination. The endoscopist
should be able to see the gastric wall being
indented, thereby confirming that this is
the appropriate place in the stomach for
the gastrostomy. The abdominal surgeon
anesthetizes the skin at this site and passes
a 14-gauge, funnel-shaped, intravenous
catheter-over-needle assembly through
the abdominal wall into the stomach. The
endoscopist, using a snare, grasps the
catheter. The needle is removed and the
abdominal surgeon passes a no. 2 silk, 60
cm long, through the catheter. This in
turn is grasped by the snare and both
snare and endoscope are withdrawn
through the mouth. One end of the silk
now lies outside the mouth and the other
end out through the abdominal wall. The
mouth end is attached to a no. 18 French
mushroom catheter, prepared with the
end opposite the mushroom invaginated
in another funnel-shaped plastic catheter
to act as an introducer. The abdominal
surgeon, pulling on the other end of the
silk, draws the introducer out through the
abdominal wall first and then stretches
the tract so that the mushroom catheter
can be exteriorized without difficulty. The
gastroscope is replaced and the position
of the mushroom catheter in the stomach
confirmed, with the stomach pulled up
against the abdominal wall. The feeding
gastrostomy is now complete and the tube
is sutured to the skin of the abdominal
wall.
Results

In three cases the procedure could not
be performed for technical reasons. In
312

one the gastrostomy tube could not be
pulled through the abdominal wall. In the
second case, a large obstructing eso
phageal cancer was a complicating factor,
and in the third patient because of a large
hiatus hernia, the stomach could not be
entered with the needle. The procedure
was otherwise well tolerated and there
were no deaths.
In 29 cases local anesthesia and mild
sedation were used, but in 16 patients
general anesthesia with hyperventilation
was preferred (by neurosurgeons, in
patients with head trauma). The mean
operative time was 32 minutes (range
from 15 to 130 minutes) (Fig. 1), decreas
ing with the surgeons’ experience so that
the current mean operative time is 23
minutes. One procedure was greatly
prolonged because of a large hiatus her
nia. Feeding was begun on postoperative
day 1 in most patients (Fig. 2).
Complications included three cases of
tube displacement, three of superficial
infection at the site of catheter insertion
and one case of asymptomatic pneu
moperitoneum. In two of the patients
with dislodged catheters, gastrostomies
were successfully re-established. In the
third patient, the displaced tube was
replaced through the tract on postopera
tive day 7 and inadvertently placed in the
peritoneal cavity. In patients who
suffered pericatheter infections, com
presses alone sufficed and wound
drainage or tube removal was not
required.
These complications all occurred early
on, with the first 10 cases. No patients
had paralytic ileus, vomiting, aspiration
or serious leakage around the tube.

inherent in general anesthesia and
laparotomy. The complication rate is
low.14-16 Recently Ponsky and
associates10 reported their cumulative
experience with no deaths and 10% mor
bidity.
A size 18 French or 20 French feeding
catheter is selected because this permits
a blenderized or liquid diet to be
administered. The catheter can be
removed without difficulty and replaced
with a balloon catheter of comparable
size.
Although percutaneous endoscopic
gastrostomy is easily performed with
minimal risk to the patient, a number of
contraindications have been proposed,9
including the presence of ascites, morbid
obesity, esophageal obstruction,
esophageal varices, previous gastric sur
gery and active peptic ulcer disease or a
complication thereof. Relative contrain
dications are severe gastroesophageal
reflux and previous abdominal surgery.
Although we have not found the latter to
be a particular problem, some difficulty
was encountered in one patient with a
large hiatus hernia.
In our study there were no instances of
catheter migration, hemorrhage or leak
age around the tube. One particularly
interesting occurrence, albeit benign, was
that of pneumoperitoneum. It was
asymptomatic and discovered incidentally
during abdominal radiology performed
for an unrelated reason; no treatment was
required. Stassen and associates17
recently reported two cases of pneu
moperitoneum associated with percutane
ous endoscopic gastrostomy. Radiologic
demonstration of the condition coincided

Discussion

Enteral alimentation should initially be
considered in malnourished patients
whose digestive tracts are still function
ing. In general, procedures to establish
enteral access are relatively simple, safe
and well tolerated. Gastrostomy and
jejunostomy perhaps provide the best
means of long-term enteral alimentation
in patients unable to swallow. O’Hara
and colleagues11 demonstrated the
beneficial effects of long-term enteric
feedings in elderly debilitated patients.
The complications associated with the
standard gastrostomy, however, may be
serious. The estimated morbidity derived
from several large series1,6'12’13 is between
3% and 35% with a death rate of approx
imately 6%.6 Complications related to
laparotomy and gastrostomy include aspi
ration pneumonia, peritonitis, hemor
rhage, herniation, dehiscence or eviscer
ation, gastric outlet obstruction and
wound infection.
Percutaneous endoscopic gastrostomy
is easily performed and can avoid the risks
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FIG. 1—Duration of procedure for 45
patients who underwent percutaneous
endoscopic gastrostomy.
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FIG. 2—Postoperative day on which feed
ing was begun.
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with acute clinical deterioration in the
first patient. In the second case, pneu
moperitoneum coincided with hematemesis from a gastric ulcer. The patient was
explored but no perforation was disco
vered. The authors commented that the
patient could have been spared surgery
had the association between percutaneous
endoscopic gastrostomy and benign pneu
moperitoneum been recognized.
As a result o f our favourable initial
experience with percutaneous endoscopic
gastrostomy, we believe it is a safe and
effective technique and that it should
become the method of choice for estab
lishing long-term enteral alimentation.
We thank Mrs. Tina Parks-Kinnear for her
assistance in the preparation of this
manuscript.
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Experience With Fine-Wire Localization Breast Biopsies
for Nonpalpable Breast Lesions Detected Mammographically
There is evidence to suggest that the
early diagnosis and treatment of breast
cancer may be associated with a better
prognosis. Technical advances such as
mammography can detect nonpalpable
breast lesions and changes associated
with early carcinoma. With fine-wire
localization under mammographic con
trol, the surgeon can reliably remove
nonpalpable lesions while sparing normal
breast tissue.
The authors describe the technique for
fine-wire localization and removal of
lesions and report their experience over
3 years with 262 women who under
went 269 biopsies for nonpalpable
lesions. Four subgroups were identified:
screened women who had no indication
for mammography other than age,
women who were referred for mammog
raphy by community physicians, a group
referred to the Cancer Control Agency of
British Columbia and a group referred to
the agency for localization biopsy after
mammography performed outside the
Vancouver area had suggested a malig
nant lesion. The yield of cancers from
biopsies was 1 0 % , 3 8 % , 4 3 % and 2 6 %
respectively. The yield was significantly
(p < 0.05) lower for the screened group.
Age over 60 years, previous breast
cancer and mammographic technique
were identified as possible predictors of
a positive biopsy. The authors have
found fine-wire localization biopsy a safe
and reliable method of removing nonpal
pable breast lesions.
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II existe des preuves a I'effet que le dia
gnostic et le traitement precoce du can
cer du sein puissent etre relies b un pronostic plus favorable. Les progres
techniques comme la mammographie
peuvent deceler des lesions mammaires
nonpalpables et les changements associes au stade precoce d'un cancer. Par
localisation d I'aiguille fine sous surveil
lance mammographique, le chirurgien
peut, avec assurance, retirer les lesions
nonpalpables tout en ecartant les tissus
mammaires normaux.
Les auteurs d£crivent la technique de
localisation et d'exer^se des lesions a
I'aiguille fine. Ils font aussi etat de leur
experience sur une periode de 3 ans
chez 262 femmes qui ont subi 269 biop
sies pour lesions nonpalpables. Quatre
sous-groupes ont 6t6 identifies: un
groupe de femmes soumises au
depistage par mammographie sans autre
indication que I'age, un groupe de
femmes repues a I'instigation de leur
medecin de famille, un groupe adresse a
I'Agence de surveillance du cancer de la
Colombie Britannique puis finalement un
groupe adresse ei I'Agence pour
localisation-biopsie aprfcs qu'une mam
mographie r6alis£e hors de la region de
Vancouver eut suggere une Igsion
maligne. Les biopsies ont rgveld des taux
de cancer respectifs de 1 0 % , 3 8 % , 4 3 %
et 2 6 % . Le taux 6tait significativement
inferieur dans le groupe de depistage
(p < 0.05). Un age sup^rieur a 60 ans,
un cancer du sein pr£alable et la tech
nique mammographique ont 6t6 identifies
comme des facteurs previsionnels possi
bles d'une biopsie positive. Les auteurs
consid&rent la biopsie-localisation a
I'aiguille fine comme m6thode sure et fiable pour I'exgrese des lesions mammaires
nonpalpables.

may offer improved prognosis.3,4 When
mammography identifies a subclinical
lesion, it can be removed reliably using
a fine-wire localization technique.
We studied retrospectively 262 patients
who had undergone mammography and
fine-wire-localized biopsy of 269 clinically
occult lesions. Our purpose was to assess
the effectiveness of this technique and to
determine the yield of cancers from the
four subgroups studied.
Patients and Methods

Between January 1982 and December
1984, 24 493 mammograms were per
formed at facilities affiliated with the
University of British Columbia. Four
patient groups were identified: group 1 —
4074 women between the ages of 40 and
59 years who had agreed to participate in
a breast screening study and were ran
domly allocated to undergo mammogra
phy between March 1983 and December
1984; group 2 — 15 869 patients referred
for varied reasons by community physi
cians in the Vancouver area to a private
radiology clinic for mammography
between January 1982 and December
1984; group 3 — 4580 patients referred
to the Cancer Control Agency of British
Columbia (CCABC) who were generally
at high risk, many with a contralateral
cancer or previous cancer of the breast;
group 4 — women (total number
unknown) referred to the CCABC for
fine-wire localization biopsy who had
undergone mammography outside the
Vancouver area and in whom the mam
mographic findings were suggestive of a
malignant lesion.
Bilateral mammography was initially
performed on all patients using dedicated
mammography units and standard tech
niques. All group 1 patients underwent
Breast cancer carries a lifetime incidence film mammography on a Picker Mammoof 9Vo in North American women1 and rex mammography unit (Picker Nuclear,
is the leading cause of death from cancer Chicago, 111.). Group 2 and group 3
among them, causing immeasurable cost patients generally underwent positive
in death and suffering. Despite this, long mode xeromammography on Picker
term survival has not improved over the Mammorex mammography units. Less
past 40 years.2 Because of improved than 5% of patients in these groups
techniques, early breast cancer can now underwent negative-mode xeromammog
be detected by mammography and this raphy; they were young women with
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dense or small breasts or women with
prostheses. Group 4 patients had initial
mammography performed on a variety of
units.
When a suspicious area was discovered
at initial mammography, the mammo
grams were interpreted by one of a group
of radiologists, and fine-wire localization
was recommended if there was distortion
of tissue, evidence of a mass, clustered
calcification or skin changes suggestive of
carcinoma. All lesions were clinically
occult.
Fine-Wire Localization Technique
The lesion is localized with xeromam
mography in two planes on a Picker
Mammorex unit using the positive mode.
It is marked with a skin marker and a fine
wire with a terminal hook is introduced
into the suspicious area through a no. 22
gauge needle guide (Fig. 1), using one of
three approaches, depending on the loca
tion of the lesion (technique of Kopans
and Meyer5). The anterior approach is
most frequently used. Vertical approaches
are used for upper one-third lesions, the
medial approach for medial lesions. The
guide needle is then withdrawn, leaving
the fine hooked wire in position (Figs. 2
and 3). The wire is bent at the skin sur
face to prevent displacem ent and
rechecked radiologically for position.
Biopsy is performed within 2 hours,
removing the tissue surrounding the end
of the wire, and an x-ray film of the
biopsy specimen made to ensure the sus
picious area has been removed (Fig. 4).
Estrogen receptor assay of the specimen
is done when indicated.
*
Results were analysed by Student’s
f-test, p < 0.05 being considered sig
nificant.

a repeat biopsy was performed in three
breasts because the suspicious area was
missed, and three more patients under
went repeat biopsy because of missed or
new lesions, but no lesion was malignant.
No repeat biopsies were required in group
3 or 4. The overall rate of repeat biopsy
was 3%. On pathological review of the
269 biopsy specimens 156 (58%) were
benign, 47 (17%) were considered to con
tain prem alignant lesions, 6 (2%)
carcinoma-in-situ (4 from group 1) and
61 (23%) contained invasive carcinoma.
The cancer yield for the 40 to 59-year
age range did not differ significantly in
any of the four groups, being 15.8% over
all. The greatest yield was in the over
60-year age group for which 51% of biop
sies (34 of 67) contained malignant cells.
This difference in yield compared with
other age groups is significant (p < 0.05).
Women with a previous breast cancer
or with cancer of the breast presenting
synchronously were excluded from group
1. Therefore, group 1 patients were
excluded in considering the predictive
value of a history of breast cancer. A his
tory of breast cancer or a synchronous
breast cancer was obtained in 19% of
group 2 women and 50% of group 3. No

FIG. 3—Hooked wire adjacent to lesion.

Results (Table I)
Of the 4074 mammograms performed
in group 1 patients, 109 were suggestive
of carcinoma. Fine-wire localization
biopsy yielded 11 cancers. For the
referred group (group 2), 101 biopsies
yielded 38 cancers. For group 3 women
(the cancer agency group) 28 biopsies
yielded 12 cancers (43%) — an expectedly
higher yield. In group 4, 31 biopsies
yielded eight cancers (26%). The yield of
cancers from group 1 was significantly
lower (p < 0.001) than that from groups
2 and 3, but the yields in groups 2, 3 and
4 were not significantly different from
one another.
Two group 1 women required repeat
biopsy of the same area. In one case, the
specimen x-ray film did not show the sus
picious area, and in the second, the biopsy
was done in a hospital where specimen
roentgenography could not be performed,
and again the suspicious area was not
removed with the specimen. In group 2,
316

group 4 patients had such a history. Of
women with a history of breast cancer
53% had a fine-wire localization biopsy
positive for cancer compared with 34%
o f those w ithout such a history
(p < 0.02). Therefore, a history of breast
cancer or breast cancer presenting syn
chronously appears to be of value in
predicting a positive result from fine-wire
localization biopsy.
There was no difference between the
four groups in the likelihood of a patient
having a positive family history, defined
as previous breast cancer in a first- or
second-degree relative. For all groups
combined, there was no difference in yield
between patients with or without a family
history of breast cancer.
The mammograms of all women who
had a biopsy were graded according to a

FIG. 1—Introduction of needle guide into
lesion under mammographic control.

FIG. 2—Fine hooked wire next to lesion.

FIG. 4—Biopsy specimen.
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modified Wolfe’s classification, which is
a method of grading the parenchymal pat
tern that can be correlated with the risk
of malignancy.6 We found no difference
in parenchymal pattern in those who had
a malignant condition and those who did
not.
As all group 1 patients had film mam
mography and all group 2 patients had
xerom am m ography, the different
methods could have accounted for the
difference in yield between these two
groups. When the 40 to 59-year age
groups are compared, there is a signifi
cant difference (p < 0.05) in yield
between group 1 and group 2 biopsies.
A calculation of cost was made at the
private clinic and the CCABC for patients
who underwent mammography in 1983
(groups 2 and 3). The cost, based on the
fee schedule for mammography, was
approximately $6000 per occult cancer
(1983 Canadian dollars). This compares
with a cost of $1600 per cancer of the cer
vix discovered by screening (Anderson G:
Personal communication, 1986).
Discussion
Modern surgical techniques and im
provement in diagnosis have resulted in
little improvement in long-term survival
for women with breast cancer, which is
their most frequently fatal cancer (28%).7
However, detection of cancer at the
preclinical stage may offer an improved
prognosis. To this end, routine screening
of asymptomatic women has been recom
mended.1,8
The American Cancer Society has
made the following recommendations for
screening asymptomatic women for
breast cancer:9
• All women should be instructed in
the technique of breast self-examination
and encouraged to examine themselves
monthly.
• Physical examination should be per
formed every 3 years for women between
the ages of 20 and 40 years, and annu
ally thereafter.

• A mammogram should be obtained
as a baseline between the ages o f 36 and
40.
• A mammogram should be obtained
every 1 to 2 years for women between the
age of 40 and 50, depending on patient
risk.
• Mammograms should be obtained
annually for women over 50 years of age.
The yield, reliability and benefit of selfexamination and physician examination
remain controversial.8 Nevertheless,
most authorities would not dispute the
American Cancer Society recommenda
tions. Numerous breast imaging tech
niques have been developed in an attempt
to improve detection of early breast
cancer.10 Mammography is the only
screening modality that has consistently
been shown to
detect
b reast
cancer.2' 4,8,10-12 The Health Insurance
Plan o f New York (HIP) s tu d y ,13
initiated in 1962 to assess the value of
mass screening, showed that 39% of
breast cancers were detected by mammog
raphy alone and that two out of five were
detected clinically but had no detectable
mammographic changes. Clinical exami
nation and mammography were found to
be complementary. Since then, improve
ments in technique have greatly increased
the sensitivity of mammography in detect
ing breast cancer. By 1982, the Breast
Cancer Detection Demonstration Project
(BCDDP)14 reported that 87% o f all
women with breast cancers had positive
mammograms. A recent study by Frankl
and Ackerman12 showed that 88% of the
cancers were correctly diagnosed by radi
ologists. With modern mammographic
technique, fewer cancers are missed, but
clinical examination remains important in
breast screening.
In addition, earlier lesions are being
detected. In the BCDDP study, 13.8% of
all cancers were either noninfiltrating or
less than 1 cm in dimension. O f these
lesions 59% were nonpalpable.14 This
contrasts with the HIP study in which
only 3.5% of cancers were 1 cm or less
in size. These data suggest that mammog
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raphy is becoming more sensitive in
detecting smaller lesions. The H IP study
concluded that in the over 50-year age
group, survival was greatly improved in
patients who were screened by mammog
raphy over those who were n o t.1 With
today’s techniques, the improvement
could be even greater.
Minimal breast cancer was originally
coined as an entity by Gallagher and Mar
tin in 1971.3 Since then, their definition
has been modified and is now generally
recognized to include in-situ cancer and
invasive cancer less than 1 cm in greatest
diameter. Minimal breast cancer appears
to have a better prognosis if appropriately
treated.
The American College of Surgeons
survey15 showed that the 5-year survival
for patients with minimal invasive carci
noma and negative nodes was 74.3%
versus 53% for patients with positive
nodes. Of patients with minimal invasive
cancer, 21.2% had positive nodes. In the
BCDDP study of lesions identified by
mammography that were smaller than 1
cm in diameter, 52.6% were clinically
occult and 14.3% were associated with
axillary node involvement, whereas for
lesions greater than 1 cm, axillary nodes
were involved in 29.2%. This supports the
view that minimal breast cancer has a bet
ter prognosis.
Women with lobular carcinoma in situ
treated by biopsy alone are 11 times more
likely than others to have invasive cancer
which may be in the opposite breast.3
Currently, there is no way to identify
these patients. There is controversy over
the most appropriate treatm ent for
them .3 Fine-wire localization biopsy has
a role if suspicious mammographic
changes are found in the opposite breast
at follow-up. Similarly, women with duc
tal carcinoma in situ are at increased risk
of invasive cancer in the same breast but
not the opposite breast. It is not known
whether removing such lesions improves
survival or not.
In considering these findings, three
potential biases must be reviewed. First
is the lead-time bias. Improved survival
may be entirely accounted for by the lead
time gained in finding a cancer earlier in
its course. Second, length bias states that
small tumours are slower growing and
spend more time as occult lesions. Third,
small tumours may never become aggres
sive and metastasize. These arguments
have been opposed4,8 and it appears that
minimal breast cancer behaves as true
breast cancer at an early stage.
M am m ographic tech n iq u e
has
improved greatly in recent years.11 The
sensitivity of mammography from the
H IP study contrasts sharply with that of
today’s technique.12 Moreover, the the
oretical risk of causing cancer by irradi
ating breast tissue has been lowered by a
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10-fold reduction in the required radia
tion dose since mammography first
became reliable in I960.10 Today’s theo
retical risk o f one excess death per 2 mil
lion women examined annually should be
kept in perspective when considering the
potential benefit of routine screening.16
The changes on a mammogram that
suggest cancer may be subtle. They
include clustered calcifications, a mass
effect, especially a spiculated mass, dis
torted architecture, asymmetric densities
and skin changes.17 As radiologists
become more familiar with the technique,
the sensitivity should improve.
When a subclinical lesion is considered
suspicious enough to warrant biopsy, it
may be localized using a variety of tech
niques. The technique of Kopans and
Meyer5 has been shown to be effective in
localizing these lesions and allowing
reliable removal.17 If the lesion is not
palpable, x-ray imaging of the surgical
specimen is imperative to ensure an
accurate biopsy. It may also help to local
ize small cancers within the surgical speci
m en.17 Before this technique was availa
ble, it was necessary to perform blind
biopsy resulting in the need to remove
much larger blocks of tissue to ensure the
suspicious area was excised. The fre
quency of surgical complications and
breast deformity is reduced.

Denis B ernard ,

The yield of cancers from fine-wire
localization in this study is comparable to
that from other similar studies.17 The
yield between the four groups in this study
was different. We can account for this
difference by age selection and a poten
tial improvement in sensitivity of xeroma
mmography over film. As with palpable
lesions, the older the patient, the more
likely any particular lesion is to be malig
nant. A history of breast cancer also
appears to increase the likelihood of
cancer on fine-wire localization biopsy.
Our data suggest that patients who are at
increased risk of palpable cancer are also
at increased risk of occult cancer.

Conclusions
Fine-wire localization biopsy is a relia
ble method for removing occult lesions
suggestive of breast cancer. By removing
less tissue, better cosmesis is afforded
with a lower complication rate. As breast
screening becomes more commonplace,
the need for this technique will undoubt
edly increase. The trend regarding treat
ment of minimal breast cancer is towards
conservative surgical technique, thus
making fine-needle localization biopsy a
significant step forward in the treatment
of breast cancer.

md , frc sc ;
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Selective Surgical Management
of Crohn’s Disease of the Anus
To establish specific indications for the
surgical treatment of perianal Crohn's
disease, the authors report their
experience with 102 patients (45%) with
these lesions in a series of 225 patients
with small- and large-bowel Crohn's dis
ease. Ulcerations or fissures were
present in 50% , abscesses developed in
32% and fistulas in 53%. More than one
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type of lesion was present in 59%. One
of six patients had no symptoms, in one
of five the lesion was etiologically
independent of Crohn's disease and one
of four patients did not require surgical
intervention. Severe pain indicated an
abscess that required drainage, and 57%
of patients who underwent drainage
alone or with an added seton later
required fistulotomy to become
symptom-free. Primary fistulotomy for
abscess achieved complete healing in
71% of cases and fistulotomy also
healed in 60% of chronic fistulas for a
combined fistulotomy healing rate of
63% when anal Crohn's disease was
present and 68% in all patients with
Crohn's disease. Anal dilatations with
bougies were effective in short stenoses
which were present in 7% of cases.
Twelve percent of patients required exci
sion of the rectum to be relieved of their
symptoms.

Dans le but d'6tablir les indications specifiques de la chirurgie dans la maladie
de Crohn p6rianale, les auteurs decrivent
leur experience chez 102 patients (45%)
souffrant de cette affection parmi un
groupe de 225 patients atteints d'une
maladie de Crohn du petit ou du gros
intestin. Des ulceres ou fissures etaient
presents dans 50% des cas, des abc&s
sont apparus dans 32% et des fistules
dans 53% . Dans 59% des cas, on a
observe plus d'un type de lesion. Un sur
six malades n'avait aucun symptome,
dans un cas sur cinq il s'agissait d'une
lesion dont I'etiologie 6tait etrangere 6 la
maladie de Crohn et un malade sur quatre n’a necessity aucune intervention chirurgicale. Une douleur intense a ete
I'indice d'un abces necessitant drainage,
et 57% des patients qui ont subi un drai
nage seul ou avec I'addition d'un seton
ont du subir par la suite une fistulotomie
pour faire disparaitre les symptdmes. La
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fistulotomie primaire a procure une guerison complete dans 7 1 % des cas d'abces
et elle a permis de guerir aussi 6 0 % des
fistules chroniques pour un taux combing
de guerison de 6 3 % dans la maladie de
Crohn anale et de 6 8 % pour I'ensemble
des malades souffrant de maladie de
Crohn, La dilatation anale h I'aide d'une
bougie a ete efficace pour les stenoses
courtes, lesquelles ont 6t6 vue dans 7 %
des cas. Douze pourcent des patients
ont du subir I'excision du rectum pour
soulager leurs sym ptom es.

Perianal and anal canal lesions are com
mon manifestations of Crohn’s disease.1
They may precede or accompany Crohn’s
disease, but more frequently appear after
Crohn’s disease is established more proximally in the alimentary tract.2 Anal
lesions are now recognized as segmental
(“ skip area type” ) in this portion of the
bowel.3
Because of their location anal lesions
give rise to annoying symptoms, often
more so than the intestinal disease, and
they are readily visible to the examining
Table 1-Management for Crohn's Disease
of the Anus
Drugs, including antimicrobials4
Examination under anesthesia
Dilatation of stricture
Drainage of abscess
Seton drainage
Fistulotomy
Fecal diversion
Sphincter repair
Repair of rectovaginal fistula
Rectal excision

Table II—Incidence (%) of Anal Involvement
According to Site of Intestinal
Crohn's Disease
Diseased
Normal
rectum
rectum
Site of disease
24
100
Small bowel
71
41
Small bowel and colon
57
66
Colon
100
Rectum only
72
32
All sites

physician. Nevertheless they are seldom
recognized as manifestations of Crohn’s
disease and are frequently under- or over
treated. Table I4 lists all available treat
ments for Crohn’s lesions of the anal
region. Our purpose is to establish indi
cations for specific surgical treatment of
perianal Crohn’s disease and report our
experience and results.
Patient Data

The records of 225 patients admitted
between 1970 and 1984 to the Hopital StLuc in Montreal for Crohn’s disease were
reviewed. Patients presenting with only
skin edema, skin excoriation, hemor
rhoids or skin tags were not considered
to have important anal manifestations.
Important lesions were present in 102
(45%) (38 men, 64 women). The mean
age of the 102 patients was 33 years.
A fissure or ulcer was present in 51
patients (solitary in 44, multiple in 7).
Thirty-three patients presented with an
abscess, 54 with a fistula (multiple in 20)
and 13 with an anal stenosis. Fifteen
women (23% of women) had a rectovagi
nal fistula. Hidradenitis was the problem
in 2%. More than one type of lesion was
present in 59.
In 26 (12%) of the 225 patients an anal
lesion was the initial mode of presenta
tion. In 19 (8%) it was considered to be
totally independent of Crohn’s disease, as
determined by the absence of primary
Table Ill-Procedures Performed in Patients
with Anal Crohn's Disease*
No. of patients
Procedure
Examination under
anesthesia only
Dilatation of stenosis
Drainage of abscess
Seton drainage
Fistulotomy
Rectal excision
Other

20
7 |5 repeat)
23 (4 repeat)
11
411 (2 multiple)
12
5
‘ Some patients had more than one type of
procedure.
tlncludes 12 patients with previous drainage
of abscess and 6 with previous seton drainage.

Table IV-Treatment and Results in 47 Patients With Fistula With or Without Abscess
Lost to
Failed
No. of
followup
to heal
Healed
patients
Treatment
2
2
2
6
None
1
2
14
11 (1)
Drainage or seton drainage
1
0
1
0
Diversion ileostomy
—
4
—
—
Primary proctectomy
Fistulotomy:
1
1
7
5
Primary procedure for abscess
0
3(1)
5
8
For failure of drainage or seton drainage
2
4(1)
g
15
For fistula
3
8(2*)
19
30
Total fistulotomy
( ) Late proctectomy.
* Diversion ileostomy.

Crohn’s ulcers in the anal canal and the
evidence of another cause — hidradeni
tis suppurativa (two cases) or more com
monly a typical cryptoglandular abscess
or fistula.
The frequency of anal involvement
relative to the site of disease more proximally in the gastrointestinal tract and to
the status of the rectum was determined
(Table II).
Sixteen of the 102 patients were asymp
tomatic. Pain was the dominant symptom
in 39, purulent discharge in 27, recurrent
abscesses in 12, anal stenosis in 6, incon
tinence and bleeding each in 1 patient.
Biopsy or surgical tissue from the anal
region was available for histologic exami
nation in 51 cases and revealed granu
lomas with giant cells in 22 (43%).
Treatment and Results

Patient management depended upon
the type of lesion and the severity of sym
ptoms. Twenty-four patients did not
undergo surgery. Surgical procedures per
formed are listed in Table III. Twenty
patients were examined under general
anesthesia to evaluate the lesion and per
form a biopsy. The anus was dilated in
seven patients with stenosis, and this
procedure had to be repeated up to four
times in five of them. An abscess was
drained in 23 patients and repeated in 4.
Primary fistulotomy was performed at
the time of drainage in seven and secon
dary fistulotomy was eventually required
in eight others. Seton drainage was
attempted in 11 patients; 6 later had fistu
lotomy and 1 excision of the rectum.
Fistulas were laid open in 41 instances.
Twelve patients had rectal excision, anal
disease being the main reason for proc
tocolectomy in 5 and a contributing fac
tor in 6 others.
Excluding 11 patients with fistulas con
sidered to be independent of Crohn’s dis
ease, we assessed 47 patients who had
fistula-in-ano with or without an under
lying abscess secondary to Crohn’s dis
ease, 30 of whom had fistulotomy. A
summary of treatments provided to these
patients and the results are outlined in
Table IV.
Discussion

An in-depth study by Hughes5 classi
fied the anal manifestations of Crohn’s
disease into primary and secondary
lesions. The primary lesions consist of fis
sures and ulcers of the epithelium. They
represent the initial disease process that
can lead to the more complicated secon
dary lesions, which may be mechanical or
infective; these are stenosis, rectovaginal
fistula, abscess and fistula. We agree with
this concept. In our study the proportion
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of patients with ulcers was 50% and that
of patients with a combination of lesions,
usually ulcers and fistulas, was even
higher (59%).
We should remember that in dealing
with Crohn’s disease we must alleviate
symptoms rather than eradicate lesions.6
Ulcers unaccompanied by secondary
lesions seldom give rise to symptoms and
rarely deserve special attention. Systemic
treatment of the intestinal disease will
generally improve the anal condition.
When pain is the main feature, a secon
dary complication such as stenosis,
abscess or a combination of fistula and
poorly drained abscess may be present.
Stenosis is a consequence of fibrosis in the
healing process. A short stricture, even
when very tight, can be dilated under
anesthesia. We use Hegar-type dilators,
up to size 18 or 20, about the size of an
index finger. Multiple-finger dilatation or
internal sphincterotom y should be
avoided.7,8 For long strictures or those
with associated lesions such as fistulas or
a severely diseased rectum, proctectomy
may be the only treatment, as it was in
four of our cases.
Acute severe pain is invariably caused
by abscess formation.9 Drainage should
always be done promptly; it relieves the
pain and prevents extension of the
abscess. Unless a patent, free-flowing
fistula is established, the skin opening

may close and the patient experience
either recurrence of the abscess or pain
because of a poorly drained fistula.
Drainage can be repeated or one may con
sider seton drainage or fistulotomy. We
performed seton drainage on 11 occasions
in an attempt to provide permanent or
prolonged painless drainage and prevent
recurrence of the abscess. Complete heal
ing was obtained in two and only two
more remained free of pain. All others
underwent fistulotomy and in one case
proctectomy. Success with seton drainage
has been reported by Goldberg and
colleagues10 and by Thomson.8
Fistulotomy remains a controversial
procedure, with the literature divided into
conservative and liberal attitudes. Con
servatism is advocated on the grounds of
poor or delayed healing of wounds, risk
of destroying the sphincter mechanism
and the natural history of those fistulas
that tend to heal spontaneously or
become asym ptom atic.3,7,11 We, like
others,12-14 favour a more aggressive
approach. Successful wound healing with
normal delay was achieved in 63% with
fistulotomy. A high rate o f successful
healing without delay was also reported
by Marks and associates12 (78%), Sohn
and colleagues13 (75%) and Hobbiss and
Schofield14 (70%). These authors recom
mend a more liberal fistulotomy policy,
based on the observation that the

majority of fistulas are of the simple or
low variety, tending to follow the com
mon pathways, and the rate of healing
and its duration is not significantly differ
ent from those of fistulas in patients not
having Crohn’s disease. Others such as
Hughes and Jones6 and Buchmann and
associates11 advise against extensive sur
gery because of the complexity of the
tracts and the extension of infection, espe
cially when the primary ulceration is
located above the dentate line. AlexanderWilliams and Buchmann7 also reported
that 38% of these fistulas, when left
alone, underwent spontaneous cure
within 10 years.
Rectovaginal fistulas represent a spe
cial problem. They usually result from
either a direct penetration of the vagina
by a deep rectal ulcer or spontaneous
drainage of a high anal abscess into the
vagina. Consequently they are of the
suprasphincteric type and cannot be laid
open by a conventional operation. For
tunately, because of the small dimensions
of the tract, many of them present few
symptoms and are best left alone.12
Occasional reports of successful repair,
after fecal diversion, of nonactive rec
tovaginal fistulas have been pub
lished.7,15 We have encountered only one
case suitable for such repair. The majority
(9 of 15) underwent rectal excision (7)
or fecal diversion (2) because of the
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severity of the rectal disease and the
accompanying anal lesions.
Fecal diversion for anal disease has
been recommended by the Oxford
group .16 Final results are far from
impressive as only 6 of 29 have had bowel
continuity restored, a very low rate (21%)
for a temporary procedure. Our own
experience with planned or unplanned
diversion has been disappointing, with
not one of nine patients having their con
tinuity restored and four undergoing
interval proctectomy.
Excision of the rectum is the ultimate
treatment for anal Crohn’s disease.17 Of
the 12 proctectomies in our series, 5 were
indicated solely by the anal condition. Six
of the remaining seven patients had severe
concomitant colorectal disease necessitat
ing a proctocolectomy, for an 11 % rate
of rectal excision in anal Crohn’s disease.
This rate is comparable to those of Buchmann and associates11 (9%) and Marks
and colleagues12 (15%) but is somewhat
higher than those of Hughes and Jones6
(2.5%), Homan and associates1 (3%)
and Hobbiss and Schofield14 (4%).
Hellers and colleagues17 reported a 40%
incidence of proctectomy, a rate that
increased to 89% (58 of 65) for anal
fistula when disease was present in the
rectum. Our own numbers indicated a
proctectomy rate of 29% (7 of 24) for
anal fistula with rectal involvement.

Summary and Conclusions
Serious anal disease was present in 45%
of our patients with Crohn’s disease. Only
16% were asymptomatic and 24% did not
require surgical treatment. Examination
under anesthesia allowed accurate diag
nosis of painful conditions, precise assess
ment of the extent of fistulas, sig
moidoscopy and the taking of biopsy
material in 20 patients. Fissures and ulcers
are best left alone. Stenoses can be dilated
with bougies. Abscesses must be drained
promptly. Recurrence of abscesses may
be prevented by seton drainage or, prefer
ably, by primary or secondary fistulot
omy. The concept of fistulotomy in anal
Crohn’s disease is advocated because: (a)
wound healing is better than formerly im
plied, (b) patients, although free of pain,
are not always happy because of persis
tent discharge which is unhygienic and
unpleasant, especially to young people
and (c) in some cases the fistulas may be
etiologically independent of Crohn’s dis
ease and fistulotomy is likely to achieve
complete healing. Finally, proctectomy
may be the only alternative in patients
with severe anal and rectal involvement.
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Vertical Banded Gastroplasty: Results in 233 Patients
The authors describe their experience
with vertical banded gastroplasty in 233
patients for whom the follow-up ranged
from 12 to 30 months. There were no
deaths. Intraoperatively, two gastric per
forations and one esophageal perforation
occurred; these were closed and drained.
A postoperative leak was treated
promptly by removal of the collar,
drainage and gastrostomy. There were
three instances of late obstruction, due
in one to mesh adhering to liver and in
two to stenoses; gastrogastrostomy was
followed by regained weight. Removal of
the collar was also associated with
failure to lose adequate weight. Rare
complications were intraluminal erosion
of mesh and staple-line breakdown. The
gallbladder was still present in 175
patients; of these, 25 had gallstones and
underwent a cholecystectomy at the
time of gastroplasty. Of the other 150,
symptomatic gallstones subsequently
developed in 13. At 12 months after
gastroplasty 8 0 % of patients had lost at
least 5 0 % of excess weight and at 24
months 8 3 % had lost 5 0 % or more of
excess weight (15 patients lost to
follow-up). To avoid failures, the collar
circumference should not be more than
5.0 cm. A small experience suggests
that revision of a failed horizontal gas
troplasty to vertical banded gastroplasty
is hazardous.
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Les auteurs d6crivent leur experience de
la gastroplastie par bandes averticales
chez 233 patients; la surveillance de
post-cure s'etend de 12 a 30 mois. II n'y
a eu aucun deces. Deux perforations
gastriques et une perforation oesophagienne sont survenues a I'operation; elles
furent referm6es et drainees. Une postoperatoire fut traite par retrait rapide du
collier, drainage et gastrostomie. On a
enregistre trois cas d'obstruction tardive
dus une fois a I'adhesion de la toile au
foie et deux fois & des stenoses; une
gastrogastrostomie fut suivie d'une
reprise de poids. De meme, le retrait du
collier entrama I'Schec d'une perte de
poids approprige. Les rares complications
observees comprennent I'erosion intraluminale de la toile et la rupture de la ligne
d'agrafes. La vgsicule biliaire etait intacte
chez 175 patients; parmi ceux-ci, 25
presentaient des calculs, de sorte qu'une
cholecystectomie fut pratiquee en meme
temps que la gastroplastie. Des 150
autres, 13 ont d£velopp6 subsequemment des calculs symptomatiques. Douze
mois apres la gastroplastie, 8 0 % des
patients avaient perdu au moins 5 0 % de
leur exces de poids. Aprfes 24 mois,
8 3 % avaient perdu 5 0 % ou plus de leur
exc6s de poids (15 patients ont 6t§ perdus de vue). Afin d'eviter les echecs, la
circonference du collier ne doit pas
dgpasser 5.0 cm. Une experience limitee
indique qu'il est dangereux de reviser
apr&s echec une gastroplastie horizontale
pour la convertir en gastroplastie a ban
des verticales.

having later outlet enlargement and
regaining lost weight. The long-term
failure rate has been 41%.2
In 1982, Mason described his 2-year
follow-up with a simpler, less complicated
operation, the vertical gastroplasty, which
he banded with a Marlex mesh collar to
prevent weight gain.3 We describe our
experience with the vertical banded gas
troplasty.
Patients and Methods
Since Nov. 1, 1982, 377 patients have
undergone vertical banded gastroplasty as
their initial weight loss operation at St.
Joseph’s Health Centre in Toronto. All
had failed to have sustained weight loss
on documented exhaustive conservative
treatments. They had associated serious
and debilitating sequelae of morbid
obesity. All were more than 45 kg over
weight and were usually more than twice
their ideal weight.4 Ideal weights for sur
vival changed during the study,5 but
were ultimately calculated by a formula,
corresponding to the 1983 Metropolitan
Life height-weight tables, using the
weights for medium frame.6 A loss of
50% or more of excess weight was classi
fied as a success.7
Of the 377 patients, 233 underwent ver
tical banded gastroplasty more than 12
months ago, permitting a 12- to 30-month
follow-up. These are the patients studied
in this report.
Operative Technique

A high, midline incision ending well
above the umbilicus was used. A no. 32
Obesity is the most frequent nutritional French Ewald tube was passed into the
problem in western civilization. It is stomach, and the esophagus mobilized to
difficult to estimate the incidence of mor define the cardia (Fig. 1). The upper part
bid obesity, as these patients frequently of the Polytract retractor was applied
withdraw from society. Our experience with the Gomez hand (Narco-Pilling,
with weight-loss surgery goes back to Downsview, Ont.) over the padded left
1973, when we undertook the jejunoileal lobe of the liver. An opening was made
bypass. With long-term surveillance of into the lesser sac, and a Hearn needle
possible sequelae, which consisted mainly (Richard F. Hearn, 915 East Summit
of renal stones (11%), the procedure was Avenue, Oconomowoc, WI 53066) was
superseded by the horizontal Gomez gas thrust into the centre of the anvil, guid
troplasty.1 This relatively complex proce ing the attached EEA stapler (Auto
dure resulted in many patients who ini Suture Co., St. Laurent, PQ), so that a
tially were struggling with a tiny outlet 28-mm window, above the crow’s foot,
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was cut against the Ewald tube. Through
a retrogastric tunnel, a rubber catheter
guided the attached foot-piece of a reus
able TA90 stapler (Auto Suture Co.) with
4.8-mm staples, and the wing-nut was
screwed to stabilize the instrument. With
sponge-sticks pulling the upper stomach
to the left, the TAW stapler delivered a
double staggered line of staples, from the
lesser curvature side of the window to the
angle of His. A second application of the
TAW stapler was made about 3 mm to
the left of the first, to make a secure par
tition with fibrosis between the staple
lines. If the first staple line was not suffi
ciently to the right, the second applica
tion was made to the right of the first. At
the level of the window, a tunnel was
carefully developed deep to the vagi,
bringing through a pre-marked Marlex
strip that was sutured to itself with three
centrally placed 3-0 polypropylene
sutures, so that its circumference was 5.0
cm. The Ewald tube was removed after
the first polypropylene suture was placed
and before it was tied. The Marlex collar
was pre-cut so that its stretching ability
was in its 1.5-cm width and not trans
verse. A small metal clip was placed
across the lower margin of the overlapped
collar as a future radiologic marker. A
no. 16 French nasogastric tube was
guided through the channel and the
greater omentum tacked over the collar
to the lesser omentum with a few fine cat
gut sutures.
Thoracic epidural, supplemented by
light general anesthesia, was frequently
used. The patients received cefazolin, 1
g, at the beginning of surgery and once
postoperatively, and were given raniti
dine, 50 mg every 8 hours, throughout the
period the intravenous line was main
tained. The massively morbidly obese
required extra-large gowns, a plywood
board widened at the hips over the oper

ating table, a canvas sheet with multiple
handles for lifting, and their own heavyduty bed when they were too large for a
stretcher.8 A liquid diet was started 4
days after operation and blended foods
4 weeks postoperatively.
Results
The 210 women and 23 men (mean age
34 years, range from 17 to 58 years) had
a mean preoperative weight of 128 ± 22
( ± SD) kg (excess weight 68 ± 18 kg or
112% ).
Intraoperative Complications
Intraoperatively there were two gastric
perforations and an esophageal perfora
tion. The first gastric perforation
occurred when the curved clamp was
passed around the lesser curvature side of
the channel to tunnel the Marlex strip.
The hole was closed, the mesh collar was
brought through cephalad, and the
closure sutures were brought through
greater omentum and tied again. The
second perforation occurred in the
posterior wall of the stomach near the
cardia. It was closed from within the
stomach through an anterior gastrotomy,
and the staple lines were applied on either
side of the repair. In one patient, the
Ewald tube perforated the lower esopha
gus and the repair was reinforced by Nissen fundoplication. It is recommended
that the surgeon manually guide the
Ewald tube through the cardia. Largebore gastrostomy tubes were inserted near
the greater curvature to ensure decom
pression in these patients, and recovery
was smooth.
Concomitant Operations (Table I)
Cholecystectomy had previously been

partition from two applications of TA 9 0

performed on 58 (25%) patients. Of the
remaining 175 patients, 25 (14%) were
found to have gallstones on preoperative
ultrasonography or gallbladder series plus
palpation (Table I).9 Palpation alone is
inaccurate in detecting gallstones, and
needle aspiration was not done. The seven
ventral hernias were through previous
cholecystectomy incisions. The eight gas
trostomies were performed to prevent
postoperative gastric distension when the
vertical banded gastroplasty had not gone
smoothly. Although gastroesophageal re
flux and hiatus hernias are not uncom
mon in these patients,10 no specific
procedures were added, as vertical banded
gastroplasty is in itself an excellent
antireflux procedure.
Postoperative Complications (Table II)
In one patient a leak occurred at the
window where a staple had fallen out of
the EEA cartridge. This was treated by
removing the mesh collar, drainage and
gastrostomy, resulting in inadequate
weight loss. All subsequent gastroplasties
had the window border reinforced by a
running 2-0 chromic catgut suture.
Wound infections were occasionally deep
in the subcutaneous tissue and difficult
to diagnose.
There were three late obstructions. One
was due to kinking, as the superior edge
of the mesh adhered to the liver; it was
released and further omentum sutured
over the collar. Two rigid stenoses under
the mesh were treated by anterior gastrogastrostomy over the partition, but
rapid regain of weight followed. A patient
who underwent gastroscopy for vomiting,
was found to have Marlex mesh in the
lumen; she has refused to have the Marlex
removed and is doing well 20 months
Table 1-Concomitant Operations
Operation
Cholecystectomy
Umbilical hernia repair
Ventral hernia repair
Gastrostomy

#32 F Ewald tu b e -*
window cut by
E E A stapler
omentum sutured
over collar at end
of procedure
polypropylene
mesh overlapped
to produce
5.0 cm collar
(1.5 cm high)

No. of
patients
25
10
7
8

Table II—Postoperative Complications
Complication
Early
Leak
Seroma
Wound infection
Late
Outlet obstruction*
Intraluminal erosion of mesh
Staple-line breakdown
Ventral herniat

No. of
patients
1
11
8
3
1
1
18

*1 adherent to liver, 2 stenoses.
16 found at lipectomy.

FIG. 1—Vertical banded gastroplasty.
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later. One patient who regained an
unlimited eating capacity was found
endoscopically to have a breakdown in
the upper portion of the partition.
Subsequent Operations (Table III)
Of the 150 patients who still had gall
bladders, 13 (9%) had symptomatic,
small, yellow, cholesterol gallstones and
required cholecystectomy.9 Ten nar
rowed outlets were corrected by
endoscopic d ila ta tio n , and three
obstructed outlets required operation as
outlined above.
Excess Weight Loss
The percentage of excess weight lost is
shown in Table IV. Fifteen patients are
excluded because they could not be
located. Initially collars were 5.25 cm in
circumference, which likely accounts for
the slightly lower weight loss at 30 months
since this includes the earliest patients.
The difficult narrowings occurred mainly
in later collars less than 5.0 cm, and the
5.0 cm circumference has been utilized in
the majority of these patients. Table IV
includes six early patients who lost inade
quate weight and who had a revision.
Two had tighter collars placed through
the previous window, and four had new
windows cut cephalad to the previous
ones, against no. 28 French Maloney bou
gies. Care was taken to remain deep to
the vagi in threading the mesh. Two of
the six still failed to lose adequate weight.
One is bulimic and in the other we can
not find an explanation; endoscopically
the partition is intact. We believe that in
reoperations and in massively morbidly
obese people, 4.5 cm collars should be
used to approach ideal weight.
In addition to the patients in Table IV,
there were eight patients who underwent
vertical banded gastroplasty after failed
horizontal gastroplasties. Five success
Table Ill-Subsequent Operations
No. of
patients

Operation
Ventral hernia repair
Abdominal lipectomy
Cholecystectomy
Gastroscopy with dilatation
For outlet obstruction

17
57
13
10
3

fully lost weight, but one of them required
postoperative lysis of an omental constric
tion causing channel obstruction. Two
had a postoperative leak, resulting in
emergency rem oval o f the mesh,
prolonged gastrostomy decompression,
feeding jejunostomy and failure to lose
weight. Another had stenosis treated by
gastrogastrostomy over the vertical par
tition. These were hazardous operations,
and we believe that transfer of a failed
horizontal gastroplasty to a vertical
banded gastroplasty should rarely be
undertaken.
This study involved patients who
underwent vertical banded gastroplasty
with a follow-up of 12 months or longer.
In subsequent patients there has been one
breakdown in the centre of the partition
at 9 months (with almost full ability to
eat), and one stenosis treated at 11
months by severing the collar and sutur
ing a 1-cm length of mesh to the margins
over the gap. There have been no deaths
from the weight loss operations.
Discussion
Vertical banded gastroplasty has been
widely adopted as the operation of choice
for serious, intractable, morbid obesity.
The major hazard, fortunately quite rare,
is postoperative leak. It is heralded by
tachycardia, dyspnea, pallor and hypo
tension, and must be surgically corrected
promptly, before adult respiratory dis
tress syndrome or acute renal failure
supervenes. The area should be drained
by sump tubes, and a large decompres
sive gastrostomy on the greater curvature
of the antrum plus a feeding jejunostomy
should be established. If it produces an
obstruction distal to the leak, the Marlex
collar should be removed.
O f the late complications, outlet
obstruction may respond to dilatation
with Eder-Puestow, Savary or balloon
dilators. However, there is a limit to dila
tation and beyond that limit the Marlex
collar may appear in the lumen. With
obstruction, removal of the collar or per
formance of a gastrogastrostomy are
usually easy procedures in the now-thin
patient, but will almost always be fol
lowed by rapid gain of weight. If possi
ble, it is best to replace the collar or divide
it with suture of an intervening bridge
over a bougie (possibly no. 34 French).

Table IV-Percentage of Excess Weight Lost
Postop
follow-up, mo
12
18
24
30

Excess weight lost, % of patients

% of excess
weight lost
68
71
73
70

±
±
±
±

21
22
24
22

'Success - > 50% of excess weight lost.
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No. of patients

> 50% *

30-49%

217
146
87
31

80

13

83
-

12

_

Breakdown of the partition has been
rare but could be more frequent with
longer follow-up. It would appear that
division of the area and oversewing both
sides would be the procedure of choice,
but it carries a considerable potential
hazard.
Our small experience suggests that
transfer from a failed horizontal to a ver
tical partition gastroplasty is fraught with
danger. The crossing of staple lines and
the previously devascularized upper seg
ment of the greater curvature may result
in devitalized tissue. If a horizontal par
tition persists, a gastrogastrostomy, to
enable a vertical channel, is also
hazardous. A Roux-en-Y gastric bypass
may be the best procedure for failed
horizontal partitioning in carefully
selected patients.
As with carcinoma of the breast, duo
denal ulcer, portal hypertension and hia
tal hernia disease, the surgery for intrac
table m orbid obesity has been
developmental. It provides successful
weight loss and reversal of the serious fea
tures of morbid obesity in a high percen
tage of patients. Vertical banded gas
troplasty has been a relatively safe
procedure and weight loss so far has been
satisfactory.

Addendum
Follow-up o f the 86 patients who are now
beyond 3 years indicates that the weight loss
has been maintained. With 453 patients, we
have identified two more breakdowns of the
partition with regain in capacity to eat, interest
ingly following motor vehicle accidents.
Another stenosis was treated by cutting the
polypropylene sutures, freeing the anterior sur
face o f the Marlex collar and suturing the ends
of the collar together over a no. 34 French
bougie.
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Blood Transfusions and Survival
After Colectomy for Colorectal Cancer
This study was carried out to determine
the effect of perioperative blood transfu
sions on the survival of patients operated
on for colorectal cancers.
Cox's regression analysis was applied
to 281 patients operated for cure of
Dukes' stage A, B or C disease. Other
variables studied were age, sex, tumour
location, and preoperative hemoglobin,
lymphocyte and albumin values. Peri
operative deaths, pre- and postoperative
immunodepression, neoplasia in situ,
nonresections and stage D disease were
excluded.
It was found that the number of units
of blood transfused had a strong
influence on the prognosis of patients
with colorectal cancer, particularly
colonic cancers, but the effect could not
be demonstrated when rectal cancers
were studied separately, perhaps
because of the small number of cases.
The mechanism of action of blood
transfusions seems to be independent of
the other analysed variables. The authors
suggest that perioperative blood transfu
sions may have an immunomodulatory
effect in patients with colonic cancer, as
already shown in recipients of transfused
kidney allografts.

stade A, B ou C de Dukes. Les autres
variables 6tudi£es ont ete I'age, le sexe
et la localisation tumorale, ainsi que les
taux preoperatoires d'hemoglobine,
d'albumine et la numeration lymphocytaire. Les deces perioperatoires, les etats
d'immuno-depression pre- et postoperatoires, les cancers in situ, les interven
tions e visee noncurative et les stades D
ont ete exclus.
Les resultats ont montre que le nombre d'unites de sang administrees en
perioperatoire avait un effet pronostique
sans equivoque sur revolution des can
cers colo-rectaux. Cet effet est particulierement clair pour la population de can
cers coliques mais ii n'a toutefois pas pu
etre demontre au niveau des cancers rectaux etudies separement, peut-etre en
raison du petit nombre de cas soumis a
I'analyse a ce niveau.
Le m6canisme d'action des transfu
sions sanguines preoperatoires semble
etre independant des autres covariables
etudiees. II est possible qu'elles aient un
effet immunomodulateur chez les
patients operes pour cancer colique a
I'instar de ce qui a ete demontre chez les
receveurs d'allogreffe renale transfuses.

It is well established that transfusions
of whole blood or packed red cells
have a beneficial immunoregulatory
effect on the outcome of allograft survi
val in organ transplantation. Today, most
centres prepare their kidney recipients by
transfusing several units of blood before
grafting. Allograft survival is greatly
improved and the beneficial effect seems
to
be proportional to the number of units
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Cette etude a et6 realisee pour determi
ner I'effet des transfusions sanguines
p£riop£ratoires sur la survie des malades
operes pour cancer colo-rectal.
Des analyses de regression de Cox ont
ete appliquees a 281 patients ayant subi
une cure chirurgicale d'un cancer de

by Hyman and associates14 for colonic
and lung carcinoma respectively.
We present data on the survival of
patients operated on for colorectal
cancer, who received blood transfusions
perioperatively.
Patients and Methods
The medical records of all 587 patients
who underwent an operation for colorec
tal cancer at the Hopital Notre-Dame in
Montreal between 1962 and 1970 were
reviewed. Excluded were patients who
died within 1 month of the operation, pa
tients with immunodepressive conditions
(such as rheumatoid arthritis, renal in
sufficiency, diabetes, previous neoplasia
and amyloidosis, and those who had un
dergone chemotherapy, radiotherapy or
corticotherapy or were currently under
going such therapy), patients receiving ad
juvant therapy postoperatively, those
with carcinoma in situ, those who under
went a diagnostic or a palliative procedure
and all those with Dukes’ stage D disease.
Of primary concern was the number of
units of whole blood or packed red cells
that each patient received perioperative
ly during hospitalization.
The patients were divided into two
main groups: transfused and not trans
fused. For more specific analysis, the
number of transfusion units was divided
either into subgroups of 0, 1 to 2, 3 to
4, 5 or more units, or studied individually.
Other variables analysed were age, sex,
Dukes’ stage (A, B and C) tumour loca
tion (right, transverse, left [colon] and
rectum) and preoperative values of
hemoglobin (g/L) and serum albumin
(g/L) and the total lymphocyte count
(x 109/L).
Population distribution for each vari
able of the two main groups (transfused
and not transfused) was analysed by the
two-tailed Student’s t-test or X2 test.
Survival was defined as the time from
resection to death or the last follow-up
— a minimum of 5 years in all patients.
Death was considered in the analysis
only when it was due specifically to
colonic cancer; other causes were treated
as cases lost to follow-up.
325
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The transfused and nontransfused
groups and the transfusion-unit sub
groups were studied by the Mantel-Cox
log-rank test to compare single variables
and to draw actuarial survival curves.
Cox’s regression analysis was used for
multivariate adjustments for all covariates
studied simultaneously when the number
of blood units was analysed on an
individual basis.
Findings
O f the 587 patients, 281, operated on
for Dukes’ stage A (70 patients), B (118
patients) or C (93 patients) tumour, were
available for study after we had excluded
those who died perioperatively (57
patients), who had pre- and postoperative
immunodepression (67), neoplasia in situ
and no resection operation (178) and stage
D disease (178). (Some patients had more
than one exclusion criterion.)
Of those available for study, 236 (84%)

FIG. 1—Survival for Dukes’ stage A (70
patients), B (118 patients) and C (93 patients)
colorectal cancers (log-rank analysis) shows sig
nificant difference (p < 0.0001). Median
survival for stage A — more than 20 years,
B = 18 years, C = 4 years.

received transfusions, 45 (16%) did not.
Most of those who had transfusion
received whole blood, the rest received
packed red cells.
The transfused and the nontransfused
groups had similar distribution of age,
sex, stage, preoperative total lymphocyte
count and serum albumin levels, although
the last value was available in only 152
patients. However, patients with tumours
located in the left colon and rectum and
with lower hemoglobin levels preoperatively received more transfusions than the
others (Table I).
Analysis of survival (log-rank test), not
taking into account the transfusion vari
able, showed, as expected, a striking
difference in the evolution of stage A, B
and C cancers (p < 0.0001) (Fig. 1) and
rectal versus colonic cancers (right, trans-

FIG. 2—Survival for colonic (C, 199
patients) versus rectal (R, 82 patients) cancers
(log-rank test). Median survival for colonic
cancer was more than 20 years and for rectal
cancer 5 years. Difference is significant,
p < 0.0035.

verse and left) (p < 0.0035) Colonic
cancers, whatever the localization, had a
similar outcome (Fig. 2).
Log-rank comparison of the survival of
transfused versus nontransfused patients,
not taking into account other variables,
revealed a detrimental effect of transfu
sion (p < 0.02) (Fig. 3).
Comparison of the effect that the num
ber of blood units administered had on
patient outcome showed that the more
patients were transfused, the poorer was
their prognosis (p < 0.002) (Fig. 4).
When multivariate adjustment for all
covariates studied simultaneously (Cox’s
regression analysis) was applied to the
whole population (colonic and rectal

FIG. 3—Survival for transfused (T, 236
patients) versus nontransfused (NT, 45
patients) patients with colorectal cancer (logrank analysis) (p < 0.02). Median survival
for nontransfused patients was more than 20
years and for transfused patients 14 years.

Table I—Comparison of Variables for 236 Transfused and 45
Nontransfused Patients
Variables
Age, yr (mean ± SD)
Sex, % of patients
Male (n - 1151
Female (n - 166)
Dukes' stage, % of patients
A (n - 70]
B In - 118)
C (n = 93)
Tumour location, % of patients
Right (n - 39)
Transverse (n - 31)
Left (n = 129)
Rectum (n - 82)
Hemoglobin, g/Lt
(mean ± SD)
Total lymphocytes, X 109/Lf
(mean ± SD)
Serum albumin, g/L§
(mean ± SD)

Transfused, %
60.64 ± 10.71

Nontransfused, %

P value"

62.33 ± 10.38

NS

43
57

291
71}

NS

23
42
35

42

13.1
11.9
40.7
34.3

17.8)
6.7 I
23.3 f
2.2)

35.6)

!

NS

22.4 J

117.8 ± 26.9

125.5 ± 16.9

1.93 ± 1.04

1.94 ± 0.66

0.00001

0.01
NS

32.6 ± 7.8
34.0 ± 5.7
NS
"Two-tailed Student's f-test or X 2 test. t8 values missing. 128 values missing. SOnly 152 values
available.
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FIG. 4—Comparison of survival by number
of blood units received (log-rank analysis,
colonic and rectal cancers included). Median
survival was as follows: 0 units (45 patients)
= more than 20 years, 1 to 2 (117 patients) =
more than 20 years, 3 to 4 (66 patients) = 18.5
years, 5 or more (53 patients) = 4.5 years
(p < 0.002).
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cancers), the detrimental effect of blood
transfusions on survival was not observed
any more when the presence or absence
of blood transfusion was used as a varia
ble (p < 0.29). However, analysis by the

stage of the disease and location of the
tumour relative to the rectum gave highly
significant values (p < 0.0001 and
p < 0.002 respectively), all other varia
tions being insignificant (Table II).

Table II—Regression Analysis of Death Rates in 245 Patients With Dukes' Stages A, B
and C Colorectal Cancer With Respect to Presence or Absence of Blood Transfusion*
± SE

p value

0.18
-0 .0 0 0
0.03
0.6

0.18
0.01
0.10
0.14

0.29
0.9
0.7
0.0001

-0 .3 1
0.06
-0 .1 8
-0 .0 0 6

0.19

0.09
0.59
0.002
0.17
0.9

Correlation coefficient

Variable
Transfused versus nontransfused
Age
Sex
Stage
Location
Right versus left
Transverse versus right and left
Rectum versus colon
Preop hemoglobin
Preop lymphocyte count

-

0.11
0.06
0.004

0.000

0.000

*3 6 patients had missing values for preoperative hemoglobin or lymphocyte count. (Regression analy
sis including preoperative albumin level was done separately on 152 patients because of 129 missing
values.)

1+
C/3
m

Table Ill-Regression Analysis of Death Rate in 245 Patients With Dukes' Stages A, B and C
Colorectal Cancer With Respect to Number of Units of Blood Transfused*
Correlation coefficient

Variable

0.16
0.3
0.003
0.61

Transfusion units
Sex
Age
Stage
Location
Right versus left
Transverse versus right and left
Rectum versus colon
Preop hemoglobin
Preop lymphocyte count

-0 .2 7
0.05
-0 .1 1

0.000
0.000

p value

0.04
0.10
0.01
0.14

0.001
0.7
0.7
0.0001

0.19
0.19
0.06
0.004

0.14
0.6
0.09INS)
0.8
0.9

0.000

*3 6 patients had missing values for preoperative hemoglobin or lymphocyte count. (Regression analy
sis including preoperative albumin level was done separately on 152 patients because of 129 missing
values.)

Table IV—Regression Analysis of Death Rates in 171 Patients With Dukes' Stages
A, B and C Colonic Cancer With Respect to Number of Units of Blood Transfused*
Variable
Transfusion units
Stage
Sex
Age
|
x
Location
Preop hemoglobin
Preop lymphocyte count

Correlation coefficient

± SE

p value

0.19
0.46

0.06
0.20

0.005
0.01

NS

*2 8 patients had missing values for preoperative hemoglobin or lymphocyte count. (Regression analy
sis including preoperative albumin level was done separately on 100 patients because of 71 missing
values.)

Table V-Regression Analysis of Death Rates in 74 Patients With Dukes' Stages A, B
and C Rectal Cancer With Respect to Number of Units of Blood Transfused*
Variable
Transfusion units
Stage
Preop hemoglobin
Other variables

Correlation coefficient

± SE

p value

0.11
0.79
-0 .0 1

0.07
0.23
0.008

0.15
0.000 3
0.056
NS

*8 patients had missing values for preoperative hemoglobin or lymphocyte count. (Regression analysis
including preoperative albumin level was done separately on 33 patients because of 41 missing values.)

When the variable was the number of
blood units administered rather than the
presence or absence of a blood transfu
sion, there was again a significant effect
of this variable on the outcome (p <
0.001). The stage of the disease retained
its high prognostic value (p < 0.001), but
the tumour location lost its significance
(p < 0.09) (Table III).
The prognostic value of the number of
units transfused and Dukes’ stage
remained significant when rectal cancers
were excluded from the study (Table IV),
but the transfusion effect was lost when
rectal cancers were analysed separately
(Table V). In this group, Dukes’ stage
alone was significant while the preopera
tive hemoglobin value had a minimal
negative value.
The results were identical in all groups
when Cox’s regression analysis was
repeated for the 152 patients whose
preoperative albumin levels were availa
ble for study.
Discussion
The concept of a failing immune
response in the appearance or progression
of malignant tumours in humans is not
new. It appears that any event tending to
weaken immune defences can either
enhance the growth of a cancer or modify
the response to treatment.
It has been well demonstrated that
blood transfusions can induce an
immunomodulation in patients with
chronic renal insufficiency. Transplant
teams take advantage of this and prepare
future recipients of kidney allografts with
blood transfusions. The results are lessfrequent rejection episodes and better
graft survival.1-8 The mechanisms for
this immunoregulatory effect have been
described as a decrease of natural killer
cells, an increase of T-cell and monocytic
suppressor-cell activity and production of
anti-idiotypic antibodies against the T-cell
antigen-specific receptors.15-23
Because of the similarity between
histocompatibility and tumoral antigens,
Gantt24 proposed that blood transfusions
might also modify the immune response
in patients with cancer and consequently
enhance the production of tumour cells.
This hypothesis was verified by Francis
and Shenton9 in an animal model. They
showed that, in rats transfused with
allogeneic blood, the lymphocytic
response to mitogen stimulation was
depressed, plasma suppression activity
was increased and growth of a sarcoma
tous tumour injected subcutaneously was
enhanced. However, Jeekel and col
leagues,25 who injected rats intravenously
and subcutaneously with different types
of tumours, found that blood transfu
sions inhibited tumour growth.
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In humans, Burrows and T artter11
and then Agarwal and Blum berg12
recently suggested that blood transfusions
given perioperatively had a negative effect
on the recurrence-free intervals of patients
operated on for colo rectal" and
colonic12 cancers.
T artter
and
colleagues10 suggested a similar decrease
of the recurrence-free interval in patients
operated on for breast cancer, who
received blood transfusions periopera
tively. This last finding was not confirmed
by Foster and associates26 who studied
the effects of blood transfusions on sur
vival after surgery for breast cancer.
Ota and colleagues27 criticized Bur
rows and Tartter for including in their
study intra-abdominal colonic cancer as
well as rectal carcinoma. They argued
that, by doing so, the influence of tumour
location on the prognosis was not consi
dered. They suggested that when intra
abdominal colonic cancers are studied
alone, blood transfusions in the perioper
ative period have no deleterious effect on
survival. The outcome for patients with
rectal cancer in the same environment was
not a part of their study.
In a somewhat more-detailed statisti
cal study, Foster and associates13 showed
that survival of patients operated on for
intra-abdominal colonic cancer was far
worse if they had received transfusions,
whatever the stage of the disease. The
adverse effect persisted when the analy
sis considered age, stage, degree of
differentiation, cancer location within the
colon and preoperative hemoglobin level.
Although they did not include rectal car
cinoma per se, they suggested that trans
fusions had no adverse effects on survival
when tumours were located at this level.
The same g ro u p 14 also reported
decreased survival of patients with resec
tion for lung cancer, in conjunction with
transfusions.
We chose to study survival rather than
the recurrence-free interval of colorectal
cancer, since the exact time of recurrence
in cancer disease is difficult to determine
and subject to the time of follow-up. To
eliminate bias, we deliberately excluded
patients that were likely to suffer preoper
ative or postoperative immune depres
sion, as well as those who already had
metastatic disease (stage D). We decided
to submit to the analysis only those who
died of their colorectal cancer.
Our findings are generally in agreement
with those of Foster’s group. However,
no transfusion effect was found when
colorectal cancers were submitted to mul
tivariate analysis and when the transfu
sion variable was the absence or the
presence of perioperative blood adminis
tration, but the stage of the disease and
location of the tumour at the rectal level
had a strong prognostic effect on the out
come. In our study, it was the number of
328

units of blood administered that appeared
important. When all other variables are
controlled this adverse effect manifests
itself in the whole group of colorectal
cancers and in patients with colonic
cancer so that tumour location loses its
importance.
How does one explain that when rec
tal cancers are considered alone no trans
fusion effect is found even though these
patients received more units of blood than
those with colonic cancer (66% received
more than three transfusions compared
with 33% of colonic cancer patients)? It
may be that the timing of the transfusion
is important although we could find no
such indication. Perhaps, as suggested
recently by Wolmark and associates28
and Foster and colleagues,13 the biologic
behaviour of rectal cancer differs from
that of colonic cancer. It is also possible
that the negative prognostic value of the
rectal location is due partly to the multi
ple transfusions that are required for
cancer resection at this level. However,
the number of cases submitted for anal
ysis might have been too small to reach
any valid conclusions. That perioperative
blood transfusions have an adverse effect
on the evolution of colonic cancer is well
demonstrated in our study and in
others,13 but the exact nature of this
relationship remains to be defined.
It has been claimed that patients who
needed blood transfusion for their oper
ation were either more chronically ill or
underwent a more extensive procedure
with concomitant tumour manipula
tio n .13-14'27 Our data do not support this
hypothesis since our study was adjusted
for age, stage, preoperative hemoglobin
level, lymphocytosis and albumin level
and since patients who were
immunodepressed pre- and postoperatively were excluded. Moreover, the most
extensive and time-consuming operations
were performed on patients with rectal
cancer,
m ost
of
whom
had
abdominoperineal resection. In this
procedure perioperative isolation of the
tumour is usually impossible and, conse
quently, intraoperative dissemination of
tumour cells is more likely. Yet in this
group the transfusion effect did not
m anifest itself; also, preoperative
hemoglobin levels were highest in this
group. Finally, the exclusion of perioper
ative deaths should have eliminated most
of the “ surgical risks” of the study.
Colonic Cancers
In contrast, our colonic cancer popu
lation was quite homogeneous with
respect to all covariates studied and the
type of operation performed. Regardless
of the number of transfusions, survival
was the same whether cancers were
located in the right, transverse or left
colon.

It has also been proposed that as-yetunidentified viruses could be transmitted
by the blood products and induce a subclinical state of infection, leading to sup
pression of the immune response.14
It is tempting to attribute the deleteri
ous effect of blood transfusion on sur
vival in patients operated on for colonic
cancer to the same immunoregulating
mechanisms that have been demonstrated
in organ transplantation. But this also
remains to be proven. Clearly more exten
sive, randomized, prospective studies are
needed, ones that would, for example, use
washed or frozen red cells, known for
their lack of leukocytes that are the
histocompatibility antigens responsible
for HLA isosensitization,29 studies using
autologous blood transfusion when pos
sible, studies of the relationship of blood
transfusions and cancer development in
the transfused transplantation patients
and in others at risk.
Conclusion

Whatever the mechanisms involved, we
can only conclude that the number of
perioperative blood transfusions has a
strong negative influence on the progno
sis for patients operated on for the cure
of a colonic cancer and that the same
deleterious effect was not demonstrated
in patients operated on for rectal cancers,
when studied separately.
We thank Francine Fugere, Johane Trahan
and Guy Jean for their technical assistance in
compiling the data.
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SESAP V Question
Item 228

Which o f the following statements about aneurysms o f the thoracic aorta
is TRUE?
(A)

Atherosclerotic aneurysms are associated with other intra- and
extrathoracic aneurysms in 15% to 40% o f patients

(B)

Aneurysms o f the ascending aorta are usually atherosclerotic

(C)

The chest roentgenogram is diagnostic

(D)

Ascending aortic aneurysms are usually associated with chest or back pain

(E)

Myocardial infarction is the most common cause o f death among pa
tients with ascending aortic aneurysm who are not operated on

For the critique of Item 288 see page 387.

(Reproduced by permission from SESAP V Syllabus; Surgical Education and
Self-Assessment Program No. 5. For enrolment in the Surgical Education and
Self-Assessment Program No. 5, please apply to the American College o f Sur
geons, 55 East Erie St., Chicago, IL 60611.)
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Efficacy of Isolated Profundaplasty
Profundaplasty has been advocated as
an outflow procedure for threatened
failure of aortobifemoral grafts as well as
a primary procedure for severe claudica
tion and limb ischemia. The authors
reviewed their experience with 27
patients who underwent profundaplasty
between 1978 and 1983; five patients
(group 1) were treated for threatened or
complete aortofemoral graft thrombosis
while 22 patients (group 2) underwent
profundaplasty as an isolated procedure
to treat limb ischemia. Preoperative
angiograms were assessed for the
presence of five criteria associated with
a favourable result from profundaplasty:
stenosis of the orifice of the deep
femoral artery greater than 50%;
minimal disease of the distal artery;
disease-free collaterals; reconstitution of
a patent superficial femoral or popliteal
artery; good popliteal outflow with at
least one vessel patent to the foot.
Profundaplasty was successful in 100%
of group 1 patients but relieved symp
toms or healed lesions in only m-% of
those in group 2. In the latter group
64% required major amputation. The
number of favourable angiographic
criteria was similar in both groups. Iso
lated profundaplasty for limb salvage is
not recommended. Angiographic criteria
do not reliably identify the few patients
who will benefit from profundaplasty

From the Department o f Vascular Surgery,
University o f Chicago, Chicago, Ili.
Presented at the 7th annual meeting o f the
Canadian Society fo r Vascular Surgery held
in conjunction with the 54th annual meet
ing o f the Royal College o f Physicians and
Surgeons o f Canada, Vancouver, BC, Sept.
12, 1985
Accepted fo r publication Dec. 16, 1985
Reprint requests to: Dr. A.M. Graham,
Rm. S8-30, Division o f Cardiovascular and
Thoracic Surgery, Royal Victoria Hospital,
687 Pine A ve. W, Montreal, PQ H3A 1A1
330

alone. The principal role of the procedure
is increasing outflow for an aortic graft.
II a 6te recommande d'effectuer une
plastie de I'artere femorale profonde pour
retablir la circulation quand il y a menace
d'obstruction d'un pontage aortobifemo
ral, de meme qu'en premiere intention
dans la claudication grave et I'ischemie
des membres inferieurs. Les auteurs passent en revue leur experience chez
27 patients qui ont subi, entre 1978 et
1983, une plastie d'une artfere femorale
profonde. Cinq patients (le groupe 1) ont
6t6 traites pour menace de thrombose ou
thrombose totale d'un pontage aortofe
moral; 22 patients (le groupe 2) ont eu
une plastie d'une artere profonde comme
intervention isolee pour traiter I'ischemie
d'un membre. Les angiogrammes preoperatoires ont et6 evalues selon cinq criteres relics a un resultat favorable de
I'opgration de plastie: st£ose de plus de
50% de I'orifice de I'artere femorale pro
fonde; atteinte minimale de I'art&re dis
tale; collaterales intactes; reconstitution
d'une artere femorale superficielle ou
d'une artere poplitee permeable; bonne
circulation poplitee avec au moins un
vaisseau permeable vers le pied. La plas
tie de I'artere femorale profonde a reussi
dans 100% des cas du groupe 1, mais
n'a pu soulager les symptomes ou corriger les lesions que dans 14% de ceux du
groupe 2. Dans 64% des cas du dernier
groupe on a dO avoir recours a une
amputation majeure. Le nombre de e n ti
res angiographiques favorables etait similaire pour les deux groupes. La plastie de
I'artere femorale profonde n'est pas
recommandee comme traitement de pre
miere intention pour sauver un membre
menace par I'ischemie. Les entires
angiographiques ne permettent pas de
s6lectionner de fa^on sure les quelques
patients susceptibles de b£n£ficier d'une
plastie seule. Le rble principal de cette
intervention consiste a augmenter la cir
culation dans une greffe aortique.

Profundaplasty has been advocated to
restore the patency o f thrombosed aor
tofemoral grafts and increase the lon
gevity o f threatened graft limbs.1,2 The
procedure has also been used as a primary
operation in other patients with superfi
cial femoral artery occlusions who are
suffering severe claudication, rest pain or
ischemic ulcers.3-6
Our purpose in this study was to assess
whether profundaplasty done as an “ iso
lated” procedure reliably relieves rest pain
or leads to healing o f ischemic ulcers. We
also wished to evaluate the strength of
an giograp hic
criteria
previously
identified7 as predictors of the success of
profundaplasty to determine if there is a
subset o f patients who can be expected to
benefit from the procedure.

Patients and Methods
We performed 27 “ isolated” profundaplasties between 1978 and 1983.
Patients, divided into two groups by clin
ical presentation, included 22 women and
5 men with an average age o f 67.8 ± 4.7
(SEM) years. In group 1 were five patients
treated for thrombosis of aortofemoral
grafts (two) or threatened graft thrombo
sis (three). Group 2 comprised 22 patients
who underwent profundaplasty for limb
salvage. Seven of 22 patients had severe
rest pain, 3 had ischemic ulcers with rest
pain and 12 patients had distal areas of
gangrene. Profundaplasty was not per
formed for claudication alone, although
it was a common symptom. There were
no diabetics in group 1 compared with 12
(55%) in group 2. Age, other medical
problems and clinical presentations were
otherwise similar in both groups.
All patients underwent noninvasive
measurements of lower extremity segmen
tal pressure preoperatively and postoperatively. A good clinical result was defined
as relief of rest pain or healing of ischemic
ulcers. Preoperative angiograms were
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reviewed and the presence of the follow
ing indicators was assessed:7 (a) severe
stenosis (more than 50%) of the deep
femoral artery orifice (Fig. 1); (b)
minimal occlusive disease of the distal
artery; (c) disease-free collaterals of the
deep femoral artery; (d) reconstitution of
a patent superficial femoral or popliteal
artery; (e) good popliteal outflow with at
least one vessel patent to the foot. Each
angiogram was graded in a blinded
fashion, with a score of five indicating
that all of the above criteria were present.
Figure 2 shows the type of deep femoral
artery lesion that appears amenable to
profundaplasty. Note the tight stenosis at
the orifice of the left deep femoral artery

and the subsequent delay in flow through
its bed, compared with the arterial tree
on the right side.
The technique of profundaplasty was
as follows: the deep femoral artery was
dissected to at least its second branch. An
arteriotomy beginning at the common
femoral artery was extended at least 5 cm
down the deep femoral artery. An endar
terectomy was then performed using 2.5
x magnification loupes and followed by
a patch angioplasty. Prosthetic patches
were used in all group 1 patients. Opera
tions in 16 of the 22 group 2 patients uti
lized patches of autologous tissue
(saphenous vein in 12 or endarterectomized superficial femoral artery in 4).
Statistical analysis utilized Student’s /-test
for unpaired data; p < 0.05 was consi
dered significant.
Results

FIG. 1—Angiogram demonstrating severe
stenosis at origin of deep femoral artery with
involvement of distal vessel.

FIG. 2—Aortogram reveals delayed flow
through stenotic left deep femoral artery sys
tem compared with non-diseased right vessel.

There were no deaths in the immedi
ate postoperative period. All group 1
patients experienced good clinical results
in the follow-up period (mean 5.9 years),
and the grafts remained patent. Group 2
patients had a limb salvage rate of only
36%; 14 (64%) underwent major ampu
tations in the follow-up period (mean 4.3
years). The average time between surgery
and amputation was 2.3 months. A fur
ther five (22%) patients had no relief of
the ischemic symptoms. Thus, only three
(14%) patients had good clinical results,
defined as healing of ischemic ulcers or
relief of rest pain.
Ankle-brachial pressure indices were
measured preoperatively and postoperatively. In group 1, the mean index rose
from 0.30 ± 0.18 to 0.44 ± 0.16 (p
< 0.05). No change in index was noted
(0.29 ± 0.22 to 0.30 ± 0.23 [NS]) in
group 2 patients.
Angiographic criteria were analysed for
all patients. The average preoperative
angiographic score of group 1 patients
was 3.8 compared with 3.3 in group 2
patients (NS). The three patients in group
2 with good results all had ischemic ulcers
and patent popliteal arteries. Their
ankle-brachial pressure indices changed
from 0.23 preoperatively to 0.47
postoperatively. However, there were two
other patients in group 2 with all five
favourable angiographic criteria who had
no relief after isolated profundaplasty.
Another point of interest is the high
female to male ratio (4:1) of our popula
tion, as opposed to most other
series1,2,4'6'8 in which males predomi
nated. The reason for this is not clear as
it does not conform to our overall
experience in vascular practice.
Discussion

Profundaplasty is accepted as an

important procedure to ensure patency of
an inflow graft in the presence of
advanced superficial femoral artery dis
ease. It has been shown that both the
patency of the proximal graft1 and the
relief of symptoms9 are higher when
profundaplasty is performed in conjunc
tion with aortofemoral bypass. Goldstone
and colleagues1 reported a 5-year aor
tofemoral bypass patency rate of 93%
when deep femoral patch angioplasty was
performed in conjunction with aor
tofemoral grafting. Our small series cer
tainly confirms this belief, as all five
patients in group 1 experienced relief of
symptoms and had patent grafts during
the follow-up period.
The controversy over the benefits of
profundaplasty arises when the procedure
is used without inflow grafts. When per
formed for claudication several groups
have reported good results with profun
daplasty alone. Cotton and Roberts6
noted a 92% improvement in walking dis
tance in patients whose primary com
plaint was claudication, while MorrisJones and Jones10 reported 50% success
among their group of claudicants. The
results of isolated profundaplasty for
limb salvage are not as impressive. In
1981, Towne and associates8 reported a
limb salvage rate of only 57% at 1 year
for profundaplasty in patients with
impending loss of limb. Morris-Jones and
Jones10 reported a similar 33% success
rate in patients with severe ischemia. In
our hands, isolated profundaplasty
allowed a 36% limb salvage rate but only
14% of patients obtained relief of
symptoms.
In sharp contrast are the results of
Leather and colleagues3 who reported
limb salvage in 79% of patients who
underwent profundaplasty for tissue
necrosis and 90% of patients treated for
rest pain. In reviewing this series, it is evi
dent that the procedure varied consider
ably from ours in that 40 of the 62
patients underwent concomitant iliac or
common femoral endarterectomy in addi
tion to profundaplasty.
Mitchell and colleagues7 suggested
specific arteriographic criteria that would
predict a successful outcome from
profundaplasty. It is uncontested that the
presence of these five criteria produce an
optimal situation for the procedure, but
the number of patients meeting these
criteria is limited. In fact, the criteria
would be equally favourable to the per
formance of femoropopliteal bypass.
Finally, the predictive value of these find
ings is questionable. In our series, there
was no statistical difference in the num
ber of favourable angiographic criteria
between groups 1 and 2.
A single criterion, patency of the
popliteal artery, correlates with results of
profundaplasty in a number of ser-
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ies.4’5-11 In the review by Cotton and
R oberts6 a successful outcom e o f
profundaplasty was achieved in 81% of
patients with patent popliteal arteries and
trifurcation vessels. Poor opacification of
the trifurcation and especially poor fill
ing o f the tibial arteries at the level of the
middle calf were usually associated with
failure. In our patients requiring limb sal
vage, only 6 of the 22 had patent popliteal
arteries. Three patients who responded
well were among this minority, reinforc
ing the belief that this criterion may be
the most reliable predictor.

Conclusions
An isolated profundaplasty is a desira
ble procedure in patients with threatened
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continued from page 302
are repeated throughout the book, particularly
in the chapters dealing with complications of
pelvic ring disruptions and management of
acetabular fractures.
High-quality diagrams and numerous large
x-ray films of example cases support all expla
nations. Repetition, the use of clear English,
and the logical and interesting presentation of
the material will enhance the reader’s under
standing of the subject.
In conclusion, I highly recommend this text
book which I predict will be a frequently used
reference for orthopedic residents and surgeons
involved in managing multiply injured patients
with pelvic disruptions.

J acques A. Brunet , md , frcsc
Division of Orthopedics,
Ottawa General Hospital,
Ottawa, Ont.,
K1H 8L6
ORGAN PROCUREMENT. Proceedings of
the First International Congress on Organ
Procurement, April 14-16, 1983. Maas
tricht, The Netherlands. A Transplantation
Proceedings Reprint, February 1984.
Edited by G. Kootstra, B. Husberg and
J.A . van der Vliet. 317 pp. Illust. Grune
& Stratton, Inc., Orlando, Fla.; Academic
Press Canada, Don Mills, Ont., 1984.
$100.75. ISBN 0-1279-2344-6.

This book comprises papers presented at the
First International Congress on Organ Procure
ment held in April 1983 in Maastricht, The
Netherlands. It is the hard-cover edition of the
February 1984 issue of Transplantation
Proceedings and follows the usual format of
this journal’s publications—short, wellreferenced papers on a specific basic science
or clinical topic. The papers represent contri
butions from over 200 participants of the meet
ing from 21 countries and all continents.
The papers address topics that are grouped
under the following headings: living-related
organ donation; diseases transmitted by trans
planted organs; donor management; criteria
for choosing donors; legal aspects of organ
procurement; harvesting techniques (including
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limb loss and a stenotic femoral anasto
mosis or a recently occluded aortofemoral
graft limb. In patients at risk o f limb loss,
associated with extensive untreatable aortoiliac disease, isolated profundaplasty is
o f little benefit. In patients with such
advanced disease, angiographic criteria
have limited true predictive value.
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a separate section on multiple-organ procure
ment; and complications of retrieval and
preservation.
Most papers are clinical reports, but a hand
ful are experimental studies examining various
preservation methods and cytoprotective drugs
in renal, pancreatic, cardiac and liver preser
vation. Several centres from both sides of the
Atlantic report their experiences of the removal
and use of multiple organs from single
donors—a practice that has increased dramat
ically in recent years—and the satisfactory
function of the transplanted organs. All the
papers on transplantation of the pancreas deal
with grafting o f solid organs without any
reports on islet cell transplantation. The papers
by Stuart on the need for, supply of and legal
issues related to organ transplantation and the
one by Pegg on the future of organ preserva
tion are particularly good.
As would be expected, there is considerable
overlap and some repetition, but the papers
cover the topic of organ procurement quite
thoroughly. A noteworthy feature of the text
is the inclusion, after several sections, of an
invited commentary that provides a summary
and puts the material into perspective.
The print, paper and binding are of excel
lent quality. The one glaring typographical
error (repeated both in the contents and at the
beginning of the section) is the use of the word
“ Unrelated” when it should read “ Living
Related Organ Donation” .
The book will interest clinicians (surgeons
and nonsurgeons) involved in organ transplan
tation and, to a lesser extent, those experiment
ing in organ preservation.

W illiam J. W all , md , frcsc
Department of Surgery,
University Hospital,
339 Windermere Rd.,
London, Ont.,
N6G 2K3
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ties on the increasingly complex interrelation
ships between micro-organisms and man.
The first half of the text is concerned with
the epidemiology and pathogenesis of septic
shock. Several chapters detail microbial fac
tors in pathogenesis, host factors, including the
complement system and polymorphonuclear
leukocytes, and the mechanisms of vascular
injury in sepsis. The acute pulmonary lesion
is discussed in depth. Again, increased pulmo
nary capillary permeability is acknowledged to
be the cause and this, in some cases, is related
to aggregation of leukocytes on the pulmonary
endothelium. How activation occurs and what
is released remains unclear.
The rationale for use of opioid antagonists
such as naloxone is explained, but clinical trials
are needed to establish their efficacy.
The last half of the book covers issues of
direct clinical concern and is introduced by an
excellent chapter on the newer methods in
microbial diagnosis. It is noteworthy that the
introduction of new antibacterial compounds
over the past decade has not caused any major
changes in the treatment of blood-stream infec
tions or a major improvement in death rates.
Emphasis is shifting to augmentation of host
resistance to improve survival. The author of
the chapter on steroids in septic shock favours
their use, at least selectively, but all await the
results of definitive, prospective randomized
trials.
Although much has been learned about sep
tic shock since the first clear descriptions in the
early 1950s, this text emphasizes how little is
clinically applicable, how few are the controlled
clinical trials, how great are interspecies differ
ences in reactions to sepsis and how specula
tive are the conclusions of most of the chap
ters in this text.
This volume will be of greatest interest to
physicians and microbiologists with a strong
commitment to research in shock and sepsis.

L loyd D. M acL ean , md
SEPTIC SHOCK. Contemporary Issues in
Infectious Diseases. Vol. 4. Edited by
Richard K. Root and Merle A. Sande. 281
pp. Churchill Livingstone, Edinburgh;
Academic Press Canada, Don Mills, Ont.,
1985. $61. ISBN 0-443-08397-5.

This text consists of 17 chapters by authori

Co-editor.
Surgeon-in-Chief,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ,
H3A 1A1
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W h en you w ant an effective antibiotic at all costs.
But not at any price.
During the critical 24 to 48
hour wait for susceptibility tests,
you need an antibiotic with a clini
cally proven spectrum of activity.
An antibiotic with an excellent rec
ord of safety. An antibiotic such
as Cefobid*
When cost must also be
considered, Cefobid* remains an
antibiotic of choice. Its realistic

pricing structure and economical
twice-a-day dosage make
Cefobid* cost-effective therapy.12
Cefobid* is an advanced
cephalosporin proven effective
against a wide range of infections.
It is very well tolerated. With a
unique dual pathway of excretion,
Cefobid* at usual dosage requires
no modification of dosage in
patients with renal impairment.
Cefobid* Effective antibiotic
therapy you can well afford to use.

K irk la n d , Q u e b e c
H 9 J2 M 5
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cefoperazonesodium/pfizer

IV/IM

First-line parenteral antibiotic

First-line parenteral antibiotic therapy
Prescribing Information
Antibiotic
For Intravenous or Intramuscular Injection
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium)
results from the inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following
infections when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, Kleb
siella species (including Klebsiella pneumoniae), Pseudomonas aeruginosa, Escheri
chia coli, Proteus mirabilis, indole-positive Proteus species and Enterobacterspedes.
URINARY TRACT INFECTIONS caused by Escherichia coli, Pseudomonas aeruginosa,
Enterobacter species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylo
coccus aureus, Staphylococcus epidermidis and indole-positive Proteus species.
Due to the nature of the underlying conditions which usually predispose patients
to Pseudomonas infections of the lower respiratory and urinary tracts, a good clini
cal response accompanied by bacterial eradication may not be achieved despite
evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHO
LANGITIS caused by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Strep
tococcus agalactiae, Escherichia coli and Klebsiella species
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus
aureus, Streptococcus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND
ENDOMETRITIS) caused by Streptococcus agalactiae, Neisseria gonorrhoeae,
Escherichia coli, Bacteroides species (including Bacteroides tragiiis), Peptococcus
species and Peptostreptococcus species.
Specimens for bacteriologic culture should be obtained prior to therapy in order to iden
tify the causative organism and to determine its susceptibility to CEFOBID (cefoperazone
sodium). Therapy may be instituted before results of susceptibility testing are known;
however, modification of the treatment may be required once these results become
available.
CONTRAINDICATIONS; CEFOBID (cefoperazone sodium) is contraindicated in patients
with known allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hypersensi
tivity reactions to cephalosporins, penicillins or other drugs. CEFOBID (cefoperazone
sodium) should be administered with caution to penicillin-sensitive patients or to any
patient who has demonstrated some form of allergy, particularly to drugs. If an allergic
reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of
the drug and treat the patient with the usual agents (e.g. epinephrine, antihistamines,
pressor amines or corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of
CEFOBID (cefoperazone sodium). Therefore, in those patients administered CEFOBID
(cefoperazone sodium) who develop diarrhea, it is important to consider such a
diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone
sodium) alters the normal flora of the colon and may permit overgrowth of Clostridia.
Studies indicate that a toxin produced by Clostridium difficile is one primary cause of
antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte, and protein supplementation as indica
ted. When the colitis is not relieved by the discontinuance of CEFOBID (cefoperazone
sodium) or when it is severe, consideration should be given to the administration of oral
vancomycin.
PRECAUTIONS
General: The concomitant ad ministration of aminoglycosides and some cephalosporins
has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine
have been observed, there is no evidence that CEFOBID (cefoperazone sodium) when
administered alone causes significant nephrotoxicity. However, the effect of ad
ministering CEFOBID (cefoperazone sodium) concomitantly with aminoglycosides is not
known.
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal
volunteers, 19 to 41% of the dose is excreted in the urine, the remainder being excreted
by the hepato biliary system. The serum half-life of CEFOBID (cefoperazone sodium) is
usually prolonged and urinary excretion of the drug increased in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in these patients treated with doses in excess of 2 grams daily and dosage
should be adjusted as necessary.
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2 to 4 grams (1 to 2 grams every 12 hours) are administered. If higher doses of CEFOBID
(cefoperazone sodium) are used, serum concentrations of cefoperazone should
be monitored. If there is evidence of accumulation, dosage should be decreased
accordingly.

In one study in patients with chronic renal failure, the half-life of CEFOBID (cefopera
zone sodium) was reduced from 4.17 to 1.67 hours during hemodialysis. Thus, dosing
should be scheduled to follow a dialysis period.
In patients with both hepatic dysfunction and renal impairment, the initial dosage of
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum con
centrations of cefoperazone should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID
(cefoperazone sodium). The mechanism is most probably related to the suppression of
gut flora which normally synthesizes this vitamin. Those at risk include patients with
poor diet or malabsorption states (e.g. cystic fibrosis) and patients on prolonged intrave
nous alimentation regimens. Prothrombin time should be monitored in these patients
and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been
reported when alcohol is ingested during and as late as the fifth day after CEFOBID
(cefoperazone sodium) administration. Patients should be cautioned concerning inges
tion of alcoholic beverages in conjunction with administration of CEFOBID (cefoperazone
sodium). For patients requiring artificial feeding orally or parenterally, solutions con
taining ethanol should be avoided.
CEFOBID (cefoperazone sodium) should be administered with caution to individuals
with a history of gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of
CEFOBID (cefoperazone sodium). Patients should be observed carefully during treat
ment. If superinfection occurs, appropriate measures should be taken.
Drug Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's
solution.
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been
established. The use of CEFOBID (cefoperazone sodium) in pregnant women requires
that the likely benefit from the drug be weighed against the possible risk to the mother
and fetus.
Reproduction studies have been performed in mice, rats and monkeys at doses up to
10 times the human dose and have revealed no evidence of impaired fertility or teratoge
nic effects due to cefoperazone sodium. Animal reproduction studies, however, are not
always predictive of human response.
Nursing Mothers: Cefoperazone is excreted in low concentration (0.4 to 0.9 >»g/mL) in
human milk. Caution should be exercised when CEFOBID (cefoperazone sodium) is
administered to a nursing mother.
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not
been established.
ADVERSE REACTIONS
Hypersensitivity: Maculopapular rash, urticaria, pruritis, eosinophilia, drug fever.
Hematology - Decreases in hemoglobin and/or hematocrit have occurred. Slight
decreases in neutrophil count have been reported, and reversible neutropenia may occur
with prolonged administration. Transient eosinophilia has occurred. Hypoprothrombinemiahas been observed. Some individuals have developed positive direct Coombs’ test
during treatment.
Liver — Transient elevations in SGOT, SGFT and alkaline phosphatase levels have been
noted. One patient with a history of liver disease developed significantly elevated liver
function enzymes during therapy with CEFOBID (cefoperazone sodium). Clinical signs
and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID
(cefoperazone sodium) therapy was discontinued, the patient's enzymes returned to pre
treatment levels and the symptomatology resolved.
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been
noted.
Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported.
Most of these events have been mild or moderate, but some have been severe. In all
cases, these symptoms responded to symptomatic therapy or ceased when
cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Pseudomembranous colitis has been reported rarely in patients administered
CEFOBID (cefoperazone sodium). Symptoms of pseudomembranous colitis can appear
during or for several weeks subsequent to antibiotic therapy.
Disulfiram-like Reaction
Disulfiram-like reactions have been reported when alcohol was ingested during and as
late as the fifth day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intra
muscular administration. Occasionally, transient pain may follow administration by this
route. When CEFOBID (cefoperazone sodium) is administered by the intravenous route,
some patients develop phlebitis at the site of administration.
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone
sodium), no specific information on symptoms or treatment of overdosage is available.
Treatment should be symptomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
Dosage
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
Dosage and route of administration should be determined by severity of infection,
susceptibility of the causative organism, and condition of the patient
Adult
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams ad
ministered in equally divided doses every 8 to 12 hours (See table below). The usual
duration of treatment is 7 to 14 days.
Adult Dosage
Type ol Infection
Daily Dose
Frequency and Route
Mild to moderately severe
2 to 4 grams
1 to 2 grams
infections such as pneumonia,
every 12 hours
acute urinary tract infection,
I.M. orl.V.
wound infection

Severe infections or infections
caused by less sensitive
organisms

4 to 8 grams

2 to 4 grams
every 12 hours
IV.

Infections commonly requiring
9 grams
3 grams every
antibiotics in higher dosage
8 hours I.V.
(e.g. septicemia and life threatening
infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should be continued for
at least 10 days.
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult
patients with renal failure usually require no adjustment in dosage when daily doses of
2 to 4grams (1 to2 grams every 12 hours) of CEFOBID (cefoperazone sodium) are admin
istered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra
tions of cefoperazone should be monitored. If there is evidence of accumulation, dosage
should be decreased accordingly. For patients whose glomerular filtration rate is less
than 18 mL/minorwhose serum creatinine level is greater than 3.5 mg/dL, the maximum
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day.
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis
period.
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be
monitored in patients treated with doses in excess of 2 grams daily and dosage should
be adjusted as necessary.
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial
dosage of CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and
serum concentrations of cefoperazone should be closely monitored.
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been
established.
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular
injection into a large muscle mass such as the gluteus maximus or anterior thigh. The
maximum dose of CEFOBID (cefoperazone sodium) should be two (2) grams.
Intravenous:
Direct Intravenous (bolus) injection: The reconstituted solution should be injected
slowly over a period of no less than three (3) minutes. The maximum dose of
CEFOBID (cefoperazone sodium) should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a
period of 15 minutes to 1 hour through the tubing of an administration set while any
of the intravenous solutions (See Solutions for I.V. Infusion) are being infused. During
infusion of the solution containing CEFOBID (cefoperazone sodium), it is desirable to
temporarily discontinue administration of the other solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be
administered over a longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination
with an aminoglycoside antibiotic, each should be administered at different sites
because of a physical incompatibility. An aminoglycoside should not be mixed with
CEFOBID (cefoperazone sodium) in the same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7- [ (R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2(p-hydroxyphenyl) acetamido]-3[ [ (1-methyl-1H-tetrazol-5-yl)thio] mettiyl]-8-oxo5-thia-1- azabicyclo[4.2.0] oct-2-ene-2-carboxylate

Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________(m l)
Volume (m l)____________ (mg/mL)______
1.0
3.5
4.0
250
2.0 __________TO ________________ 8 5 __________________ 250
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to
allow any foaming to dissipate in order to permit visual inspection for complete solubili
zation. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID
(cefoperazone sodium).
For Intravenous Use:
Solutions lor Reconstitution and Dilution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)____________ (mL)___________ Volume (mL)___________ (mg/m l)_______
1
95
105
100
2____________ 1 9 5 _______________ 2 0 5 _________________ 100__________
Shake well until dissolved. The prepared solution may be further diluted to the desired
volume with any of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above.
For intermittent intravenous infusion: Reconstitute as directed above.
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The
reconstituted solution may be added to an appropriate intravenous bottle/bag containing
any of the solutions for I.V. infusion listed below:
Solution for I.V. Infusion
5% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection
5% Dextrose and 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.2% Sodium Chloride Injection (USP)
10% Dextrose Injection (USP)
Lactated Ringer’s Injection (USP)
0.9% Sodium Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection
Normosol® R
Stability of Solutions
Storage:
Reconstituted solutions fo r intramuscular injection should be used within 24 hours if
kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours
if kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein
hydrolyzates, or amino acids. CEFOBID (cefoperazone sodium) should not be mixed
together with an aminoglycoside.
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1.0 g vial — cefoperazone 1.0 g as sodium salt
2.0 g vial — cefoperazone 2.0 g as sodium salt
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and
refrigerated (2 to 8° C).
References'
1. Carlin, H.S., M.Sc and Romankiewicz, J.A., Pharm. D., The New York Hospital
- Cornell Medical Center, New York, N.Y.: ‘The impact of dosage regimen on
intravenous drug costs", presented as a scientific exhibit at the Mid-year Clinical
Meeting of the American Society of Hospital Pharmacists, New Orleans, Louisiana,
December 6-10,1981.
2. Based on costs compiled at a large Canadian hospital in Montreal, 4th Qtr 1983.
* Prepared by Pfizer Canada Inc. (R.U.)
Pfizer Inc. TM Owner.
© Pfizer Canada Inc. 1986

Molecular Formula: C!5FI26Ns0ES!Na Molecular Weight: 667.65
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol,
poorly soluble in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane.
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The
sodium content of each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion).
The pH of a 25% (w/v) solution is 4.5 to 6.5 and the solution is colorless to straw yellow
depending on the concentration.
RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
0.5% Lidocaine Hydrochloride Injection
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Assessment of Vibration White Finger Syndrome
The degree of Raynaud's phenomenon
due to the use of vibrating tools is
difficult to assess because of the epi
sodic nature of the attacks and the pau
city of vascular and neurologic signs
between attacks.
Ninety-two loggers, miners and other
workers using vibrating tools and
experiencing Raynaud's phenomenon
were examined at the Vancouver General
Hospital between 1982 and 1985.
Details of history, symptoms and occu
pation were obtained. The majority of
workers had loss of sensation in their
hands to pinprick, and the extent of this
correlated closely with the severity of
symptoms, a correlation not previously
described. In 16 subjects the loss of sen
sation was proximal to the level of
symptoms, in 50 at the same level and
in 23 distal. In three the correlation was
unknown.
The severity of the vibration white fin
ger syndrome was assessed using the
classification of Taylor. Four workers
were placed in stage 1 (occasional blan
ching of fingertips, with or without tin
gling or numbness). 30 in stage 2
(blanching of one or more fingers with
numbness in cold weather), 36 in stage
3 (frequent finger blanching affecting
most digits) and 22 in stage 4 (as stage
3 but symptoms so severe that manual
work is difficult and vibrating tools can
not be used). The correlation of symp
toms with loss of sensation to pinprick
was useful in assessing the severity of
the syndrome and in the classifying of
claimants for Workers' Compensation
Boards.
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La gravity de la maladie de Raynaud cau
sae par ('utilisation d'outils vibratoires
est difficile k evaluer du fait de la nature
6pisodique des crises et du peu de
signes vasculaires et neurologiques entre
ies attaques.
Quatre-vingt-douze bucherons, mineurs
ou autres travailleurs utilisant des outils
vibratoires qu souffraient de maladie de
Raynaud ont ete examines au Vancouver
General Hospital entre 1982 et 1985. On
a obtenu d'eux des details sur leurs ante
cedents, leurs symptomes et leur travail.
Pour la majority des travailleurs, il y avait
uen perte des sensations de la main k
une piqure d'epingle, et l'6tendue de ceci
montrait une bonne correlation avec la
gravity des symptSmes. Jusqu'a maintenant, cette correlation n'avait pas etk
decrite. Chez 16 sujets, la perte de sen
sation etait proximale au niveau des
symptomes, chez 50, elle 6tait au meme
niveau et, dans 23 cas, elle etait distale.
Dans trois cas, on ignore la correlation.
La gravity du syndrome des "doigts
blancs” provoque par Ies vibrations a ete
evaluge selon la classification de Taylor.
Quatre travailleurs ont 6te consideres au
stade 1 (decoloration occasionnelle du
bout des doigts, avec ou sans fourmillement ou engourdissement), 30 au stade
2 (decoloration d'un ou de plus d'un
doigt avec engourdissement par temps
froid), 36 au stade 3 (decoloration frequente de la plupart des doigts) et 22 au
stade 4 (tout comme pour le stade 3,
mais Ies symptomes sont severes au
point de rendre le travail manuel difficile
et interdisent ('utilisation d'outils vibratoi
res). La correlation des symptomes avec
la perte de sensation a la piqure
d'aiguille a servi a evaluer la gravite du
syndrome et k classifier Ies reclamations
k la Commission des accidents du
travail.

Most symptoms and signs of Raynaud’s
phenomenon are intermittent. Since they
are precipitated by a cold or damp
environment they are hardly ever present
in a physician’s office. To assess the
severity of the condition the physician
must rely on the history given by the wor
ker and, as compensation may be
involved, this has its drawbacks. We have
found that the level of the symptoms of

pallor and numbness of the fingers and
hands correlates well with the level of loss
of sensation to pinprick. This observation
has assisted in staging the syndrome.
Patients and Methods
Between January 1982 and August
1985, 92 workers, all men, were examined
at the request of the Workers’ Compen
sation Board of British Columbia and
found to have vibration white finger syn
drome. The diagnosis was based on a his
tory of episodic numbness and blanching
of the fingers precipitated by exposure to
a cold or wet environment. The history
included the level of symptoms, their fre
quency, duration and date of onset. The
upper extremities were examined for vas
cular and neurologic signs and, when
necessary, tests were performed for
thoracic outlet syndrome and systemic
collagen diseases. A history was obtained
of occupational exposure to vibrating
tools for several years before the onset of
symptoms. Cases of Raynaud’s disease

Y ea r s

FIG. 1—Age of subjects at time of first
examination.

FIG. 2—Occupation of 92 patients.
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workers experienced symptoms in winter
only, but most had them year round. The
most proximal level of symptoms is illus
trated in Fig. 6, and the duration of
symptoms is indicated in Fig. 7.
Examination of the upper extremities
in the office disclosed that there was no
atrophy or gangrene of the finger tips, the
hands were almost always pink and
warm, and good radial and ulnar pulses
were present with few exceptions. No
Findings
arterial hypotension was encountered and
The ages and occupations of the wor there was no sensory loss to light touch
kers are shown in Figs. 1 and 2 respec unless some incident of trauma had
tively. The category of “ other” includes resulted in nerve injury. There was,
combinations of logging, mining and con however, loss of sensation to needle prick
struction, or autobody repair and grind in almost all workers, and this usually
ing. The time spent in occupations using corresponded closely with the level of
vibrating tools is shown in Fig. 3. symptoms of pallor and numbness they
Although almost all the workers were described. Care was taken to apply the
engaged full time in occupations using needle to the lateral sides of the fingers
vibrating tools, the onset of symptoms as the volar aspects were frequently cal
was delayed for a variable number of loused.
Fig. 8 illustrates the correlation
years, in one case for over 35 years (Fig.
4). The proportion of workers with, between the level of symptoms and the
symptoms rose steadily from 19% after 5 number of patients experiencing each
years to 95% at 30 years (Fig. 5). Some level of sensory loss. In the majority of

(constitutional white finger), Raynaud’s
phenomenon secondary to penetrating
trauma, carpal tunnel syndrome and
Buerger’s disease were encountered and
excluded from the study. No case of
scleroderma was encountered.
The data was processed on an IBM PC
computer using the Lotus 1-2-3 spread
sheet.
FIG. 3—Duration of use of vibrating tools.

FIG. 4—Number of symptom-free years.
Unkn = unknown.

FIG. 5—Proportion of workers with syn
drome correlated with duration of use of
vibrating tools.

FIG. 8—Correlation between level of symptoms and sensory loss. PIP interphalangeal. M-P = metacarpophalangeal.

FIG. 6—Most proximal level of symptoms.

Stage
0r 0N
1
2

3

4
FIG. 7—Duration of symptoms. Unkn =
unknown.

proximal

Table I—Taylor's Classification of Symptoms of Vibrating White Finger Syndrome
Consequences
Condition of digits
Intermittent tingling or numbness

-

Occasional blanching of one or more finger
tips, with or without tingling or numbess
Blanching of one or more fingers with
numbness during cold weather

No interference with activities

Frequent, year-round episodes of finger
blanching, affecting most digits. Permanent
reduction in tactile sensitivity can often
be detected
Same as stage 3

Slight interference with some activities,
particularly those during which attacks have
been experienced
Interference with manual work and
recreational activities. Cessation of some
hobbies
Same as stage 3, but difficulty with manu
al work is sufficient to preclude continued
operation of vibrating tools
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cases the sensory loss was at the same level
as the symptoms. A few workers had no
sensory loss. In all workers with sensory
loss, the level of loss was within two
levels of symptoms.
Following the clinical examination wor
kers were assigned to one of the stages of
Taylor (Tables I and II).
Discussion
Since Raynaud published his thesis on
local asphyxia and symmetrical gangrene
of the extremities,1 it has been recog
nized that he was referring to a mixture
of entities. Raynaud’s phenomenon due
to the use o f vibrating tools was first

Table II -Staging of 92 Workers According
to Classification of Taylor
Stage
No.
1
4
2
30
3
36
4
22

noted among Italian miners in 1911.
Gasoline-powered chain saws were
introduced into the logging industry in the
late 1940s and the first report of Ray
naud’s phenomenon in tree fellers
appeared in 1964. Pneumatic hammers
and grinders have also induced the con
dition.2 In British Columbia, 51% of all
tree fellers have been found to have vibra
tion white finger syndrome.3 After work
ing between 11 and 15 years, 70% of
fellers have acquired the syndrome, and
after 20 years, 75% of them have it.
Recognition of the entity has led to a
need to quantitate the degree of severity,
particularly for the assessment of com
pensation. Because of the paucity of clin
ical signs several physiologic tests have
been devised.
Taylor devised methods for testing
depth perception and two-point discrimi
nation.4 Photocell plethysmography has
been used to measure changes in blood
flow in the finger tips when the hand is
immersed in ice water. X-ray films of the
hands have been obtained to look for

D .L . D o y l e ,

m d , frcsc,

J. Y u ,

bone cysts. Although differences have
been observed between groups of
vibration-exposed workers and controls,
none of the tests has been found reliable
for staging the condition individually.5
The loss of sensation to pinprick,
although well recognized as a clinical
finding in this condition has not previ
ously been recorded as correlating closely
with the history of symptoms of pallor
and numbness. We have found this sim
ple test useful in confirming the history
and in staging the severity of the syn
drome.
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Comparison of Doppler and Strain-Gauge
Plethysmography to Detect Vasculogenic Impotence
Doppler penile-pressure determinations to
diagnose vasculogenic impotence require
an experienced technician, can be timeconsuming, yield inconsistent results and
require much penile manipulation. There
fore the authors assessed and compared
strain-gauge plethysmography as an
alternative noninvasive procedure.
Sixty-one patients with erectile failure
had penile blood pressure determined by
Doppler and indium-gallium alloy in Silas
tic strain-gauge plethysmography. Penile
brachial indices were calculated. Straingauge results agreed with the Doppler
measurements in all but three patients
whose indices were found to be normal
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by Doppler and borderline by straingauge plethysmography. The sensitivity,
accuracy and specificity of strain-gauge
plethysmography were 93% , 95% and
100% respectively. Doppler determina
tions required an average of 20 minutes
to perform, strain-gauge measurements
only 4. The authors conclude from this
study that strain-gauge plethysmography
is a rapid, reliable, accurate method of
determining penile blood pressures.
Le diagnostic de I'impuissance d'origine
vasculaire par determination de la pression sanguine penienne a I'aide d'une
sonde de Doppler exige la presence d'un
technicien experiment^; la technique
peut Stre longue, elle donne des r£sultats
inconsistants et requiert beaucoup de
manipulation du penis. Les auteurs ont
done evaluer de fagon comparative la
piethysmographie par tensiometre
comme technique non sanglante de
rechange.
La pression sanguine penienne a ete
mesuree chez 61 patients incapables
d erection & I'aide d'une sonde de Dop
pler et par piethysmographie avec un
tensiometre construit d'un alliage
d'lndium et de gallium dans du Silastic.

Les indices brachiaux peniens ont ete
calcules. Les mesures au tensiometre ont
coincide avec ceux de la sonde de Dop
pler dans tous les cas sauf trois chez qui
les indices etaient normaux a la sonde de
Doppler mais douteux au plethysmographie avec tensiometre. La sensibilite, la
precision et la sp6cificite de la piethysmographie par tensiometre ont ete respectivement de 93% , 95% et 100%.
Les determinations par sonde de Doppler
ont necessite 20 minutes en moyenne;
les mesures au tensiometre, 4 minutes
seulement. De cette etude, les auteurs
concluent que la piethysmographie par
tensiometre constitue une methode
rapide, fiable et precise de mesurer les
pressions sanguines peniennes.

The causes of erectile failure are many.
Recently interest has increased in making
an accurate etiologic diagnosis of impo
tence. Doppler penile-pressure studies are
generally accepted as the most accurate
noninvasive means of diagnosing vasculo
genic impotence, but they require an
experienced technician, can be timeconsuming, yield inconsistent results and
require a good deal of penile manipula
tion which can be embarrassing to both
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patient and technician. Thus, other means
of quantifying penile blood flow noninvasively are being examined. Strain-gauge
plethysmography is used in many labora
tories to assess blood flow. Since 1971
when Britt and colleagues1 published a
preliminary report on the use of straingauge plethysmography to assess penile
blood flow, no reports of this application
of the technique have appeared in the
English literature. Therefore we set out
to assess the accuracy, reliability and
speed of strain-gauge plethysmography in
measuring penile pressure.
Patients and Methods
All 61 patients referred to the diagnos
tic vascular laboratory at the University
of British Columbia Health Sciences
Centre Hospital between December 1984
and June 1985 for assessment of erectile
failure agreed to be included in the study.
A Medasonics continuous wave Dop
pler (Medasonics Inc., Mountain View,
Calif.) with an 8 MHz probe was used to
measure the blood pressure in each arm,
twice, and the results from the arm with
the higher pressure were averaged. The
brachial pressure thus obtained was later
used to calculate penile-brachial indices.
In all studies an appropriately sized
blood-pressure cuff was placed round the
shaft of the penis near its base. The cuff
was connected to a Hokanson anaeroid
sphygmomanometer (D.E. Hokanson,
Issaquah, Wash.). For strain determina
tions an indium-gallium alloy in Silastic
strain gauge was wrapped around the
penis distal to the blood-pressure cuff.
The strain-gauge was coupled to a Meda
sonics strain-gauge plethysmograph and
chart strip recorder. A baseline tracing
was obtained. The penile-pressure cuff
was then inflated to suprasystolic pressure
and slowly deflated. The pressure at
which the waveform first reappeared was
recorded.
Doppler penile-pressure determinations
of the superficial dorsal, corpora spongiosal and deep cavernosal arteries were
made with an 8 MHz Doppler probe just
distal to the penile-pressure cuff. The cuff
was then inflated to suprasystolic pressure
and slowly deflated. The pressure at
which the Doppler signal could be heard
again was recorded. When the deep caver
nosal signals were faint or otherwise un
obtainable, the arteries were approached
from the ventral rather than the lateral
side of the penis. The arterial signals are

first located proximally on the penis,
where they are strongest. The course of
the artery is then traced distally and the
pressure cuff applied.
The time required to perform these
diagnostic procedures was recorded.
Penile brachial indices were calculated.
According to Kempczinski,2 indices
greater than 0.75 were classified as nor
mal, those less than 0.60 as abnormal and
those falling between as borderline. As
the deep cavernosal blood flow is believed
the most important in erection,3'4 we
considered the results normal if Doppler
corpora cavernosal indices were both
greater than 0.75. If they disagreed then
the superficial dorsal and corpora spongiosal indices were considered and the
final diagnosis determined by the average
of all six indices.
Results
Strain-gauge results agreed with Dop
pler findings in all but three patients
(Table I). These three had normal Dop
pler and borderline strain-gauge indices.
If one assumes that all borderline results
are normal, the sensitivity, specificity and
accuracy of the strain-gauge results were
all 100% (Table II). If, on the other hand,
one assumes that all borderline results are
abnormal, then the sensitivity of straingauge plethysmography was 93%, its
Table II—Sensitivity, Specificity, Accuracy,
Assuming All Borderline Results Are Normal
Strain-gauge plethysmography
Doppler study

Normal

Abnormal

Normal
57
0
Abnormal____________0_______________4
Sensitivity - 57, specificity = 4,
57
4
accuracy = 57 + 4.
57 + 4

Table Ill-Sensitivity, Specificity, Accuracy,
Assuming All Borderline Results Are Abnormal
Normal__________Abnormal

Normal
43
0
Abnormal__________ 3________________ 15
Sensitivity = 43 = 93%,
46
specificity = J 5 = 100%,
15
accuracy =
43 + 15
= 95%.
43 + 3 + 15

Strain-gauge plethysmography
Normal
Borderline
Abnormal

Discussion
Inadequate penile blood flow has been
recognized as a cause of erectile failure
since Leriche’s5 description of impotence
associated with aortic occlusion. In the
past decade Doppler penile pressures have
been used widely to quantitate penile
blood flow, but the method has its dis
advantages: an experienced technician is
necessary and even then the study can be
quite time-consuming, Doppler penile
pressures are not always reliable, the deep
cavernosal and corporal spongiosal arter
ies are difficult to locate, the signals are
often weak and if one is not careful to
deflate the cuff slowly and listen carefully
for the return of an often faint signal, the
pressure obtained may well be artificially
low.
The technician in this study had been
performing six-vessel Doppler penilepressure determinations for nearly 4
years. Despite experience with hundreds
of examinations he required 20 minutes
to complete each examination. Even using
the ventral approach for the deep caver
nosal arteries he was unable to locate 15%
of them . Despite these and other wellrecognized problems with Doppler assess
ment, it has been accepted as the “ gold
standard” fpr noninvasive penile bloodflow determination.
Photoplethysmography has recently
become popular for penile blood-flow
assessm ent.6,7 O ur laboratory has
assessed this method but found it not
quite as accurate as strain-gauge plethys
m ography.8
We recommend strain-gauge plethys
mography for noninvasive measurement
of penile blood flow. The technique is
easily learned and is rapid, reliable and
accurate.

Strain-gauge plethysmography
Doppler study

Table 1—Comparison of Results in 61 Patients
Doppler study

accuracy 95% and specificity 100%
(Table III).
Doppler studies required an average
of 20 minutes to perform, strain-gauge
plethysmography only 4.

Normal

Borderline

Abnormal

43
0
0

3
11
0

0
0
4
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Symposium on Acute Arterial Insufficiency
Paul M. W alker, md , ph d , frcsc

1. Pathophysiology of Acute Arterial Occlusion
Acute arterial occlusion may cause
prolonged ischemia of the lower
extremity. Since skeletal muscle is the
major component, its reaction to the
stress of ischemia best determines the
final outcome for the limb. The combina
tion of cellular damage during the period
of ischemia and its exacerbation during
reperfusion may result in the production
of skeletal muscle necrosis. The relative
resistance of skeletal muscle to normothermic ischemia is related to its low
resting energy demands and large
intracellular stores of available energy. If
the period of ischemia is long enough,
restoration of the circulation may exacer
bate cellular damage, due in part to
washout of adenine nucleotide precursor,
free-radical-mediated injury and finally
calcium-dependent necrosis. In addition
to the clinical manifestation of local
swelling, rhabdomyolysis can lead to
systemic complications of hyperkalemia,
renal failure or death. Therapeutic inter
ventions aimed at reducing reperfusion
damage may result in the salvage of
functional lower limbs that might other
wise be lost.

Une occlusion artgrielle aigue peut entralner une ischgmie prolongee des membres
inf6rieurs. Comme le muscle stri6 constitue un Element majeur, sa reaction au
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stress de I'ischemie determine la perte
ou la conservation du membre. L'association des dommages celiulaires subis
durant I'ischemie et leur exacerbation
durant la reperfusion peuvent produire
une necrose du muscle strie. La resis
tance relative des muscles stries a
I'ischemie normothermique est reliee a sa
faible demande d'energie lorsqu'il est au
repos et aux importantes reserves
d'energie intracellulaires disponibles. Si la
periode d'ischemie est suffisamment pro
lon g ^, le retablissement de la circulation
peut exacerber les dommages celiulaires,
& cause, en partie. de la dgperdition du
pr6curseur de I'adenine nucleotide, des
lesions provoquees par les radicaux libres
et, finalement, de la necrose calciumdependante. En plus des manifestations
cliniques qui se traduisent par une
inflammation locale, la rhabdomyolyse
peut entrainer des complications generaies
telles que hyperkaliemie, insuffisance
r6nale ou dec6s. Une approche therapeutique visant a reduire les dommages de
la reperfusion peut favoriser la conserva
tion de membres inferieurs fonctionnels
qui, autrement, seraient perdus.

Tolerance to normothermic ischemia
varies between tissues, those in the lower
extremity being the most resistant.
Irreversible changes occur after 5 to 10
minutes of brain ischemia,1 17 to 20
minutes of myocardial ischemia2 and 40
to 50 minutes of renal ischemia,3 In
comparison a lower extremity may be sal
vaged 5 to 6 hours after an acute arterial
occlusion.4 The lower extremity is com
posed of several different types of tissue
including skin, skeletal muscle, bone, ten
don and nerve. For various reasons,
skeletal muscle seems to be the most
important component in ischemia. First,
it represents 95% of the metabolic activity
of the lower extremity by virtue of its rela
tive predominance by weight, blood flow,
and energy demand.5 Second, other tis
sues, with the possible exception of
nerves, seem more tolerant of ischemia.6
Third, skeletal muscle ischemia may

induce profound systemic reactions dar
ing the reperfusion phase.
Overall ischemic effects are a combi
nation of events that occur during the
period of ischemia and the subsequent
reperfusion, when an exacerbation of
ischemic damage can lead to an even
greater degree of necrosis.
Metabolic reactions of skeletal muscle
to prolonged circulatory deprivation are
based on the delicate balance between
supply and demand. Initially, the usual
availability of blood-borne substrates and
removal of metabolite waste or by
products are lacking. Balanced against
this are the altered energy demands of the
now-isolated skeletal muscle fibres. An
explanation for the tolerance of skeletal
muscle to ischemia lies in the fact that the
demands of skeletal muscle, when at rest,
are remarkably small. Instead of the usual
massive dem ands for adenosine
triphosphate for the forming and break
ing of bonds between contractile proteins,
and the need to pump calcium between
compartments during exercise, energy
demands during ischemic rest are small,
used predominantly for maintaining
membrane potentials and the compartm entalization of ions.7 There is a
remarkably large store of potential energy
present in.each muscle fibre. Adenosine
triphosphate itself is found in large quan
tities in skeletal muscle, where highenergy phosphate bonds are also stored
as creatine phosphate.8 The myokinase
reaction that transform s adenosine
diphosphate and adenosine monophos
phate to ATP is active in skeletal muscle.
Although normally produced through
oxidative phosphorylation, ATP can be
produced anaerobically by glycolysis.
Glycogen is stored in abundance in skele
tal muscle, and cytoplasmic enzymes re
quired for conversion to lactate and
production of ATP are readily available.9
Thus, the resistance of skeletal muscle to
prolonged ischemia can be partially
explained by a beneficial ratio of supply
to demand.
Despite this tolerance, irreversible
changes do occur when the ischemic stress
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becomes too great. An interesting and
confounding problem in the investigation
of ischemic events is the requirement for
reperfusion. We have shown that a mus
cle made ischemic for 4 hours shows no
evidence of necrosis when stained with
tetrazolium before reperfusion; yet upon
reperfusion large areas of necrosis are
apparent. This interplay between intracel
lular events during ischemia and exacer
bation or improvement during reperfu
sion together seem to determine whether
a specific period of ischemia is reversible
or not. There is a spectrum that is timedependent, and our studies have shown
that 1, 2 and up to 3 hours of complete
ischemia are totally reversible while at 4
hours there is 30% necrosis,10 at 4V4
hours 60% and after 5 hours virtually
100% necrosis. Events that occur during
reperfusion may be both beneficial and
harmful and include attempts at ATP
normalization, as well as the effects of
free-radical-mediated damage and cal
cium-mediated damage.
Depletion of Adenosine Triphosphate

After up to 3 hours of ischemia, ATP
levels can be restored quickly by oxida
tive rephosphorylation due to a normal
functioning of mitochondria and the
availability of suitable substrates.11
However, with longer periods of ischemia
several factors inevitably lead to inade
quate restoration of ATP levels and sub
sequent cell death.12 There is a gradual
conversion of nucleotides ATP, ADP,
AMP to inosine, hypoxanthine and xan
thine, which are lipid soluble and during
reperfusion are washed out of the cell.
This leaves no precursors to accept highenergy phosphate bonds produced by
oxidative phosphorylation. As a partial
explanation for the relative resistance of
skeletal muscle to ischemia it has been
suggested that adenine nucleotide
degeneration may proceed along alterna
tive pathways.13 We believe that while
the relative rate of adenine neucleotide
degeneration may be slower in skeletal
muscle than in other tissues, lack of
precursors is a feature of irreversible
injury. We have shown that early oxygen
uptake and the subsequent rate of forma
tion of high-energy bonds from function
ing mitochondria is stalled because of a
lack of precursors, preventing an increase
in ATP levels. Normalization of ATP is a
requirement for restitution of skeletal
muscle following ischemia and its failure
may be due to several causes.
Free-Radical-Mediated Damage

Production of oxygen-free radicals is
the cause of cell necrosis in liver poisoned
with carbon tetrachloride and also of
local tissue damage following ionizing

radiation.14 The production of oxygenfree radicals has also been demonstrated
following periods of ischemia to kidney,
heart, brain and lung, and we have
recently found evidence of free-radicalmediated damage in skeletal muscle.15
Briefly, a normal chemical bond consists
of a pair of electrons opposite in spin and
sharing a single molecular orbit. A free
radical is a molecule containing an odd
number of electrons and thus may be con
sidered to contain an open or half bond.
Molecular oxygen is a paired, magnetic
biradical and contains two unpaired elec
trons with parallel electron spins. Most
organic compounds that react with oxy
gen contain paired electrons and the
simultaneous insertion of two paired elec
trons into a molecule of oxygen would
violate rules of quantum mechanics.
Acceptance of a single electron (univalent
reduction) produces an oxygen-free rad
ical. Under normal conditions mitochon
drial enzymes reduce oxygen to water by
tetravalent reduction without the forma
tion of these intermediates, although up
to 5% can proceed by univalent path
ways. These small quantities of free rad
icals are quenched by intracellular
scavengers. During the ischemic phase the
accumulation of reduced cytochromes
and cytoplasmic-reducing equivalents sets
the stage for a large production of toxic
oxygen-free radicals with the sudden rein
troduction of oxygen during reper
fusion.16
With the acceptance of the first elec
tron by the oxygen molecule, the superox
ide anion is produced. The danger inher
ent in this radical is its intense reactivity
if not scavenged. It may be reduced to
hydrogen peroxide by superoxide dismutase, which in turn may be effectively
scavenged by the action of glutathione
peroxidase or catalase and reduced to
harmless water. However hydrogen
peroxide accumulation can lead to the
production of the hydroxy-free radical by
either the Fenton reaction or the HaberWeiss reaction using a metal chelator,17
which is potentially much more harmful.
Following a period of ischemia, normal
intracellular scavengers can be overcome
by a large production of free radicals dur
ing the initial respiratory burst.18 Free
radicals may exhibit their toxic effects by
the sequence of lipid peroxidation, which
renders the phospholipid bilayer of the
cell membrane leaky, allowing both the
efflux of necessary cytoplasmic enzymes
and the influx of undesired intravascular
substances. In addition, membranes of
intracellular organelles including
mitochondria and sarcoplasmic reticulum
may be injured by the same reaction.19
Calcium-Mediated Damage

Finally, abnormalities of calcium
metabolism occur during the reperfusion

phase and may represent the final event
in cellular necrosis. The lack of ATP to
provide energy for pumping calcium out
of the cell and the presence of sarcolemmal defects, result in a greater free
cytoplasmic calcium concentration.
Increased uptake of calcium by the
mitochondria occurs, leading to both
functional and structural changes in the
mitochondria. Calcium uncouples oxida
tive phosphorylation, which further com
pounds the lack of energy.20 In addition
to its direct toxic effects, calcium may
itself activate membrane-bound phos
pholipases, increasing sarcolemmal
defects. Although calcium influx may be
the final event in cellular necrosis, close
interactions between free-radicalmediated injury and lack of normaliza
tion of high-energy stores contribute to
the degree of calcium influx and help in
determining life or death for the skeletal
muscle cell.21
Clinical Manifestations of Prolonged
Muscle Ischemia

If we extrapolate from these intracel
lular events during both ischemia and
reperfusion, the clinical findings
associated with acute arterial occlusion
become more understandable. The com
pleteness of ischemia in the extremities
may vary depending on collateral blood
flow; thus, periods of ischemia may not
be totally comparable. During the reper
fusion phase, local changes indicating
cell-membrane dysfunction are shown by
increased swelling of the muscles; the
onset of this may vary from a few minutes
up to 48 hours, and a compartment syn
drome may result. The adequacy of revas
cularization, duration of ischemia and
underlying arterial occlusive disease may
all determine the onset of maximal mus
cle swelling.22 Muscle hypercontraction
may become evident, and subsequently
rhabdomyolysis may result.
The systemic effects of prolonged
skeletal muscle ischemia are essentially
evidence of perfused ischemic or necrotic
skeletal muscle cells. A profound meta
bolic acidosis,23 in association with
hyperkalemia, lactate acidosis and
hemoconcentration indicate leaky mem
branes in skeletal muscle cells, but with
adequate perfusion. Myocardial contrac
tility may be reduced, irritability increased
and finally hypotension result.24 Larger
molecules may be washed out during the
reperfusion phase including myoglobin,
which is a direct renal tubular toxin. In
association with acidosis and low urine
output, myoglobinuria may lead to com
plete renal failure.25
While the revascularization of these
patients may be straightforw ard,
biochemical abnormalities associated with
prolonged limb ischemia may be devastat-
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ing. We may be able to improve our
m anagem ent o f these patients by
appropriate therapeutic interventions,
based on events occuring during both the
ischemic phase and reperfusion phase.
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2. Occlusion of the Aortofemoral Prosthetic Graft
The commonest late complication of aor
tofemoral prosthetic grafting is graft-limb
occlusion, the usual cause of which is
outflow obstruction due to anastomotic
neointimal hyperplasia or progressive
atherosclerosis in the deep femoral
artery. Occasionally graft-limb occlusion
is due to thrombosis of an anastomotic
false aneurysm or is associated with
graft infection. Inflow occlusion at the
aortic anastomosis is uncommon unless
the aortic anastomosis is at the lower
end of the aorta distal to the inferior
mesenteric artery. When graft-limb
occlusion occurs, severe ischemia
usually necessitates urgent revasculariza
tion to save the leg. Graft thrombectomy
and profundaplasty may be successful;
however, a cross-femoral graft to the
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distal patent deep femoral artery is prob
ably the simplest procedure and is
usually effective. Occasionally a distal
femoropopliteal reconstruction is neces
sary to establish a satisfactory outflow.
Unsuccessful reconstruction of a graftlimb occlusion usually necessitates a
high, above-knee amputation.
L'occlusion du greffon est la complica
tion tardive la plus frequente de la greffe
prothetique aortofemorale. La cause est
habituellement une obstruction du d6bit
due b une hyperplasie neointimale au
point d'anastomose ou une atherosclgrose progressive de I'art6re femorale profonde. Occasionnellement, l'occlusion du
greffon est due b une thrombose d'un
faux an6vrisme anastomotique ou
encore, elle est associ6e a une infection
du greffon. Le blocage de I'afflux sanguin a I'anastomose aortique est peu
courant, sauf lorsque I'anastomose aorti
que se trouve a I'extremite inferieure de
I'aorte, distale & I'artere mesenterique
inferieure. En cas d'occlusion du greffon,
la grave ischgmie qui s'ensuit necessite
une revascularisation d'urgence pour
sauvegarder la jambe. Une thrombectomie avec plastie profonde du greffon
peut etre couronnee de succ&s; n6anmoins, une greffe crois&e vers la partie
distale permeable de I'artere femorale

profonde est probablement I'intervention
la plus simple et elle est habituellement
efficace. A I'occasion, une reconstruc
tion femoropoplitee est necessaire au
retablissement d'une circulation satisfaisante. En cas d'echec de la reconstruc
tion d'une occlusion du greffon, il est
habituellement necessaire de proceder e
une amputation haute, au-dessus du
genou.

Graft-limb occlusion occurs in 1% to 2%
of patients in the perioperative period and
is then usually due to technical problems
such as unrecognized thrombosis in the
graft, an intimal flap at the anastomosis,
a kinked limb or inadequate femoral out
flow. Late occlusion occurs in 10% to
15% o f graft limbs, generally 3 to 4 years
after the primary reconstruction. The
commonest cause of graft-limb occlusion
is outflow obstruction, which may be due
to progression o f the arteriosclerotic
occlusive disease, especially in the deep
femoral artery, or to the development of
intimal hyperplasia at the distal anasto
mosis. Over two-thirds o f patients with
aortoiliac occlusive disease who require
operative intervention have associated
superficial femoral artery disease and
therefore are dependent on deep femoral
artery outflow at the time o f the initial
operation. Long-term patency depends on
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the establishment of excellent outflow
from the deep femoral artery at the first
operation; to achieve this a profundaplasty may be required. On occasion a
graft-limb occlusion will be caused by
acute thrombosis of an anastomotic false
aneurysm or an associated graft infection.
Diagnosis
Graft-limb occlusion in the aortobilateral femoral graft usually causes
severe ischemia. In our experience, over
80% of patients suffer limb-threatening
ischemia with late, acute occlusion of the
graft limb. A small group of patients will
have worsening claudication or gradual
onset of rest pain. Physical examination
will usually confirm the absence of a
femoral artery pulse on the affected side,
and a loud, high-pitched bruit over the
patent limb may suggest a local outflow
stenosis. Angiography by the translumbar route will confirm the diagnosis of
graft-limb occlusion and identify anasto
motic stenosis on the patent side in some
instances. In any case, angiography
should always be performed to identify
the proximal anastomosis, the graft bifur
cation and the deep femoral outflow on
both sides. It is important to look for clot
at the bifurcation of the graft and also to
examine the outflow on the patent side.

Management
Since most of these patients have limbthreatening ischemia, emergency revas
cularization is usually indicated. If the
ischem ia is not immediately limb
threatening, the patient should be
heparinized, a full investigation carried
out and the patient prepared for urgent
reconstruction. Although graft-limb
thrombectomy and profundaplasty are
popular, they are not necessarily easy or
always successful. One must be prepared
to establish both an adequate inflow and
outflow as a principle of management.
Usually the limiting factor in successful
secondary reconstruction for graft occlu
sion is the establishment of adequate out
flow in the deep femoral artery. The
superficial femoral artery is usually
occluded at the time of graft occlusion so
that it is necessary to perform a profun
daplasty or do a separate deep femoral
artery anastomosis distal to the previous
one. The adequacy of deep femoral artery
outflow depends on the formation of col
lateral vessels into the popliteal system.
If there is inadequate collateralization it
may be necessary to consider a more dis
tal reconstruction such as a femoropopliteal or femorotibial bypass. With the
knowledge that one cannot be certain of
the extent of the reconstruction that will
be required, the patient should be fully

prepared and draped for aortofemoral
and femoropopliteal reconstruction.
Thrombectomy and Profundaplasty
The initial approach should be explo
ration of the graft limb at the site of
occlusion at the distal anastomosis. The
graft is opened longitudinally proximal to
the anastomosis after loop control of the
deep femoral branches. When there is
recent clot in the graft limb, thrombec
tomy with a Fogarty catheter may be suc
cessful. If organized clot is present,
thrombectomy may be more difficult.
Manipulation with an endarterectomy
stripper threaded over the Fogarty
catheter may be successful, but aggressive
attempts at retrograde thrombectomy
against resistance seems ill-advised. If
thrombectomy establishes a good inflow,
then attention can be turned to the cause
of the obstruction, usually located at the
distal anastomosis. The graft incision can
be extended across the suture line into the
deep femoral orifice. The arteriotomy
must be extended distally beyond signifi
cant deep femoral disease. Usually it is
necessary to perform a local endarterec
tomy. This arteriotomy and “ graftotom y” are then closed with an onlay
autogenous patch using the endarterectomized superficial femoral artery or a
segment of saphenous vein. An angio
gram obtained at the end of the procedure
should include the bifurcation of the graft
as well as the deep femoral reconstruction
and collateral run-off. When monofila
ment suture material has been used for
the original prosthetic anastomosis, it is
preferable to transect the graft limb
before performing the thrombectomy, as
described by Bernhard and associates.1
The profundaplasty is then performed
separately and the graft limb is reanas
tomosed to the patched femoral artery or
an extension is added to the graft limb.
Cross Graft and Profundaplasty or
Deep Femoral Anastomosis
When thrombectomy is unsuccessful or
the occlusion long-standing, it is often
preferable to proceed immediately with an
alternative inflow procedure such as the
use of the patent limb. Again the area
of deep femoral artery outflow is exposed
initially. If there is only a deep femoral
outflow, the artery is prepared for an endto-end anastomosis near its origin or an
end-to-side anastomosis further down
stream. The patent limb is exposed either
at the groin or proximal to the inguinal
ligament. Our more-recent experience
suggests that it is easier to approach the
proximal limb through a small muscle
splitting incision above the inguinal liga
ment. An appropriate graft (usually
8-mm knitted Dacron) is anastomosed to

the side of the patent limb with proximal
and distal control. The limb is then
anastomosed to the deep femoral artery.
Again a completion angiogram should be
obtained through the graft.
Complete Femoral Outflow Obstruction
In some instances complete femoral
outflow occlusion precludes a femoral
outflow procedure. One must then con
sider using the popliteal artery either
proximal or distal to the knee joint. Again
the inflow may be obtained from the
patent limb and a cross graft taken to the
proximal or distal portion of the popliteal
artery. The long saphenous vein or 6-mm
polytetrafluoroethylene has been used
successfully for these long grafts.
Complete Graft Occlusion
In the presence of complete occlusion
of the graft a new source o f inflow must
be sought either from the axillary artery
or from the more proximal aorta with
implantation of a new bifurcation graft.
Anastomotic Stenosis With a Patent
Graft Limb
A patient may present with worsening
claudication and still have patent graft
limbs. Anastomotic stenosis preceding
graft occlusion may be suspected when
there are changes in pressure measure
ments, and this emphasizes the impor
tance of follow-up by noninvasive studies.
If there is a worsening of claudication or
a deterioration in ankle pressures, angiog
raphy should be performed to identify
anastomotic stenosis before thrombosis
of the graft limb occurs. It is simpler to
repair an anastomotic stenosis by the
angioplasty technique before the graft
becomes occluded.
Results
The results of secondary repair are not
as good as the initial one, usually because
associated distal disease has progressed.
Bernhard and colleagues1 obtained good
results in 75% of repairs using thrombec
tomy and profundaplasty. Malone and
associates2 recommended profundaplasty
with autogenous tissue repair, but Craw
ford’s group3 recommended graft replace
ment as the inflow procedure, because of
poor results with graft thrombectomy.
Similar poor results with thrombectomy
have been reported by Benhamou and
associates.4 LeGrand and associates5
have also suggested that a new graft may
give better long-term results. It is appar
ent that one must tailor the procedure to
the patient and the circumstances. In
recent occlusions, thrombectomy may be
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simple and successful as the inflow proce
dure, whereas long-standing occlusions
with organized attached thrombus will
make thrombectomy more difficult and
potentially hazardous. There is always
danger of embolization to the patent
limb. It has been our experience that a
new anastomosis to a good deep femoral
artery is a simpler method of providing
outflow. This method of outflow recon
struction has provided results equal to
those obtained with profundaplasty.
The severity of ischemia accompanying
graft-limb occlusion is emphasized by
the am putation rate of 24% reported
by LeGrand and colleagues.5 In our

experience with 61 limbs at risk, the
amputation rate was 18%, with all but
one amputation being above the knee.
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3. Management of Primary Acute Arterial Occlusion
The management of primary acute
arterial occlusion depends upon distin
guishing between embolism and throm
bosis. Emboli are sudden in onset, have
a demonstrable source and lodge most
frequently at the common femoral bifur
cation. Embolectomy is the treatment of
choice. Acute thrombosis is usually
preceded by prolonged, progressive,
ischemia, is less abrupt in onset and
occurs most commonly in the superficial
femoral artery. The initial treatment is
anticoagulation with heparin, followed by
artery repair if indicated. Emergency sur
gical reconstruction is necessary if the
condition of the limb deteriorates despite
heparin therapy. Nonviable limbs are best
amputated early, and ischemic myositis is
the best clinical predictor of viability.
The use of streptokinase intra-arterially is
a reasonable alternative in patients with
thrombosis, although the selection of
patients is difficult. It must be followed
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by treatment of the underlying lesion,
using either balloon angioplasty or surgi
cal repair.
Le traitement des occlusions art6rielles
air ues primaires repose sur la distinction
entre I'embolie et la thrombose. L'embolie
est d'apparition brutale, possfede une
source identifiable et se loge le plus souvent
b la bifurcation de i'art&re f6morale.
L'embolectomie est le traitement de pre
mier choix. La thrombose aigue est habituellement prec6d6e d'une periode
d'isch6mie progressive prolong£e; elle
est d'apparition moins brutale et touche
le plus souvent I'artfere f£moraie superficielle. On a recours initialement b une
anticoagulothgrapie & I'hgparine, suivie
d'une reparation arterielle lorsque c’est
indique. Une reconstruction chirurgicale
d'urgence est necessaaire quand l'6tat
du membre se d£t£riore malgr£ ('adminis
tration d'heparine. II vaut mieux ampute
tot les membres non viables; la myosite
ischemique est le meilleur indicateur Cli
nique de viability. L'emploi de streptoki
nase intra-arterielle est un choix accepta
ble pour les patients souffrant de
thrombose, bien que le choix des candidats au traitement soit difficile. II est
ndcessaire de faire suivre par un traite
ment de la lesion sous-jacente soit par
angioplastie par ballonnet. soit par refec
tion chirurgicale.

Conventional management of acute
thromboembolic ischemia depends upon

an accurate determination of the cause of
the arterial obstruction. If it is due to
embolism, balloon-catheter embolectomy
offers a simple, safe and satisfactory
method of treatment that has become
standard in most institutions since its
introduction by Fogarty and colleagues in
1963.1 If the arterial occlusion is caused
by acute thrombosis, there is no uni
formly satisfactory surgical approach,
and controversy remains as to the opti
mal method of therapy.
Embolism

Peripheral emboli account for 40% of
the episodes of acute limb ischemia
treated in our institution.2 The majority
(87%) are cardiac in origin with chronic
atrial fibrillation being the commonest
cause. The remaining 13% arise from the
proximal arterial tree, due either to
aneurysm or to severe atherosclerosis with
ulceration and mural thrombosis. Most
emboli obstruct lower limb arteries
(94%),2 the common femoral bifurcation
being the commonest site (47% of these).
Profound limb ischemia is severe since the
deep femoral branch, in addition to the
superficial femoral artery, is obstructed,
and the collateral circulation is severely
compromised. The problem is aggravated
by propagation of the distal thrombus.3
The clinical diagnosis of embolism
depends upon the sudden onset of severe
limb ischemia and the demonstration of
a possible source. In a 1-year prospective
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chronic arterial insufficiency. Previous
intermittent claudication was reported by
47 of 50 patients with acute thrombosis
admitted to our unit during a 12-month
period,2 and 19 had a history of
peripheral arterial surgery. The onset of
symptoms tends to be more gradual, as
was reported in 31 of our patients. The
absence of an obvious source of emboli
is also important diagnostically. Most
cases of acute thrombosis involve the
lower limb, and the most common site is
the superficial femoral artery (24 of 32
occlusions). Common femoral thrombo
sis is rare in comparison with common
femoral embolism.
Therapeutic options in patients with
acute thrombosis include arteriography
followed by definitive arterial reconstruc
tion or an initial course of heparin
intravenously followed by elective surgery
if indicated. We adopted the latter
approach. Our rationale was that since
acute throm bosis is preceded by
prolonged chronic ischemia, a collateral
circulation has likely developed, and
heparin anticoagulation preserves this by
preventing distal propagation of
thrombus. We have found the results of
emergency reconstruction to be unsatis
factory.
Once the diagnosis of acute thrombo
sis is established we give a bolus of 100
units/kg of heparin intravenously. This
is followed by a continuous infusion of
the drug, sufficient to maintain the par
tial thromboplastin time at twice to two
and a half control levels, for 10 to 14
days. The patient is then investigated
by noninvasive means and by arteriogra
phy if significant ischemia persists. This
is followed by appropriate arterial recon
struction if the lesion is suitable.
During the initial phase of heparin
treatment, the limb is monitored closely;
if it does not show prompt improvement,
emergency arteriography is carried out
followed immediately by artery repair.
It is important to assess viability and
to amputate early if a limb is clearly not
viable.
The results of this therapeutic approach
in 50 patients, studied prospectively, are
presented in Table I. In seven patients the
limb was judged to be nonviable, and

study2 of patients with acute arterial
occlusion carried out in our unit, there
were 34 emboli and in 33 of these, the
patients reported sudden onset of symp
toms. The source of the embolus was
cardiac in 27 incidents and the common
femoral artery was involved in 15 of 33
lower-limb emboli.
Once a diagnosis of embolism is made,
the preferred treatment is prompt
embolectomy, using a Fogarty balloon
catheter. This is usually done under local
anesthesia and can be performed safely
in high-risk patients who have had recent
acute myocardial infarction. Heparin is
given intravenously during the procedure
and its action reversed before wound
closure if there is a problem with bleed
ing from the arteriotomy. Patients whose
emboli are cardiac in origin are started on
anticoagulants orally within 24 hours, and
anticoagulant therapy is continued on a
long-term basis. We prefer not to use
heparin intravenously after the procedure
because of possible hematoma formation,
with the potential for wound breakdown
and sepsis.
It is important to avoid embolectomy
in a nonviable limb as this may result in
a late revascularization syndrome, as
described by Haimovici.4 We have not
encountered this complication after
embolectomy, although it has occurred
after late repair of an arterial injury. If
a limb is judged to be nonviable, emer
gency amputation is the recommended
treatment.
Results of this treatment policy are
satisfactory. Of 27 embolic episodes in 23
patients managed by embolectomy dur
ing our study, there were two limbs that
required amputation (7.4% of episodes)
and two patients died (8.7%). These
results compare favourably with those of
other series.3,5'6
Thrombosis

Thrombosis, in our experience, is a
more common cause of acute limb ische
mia than embolism, accounting for 60%
of cases. Since it represents the end stage
of progressive atherosclerotic stenosis, the
most useful feature in establishing a clin
ical diagnosis is a history of symptoms of

Table 1-Management of Thrombosis (50 Patients)
Treatment
Early definitive amputation
Emergency operation alone
Heparin intravenously
followed by:
No further treatment
Elective operation
Emergency operation
Late amputation
No treatment

No. of
patients
7
4

Died
1
1

37
9
16
8
4
2

1
1
1
1
1

Amputation

Recovered

Impaired limb
function

7
1

1

1

3

8
15
1

3

1

amputation was performed early. Thirtyseven patients were given heparin therapy.
In 9 of the 37 there was sufficient resolu
tion of the ischemia that no further treat
ment was necessary. Sixteen required elec
tive arterial surgery. There were four late
amputations.
Emergency reconstruction was carried
out in 12 patients; in 4 as a definitive
treatment and in 8 because the limb failed
to improve promptly with heparin.
Results were poor: there were four ampu
tations, four patients were discharged
with impaired limb function, and in only
two were results good.
Of 50 patients with 55 episodes of acute
thrombosis, there were 7 deaths (14%)
and 11 amputations (22%).2
Problems of Conventional Management

The distinction between embolism and
thrombosis, crucial to this method of
management, was based on clinical
criteria alone. Angiography was used
before emergency repair in cases of pos
sible thrombotic occlusion, when the limb
failed to improve with heparin therapy.
It has been estimated by Fogarty7 that
embolism and thrombosis are indistin
guishable in 15% of patients.
In our own series of 79 patients the ini
tial diagnosis was found to be incorrect
in 7. Two of these cases involved emboli
without an obvious source, in patients
with evidence of chronic arterial disease,
and the correct diagnosis was made by
arteriography. Both had late embolec
tomy, performed at 5 and 7 days respec
tively, with a successful outcome. In five
patients the diagnosis was found to be
incorrect at operation when no embolic
material was found. Two had small
thrombosed popliteal aneurysms, one a
superficial femoral thrombosis and one
had an iliac artery thrombosis.
One of the seven patients with incor
rect diagnoses required amputation. It is
difficult to determine the extent to which
diagnostic error contributed to morbidity.
There may have been patients, thought to
have thrombosis and treated with hepa
rin who, in fact, had embolic obstruc
tions.
Another major problem is the assess
ment of limb viability. This assessment
should be as reliable as possible, since late
revascularization may be ineffective, or
can lead to a late revascularization syn
drome, with renal failure or hyperkalemic
cardiac arrest.
The most useful clinical feature in our
experience, is the presence and severity of
ischemic myositis, with its muscle tender
ness, swelling and rigidity.
Forty-one patients in our study with a
diagnosis of thrombosis were initially
thought to have potentially viable limbs.
Twenty of these, when first seen, had evi
dence of muscle tenderness and rigidity,
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and 7 eventually required amputation.
The other 21 had no muscle tenderness
or rigidity, and only 1 (5%) subsequently
underwent amputation. Accordingly we
rely heavily on this clinical observation.
So far, we have been unable to provide
quantitative, predictive data based on
measurement of muscle compartment
pressure.

sions in patients with arterial obstruction,
reported by Martin,9 a standard loading
dose of 250 000 units was given
intravenously over 20 minutes. This was
followed by a treatment dose of 100 000
U/h for 36 hours. Heparin was added on
day 2 at 1500 units/h and was continued
until oral anticoagulants became effec
tive. Oral anticoagulants were then con
tinued on a long-term basis. Strepto
kinase, plasminogen and fibrin concen
Streptokinase in Acute Arterial Occlusion
trations were monitored, as well as fibrin
degradation products.
There has been great interest in fibrino
The results were not encouraging. In
lytic treatment for both acute and chronic patients with femoral artery obstruction,
arterial obstruction during the past 15 clearance was obtained in only 20 (8.9%)
years.
of 225 patients. In iliac artery occlusions,
Streptokinase is an exotoxin produced clearance was demonstrated in 33 (19.5%)
by /3-hemolytic streptococci, group C. It of 169 patients. The results depended on
combines with plasminogen, a protein the duration of the obstruction and were
produced by the liver, to form an activa best if infusion was carried out within 2
tor complex. This enzymatically converts weeks of the onset of symptoms.
plasminogen to plasmin, an active proteo
Follow-up was obtained in 68 arteries
lytic enzyme. Plasmin breaks fibrin and initially cleared. In 10 (14.7%) of these,
fibrinogen into degradation products.8 reocclusion occurred during the same
Its action is nonspecific, and it also causes hospitalization period, from 1 to 20 days
breakdown of prothrombin and blood after the streptokinase infusion had been
factors V and VIII. Antistreptokinase is stopped. There was a progressive rate of
an antibody formed against streptokinase late reocclusion (20% to 30% per year).9
and is present in the normal population,
Reocclusions in iliac lesions were less fre
although to a progressively lesser degree quent than in femoral lesions. Also the
as streptococcal infections become less reocclusion rate was greatly increased if
common. Urokinase is a protein therapeutic oral anticoagulation was not
produced by renal tubular cells and can maintained.
be isolated from urine. It is a direct plas
Bleeding was the most serious compli
minogen activator, catalyzing its conver cation, occurring in 10% of patients; four
sion to plasmin without the preliminary deaths resulted from intracranial hemor
formation of an activator complex.8 Its rhage. Other complications were fever
major advantage is that it is non- (22% of patients) and allergic skin rashes.
antigenic. It is produced commercially Additional arterial occlusions occurred
from renal tissue cell cultures, and the due to distal embolization during the
main drawback to its use has been its high streptokinase infusion (three patients) or
cost. Accordingly, the fibrinolytic treat shortly after its completion (11 patients).
ment of arterial obstruction usually When there was major bleeding the strep
employs streptokinase.
tokinase infusion was discontinued and
There are several contraindications to fibrinogen levels were restored to at least
the use of streptokinase. Absolute con 0.8 g/L. The half-life of streptokinase
traindications include generalized bleed was found to be 20 minutes, and little
ing disorders, uncontrolled hypertension streptokinase activity could be detected
and the presence of a recent cerebrovas after 90 minutes.
cular process (stroke, hemorrhage, injury
or surgery). Relative contraindications Intra-arterial Streptokinase
include uncontrolled atrial fibrillation
previous streptokinase therapy (3 days to
Because unsatisfactory results with sys
3 months), liver or kidney failure, recent temically administered streptokinase in
puncture (intramuscular, thoracentesis, patients with arterial occlusion, and
paracentesis), surgery or delivery.
because of potentially serious bleeding
associated with a systemic lytic state, there
Systemic Streptokinase Therapy
has been increasing interest in localized
low-dose fibrinolytic treatment. Dotter
Systemically administered strep and colleagues10 in 1974 reported on 17
tokinase has been used in treating venous patients with thrombosis or embolism
thrombosis and pulmonary embolism as treated intra-arterially with low-dose
well as arterial occlusion. It involves the streptokinase. Lysis of thrombotic
intravenous infusion of a loading dose material was demonstrated in 11 patients;
sufficient to neutralize the antistrep systemic thrombolytic side effects, requir
tokinase content of the patient, followed ing termination of treatment, occurred in
by a treatment dose to produce a systemic 3 patients. There are a number of reports
lytic state.
of small series of patients treated by this
In a series of 600 streptokinase infu technique, with successful clot lysis and
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few or no major hemorrhagic complica
tions.11-12 Intra-arterial streptokinase has
been used successfully in the immediate
postoperative period to manage throm
botic complications of arterial repair.13
A large experience with intra-arterial
streptokinase therapy in arterial occlu
sions was reported by Hess and
colleagues14 in 1982. A catheter was
introduced percutaneously through the
common femoral artery into the obstruct
ing thrombus for 1 cm and 1 to 3 ml of
a streptokinase solution (1000 U/ml)
was injected into the thrombus.
The catheter was advanced under
fluoroscopic control every 5 to 15
minutes, and streptokinase infiltration of
the thrombus repeated until unobstructed
distal lumen was encountered and con
firmed by angiography. If a dilatable ste
nosis was dem onstrated, balloon
angioplasty was performed. After the
procedure, patients were started on long
term acetylsalicylic acid and dipyrida
mole. The duration of fibrinolytic ther
apy was 1 to 5 hours and the total dose
of streptokinase between 4000 and
180 000 units.
Using this regimen, Hess and
associates14 reported recanalization in 94
of 136 femoral, popliteal and iliac artery
occlusions; however, 20 of these became
reoccluded within 2 weeks. Better results
were obtained with occlusions less than
25 cm long, and in those present for less
than 6 months. Treatment was attempted
as long as 1 year after the onset of sym
ptoms. The cumulative patency rate 1
year after successful recanalization was
reported to be 70%.
Distal embolization was noted in 19
(14%) of the 136 patients. Bleeding from
the puncture site occurred in three
patients. There were no major hemor
rhagic complications.
Reports such as this are somewhat
difficult to evaluate, since thrombotic and
embolic occlusions were not always iden
tified and treatment included chronic
lesions present for up to 1 year as well as
acute obstructions. However, there is evi
dence from this and other reports that ini
tial vessel clearance is possible in 70% to
85% of acute arterial occlusions, and that
the serious complications of systemic
bleeding may be successfully avoided.
Results from our university division
come from the Ottawa General Hospital
and were reported by Wellington15 in
1985. Eleven patients with acute arterial
occlusions were treated intra-arterially
with streptokinase; 5 of these were
obstructed femoral artery grafts.
An intra-arterial streptokinase infusion
of 100 000 U/h was used for a maximum
of 4 hours. Complete or partial recanali
zation took place in nine patients. There
were two treatment failures, both in
patients with obstructed femoral artery
grafts. Complications observed were local
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bleeding in two cases and distal emboli
zation in one. Of the nine patients with
clot lysis, further revascularization was
obtained by surgical repair in six, and by
percutaneous transluminal angioplasty in
one. Only two patients required further
treatment.
The indications for intra-arterial strep
tokinase therapy in acute limb ischemia
are not yet well established. There appears
to be little reason for its use in patients
with embolism, since emboli can readily
and safely be removed by the balloon
catheter. Results of attempted surgical
thrombectomy or emergency arterial
reconstruction are much less satisfactory,
and consequently intra-arterial fibrino
lytic treatment will likely prove to be most
valuable in patients with acute thrombo
sis. It appears to be especially useful in
popliteal obstruction affecting the run-off
vessels in the calf, where restoration of
outflow greatly improves the success of
subsequent surgical repair.
It seems clear that streptokinase ther
apy alone is insufficient in all but a few
cases, and that subsequent treatment of
the underlying lesion, either by percutane
ous transluminal angioplasty or surgery,
is necessary to prevent rethrombosis.
I am not aware of a prospective trial
comparing intravenous heparin alone
with intra-arterial streptokinase as the ini
tial treatment in patients with acute
thrombosis, and the superiority of strep
tokinase has yet to be established.
New Trends in Fibrinolytic Treatment

Tissue-type plasminogen activator is a
naturally occurring protease that activates
the fibrinolytic system physiologically. It
binds avidly to fibrin, and circulating
plasminogen binds to the activator-fibrin
complex. Plasminogen conversion to
plasmin occurs at the fibrin surface of the
clot, and any plasmin that escapes into
the systemic circulation is rapidly inacti
vated by antiplasmin. As a result, a sys
temic lytic state is not induced.16
A tissue-type plasminogen activator has
been obtained from a human melanoma
cell culture and used to produce throm
bolysis in dogs with experimentally
created coronary artery thrombosis.17
The use o f this material in a small group
of patients with acute myocardial infarc
tion has been reported by Van de Werf
and colleagues.16 Clearance of thrombus
was demonstrated angiographically in six
of seven patients; none had evidence of
a systemic lytic state and no complication
occurred.
Since Van de Werf’s study was under
taken to obtain experience, no standard
dosage was determined, and the material
was given both intra-arterially and intra
venously. Van de Werf and colleagues
noted that any large trials of tissue-type
plasminogen activator would require a

more readily available source of this
material, and this might be possible using
genetic recombinant technology.18
Summary and Conclusions

The results of conventional treatment
of embolism by surgical embolectomy are
satisfactory. In patients with acute throm
bosis, whose limbs are judged to be via
ble, an initial trial of intravenous hepa
rin is worthwhile, with close observation
and subsequent elective arterial repair
where indicated. Emergency reconstruc
tion is necessary if the limb fails to
improve promptly, but the results are
poor.
Intravenous streptokinase therapy is
not sufficiently effective in acute arterial
occlusion and is associated with an exces
sive rate of systemic bleeding complica
tions as well as distal embolization.
Intra-arterial streptokinase appears to
be a promising therapeutic method in
selected patients with thrombosis, but the
indications for its use are not yet well
established and case selection remains
difficult.
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PIPRACIL
Parental Antibiotic for Intravenous and Intramuscular Use
INDICATIONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the
designated organisms in the conditions listed below. Intra abdominal Infections including hepatobiliary and
surgical infections caused by Escherichia coli, Pseudomonas aeruginosa, enterococci. Clostridium s p , anaerobic
cocci, and Bacteroides sp., including B. fragilis. Urinary Tract Infections (complicated and uncomplicated)
caused by Escherichia coli, Klebsiella sp., Pseudomonas aeruginosa, Proteus mirabilis and enterococci. Also
uncomplicated urethritis caused by Neisseria gonorrhoeae Gynecological Infections including endometritis and
pelvic inflammatory disease caused by Bacteroides sp., including B. fragilis, anaerobic cocci, Neisseria
gonorrhoeae, and enterococci (Streptococcus faecalis). Septicemia caused by Escherichia coli, Klebsiella sp.,
Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci, Pseudomonas aeruginosa, Bacteroides sp. and
anaerobic cocci. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp.,
Pseudomonas aeruginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci.
Although improvement has been noted in patients w ith cystic fibrosis, lasting bacterial eradication may not be
achieved. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp.,
Acinetobacter sp., Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis,
Bacteroides sp., including B. fragilis, anaerobic cocci and enterococci. Bone and Joint Infections caused by
Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci. PIPRACIL* is useful for the
treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms;
infections produced by organisms resistant to other penicillins, some aminoglycosides and cephalosporins; and
infections at various sites caused by streptococcus species including Group A beta-hemolytic Streptococcus and
Streptococcus pneumoniae.
PIPRACIL* may be administered as single drug therapy in some situations where normally two antibiotics might
be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
bacterial strains. PIPRACIL* has been used clinically w ith aminoglycosides, especially in patients w ith impaired
host defences. Both drugs were used in full therapeutic doses. PIPRACIL'can be used safely in combination with
a penicillinase-resistant penicillin, e.g. oxacillin, in mixed infections when beta-lactamase-positive Staphyloccus
aureus is isolated along with piperacillin-susceptible organisms. It may be administered concomitantly w ith a
cephalosporin, provided that an additive or synergistic antibacterial action of the tw o antibiotics is ascertained
through in vitro tests. Based on in vitro data, cefoxitin should not be given w ith piperacillin when Pseudomonas
infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients w ith
hepatobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic
reactions to other drugs, with appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if
appropriate, once the results are known.
CONTRAINDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
WARNINGS: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in
patients receiving therapy with penicillins. These reactions are more apt to occur in persons w ith a history of
sensitivity to multiple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy
w ith PIPRACIL* careful inquiry should be made concerning previous hypersensitivity reactions to penicillins,
cephalosporins and other allergens.
If an allergic reaction occurs, the antibiotic should be discontinued. SERIOUS ANAPHYLACTOID REACTIONS
REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS,
AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS NECESSARY.
PRECAUTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics
including piperacillin. These reactions have sometimes been associated w ith abnormalities of coagulation tests
such as clotting time, platelet aggregation and prothrombin time and are more likely to occur in patients w ith
renal failure.
If bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
therapy instituted.
The possibility of the emergence of resistant organisms and the development of superinfections should be kept in
mind, particularly during prolonged treatment. As w ith other penicillins, patients may experience neuromuscular
excitability or convulsions if higher than recommended doses are given intravenously.
Dosage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na + per gram based on
vial content which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
mEq/g (42.55 mg). Periodic electrolyte determinations should be made in patients w ith low potassium reserves
and the possibility of hypokalemia should be kept in mind w ith patients who have potentially low potassium
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
prolonged-treatment in patients w ith impaired cardiac function.
Prior to treatment, patients w ith gonorrhea should also be evaluated for syphilis. Specimens for darkfield
examination should be obtained from patients w ith any suspected primary lesions, and serologic tests should be
performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
minimum of 4 months.
The use of penicillins lampicillin, amoxicillin) has been associated w ith morbilli form rashes in some cases of
infectious mononucleosis. PIPRACIL* should be used w ith caution in the treatment of patients w ith infectious
mononucleosis.
Drug Interactions: The mixing of PIPRACIL* w ith an aminoglycoside in vitro can result in substantial inactivation
of the aminoglycosides.
Usage During Pregnancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined.
Because animal reproduction studies are not always predictive of human response, this drug should be used
during pregnancy only if clearly needed. It has been found to cross the placenta in rats. Caution should be
exercised when PIPRACIL* is administered to nursing mothers. It is excreted in low concentrations in milk.
Pediatric Use: Dosages for children under the age of 12 have not been established
ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been
local in nature, following intravenous or intramuscular injection. The following adverse reactions may occur:
Local Reactions-ln clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or
induration at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis
and hematomas. Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less
frequent findings: Pruritus, vesicular eruptions, positive Coombs tests Gastrointestinal-Diarrhea and loose
stools were noted in 2.8% of patients. Less frequent reactions: vomiting, nausea, bloody diarrhea.
H epatic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
Renal-Elevations of creatinine or BUN. Central Nervous System-Headache, dizziness, fatigue. Hemic and
Lymphatic-Reversible leukopenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin
time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged
therapy at high dosages or in association w ith drugs known to cause this reaction. Serum Electrolytes Individual;
w ith liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a
decrease in serum potassium concentrations w ith high doses of PIPRACIL*. Musculo-Skeletal-Rarely, prolonged
muscle relaxation. Other-Superinfection, including candidiasis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular adminstration of 6 to 8 g
daily of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for
maintenance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin
sodium treatment. Administration should not exceed 2 g per injection at any one site. This route has been used
primarily in the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular
injection. The preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also
may be given in the mid-lateral muscles of the thigh. The deltoid area should be used only if w ell developed, and
then only w ith caution to avoid radial nerve injury. Intramuscular injection should not be made into the lower or
mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted w ith 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein
irritation. The reconstituted and diluted solution may be administered by intermittent or continuous drip.

Intermittent infusion should be administered over a period of about 30 minutes. During intermittent infusion it is
desirable to discontinue the primary intravenous solution. Any unused portion must be discarded. For continuous
infusion the solution may be administered over a longer period of time
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for injection, or if required Bacteriostatic
Water for Injection, Lidocame HC1 0.5 or 1% (without epinephrinel-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required. Bacteriostatic Water
for Injection. Either parabens or benzyl alcohol. Lidocaine HC1 is contraindicated in patients w ith a known history
of hypersensitivity to local anesthetics of the amide type.
RECONSTITUTION TABLE
Volume of Diluent
to be added

Approximate Available
Volume

Approximate Average
Concentration

Vials 2 g
3g
4g

4.0 mL
6.0 mL
7.8 mL

5.0 mL
7.5 mL
10.0 mL

1 g/2.5 mL
1 g/2.5 mL
1 g/2.5 mL

Infusion Bottles
3g
4g

15 mL
20 mL

17 mL
23 mL

Product Size

The prepared solution may be further diluted to the desired volume w ith any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing any
of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
Intravenous Admixtures:
5% Dextrose in Water (D&W).
Normal Saline I + KCL 40 mEq.)
0.9% Sodium Chloride (Normal Saline) (NS).
5% Dextrose/Water ID'.WI I + KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride (DsNSI
5% Dextrose/Normal Saline IDsNSI I + KCL 40 mEq).
Lactated Ringer's Injection, U.S.P.
Ringer's Injection, U.S.P. I + KCL 40 mEq).
Dextran 6% in 0.9% Sodium Chloride
Lactated Ringer's Injection, U.S.P. I + KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted w ith
recommended diluents and further diluted w ith the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity! through 24 hours at room tern
perature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recommends
discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated. If used as a
multi-dose container, the vials must be reconstituted only w ith the bacteriostatic diluents noted above
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous
administration with solutions containing sodium bicarbonate.
PIPRACIL* should not be added to blood products, protein hydrolysates or ammo acids.
When PIPRACIL* is given concurrently w ith aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed w ith an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation to the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of
piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g/vial-3879 48 3 g/vial-3882 49 4 g/vial-3880 50
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium powder
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Urinary Tract Infection
(complicated)

Serious Systemic
Infection

12 g/day 4 g every 8 hrs.
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4. Occluded Infrainguinal Reconstructions
The reasons for occlusion of arterial problem and may account in part for the
reconstructions below the inguinal liga better patency rates reported by several
ment vary with the graft material used. groups using this technique. It seems
Since there is widespread agreement that probable that the proximal hyperplastic
autogenous vein is the most suitable lesion occurs as a result of intimal injury
material for infrainguinal bypass grafts, from the flow disturbance caused by the
it is appropriate to consider failure of narrowed proximal anastomosis.
A good deal of experimental and clini
autogenous vein grafts first.
cal evidence suggests that the intimal
hyperplastic lesions in reversed vein grafts
Autogenous Vein Grafts
are related to intimal injury at the time
Several years ago we reported our of graft harvesting.2'3 A number of solu
experience with 109 failed femoropo- tions to this problem have been proposed,
pliteal vein grafts.1 We were particularly and it has been demonstrated experimen
interested in the cause of graft failure and tally that the use of papaverine to prevent
the results using various techniques to vein-graft spasm at the time of harvest
repair such failures. We were able to ing and constant gentle dilatation of the
Les causes d'echec de la reconstruction
determine the cause of failure in approx graft may avoid intimal injury.3 The
arterielle sous-inguinale varient selon la
imately 70% of these grafts. It became clinical proof that such techniques are
methode de reconstruction utilis6e. Dans
apparent that the cause varied with the helpful has not yet been obtained.
les cas de greffe veineuse autogene, la
time after initial placement that the failure Another approach to prevent myoin
cause la plus fr6quente d'echec est
occurred. Graft failures within the first timal hyperplastic lesions in vein grafts
I'hyperplasie de la musculeuse intimale
30 days were invariably due to technical has been the use of antiplatelet therapy
du greffon lui-meme. D'autre part, la
errors — distal intimal flaps at the lower postoperatively. The aim is to reduce
cause la plus courante d'echec des grefanastomosis, anastomotic narrowing and platelet adhesion to the injured vein-graft
fons de polytetrafluoroethyldne semble
graft kinking. We concluded that the best wall thereby preventing the release of
etre une hyperplasie de la musculeuse
means of avoiding such errors was to platelet-derived growth factors thought to
intimale de I'artere au point d'anastoobtain an arteriogram on completion of be responsible for the hyperplasia of
mose distal, ou juste au-dela. On comthe surgical procedure before the patient myofibroblasts in the vessel wall at the
mente les diverses strategies qui
left the operating room. Thus, a true pic time of intimal healing.2 Unfortunately,
s'offrent pour faire face h ces deux for
ture
of the technical adequacy of the graft as far as infrainguinal reconstructions are
mes d'echecs de pontage, y compris
could
be obtained and necessary correc concerned, there is no clinical evidence
('utilisation d'une thSrapie thrombolytions
made.
In our experience completion that such therapy has improved vein-graft
tique.
arteriograms will show technical problems patency. A controlled study, in which our
requiring surgical correction in approxi service participated, failed to show any
effect of antiplatelet agents on vein-graft
mately 5% of graft procedures.
Vein-graft failure from 1 to 18 months patency.4
after insertion was usually caused by Vein-graft failure beyond 2 years can
myointimal hyperplastic lesions within the be caused by progression of the
graft.1
These included single or multiple atherosclerotic disease in the host arter
From the Department of Surgery, Brigham
areas
of
fusiform narrowing of the graft ies or even in the graft itself.1 However,
& Women's Hospital, Boston, Mass.
lumen or, in some instances, hyperplasia this cause of failure is not as common as
Presented as part of a symposium on acute of a valve apparatus with localized nar myointimal hyperplasia, which, in our
arterial insufficiency at the 54th annual
experience, accounts for the majority of
meeting of the Royal College o f Physicians rowing. One of the commonest areas for
failures.
and Surgeons of Canada by the Royal Col a myointimal hyperplastic lesion was graft
The reported superior patency of inlege in cooperation with the Canadian Soci approximately 2 cm distal to the proximal
ety for Vascular Surgery, Vancouver, BC,
anastomosis of a reversed vein graft. This situ saphenous vein grafts in the infrain
Sept. 11, 1985
was almost invariably associated with nar guinal position may be related to the fact
rowing of the inflow to the graft at the that intimal injury is avoided by leaving
Accepted for publication Dec. 16, 1985
heel of the upper anastomosis where the the graft for most of its length in its native
Reprint requests to: Dr. J.A. Mannick,
vein was attached to a thickened femoral bed and perfusing it only with arterial
Department of Surgery, Brigham &
artery. The recent widespread use of in- blood under normal pressure.5 In our
Women's Hospital, Boston, MA 02115,
situ saphenous vein grafts avoids this experience, these grafts appear to perform
USA
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The causes of failure of infrainguinal
arterial reconstruction vary with the
method of reconstruction used. The
commonest cause of autogenous veingraft failure is myointimal hyperplasia of
the graft itself. The commonest cause of
polytetrafluoroethylene-graft failure, on
the other hand, appears to be a myoin
timal hyperplastic lesion of the artery at,
or just beyond, the distal anastomosis of
the graft. Strategies for dealing with
these two forms of graft failure, includ
ing the use of thrombolytic therapy, are
discussed.

better than reversed vein grafts. Myointimal hyperplastic lesions, when they
occur in in-situ grafts, appear in the dis
tal end of the graft, which must be freed
up so that it can be attached to the host
artery.
Polytetrafluoroethylene Grafts

Polytetrafluoroethylene (PTFE) grafts
have been used widely for infrainguinal
arterial reconstruction over the past
decade. Failure of these grafts, both
experimentally and clinically, is fre
quently associated with a myointimal
hyperplastic response at the lower anasto
mosis. The response apparently begins in
the host artery and extends for a varia
ble distance into the graft itself.6 Grafts
of PTFE, in common with other grafts
of artificial material, will not remain
patent at very low flow rates and there
fore are less suitable than vein grafts for
use when outflow or run-off is restricted.
Early graft failure can be anticipated
under such circumstances.
Finally, it can be shown that PTFE
grafts, in common with Dacron grafts,
which are now used much less frequently
for lower extremity reconstruction,
buckle when the knee is flexed to 90° or
beyond if the grafts cross the knee joint.
This is likely an important cause of failure
in the infrapopliteal position. These
observations suggest that, in order to
avoid early graft failure, PTFE grafts
should not be used below the knee and
when run-off is restricted.
Umbilical Vein Grafts

Fluman umbilical vein grafts have also
received considerable attention as substi
tutes for autogenous vein in infraingui
nal reconstruction. Although there are
several reported series suggesting that
these grafts remain patent longer and
more often than PTFE grafts when used
for femoropopliteal reconstruction,7-9
we have not been able to duplicate these
results and have found that umbilical vein
grafts have a disappointing late patency
rate. These grafts are technically difficult
to use and are plagued by unpredictable
early failure even when the surgeon is
experienced in handling and suturing the
tissue. Late failure of umbilical vein grafts
can also be associated with myointimal
hyperplasia of the distal anastomosis and
by false aneurysm formation within the
graft.10
Management

The treatment of infrainguinal graft
failure will vary with the clinical status of
the involved extremity. Sometimes graft
failure is tolerated relatively well. If the
extremity remains viable and free of sym
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ptoms suggesting ischemia at rest, graft
failure may best be managed without
treatment. However, if the graft was
originally inserted as a limb-salvage
procedure, its failure usually leads to a
recrudescence of limb-threatening ische
mia, in which case a further attempt at
re-establishing arterial circulation is
usually indicated. Early graft failure,
within the initial postoperative period,
should invariably be managed by surgi
cal re-exploration and correction of the
technical problem if possible. Later graft
failure may be managed in many institu
tions by thrombolytic therapy in the radi
ology department. We have been partic
ularly impressed by the effectiveness and
tolerance of urokinase infusion into the
occluded graft through a small arterial
catheter introduced percutaneously. Our
recent experience suggests that this tech
nique will permit re-establishment of graft
patency in approximately 70% of
patients. It has the distinct advantage of
providing angiographic delineation of the
precise cause of graft failure, which then
permits surgical correction of the
problem.
This technique has been particularly
helpful in patients with failed autogenous
vein grafts. Previous experience on our
service had demonstrated that if veingraft stenosis was detected and repaired
before vein-graft thrombosis, the late
results were excellent, whereas if the ste
nosis that had caused graft thrombosis
was treated by graft thrombectomy, using
Fogarty catheters and correction of the
stenotic lesion, late graft patency was
extremely poor.1 Our early experience
with thrombolysis and subsequent patchgraft angioplasty suggests that this com
bined technique may result in considera
bly greater late patency of the vein graft.
Thrombolytic therapy is also often suc
cessful with thrombosed PTFE grafts in
the lower extremity and may permit a sub
sequent patch-graft angioplasty of the
commonly found distal hyperplastic
lesion just at or below the distal graft
anastomosis. We prefer to use an
autogenous venous patch graft for such
corrective angioplasties. Percutaneous
transluminal angioplasty is another pos
sible treatment for hyperplastic lesions of
vein and PTFE grafts. However, per
cutaneous transluminal angioplasty has
not been as successful in our experience
below the inguinal ligament as it has been
above.
Unfortunately we have had very little
success in repairing thrombosed umbili
cal vein grafts and almost invariably have
had to replace them with grafts of other
material.
Thrombolytic therapy itself is not free
of complications. The most serious
problem is bleeding at the catheter punc
ture site, but this has become less of a
problem on our service as radiologists

have learned to introduce small-bore
catheters using only one arterial puncture.
Thrombolytic therapy may also be com
plicated by embolization of thrombus to
the distal arterial tree at the time of
thrombolysis within the graft. This was
once considered a major drawback to the
treatment, but further experience has
demonstrated that the embolic clot will
often lyse with continued infusion of the
thrombolytic agent. Thrombolytic ther
apy is, of course, not applicable in the
immediate postoperative period because
of the dangers of anastomotic and wound
hemorrhages. It is not suitable for the
treatment of thrombosed Dacron prostheses for several months after graft inser
tion because of the danger of lysing the
fibrin within the interstices of the graft
wall and inducing serious hemorrhage
around the graft.
Our past experience indicates that
repair or replacement of thrombosed
grafts in the infrainguinal position results
in a 5-year limb salvage rate of only
50%.’ The recent combined use of
thrombolytic therapy and surgical correc
tion of specific lesions appears to be
associated with better results but the late
follow-up of these patients is not yet
available.
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ORIGINAL ARTICLES
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Internal Fixation of Femoral Neck Fractures:
a Prospective Study
To determine the adequacy of reduction
and the soundness of the technique of
primary internal fixation, the authors
studied prospectively 96 femoral neck
fractures over 6 ‘A years. Patients were
followed up for an average of 1 1
months. The mean patient age was 70
years. Both clinical and radiologic data
were collected at 3-month intervals for 6
months and then annually. Radiologic
indices recorded included the Garden
classification and index, shear angle.
Western Infirmary Glasgow angle, lateral
angle, nail placement, occurrence of
bony union and presence of avascular
necrosis.
The fixation devices included sliding
compression screw and side plate, multi
ple Knowles pins and a 130° A O blade
plate. A high rate of varus reduction,
excessive ante- or retroversion and poor
nail placement were all noted. Twentythree patients required a total of 36
reoperations. There were six deaths in
the first 6 months after operation.
Eighty-five patients (mean age 79
years) with femoral neck fractures
treated by hemiarthroplasty (71) or total
hip replacement (14) during the same
period were also reviewed. Follow-up
averaged 8 months. Tw o patients
required reoperation. The general mor
bidity was similar to that of the group
treated by internal fixation, but there
were eight deaths.
Femoral neck fractures, if treated by
From the Department o f Surgery, The
Wellesley Hospital, Toronto, Ont.

internal fixation, demand accurate reduc
tion and fixation for optimum results.
Primary prosthetic replacement should be
reserved for elderly patients with poor
bone stock.
Dans le but de determiner la valeur de la
reduction et de la technique de fixation
primaire interne, les auteurs ont 6 tudi6
de fagon prospective, sur une periode de
6 1/2 ans. 96 cas de fractures du col du
f6 mur. Les patients ont fait I'objet d'examens de contrdle pendant 11 mois en
moyenne. L'age moyen des patients etait
de 70 ans. Les donn6es cliniques et
radiologiques ont ete accumulees aux 3
mois pendant 6 mois, puis annuellement
par la suite. Les index radiologiques suivants ont ete compiles: index et classifi
cation de Garden, angle de cisaillement,
angle Western Infirmary Glasgow, angle
lateral, emplacement d'enclouage, appa
rition de la fusion osseuse et presence
d'une necrose avasculaire.
Parmi les instruments de fixation on a
utilise la vis de compression par glissement avec plaque laterale, les broches
multiples de Knowles et une lame 130°
AO. On a note un taux 6 leve de reduc
tions tournees vers le dedans, de retro
versions et d'ant 6 versions excessives et
de mauvais enclouage. Vingt-trois
patients ont necessite un total de 36
^interventions. II y a eu 6 dec^s au
cours des 6 mois qui ont suivi I'operation.
On a aussi etudie les cas de 85
patients (age moyen: 79 ans) ayant subi
une fracture du col femoral qui ont ete
traites durant la meme periode par
hemiarthroplastie (71) ou arthroplastie
totale de la hanche (14). Les examens de
surveillance s'etalent sur 8 mois en
moyenne. Deux patients ont du etre r6 op6 r6 s. La morbidite generale a ete semblable 6 celle du groupe traite par fixa
tion interne, mais il y a eu huit d6 c 6 s.
Les fractures du col femoral traitees
par fixation interne requierent une reduc
tion et une fixation precises si Ton desire

des resultats optimums. Les prothdses
primaires doivent etre reservees pour
patients ages qui ont une mauvaise
reserve osseuse.

The management of femoral neck frac
tures continues to be a great problem
despite advances in methods and tech
niques of internal fixation.1 Chan and
Hoskinson2 reported that these fractures
were the commonest cause of death from
injury in patients over 75 years old. Treat
ment has important socioeconomic impli
cations as our population of elderly
patients increases.3 Many who sustain
this fracture lose their independence and
require institutionalized care.
Although the treatment of femoral
neck fractures in the elderly is still con
troversial,4"13 accurate closed reduction
and internal fixation of the fracture, if
technically possible, give better results
than primary prosthetic replacement. This
comment is substantiated by a decreased
death rate at 6 months, a lower rate of
infection, the avoidance of prosthetic dis
location and the ease with which secon
dary salvage procedures may be per
formed if complications ensue.6' 13
A prospective study of femoral neck
fractures was started at The Wellesley
Hospital, Toronto, in December 1977.
Our aim in this study was to document
the patients sustaining this fracture, their
treatment course and complications. This
experience should help us identify factors
that could lead to the failure of treatment.
Patients and Methods

All 182 patients sustaining a femoral
neck fracture and treated at The Welles
t Professor o f surgery, University o f
ley Hospital from December 1977 to July
Toronto, Toronto, Ont.
1984 were entered in the study. Those
with pathologic fractures due to bone
Accepted fo r publication Feb. 28, 1986
tumours were excluded.
Reprint requests to: D r. J. Schatzker, Chief
Ninety-six patients (27 men, 69 women,
o f Orthopedic Surgery, Sunnybrook Medi
mean
age 70 years) were treated by inter
cal Centre, Ste. 3015, 2075 Bayview Ave.,
nal fixation with a mean follow-up of 11
Toronto, Ont. M 4 N 3M5
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months. Eighty-five patients (8 men, 77
women, mean age 79 years) underwent
primary prosthetic replacement and were
followed up an average of 8 months. One
patient was treated nonoperatively
because of severe illness.
Generally, patients were operated on
within 24 hours of diagnosis if they were
medically stable. Several different treat
ment methods were used: closed reduc
tion and internal fixation with Knowles
pins or the compression screw plate device
or AO blade plate, hemiarthroplasty
(Moore, Thompson, Muller or Bateman
type) or total hip replacement. No firm
treatment protocols existed. The decision
on the method of treatment was left to
the orthopedic surgeon. The use of antibi
otics prophylactically was also discre
tionary.
The patients were mobilized the day
after surgery with the aid of a walker and
weight bearing was allowed as tolerated.
Once their gait was steady they were
gradually transferred to the use of canes
and then discharged to a convalescent
hospital or nursing home, depending on
their individual needs and degree of
independence.
Follow-up clinical and radiologic
examinations were carried out at 12 and
24 weeks and then annually. The patient
population was a composite group from
a teaching hospital under the supervision
of four orthopedic surgeons, hence no
uniform prospective follow-up protocol
existed. Some patients were discharged
from care at 3 or 6 months if the frac
ture was united and satisfactory ambula
tion was achieved.

FIG. 1—Garden stage I fracture. Fracture
is impacted into valgus.
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In March 1985 we attempted to contact
all patients in the study by telephone with
questions about mobility and functional
level, the use of walking aids and com
plications of treatment. We asked patients
to come for clinical and radiologic exami
nation, but most patients declined
because of age and difficulties posed by
a return visit. The follow-up period is the
time from operation to the last full clini
cal and radiologic examination.

All pre- and postoperative x-ray films
were carefully examined and the follow
ing data recorded, where applicable:1’4’5
Garden classification, shear angle,
Garden index, Western Infirmary Glas
gow (WIG) angle, lateral angle, nail
placement, the presence of bony union
and avascular necrosis.
The Garden classification subdivides
fractures of the femoral neck into four
stages: stage I — a fracture impacted into

FIG. 2—Garden stage II fracture. Fracture
is complete but without displacement.

FIG. 4—Garden stage IV fracture. Fracture
fragments have completely displaced, as con
tact between fracture surfaces has been lost.
Distal fragment is externally rotated and lies
anterior to proximal fragment.

FIG. 3—Garden stage III fracture. Partially
displaced fracture has fallen into varus with
external rotation and has shortened.

FIG. 5—Garden index or angle.
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valgus (Fig. 1); stage II — a complete
fracture without displacement (Fig. 2);
stage III — a complete fracture in which
the fracture surfaces are still in apposi-

FIG. 6—Western Infirmary Glasgow (WIG)
angle and shear angle. Arrow identifies direc
tion of forces acting on hip.

Garden
fracture type
II
II
III
III
IV
III

tion posteroinferiorly, but the fracture
has fallen into varus, and the leg is exter
nally rotated and shortened (Fig. 3); stage
IV — a fracture in which fragments are

FIG. 7—Lateral angle.

completely displaced and surface contact
has been lost (Fig. 4).
The Garden index is the angle sub
tended by the central axis o f the medial
group o f trabeculae in the head fragment
and by the line of the medial femoral cor
tex (Fig. 5). On the anteroposterior film
this angle measures the alignment o f the
femoral head on the neck after reduction.
Garden considers the reduction to be ade
quate if this angle measures between 160°
and 180°. A value greater than 180°
signifies too much valgus, and a value
less than 160° too much varus.
The WIG angle is a measure o f the
amount o f upward or downward shift o f
the distal fragment on the proximal one.
This angle is measured by connecting
three points on the anteroposterior film:
the centre of the head, the centre o f the
fracture line and the base o f the greater
trochanter (Fig. 6). If the fracture is
reduced, the WIG angle measures be
tween 140° and 160°. A value less than
140° signifies a reduction in too much
valgus, and a value greater than 160° sig
nifies too much varus.
The shear angle is the angle between the
fracture line and a line drawn parallel to
the medial femoral cortex on the antero
posterior roentgenogram (Fig. 6). A
higher shear angle allows the physiologic

Table 1-Patients Who Required Reoperation After Internal Fixation
Lateral
Nail
Garden
WIG
Shear
position
angle, °
angle, °
index
angle,0

Reason for reoperation
171
-5 5
171
50
Loss of reduction
?
7
?
7
Loss of reduction
24
171
+ 11
153
Loss of reduction
?
178
40
118
Loss of reduction
?
?
166
50
Loss of reduction
7
160
21
170
Loss of reduction
Loss of reduction,
7
150
70
110
III
nail penetration
Loss of reduction,
152
-2 9
155
48
II
nail penetration
Loss of reduction,
nail penetration,
7
162
32
123
1
avascular necrosis
Loss of reduction,
nail penetration,
?
0
162
62
III
avascular necrosis
Loss of reduction,
nail penetration.
?
?
151
52
IV
avascular necrosis
Loss of reduction,
162
-1 7
45
158
III
avascular necrosis
-2 9
152
82
180
IV
Avascular necrosis
Nail penetration,
?
-3 7
130
1
51
avascular necrosis
?
152
0
62
1
Nail penetration
?
-3 0
160
III
50
Nail penetration
?
?
158
46
III
Nail penetration
-11
146
29
165
IV
Nail penetration
155
-31
37
180
II
Resorption of neck
-2 8
152
42
170
IV
Resorption of neck
7
0
140
III
68
Pain
?
?
180
55
III
Pain
0
174
136
IV
40
Pain
C - centre, H - high, L - low, A - anterior, P = posterior, THR = total hip replacement, UA G - Girdlestone arthroplasty and EF - excision of fixation.

Type of
fixation

Revised to

Nail plate
Nail plate
Nail plate
Knowles pin
Nail plate
Nail plate

G, UA
UA
RF
UA X 2, G
RF
UA, G, THR

H, A

Nail plate

THR

C, A

Nail plate

THR

C, ?

Knowles pin

UA

C, C

Nail plate

UA

C, ?

Nail plate

THR

C, C
C, C

Nail plate
Nail plate

THR
THR

C,
H,
C,
C,
C,
C,

A
P
C
?
P
?

THR
Knowles pin
C, A
RF
Knowles pin
L, C
UA
Nail plate
C, A
Nail plate
UA
C, ?
EF
Nail plate
C, C
UA
Nail plate
C, C
THR
Nail plate
C, C
EF
Nail plate
C, C
UA
Nail plate
C, A
THR
Nail plate
C, C
unipolar arthroplasty, RF - revision fixation,
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forces around the hip joint to exert com
pression on the fracture site after reduc
tion, making it more inherently stable
than a fracture with a lower angle, which
is more subject to shear.
On the cross-table lateral film, the
lateral angle is the one subtended by a line
drawn from the midpoint of the fracture
surface of the distal fragment to the
centre of the femoral head, and a line
drawn through the central axis of the neck
(Fig. 7). This angle indicates the degree
o f anterior or posterior angulation of the
head on the neck after reduction. In a per
fectly reduced fracture, the lateral angle
measures 0°.
Nail placement in relation to three seg
ments of the femoral head was noted on
both the anteroposterior (placement high,
central or low in the head) and lateral
(placem ent anteriorly, centrally or
posteriorly in the head) films. Optimally,
on anteroposterior and lateral films the
nail should appear in the centre of the
head and neck.1,10 This region is the
junction of the tension and compression
trabeculae of the head and neck and
represents the strongest bone for fixation.
A high or anterior position has been
associated with poor results due to loss
o f fixation.1 The nail tip should rest
against the subchondral bone approxi
mately 5 to 10 mm from the jo in t.10

17 stage I, 26 stage II, 37 stage III and
16 stage IV. The shear angle averaged 46°
(range from 19° to 82° ). The appliances
used for internal fixation included
compression-screw devices (Richards or
Dynamic hip screw) in 77 cases, multiple
Knowles pins in 18 hips and a 130° AO
blade plate in 1 case. Operative time aver
aged 66 minutes. Antibiotics were given
prophylactically in 44 cases (46%).
The Garden index5 was difficult to
calculate on the immediate postoperative

anteroposterior film as the trabecular
alignments in the head and neck are vari
able and the fixation device often
obscured the pattern of lines. However,
in the 69 cases in which we could calcu
late this index, the mean value was 169°
(range from 110° to 202°). In only 32
(46%) of the 69 cases was the index within
the recommended range of 160° to 180°.
Nineteen fractures (28%) were reduced
into valgus (greater than 180°) and 18
(26%) were reduced into varus (less
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Results

§8 Internal Fixation

Fig. 10a

According to the Garden classification,
the 96 internally fixed fractures comprised

Fig. 9a
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FIG. 8—Garden stage IV subcapital fracture
of femur.
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Fig. 9b
FIG 9—(a) Postoperative anteroposterior
view. WIG and Garden angles are within
acceptable range, (b) Lateral view. Reduction
is in marked retroversion.

Fig. 10b
FIG. 10—Films obtained 10 months later,
(a) Anteroposterior view. Femoral neck has
collapsed and is partially resorbed, hip is in
functional varus (greater trochanter above
centre of femoral head) and hip, which was
painful, is subluxated, (b) Lateral view. Aspi
ration of fluid from hip showed no growth of
bacteria.
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than 160°). The WIG angle was easier to
calculate than the Garden index and was
available in 89 cases. The WIG angle
averaged 151° (range from 106° to 189°).
Forty-two (47 Vo) of the 89 hips had a
reduction within the acceptable limits of
140° to 160°. Twenty patients (22%) had
a reduction less than 140° (valgus) and 27
(30%) had a reduction greater than 160°
(varus).
The lateral angle was calculated on the
cross-table lateral x-ray film. This value
is 0° in an anatomically reduced fracture.
Negative values signify retroversion and
positive values anteversion. The lateral
view was either not obtainable or
the lateral angle not calculable in 31 hips.
In the 65 hips for which this angle was
recorded, the range was from -60° to
+ 28°. If one accepts a range of -10° to
+10° for adequate reduction, then 33
(51%) of the 65 hips were adequately
reduced; 24 (37%) were reduced into
retroversion and 8 (12%) into antever
sion. If one broadens the range of accep
tance to -20° and +20°, 20 (31%) hips
lay outside this range.
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Optimally, the nail should appear in the
centre of the head and neck on the
anteroposterior and lateral roentgeno
gram s.1,10 The nail was placed high in 4
(4%) of 96 hips and anteriorly in 13
(18%) of 74 cases (22 unavailable). The
fixation device was noted to be right up
to the cartilage of the head or into the hip
joint in six cases. Some hips had multi
ple infractions. Overall, 19 of the 74 hips
for which both anteroposterior and lateral
x-ray films were available had poor place
ment of the internal fixation.
There were 12 cases o f documented
avascular necrosis: two stage I, one stage
II, four stage III, five stage IV fractures.
Radiologic bony union was achieved in
all 73 fractures not requiring reoperation.
Twenty-three (24%) of the 96 patients
required reoperation — one operation in
15, two in 4, three operations in 3 and
four subsequent operations in 1 patient.
Table I summarizes these cases according
to the reason for reoperation. Three
patients had one or more revisions of their
internal fixation: two for loss of reduc
tion and one for nail penetration. Two
patients required removal of the internal
fixation device because of nail penetra
tion or local pain. Eighteen patients had
revision to uni- or bipolar arthroplasty.
O f these, 10 had reoperation because of
loss of reduction, with or without nail
penetration or avascular necrosis, 2
because of avascular necrosis, 2 for nail
penetration, 2 for femoral neck resorp
tion with pain (Figs. 8 to 11) and 2
because of painful coxarthrosis. O f the
18 patients requiring secondary arthro-

►*■
Table Ill-Deaths and Complications in the
Internal Fixation Group (96 Patients)
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FIG. XI—Total hip replacement was subse
quently performed. All intraoperative cultures
were negative for bacteria.
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No. of
patients

Death/complication

-■ v

Died within 6 mo
Deep vein thrombosis
Pulmonary embolism
Cerebrovascular accident
Bowel obstruction
Gastrointestinal hemorrhage
Deep infection - primary
after revision
Pneumonia
Cardiac (arrhythmia, congestive
heart failure)

6
2
1 (fatal)
2
1
1
1
2
1
2

Table II—Comparison of Patients With Primary Internal Fixation Who
Did and Did Not Undergo Reoperation
Variables
Varus reduction
Garden index
WIG angle
Lateral angle < -1 0 ° (retroversion)
Poor pin placement*

No reoperations,
no./total no. (%)
12/55
20/68
15/51
12/56

(21.8)
(29.4)
(29.4)
(21.4)

*74 cases had anteroposterior and lateral x-rays available.

Reoperation,
no./total no. (%)
6/14
7/21
9/14
7/18

(42.9)
(33.3)
(64.3)
(38.9)

plasty 4 (22%) required an open or closed
reduction for dislocation of the prosthe
sis and treatment with boots and bars for
6 weeks. Three (13%) of the 23 hips
requiring revision became infected after
one or more reoperations and eventually
excision arthroplasty was necessary.
From Table I one can correlate the
radiologic findings with the poorer clini
cal results. O f the 14 revised hips in which
the lateral angle could be measured, 10
(71%) had an unacceptable reduction (9
retroverted to an average of 30°, 1
anteverted to 11°). In 4 of these 10 cases,
the reduction was lost; 2 had avascular
necrosis o f the head and the other 2
resorption of the femoral neck. Using
Garden’s index, 6 (43%) of 14 hips that
required reoperation were pinned in
excessive varus and, in all, the reduction
was lost. None of the 14 hips was pinned
in excessive valgus. When the WIG angle
is considered, 7 (33%) of 21 hips that
required reoperation were fixed in exces
sive varus and 2 (10%) were fixed in
valgus. In all hips pinned in varus, the
reduction was lost. In one of the two hips
pinned in excessive valgus, avascular
necrosis subsequently developed. The
shear angle was less than 50° in 14 (64%)
of 22 revised hips. In 8 (57%) of these 14
cases, the reduction was lost.
In Table II, patients requiring reoper
ation are compared with those not requir
ing reoperation, using three different vari
ables: varus reduction, lateral angle and
pin placement. Definite trends were
noted. Inadequate reduction (varus or
retroversion) and fixation (pin placement
anteriorly, high, or into the joint) were
associated with a higher reoperation rate.
Other complications are listed in Table
III. We had knowledge of six deaths in
the immediate postoperative period (6
months), five of which occurred in the
first 3 months.
Thirty-six (37.5%) of the 96 patients
were contacted in our telephone inter
views in March 1985. The mean follow
up o f this group was 15 months and
included 8 patients requiring reoperation.
Whereas 23 (82%) of 28 patients not
requiring further surgery had a pain-free
hip, only 4 o f 8 patients who required
reoperation were free of pain. The use of
walking aids was higher in the patients not
requiring further surgery (11 [39%] of 28)
than in patients requiring reoperation (2
[25%] of 8).
By Garden’s classification, the 85 frac
tures treated by prosthetic replacement
comprised 1 stage I, 3 stage II, 35 stage
III and 43 stage IV fractures (3
unknown). The prostheses used included
27 uncemented Moore hemiarthroplasties,
18 uncemented Thompson hem iarthro
plasties, 14 cemented Thompson hemiar
throplasties, 8 Muller hemiarthroplasties,
4 Bateman universal prostheses and 14
total hip replacements.
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Primary Arthroplasty
Eight of the 85 patients who underwent
primary arthroplasty died, all within the
first month after operation. There was
one deep infection with prosthetic dislo
cation, resulting in excisional arthro
plasty. There were two calcar fractures,
two greater trochanteric fractures and two
cases of myositis ossificans. One painful
hemiarthroplasty was revised to a total
hip replacement, 9 months postoperatively. Other general complications are
listed in Table IV.
Twenty-six (31%) of the 85 patients
were contacted by telephone an average
of 39 months after operation (range 8 to
84 months). Nineteen (73%) were free of
pain but only 5 (19%) did not use walk
ing aids.
Discussion

Despite advances in methods and tech
niques of internal fixation, fractures of
the fem oral neck continue to be
associated with a high morbidity and
mortality in the elderly. A certain com
placency has been associated with the
treatment of this fracture, with reliance
on a fixation device and disregard to the
criteria for a good reduction and proper
device placement. The study reported by
Barnes and colleagues1 clearly showed
that if closed reduction and internal fix
ation are chosen for a femoral neck frac
ture, the fracture should be accurately
reduced and the fixation device placed
correctly for optimal results. Stability
should be ensured by impaction of the
fracture at the time of operation. These
points, together with the type of fracture
(Garden classification), have prognostic
importance. Varus reduction, excessive
ante- or retroversion and poor nail place
ment have been correlated with loss of
reduction and nonunion. Extreme valgus
reduction has been associated with avas
cular necrosis.1
The poor results in our series point to
continuing difficulties in the treatment of
this fracture in a teaching institution. On
the anteroposterior film, the WIG angle
was outside the accepted range in 53% of
Table IV—Deaths and Complications Prosthetic Group (85 Patients)
Deathfcomplication
Death
Deep vein thrombosis
Cerebrovascular accident
Bowel obstruction
Myocardial infarction
Respiratory failure
Seizure
Gastrointestinal hemorrhage
Feeding gastrostomy
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No. of
patients
8
2
2
1
1
2
1
1
1

cases. Similarly, the Garden index was
beyond the accepted range in 54%. The
lateral angle was abnormal in 49%. The
percentage of varus reductions averaged
between 25% and 30%, depending on the
method of calculation.
In our series of fractures treated with
internal fixation, the reoperation rate was
24%. In most cases, the reason for
reoperation correlated with poor reduc
tion and fixation methods. One-third of
the patients who underwent reoperation
subsequently required multiple proce
dures with the associated risks of infec
tion, dislocation of the prosthesis and
general com plications. These facts
emphasize the necessity for initial
accurate reduction and fixation.
If closed reduction and internal fixa
tion are chosen as the method of treat
ment, the fracture should be reduced on
a fracture table under radiologic control.
We agree with Hunter10 that the Flynn
maneuver rather than the more traumatic
Leadbetter manipulation should be used
for reduction. The former entails gentle
flexion of the limb beyond 90°, traction
in the line of the neck of the femur, then
gentle internal rotation as the leg is
extended. The limb is then fixed in exten
sion, internal rotation and 10° of
abduction.
Anteroposterior and lateral views of
the reduction, using the image intensifier,
are then obtained. On the anteroposterior
view, an anatomic or slight valgus reduc
tion is acceptable; a varus reduction is
not. On the lateral view, anatomic or
slight anterior angulation is acceptable,
but not posterior angulation. One should
not proceed with fixation until an accept
able reduction has been obtained. A com
pression screw is then placed under radi
ologic control, up the centre of the neck
into the head, as viewed on the
anteroposterior and lateral views. The tip
of the screw should come to lie 5 mm to
10 mm from the articular surface of the
femoral head. Before closure, the fracture
should be impacted by releasing the trac
tion, using an impaction screw or by
delivering several blows with a punch and
mallet to the side plate device in the line
of the femoral neck.
If the fracture cannot be reduced by the
closed method, we recommend an open
reduction if the patient is young and
healthy and if the bone stock is adequate.
If the patient is elderly, infirm and has
poor bone stock, prosthetic replacement
should be performed. These options
should be anticipated preoperatively, so
that a consent form can be signed and the
operative team notified. The appropriate
option is then carried out under the same
anesthetic as the closed reduction, if
necessary.
An open reduction is accomplished by
extending the incision proximally, per
forming a capsulotomy of the hip joint

and reducing the fragments under direct
vision. During this procedure, the trac
tion is released to allow gentle manipula
tion of the fragments. Internal fixation
is performed with a compression screw
and side plate if the reduction, as assessed
by direct vision and the image intensifier,
is considered adequate.
When prosthetic replacement is neces
sary in the elderly because closed reduc
tion has failed, much greater morbidity
and mortality than with primary pros
thetic replacement has been reported.12
Therefore, primary prosthetic replace
ment is recommended in elderly patients
with poor bone stock, instead of closed
reduction and internal fixation.
We are indebted to Dr. Gordon Hunter for
his constructive criticisms. We also thank the
departments o f medical records, radiology and
photography o f The Wellesley Hospital, and
Jane Goodman and Liliana Tari for their dili
gent work.
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Reduction of Intimal Hyperplasia in Canine Autologous
Vein Grafts With Cod-Liver Oil and Dipyridamole
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To determine the effects of cod-liver oil
and a combination of cod-liver oil and
dipyridamole on vein-graft intimal hyper
plasia, 76 segments of undistended jugu
lar vein were interposed between bilater
ally divided femoral arteries in 38
mongrel dogs who received a 2 %
cholesterol diet. Ten control animals
received the diet alone, 8 received codliver oil containing 1.8 g of eicosapentaenoic acid daily 1 week before and for
6 weeks after operation, and 20 dogs
received 1.8 g of eicosapentaenoic acid
and 75 mg of dipyridamole daily 1 week
before and for 6 weeks after operation.
A similar and significant (p < 0.01)
increase in serum cholesterol was
observed in all three groups. Prothrom
bin, partial thromboplastin and clotting
times and the platelet count were
unchanged in the controls and in those
receiving cod-liver oil. Clotting time
increased in the animals receiving a com
bination of cod-liver oil and dipyridamole
(p < 0.001). Measurements (406 ± 2 7 )
of intimal thickness were made from
each graft. Intimal thickness was
3.7 ± 0.1 nm before implantation and
increased to 78 ± 8
after in the con
trols. Cod-liver oil limited the increase in
intimal thickening, to 24 ± 3 jtm (p <
0.001); cod-liver oil and dipyridamole
further reduced the increase in intimal
thickening, to 17 ± 1.4 /im (p < 0.001).
The data indicate that a combination of
cod-liver oil and dipyridamole is more
effective than cod-liver oil alone in
reducing canine vein-graft intimal hyper
plasia (p < 0.03).
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Dans le but d'gvaluer les effets de I'huile
de foie de morue et d'une association
d'huile de foie de morue et de dipyrida
mole sur I'hyperplasie de I'intima des
greffes veineuses, 76 segments de veines jugulaires nondistendues ont 6t6
interposees entre les art&res fSmorales
bilateralement divisees de 38 chiens
batards a qui Ton administrait un regime
contenant 2 % de cholesterol. Dix animaux temoins ont recu le regime seul;
8 ont regu quotidiennement de I'huile de
foie de morue renfermant 1.8 g d'acide
eicosapentaenoique a partir d'une
semaine avant I'operation et jusqu'a la
6e semaine apr&s; et 20 chiens ont recu
chaque jour, 1.8 g d'acide £icosapenta&noique et 75 mg de dipyridamole pen
dant la meme periode. On a observe
dans les trois groupes une augmentation
significative semblable (p < 0.01). Chez
les tgmoins et chez les animaux qui ont
regu de I’huile de foie de morue, on n'a
observe aucun changement des temps
de prothrombine, de cgphaline, de coa
gulation et de la numeration des plaquettes. Le temps de coagulation s'est
allonge chez les animaux qui recevaient
■'association d'huile de foie de morue et
de dipyridamole (p < 0.001). Des mesures (406 ± 2 7 ) de l'6paisseur de I'intima
ont 6t6 realisee sur chaque greffon.
L'epaisseur de I'intima s'est accrue chez
les animaux temoins de 3.7 ±0.1 ^m
avant la greffe 78 ± 8 jim aprfcs. L'huile
de foie de morue a limits I'epaississement de I'intima, & 2 4 ± 3 /rm (p <
0.0 0 1 ); I'huile de foie de morue et le
dipyridamole ont reduit davantage
I'epaississement de I'intima & 17 ± 1.4
jtm (p < 0.001). Ces resultats indiquent
qu'une association d'huile de foie de
morue et de dipyridamole est plus efficace que I'huile de foie de morue seule
pour reduire I'hyperplasie de I'intima
des greffes veineuses chez le chien
(p < 0.03).
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Platelet inhibition is currently used to
reduce vein-graft intimal hyperplasia and
to improve graft patency following
arterial reconstruction.1-3 Cod-liver oil
and dipyridamole interfere with platelet
VOLUME 29, NO. 5, SEPTEMBER 1986 / THE CANADIAN JOURNAL OF

metabolism and reduce platelet aggrega
tion. Cod-liver oil, containing the unsatu
rated fatty acid eicosapentaenoic acid,
decreases platelet membrane synthesis of
thromboxane A2;4>5 and dipyridamole
inhibits the platelet enzyme, phos
phodiesterase, resulting in an increase in
cyclic adenosine 5-n:onophosphate.6
This study was designed to determine the
effects of cod-liver oil alone and in com
bination with dipyridamole on vein-graft
intimal hyperplasia in dogs that under
went femoral artery bypass.
Materials and Methods
Thirty-eight adult mongrel dogs,
weighing between 25 and 30 kg, were fed
a 2% cholesterol diet (I.C.N. Nutritional
Biochemicals, Cleveland, Ohio). Ten con
trol animals received the lipidsupplemented diet alone, 8 animals
received cod-liver oil containing 1.8 g of
eicosapentaenoic acid daily 1 week before
and for 6 weeks after operation and a fur
ther 20 animals received 1.8 g of
eicosapentaenoic acid and 75 mg of
dipyridamole daily 1 week before and for
6 weeks after arterial reconstruction.
The animals were sedated with 1 ml of
Innovar, anesthetized with sodium pen
tobarbital (5 mg/kg) and ventilated with
a pressure-regulated ventilator. The left
external jugular vein and the femoral
arteries were exposed, using sterile tech
nique. A long segment of external jugu
lar vein was then removed and placed in
plasmalyte solution. A 1-cm segment of
the vein graft was immediately fixed in
formaldehyde for later examination under
the light microscope. After systemic
administration of heparin (2 mg/kg) the
femoral arteries were isolated between
vascular clamps and a 2.5-cm segment of
external jugular vein was interposed
between bilaterally divided femoral arter
ies with running 6-0 Prolene suture, using
optical magnification. The incisions were
closed. The vein grafts were harvested at
6 weeks and immediately fixed in for
maldehyde. They were stained with Mas
son stain. Multiple cross-sections were
prepared at 2-mm intervals throughout
the entire length of the grafts. Intimal
SURGERY
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thickness was measured at 100 /rm inter
vals around the entire circumference of
the vein graft with a Zeiss computerized
microscope (Karl Zeiss Canada Ltd., Don
Mills, Ont.). The resolution of the meas
uring equipment was calculated at ± 0.52
fim.

The serum cholesterol value, prothrom
bin, partial thromboplastin and clotting
times and platelet count were measured
before the 2% cholesterol diet was
started, after 1 week of the diet and at 2
and 4 weeks after operation.
The results are reported as the arith
metic mean with corresponding standard
error; Student’s /-test was used for
statistical comparison.
Results
Lipid supplementation resulted in a
similar increase in serum cholesterol
values in all three groups. The value rose
from a baseline of 4.6 ± 0.9 m m o l/L to
9.0 ± 1 mmol/L in the control animals,
to 7.1 ± 0.5 mmol/L in animals receiv
ing cod-liver oil alone and to 7.1 ± 0.3
m m ol/L in the animals receiving a com
bination of cod-liver oil and dipyridamole
(p < 0.01). Prothrombin, partial throm 
boplastin and clotting times and the
platelet count were unchanged in
the control animals and those animals
receiving cod-liver oil alone. How
ever, clotting time increased from
160 ± 3 seconds to 226 ± 6 seconds in dogs
receiving a combination of cod-liver oil
and dipyridamole (p < 0.001).
Intimal thickness was measured at 6
weeks with a Zeiss computerized micro
scope, taking 406 ± 27 measurements
from each graft. Intimal thickness meas
ured 3.7 ± 0.1 imm before implantation
and increased to 78 ± 8 //m in the con
trol animals (Fig. 1). Cod-liver oil reduced
intimal hyperplasia to 24 ± 3 /un (p <
0.001), while the combination of cod-liver
oil and dipyridamole further reduced

FIG. 1—Intimal thickness (/im ) of grafts
(406 ± 27 measurements per graft) with cor
responding standard error of mean. CLO =
animals receiving cod-liver oil alone, CLO-D
= animals receiving combination of cod-liver
oil and dipyridamole.
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intimal hyperplasia to 17 ± 1.4 pm (p <
0 . 001).

Discussion
Experimental studies indicate that
platelets stimulate the proliferation of
smooth-muscle .cells in the wall of an
injured artery and in vein grafts used for
arterial reconstruction.'•2-1 Ross and
colleagues8 isolated a mitogenic plateletreleased serum factor that stimulates the
proliferation of smooth-muscle cells in
the media of an injured artery; while
Imparato and associates,9 with the aid of
the electron microscope, have shown that
the proliferating medial cells migrate
toward the intima, ultimately resulting in
intimal thickening. Intimal hyperplasia
and early atherosclerotic lesions develop
in the region o f arterial injury in animals
receiving lipid supplementation; whereas
intimal hyperplasia is reduced and early
atherosclerotic lesions are absent in
animals with platelet-deficient serum or
in animals receiving platelet-inhibiting
medication.7 Similar histologic findings
are present in autologous vein grafts used
for arterial bypass. Intimal thickening
occurs within 6 to 12 months of arterial
reconstruction,10”13 and atherosclerotic
lesions are present in the wall of occluded
grafts examined 5 to 10 years after
implantation.14 These observations sug
gest that proliferation of smooth-muscle
cells is a physiologic response to blood
vessel injury and that the hyperplastic
intima gradually takes up serum lipids.
Cod-liver oil and dipyridamole reduce
platelet aggregation by interfering with
platelet metabolism. Cod-liver oil, rich in
the unsaturated fatty acid eicosapentaenoic acid, competes with arachidonic
acid for the enzyme cyclo-oxygenase and
is metabolized by platelet membranes to
a weakly aggregatory prostanoid, throm
boxane A3, while blood vessels convert
eicosapentaenoic acid to antiaggregatory
prostacyclin I3.4-5"15.16 Dipyridamole
inhibits the enzyme phosphodiesterase,
resulting in increased platelet synthesis of
cyclic adenosine 5-monophosphate.6 The
effects of these antiplatelet drugs on
platelet aggregation suggest that cod-liver
oil alone or in combination with dipyrida
mole would be a logical choice for an
antiplatelet drug regimen to prevent
platelet-mediated intimal hyperplasia.
Platelet inhibition with acetylsalicyclic
acid (Aspirin) and dipyridamole reduces
intimal hyperplasia in canine autologous
vein grafts2 and recently has been used
to improve long-term graft patency after
myocardial revascularization.3 We com
pared Aspirin and dipyridamole with codliver oil17 and found that cod-liver oil
was more effective, although both drug
regimens reduced canine vein-graft
intimal hyperplasia. In the current study

Aspirin was deleted from the accepted
antiplatelet regimen and dipyridamole
was combined with cod-liver oil, because
previous reports have shown that Aspi
rin may reduce blood-vessel biosynthesis
of prostacyclin, thus interfering with the
prostacyclin-thromboxane ratio.61819
Our data indicate that the combination
of these two selective platelet-inhibiting
drugs is more effective than cod-liver oil
alone and suggests that there may be
alternative and more-effective antiplate
let drug regimens to reduce intimal hyper
plasia in vein grafts used for arterial
reconstruction.
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Metastatic Tumours of the Testes
Metastatic tumours of the testes are
uncommon, making up little more than
2% of all testicular neoplasms. The most
frequent primary sites are the lung and
prostate. Only rarely do these lesions
present clinically either as the first sign
of malignant disease or as a complicating
factor during the course of known dis
ease. The authors present two cases
illustrating both of these occurrences.
The first, a man with carcinoma of the
common bile duct, initially had a mass in
the testicle and the second, a patient
with carcinoma of the prostate, had his
clinical course complicated by a sympto
matic metastasis to the right testis. The
authors also reviewed their local autopsy
experience and identified 16 more cases.
Metastases were grossly visible in 38%
(6 of 16). The most frequent primary
sites were lung (four cases), stomach
(four) and prostate (three). Routes of
spread as well as possible explanations
for the low incidence are discussed.

Les metastases testiculaires sont rares.
Elies comptent pour ^ peine plus de 2%
de tous les cancers testiculaires. Les
foyers primaires les plus frequents sont
le poumon et la prostate. Ce n'est que
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rarement que ces lesions font partie du
tableau clinique soit comme premier
signe d'une tumeur maligne, soit comme
complication dans revolution d'un cancer
connu. Les auteurs decrivent deux cas
qui illustrent bien ces deux possibility.
Dans le premier cas, il s'agissait d'un
homme atteint d'un cancer du choledoque qui a presente initialement une
masse testiculaire; le second cas, un
patient souffrant d’un cancer de la pros
tate, a vu revolution de sa maladie se
compliquer d'une metastase symptomatique du testicule droit. Les auteurs ont
egalement etudie les rapports d'autopsies pratiquees dans leur milieu et ont pu
identifier 16 autres cas. Des metastases
macroscopiques ont 6te observes dans
38% des cas (6 sur 16). Les tumeurs
primitives gtaient localisees le plus souvent au poumon (quatre cas), & I'estomac (quatre) et k la prostate (trois). On
commente les voies d'envahissement et
les raisons probables de leur faible fre
quence.

Tumour metastases involving the testes
are rare and most often are incidental
findings at autopsy. The reported inci
dence in autopsy series varies from
0.02%' to 2.5% .2 There are occasional
reports in the literature3'8 of malignant
lesions presenting as metastatic tumour in
the testes or o f tumour metastasizing to
the testes during the course of known
malignant disease.9'11 We recently saw
two patients whose clinical courses illus
trate both o f these phenomena. Because
this occurrence is rare and because o f the
100-fold variance in reported incidence,
we reviewed our experience.

Case Reports
Case 1
An 80-year-old man complained of an
enlarging, painful, right testicle, low back pain
and a 14-kg weight loss. His medical history
was non-contributory. He had no cardiovas

cular, chest or gastrointestinal symptoms. He
had noted urinary frequency and nocturia with
no dysuria or hematuria.
On examination positive findings were
limited to the genitourinary tract. The right tes
tis was non-tender, hard, smaller than the left
and retracted out of the scrotum. The sper
matic cord felt hard and nodular. There was
no inguinal lymphadenopathy. Rectal exami
nation revealed a rubbery, symmetrically
enlarged prostate gland.
Laboratory findings included a hemoglobin
level of 123 g/L with normal red-blood-cell
indices, leukocyte count 15.2 x 109 L with
90% neutrophils, 4% lymphocytes and 6%
monocytes, serum urea nitrogen 13 mmol/L
urea, creatinine 210 nmol/L, alkaline phospha
tase 330IU/L, lactate dehydrogenase 460IU/L
and aspartate aminotransferase 60 IU/L. The
remaining biochemical findings including
measurement of serum electrolyte levels, total
protein, albumin, bilirubin and prostatic acid
phosphatase were within normal limits. Ab
dominal and chest x-ray films appeared nor
mal as did an intravenous pyelogram.
A right radical orchiectomy was performed.
The results of subsequent radiologic investiga
tions including an upper gastrointestinal ser
ies, roentgenography after a barium enema and
retrograde pyelography were reported to be
normal. The patient died suddenly 10 days
postoperatively without a primary tumour site
being found.
Pathological findings.—Examination of the
operative specimen revealed a 2.0-cm solid
tumour nodule within the spermatic cord. A
single, firm, grey-tan nodule measuring 2.5 cm
in greatest diameter was adherent to the tun
ica albuginea of the testis. The nodule
encroached on but did not invade the testicu
lar parenchyma. Several tiny grey-white nod
ules were present on the surface of the tunica
vaginalis (Fig. 1).
Histologically, the nodules consisted of small
nests of moderate to poorly differentiated
adenocarcinoma within a dense collagenized
stroma (Fig. 2). The testicular parenchyma
showed a fibrotic reaction beneath the large
nodule, but there was no invasion by the
tumour.
An autopsy revealed a primary adenocarci
noma of the common bile duct with metastases
to liver (numerous nodules), pancreas, adrenal
glands, large-bowel serosa and peripancreatic
lymph nodes. There was direct invasion of the
right hepatic vein with thrombosis. The
immediate cause of death was pulmonary
embolism.
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Case 2
A 74-year-man was found to have adenocar
cinoma of the prostate with symptoms of
obstruction and testicular pain. After trans
urethral prostatectomy, the testicular pain
resolved. The testes appeared normal. A bone
scan showed a single lesion in the body of a
thoracic vertebra. Serum prostatic acid phos
phatase was 1.54 IU /L. He was treated with
diethylstilbestrol, 1 mg, twice daily.
Eight months later he was admitted, again
complaining of testicular pain and obstructive
urinary tract symptoms. The testicular pain was
bilateral but worse on the right. On examina
tion of head and neck, chest, cardiovascular
system and abdomen, nothing abnormal was
found. The testes were tender bilaterally with
the right feeling firmer and more full than the
left. The prostate was hard and tender.
Results o f laboratory tests included a
hemoglobin level of 112 g/L with normal
indices. Leukocyte and platelet counts were
within norm al limits. Other routine tests gave
normal results. The serum prostatic acid phos
phatase was 1.2 IU /L . A bone scan showed
widespread lesions involving multiple cervical
and thoracic vertebrae, skull, ribs, both femora
and both humeri.
Bilateral orchiectomy and a repeat tran
surethral prostatectomy were performed but
the patient did poorly and died 3 months later.
No autopsy was performed.
Pathological findings.—The external surface
of the right testis appeared normal, but the cut
surface showed extensive replacement by a
grey-white tumour with foci of hemorrhage
(Fig. 3). The left testis, which was slightly
smaller than the right, grossly was normal.
Histologically, the tumour in the right tes
tis consisted of pleomorphic cells with large
vesicular nuclei and prominent nucleoli. They
were cohesive and extensively infiltrated the
interstitium. There was a striking intratubular

growth pattern which in some areas was the
sole component (Fig. 4). Numerous sections of
the spermatic cord showed no tumour. The
transurethral prostatectomy specimen showed
an undifferentiated carcinoma infiltrating vir
tually all tissue submitted. The appearance was
identical to the tumour within the testis.
A diagnosis o f carcinoma metastatic to the
testes consistent with prostatic origin was
made.

Material and Methods
We reviewed all autopsy cases at this
institution covering the years 1962 to
1981. The bodies o f all men over the age
o f 20 years were evaluated for a malig
nant lesion at the time o f autopsy. Those
in which the status o f the testes could not
be evaluated were excluded. When the
microscopic appearance was not de-

F1G. 2—Case 1. Tumour nodule in tunica
albuginea, illustrating metastatic adenocarci
noma with gland formation (hematoxylin and
eosin, original magnification x 250).

F IG .l—Case 1. Metastatic tumour deposits
in right spermatic cord (A) and tunica
albuginea (B) and tunica vaginalis (C) of right
testis.
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scribed but an abnormality had been
noted on gross examination, we reviewed
the slides. Only histologically proven
metastases were accepted for the study.
Findings
Of the 12 877 autopsies performed dur
ing the study period, 7364 were on men
over the age o f 20 years. Of these, 2146
had one or more malignant tumours. A
total of 331 cases had to be omitted for
various reasons, including 56 cases of
prostatic carcinoma in which bilateral
orchiectomy had previously been per
formed. In 150 cases more than one
malignant lesion was present, giving a
total of 1965 tumours available for evalu-

FIG. 4—Case 2. Right testis demonstrating
both intratubular and interstitial growth pat
terns of metastatic adenocarcinoma (hematox
ylin and eosin, original magnification X 26).

FIG. 3—Case 2. Metastatic tumour deposit in right testis. Note variegated appearance
with focal areas of hemorrhage.
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ation. There were 250 non-solid tumours,
32 of which showed testicular involve
ment, most commonly by leukemia (18
cases) and lymphoma (9 cases).
Of the 1715 solid tumours, the most
frequent primaries were lung (623,
36.3%), prostate (221, 12.9%), large
bowel (188, 11.0%), stomach (114,
6.6%), bladder (105, 6.1%), kidney (66,
3.8%), pancreas (63, 3.7%) and esopha
gus (52, 3.0%). In 16 cases (0.93%) there
was involvement of one or both testes, the
sites of origin being lung (4 cases),
stomach (4), prostate (3), large bowel (1),
skin (1), common bile duct (1), bladder
(1) and urethra (1).
The metastatic deposits were visible in
six cases (38%), the remainder being
microscopic. Histologically, the tumour
deposits showed three patterns — inter
stitial, intratubular and mixed — the
mixed type being the most frequent.
Discussion
The incidence of involvement of the
testes by metastatic tumour has been very
low in most series,1’1213 although a
recent study by Tiltman2 found a much
higher frequency of 2.5%. In our autopsy
study we found that the testes were
involved in slightly more than 0.9% of
men with malignant nonlymphatic and
nonhematopoietic tumours, a figure more
in keeping with that of Tiltman’s series.
Clinically, these are most often not
important. However, the literature con
tains scattered reports of patients with
malignant lesions first presenting with tes
ticular masses3-8 or as a complicating
factor during the course of known dis
ease.9-11 In our first case the patient
presented with symptoms from the
metastatic tumour in the testis. Autopsy
revealed disseminated tumour, the extent
of which had not been apparent clinically.
The primary site is, to our knowledge, an
uncommon one, and this is the first
reported case of carcinoma of the com
mon bile duct presenting in this manner.
In our case 2 testicular pain was present
when the patient was first admitted. No
mass was noted and the pain disappeared
following the transurethral prostatec

Site of
primary

tomy. When the testicular pain recurred
it was accompanied by tenderness and
firmness. The pain was subjectively
bilateral although it was worse on the
right, but the swelling and tenderness
were restricted to the right. Metastatic
tumour was found only in the right tes
tis, casting some doubt as to the relation
between tumour and symptoms. No other
local disease was demonstrated so it seems
that the presence of testicular pain with
or without a mass in the setting of malig
nant disease is suggestive of a metastatic
lesion.
Our series, like others (Table I1,3,12,13)
shows that the lung and prostate are the
most frequent sites of primary tumours
metastasizing to the testes. Primary gas
trointestinal tract tumours, including
stomach and colon, are also frequent. In
patients with primary tumours at these
sites, therefore, metastatic involvement of
the testes must be considered. Conversely,
in patients presenting with metastatic
tumour in the testes, these sites would be
the most likely sources; they accounted
for 75% of the primary tumours in this
series.
Possible routes of metastasis would
include arterial, retrograde venous, retro
grade lymphatic and by way of the vas
deferens. From sites such as lung and skin
that are anatomically remote from the
testes, hematogenous spread would be the
likely route. Retrograde venous extension
through the spermatic vein has been
directly implicated in renal carcinoma,1
and such retrograde venous dissemination
may also play a part in urinary bladder
and prostatic tumours. Retrograde lym
phatic spread is implicated in all intra
abdominal or other malignant tumours
that have metastasized to the para-aortic
lymph nodes. Direct spread by way of the
vas deferens could also occur with
prostatic tumours.
Many explanations have been proffered
to explain the low incidence of metastases
in the testes. Their location within the
scrotum with its lower temperature14
may be a factor, but probably more
important is their “ out-of-the-way” ana
tomic site. The seminiferous tubules and
stroma may also be an unfavourable sub

Tabe 1-Sites of Primary Malignant Tumours Metastasizing to the Testes
Reported in Literature_______________________
Werth and
Hanash and
Pienkos and
Price and
colleagues,
colleagues,
Jablokow,
Mostofi,
19823
19691
197213
195712

Lung
Prostate
Skin (melanoma)
Kidney
Gastrointestinal tract
Pancreas
Adrenal gland
Other
Totals

14
12
0
3
5
2
0
2
38

7
0
2
1
1
1
0
3
15

0
3
1
2
2
0
1
1
10

58
38
28
22
20
6
8
20
200

strate for seeding and subsequent prolifer
ation of the malignant cells. As demon
strated in this review, about 60% of these
deposits are microscopic. These will not
be discovered unless adequate numbers of
tissue blocks are selected and carefully
examined.15
Conclusions
Although the testis is an uncommon
site for metastases, their occurrence is not
so rare as earlier series suggested. Patients
with primary malignant tumours of the
lung, prostate or gastrointestinal tract are
at greatest risk. Arterial dissemination
and retrograde lymphatic permeation ap
pear to be the major routes of spread
while the anatomic location as well as
intrinsic factors probably explain the low
frequency of metastatic tumours of the
testes.
We thank Mrs. Paula Miller for secretarial
assistance.
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CAUTION
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CIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE
WARNINGS AND PRECAUTIONS). BLOOD COUNTS SHOULD BE TAKEN AT FRE
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CARDIAC DISEASE
PHARMACOLOGICAL ACTION
Although its mechanism of action has not been determined, mitoxantrone is a DNAreactive agent. It induces nuclear aberrations with chromosome scattering in cell
cultures (human colon carcinoma line) and is a potent inhibitor of RNA and DNA
synthesis. Compared on an equimolar basis, mitoxantrone is seven times more
potent than doxorubicin in inhibiting the uptake of 3H-uridine and four times more
potent in inhibiting the uptake of 2H-thymidine by mouse lymphoma L5178Y cells in
vitro.
INDICATIONS
NOVANTRONE' is indicated for chemotherapy in patients with carcinoma of the
breast, including locally advanced and metastic disease. Also for relapsed adult
leukemia and lymphoma patients with hepatoma.
CONTRAINDICATIONS
NOVANTRONE' is contraindicated in patients who have demonstrated prior hyper
sensitivity to anthracyclines.
WARNINGS
Since NOVANTRONE' produces myelosuppression [see ADVERSE EFFECTS], it
should be used with caution in patients in poor general condition or with pre-existing
myelosuppression.
Cases of functional cardiac changes, including congestive heart failure and
decreases in left ventricular ejection fraction have been reported. These cardiac
events have occurred almost exclusively in patients who have had prior treatment
with anthracyclines, prior mediastinal radiotherapy or with pre-existing heart disease.
Cardiac monitoring is advisable in such patients. It is suggested that cardiac monitor
ing also be performed in other patients during therapy exceeding 160 mg/m2
(approximately 12 courses) of NOVANTRONE', as experience during prolonged
treatment is limited.
NOVANTRONE' may impart a blue-green colouration to the urine for 24 hours
after administration, and patients should be advised to expect this during active
therapy. A reversible blue coloration in the sclerae has been reported in two cases.
Safe use of NOVANTRONE * in pregnancy has not been established. No information
is available concerning the presence of NOVANTRONE* in the milk of nursing
mothers. Safety for intrathecal use of NOVANTRONE' has not yet been established.
PRECAUTIONS
Full blood counts should be undertaken serially during a course of treatment. Dosage
adjustments may be necessary based on these counts [see DOSAGE section].
It is recommended that NOVANTRONE' not be mixed in the same infusion with
other drugs. [See DRUG COMPATIBILITY section],
ADVERSE EFFECTS
NOVANTRONE * is clinically well tolerated, demonstrating a low overall incidence of
adverse events, particularly those of a severe, irreversible or life-threatening nature.
Some degree of leucopenia is to be expected following recommended doses of
NOVANTRONE*. With dosing every 21 days, suppression of WBC counts below
1000/mm3 is infrequent; leucopenia is usually transient, reaching its nadir at about 10
days after dosing, with recovery usually occurring by the 21st day. Thrombocytope
nia can occur, and anaemia occurs less frequently. Myelosuppression may be more
severe and prolonged in patients having had extensive prior chemotherapy or radio
therapy or in debilitated patients.
The most commonly encountered side effects are nausea and vomiting, although
in the majority of cases these are mild (WHO Grade 1) and transient. Alopecia may
occur, but is most frequently of minimal severity and reversible on cessation of
therapy.
Other side effects which have occasionally been reported include allergic reactions
(one with anaphylaxis), abdominal pain, amenorrhoea, anorexia, constipation,
diarrhoea, dyspnoea, fatigue, weakness, fever, gastrointestinal bleeding, stomatitis/
mucositis, and non-specific neurological side effects. Tissue necrosis following
extravasation has been reported rarely.
C hanges in laboratory test values have been observed infrequently, e g.,
increased liver enzyme levels, elevated serum creatinine and blood urea nitrogen
levels (with occasional reports of severe impairment of hepatic function in patients
with leukemia).
Cardiovascular effects, which have only occasionally been of clinical significance,
include decreased left ventricular ejection fraction (determined by ECHO or MUGA
scan), EKG changes and acute arrhythmia. Congestive heart failure has been
reported. Such cases generally responded well to treatment with digitalis and/or
diuretics. In patients with leukemia there is an increase in the frequency of cardiac
events, the direct role of NOVANTRONE' in these cases is difficult to assess, since
most patients had received prior therapy with anthracyclines and since their course is
frequently complicated by anemia, fever, sepsis, and intravenous fluid therapy.
In leukemia patients treated with a single course of 12 mg/m2 1.V. daily x 5 days, the
following drug-related toxicities occured: moderate or severe jaundice or hepatitis in
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9-29%, diarrhea in 9-13%, and moderate or severe alopecia in 11%.
CLINICAL RESULTS
Introduction
Clinical trials experience has established the dosage range, efficacy and safety pro
file of NOVANTRONE.
A single dose can be given intermittently every three or four weeks. The recom
mended initial treatment dose in good risk patients is 14 mg/m2.
Efficacy
Breast
Efficacy data are available on 349 patients with locally advanced or metastatic breast
carcinoma. Results are dependent on many predisposing factors including prior
chemotherapy and/or radiotherapy, the health of the patients, sites of metastases,

and dose of the agent employed. In a European multi-centre first-line single-agent trial
using an initial dose of 14 mg/m2, the overall response rate was 39%, which com
pared favourably to doxorubicin therapy at a dose of 60-75 mg/m2 when given to
patients with similar stage disease. In an ongoing study of a direct comparison with
doxorubicin, given as second-line therapy to breast cancer patients who failed a
standard first-line combination, response rates are 27% for NOVANTRONE and 23%
for doxorubicin. The mean duration of response observed after NOVANTRONE was
greater than those reported after doxorubicin. Responses have been seen in all major
sites of metastases including lymph nodes, lung, bone, skin and viscera, in patients
both with and without prior horm onal therapy. Available data suggest that
NOVANTRONE is comparable in efficacy with doxorubicin in the treatment of
advanced breast cancer. Myelosuppression with 21-day treatment intervals is com
parable with that observed with doxorubicin. Multiple courses of single-agent
NOVANTRONE therapy, in some cases for longer than twelve cycles, have been
administered with excellent tolerance and a good response. NOVANTRONE showed
incomplete cross-resistance with doxorubicin since responses have been observed
in patients in whom doxorubicin had failed or who relapsed after response to that
drug. A continuing large-scale clinical trials program with combination therapy also
demonstrated early positive results for efficacy and safety. In seven studies, over 100
cycles of combination therapy have been given to 77 patients.
Additional Indications
A total of 966 patients have been treated with NOVANTRONE' for three other indica
tions of which 259 patients had non-Hodgkin's lymphona (NHL). 546 had leukemia,
and 161 had hepatocellular carninoma (HOC). The following summarizes the accrual
of these 966 patients:

Indication
NHL
Leukemia
(including pediatric cases)
HCC

Lederle-Sponsored
Studies
(No. Treated)
186
282

Independent Studies
Reported in the
Literature
(No. Treated)
73
264

75
86
543
423
NON-HODGKIN'S LYMPHOMA. Three key studies evaluated single agent
NOVANTRONE * in 148 patients with relapsed or refractory advanced NHL at a dose
of 14 mg/m2, IV, every 3 weeks. Of 127 patients evaluable for response in two trials,
there were 10 complete responses (CR) and 42 partial responses (PR) producing an
overall therapeutic response rate of 41%. The median duration of responses in the
multicenter study (122 evaluable patients) was 195 days. Many patients' responses
lasted in excess of one year. Responses were seen in all histological subtypes of
NHL. Response to NOVANTRONE* was independent of prior chemotherapy and
independent of whether the patient received prior doxorubicin. This demonstrated a
lack of complete cross-resistance between NOVANTRONE * and other drugs includ
ing anthracyclines.
NOVANTRONE* was evaluated in combination with other agents for the treatment
of NHL. A total of 28 patients were treated with different regimens. A first-line compar
ative trial of the combination of intermediate dose METHOTREXATE with LEUCOVORIN rescue + bleomycin + doxorubicin + cyclophosphamide + vincristine +
dexamethasone (m-BACOD) versus the same com bination with 10 m g/m 2
NOVANTRONE* replacing doxorubicin (m-BNCOD) has shown activity: 4 PRs in 6
evaluable patients with m-BNCOD and 3 PRs in 6 with m-BACOD. The combination
of NOVANTRONE* at 10 mg/m2, daily for 3 days, + vincristine + dexamethasone
(NOD) produced 3 PRs in 5 evaluable patients. A first-line comparative trial of the
combination of cyclophosphamide + vincristine + prednisone + doxorubicin
(CHOP) versus the same combinations with 10 mg/m2 NOVANTRONE* replacing
doxorubicin (CNOP) has only recently begun.
NOVANTRONE * at 5 mg/m2, daily for 3 days every 3 weeks produced one CR and
2 PRs in 8 evaluable patients with NHL; ten patients were enrolled. Several other
studies reported in the literature and not sponsored by Lederle support the activity of
NOVANTRONE* in the treatment of NHL.
LEUKEMIA. Four key studies sponsored by Lederle evaluated single agent
NOVANTRONE* in 181 adult patients with refractory or relapsed acute nonlymphocytic leukemia (ANLL) or chronic myelogenous leukemia in blast crisis (BCML) at doses ranging from 8 to 12 mg/m2, IV, daily for 5 days, every 3 weeks. A dose
response effect was evident. Optimal activity was seen at a dose of 12 mg/m2, daily for
5 days. At this dose level, there were 19 CRs in 49 evaluable adult patients with ANLL
in relapse producing an overall response rate of 39%. The median duration of com 
plete response in the largest (121 patients) single agent study was 98 days. Several
patients had remissions lasting in excess of one year. There were four studies com
prising 63 patients in which NOVANTRONE* was evaluated in combination with
other agents in the treatment of leukemia. The highest complete remission rate of
4 9 % (11 CRs in 23 e v a lu a b le pa tie n ts w ith A N LL) was o b ta in e d w hen
NOVANTRONE* at 10 to 12 mg/m2, daily for 3 days, was combined with cytosine
arabinoside at 100 mg/m2 daily for 7 days. When NOVANTRONE* at 10 mg/m2, daily
for 5 days was combined with the same dose of cytosine arabinoside, it produced 2
CRs in 8 evaluable patients. Treatment of patients with acute lymphoblastic leukemia
using 10 mg/m2 NOVANTRONE*, daily for 3 days, + vincristine + prednisone
produced 10 responses in 16 evaluable patients, for a response rate of 62.5%.
Activity was also seen in B-CML. Since no standard therapy exists for this disease
and bone marrow is never truly normal in this disorder, both CRs and PRs were
considered evidence of efficacity. The optimal dose of NOVANTRONE* was 12
mg/m2, daily for 5 days, producing 6 responses in 17 evaluable patients.
Experience in pediatric leukemia patients is limited. Twenty-four patients were
treated with 6 to 8 mg/m2 NOVANTRONE*, daily for 5 days. There were 3 responses
in 24 evaluable children.
Fourteen adult leukemia patients received 20 to 37 mg/m2 NOVANTRONE * once
every two weeks. No therapeutic responses were observed using this schedule.
Several other studies reported in the literature and not sponsored by Lederle
support the activity of NOVANTRONE* in the treatment of ANLL and B-CML.
HEPATOCELLULAR CARCINOMA. Three clinical trials sponsored by Lederle have
been conducted using NOVANTRONE* in the therapy of HCC. NOVANTRONE*
was administered to 65 patients intravenously at 12 mg/m2 every 3 weeks in two
studies, and in one study with 10 patients at 6 to 10 mg/m2/day by continuous hepatic
artery infusion for three consecutive days, every 3 weeks. Considering the short life
span of patients presenting with HCC, a response of stable disease was included
along with PRs and CRs in assessing efficacy. In these three studies, the overall
therapeutic response rate was 46.7% (11 CRs and PRs + 10 stable disease in 45
evaluable patients). Activity was confirmed in other studies not sponsored by Lederle.
Durations of response were variable among these studies and ranged between 3 and
52 weeks.

Safety
Data on the overall safety profile of NOVANTRONE (based on 989 patients) demon
strated advantages of NOVANTRONE compared to the anthracyclines with respect
to both the quality of life and the long-term safety of patients. The majority of side
effects with NOVANTRONE are mild in nature. R em oval of patients from
NOVANTRONE treatment for reasons of toxicity has been rare in clinical studies. A
number of patients have reported no side effects at all. In addition, the relatively low
risk of serious side effects has permitted treatment of patients on an out-patient basis.
The most common acute effects were nausea and/or vomiting (only 3 5% severe or
very severe with NOVANTRONE, compared to 10-15% reported with doxorubicin),
stomatitis/mucositis (only 0.3% severe or very severe with NOVANTRONE) and
alopecia (only 0.9% severe or very severe, and 15% overall with NOVANTRONE
compared with 85% severe or very severe and 100% overall reported with doxoru
bicin). Serious local reactions have been reported rarely following extravasation of
NOVANTRONE at the infusion site.
With respect to myelosuppression, initial NOVANTRONE doses of 14 mg/m2 every
three weeks are well tolerated in good-risk patients. Severe degrees of myelosup
pression have been rare. The median white cell nadir in a European second-line
study was 2.5x103; in a European first-line study only 4 8% (2/42) of patients experi
enced a nadir of less than 1,000. The nadir usually occurs around day 10 or 11 and
returns to normal baseline value by day 21, in time for the next course of treatment.
After multiple courses of NOVANTRONE, white blood cell and platelet nadirs show no
further decrease beyond those observed in the first few cycles, indicating no cumula
tive or permanent effects of NOVANTRONE on marrow reserves.
NOVANTRONE* had an exceptional safety profile and was well-tolerated by
patients treated for NHL, leukemia and hepatoma, as well as for breast cancer.
However, due to the pathophysiology of leukemia and the higher doses of
NOVANTRONE* employed, the safety profile differed from that seen in NHL and in
hepatoma (see ADVERSE EFFECTS). The most severe and life-threatening events,
i.e. bleeding and infection, are well described morbid complications of acute
leukemia. Many of the episodes of hepatic dysfunction were probably related to the
increased bilirubin load and increased exposure to hepatitis viruses as a result of the
multiple transfusions of blood products necessary in the proper treatment of this
disorder.
Cardiotoxicity
Adverse cardiac experiences have been infrequent In contrast, doxorubicin has
been reported to produce chronic cardiomyopathy and irreversible congestive heart
failure in up to 11% of patients given nine or more courses of that drug at the usual
dose schedule (60 m g/m 2 every three weeks) W hether or not related to
NOVANTRONE, only 119 cardiac-related episodes have been reported from a total
data-base of more than 3,200 treated patients, including only 29 (0.9%) reports of
clinical congestive heart failure, of which only one had no other known predisposing
factors. The risk of cardiotoxicity is increased with prior anti-neoplastic drug or radia
tion therapy. In patients without predisposing factors, development of congestive
heart failure with NOVANTRONE therapy is rare
Clinical experience suggests there is no need to lower the dose tor patients with
existing renal or hepatic disease.
In summary, NOVANTRONE* is well tolerated and provides a better quality of life
for patients compared with doxorubicin and yet shows comparable efficacy.
NOVANTRONE has been used alone or in combination in patients with or without
prior chemotherapy, as well as in those who have received prior adjuvant therapy. It is
less cardiotoxic than anthracyclines such as doxorubicin and thus represents a clear
therapeutic advance over currently available compounds.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no known specific antidote for NOVANTRONE As would be expected from
the pharmacological actions of the drug, haematopoietic, gastrointestinal, hepatic
and renal toxicity may be seen, depending on the dosage given and the physical
condition of the patient. The management of overdosage is symptomatic and sup
portive and patients should be monitored closely. (See also the sections "WARN
INGS", "PRECAUTIONS" and “ ADVERSE REACTIONS").
DOSAGE
Breast Cancer, Lymphoma, Hepatoma
The recommended initial dosage for use as a single agent is 14 mg/m2 of body
surface area, given as a single intravenous dose, which may be repeated at 21-day
intervals, A lower initial dose (12 mg/m2 or less) is recommended in patients with
inadequate marrow reserves due to prior therapy or poor general condition.
Dosage modification and timing of subsequent dosing should be determined by
clinical judgement depending on the degree and duration of myelosuppression. If
21-day white blood cell and platelet counts have returned to adequate levels, prior
doses can usually be repeated The following Table indicates a guide to dosing based
on myelosuppression.
WBC AND
TIME TO
PLATELET NADIR
RECOVERY
IF WBC NADIR>1 500
RECOVERY
AND
< 2 1 DAYS
PLATELET NADIR> 5 0 000
IF WBC NADIR > 1 500
RECOVERY
AND
> 2 1 DAYS
PLATELET NADIR > 5 0 000
IF WBC NADIR < 1 500
ANY DURATION
OR
PLATELET NADIR < 5 0 000
IF WBC NADIR <1 000
ANY DURATION
OR
PLATELET NADIR < 2 5 000

SUBSEQUENT DOSING
REPEAT PRIOR DOSE OR
INCREASE BY 2 mg/m2 IF
MYELOSUPPRESSION NOT
CONSIDERED ADEQUATE
WITHHOLD UNTIL RECOVERY
THEN REPEAT PRIOR DOSE
DECREASE BY 2 mg/m2 FROM
PRIOR DOSE AFTER RECOVERY
DECREASE BY 4 mg/m2 FROM
PRIOR DOSE AFTER RECOVERY

Combination Therapy for Breast Cancer, Lymphoma
NOVANTRONE * has been given in various combination regimens with the following
cytotoxic agents for the treatment of breast cancer and lymphomas: cyclophos
phamide, fluorouracil, vincristine, vinblastine, bleomycin, METHOTREXATE (stan
dard dose or 200 mg/m2 with LEUCOVORIN rescue) and glucocorticoids.
As a guide, when used in combination chemotherapy with another myelosuppressive agent, the initial dose Df NOVANTRONE* should be reduced by 2-4 mg/m2
below the doses recommended above for single agent usage; subsequent dosing,
as outlined above, depends on the degree and duration of myelosuppression.
Dosage for Patients with Acute Leukemia in Relapse
The recommended dosage for induction is 12 mg/m2 of body surface area, given as a
single intraveneous dose daily for five consecutive days (total of 60 mg/m2).
In clinical studies, with a dosage of 12 mg/m2 daily for 5 days, patients who
achieved a complete remission did so as a result of the first induction course

Re-induction upon relapse may be attempted with NOVANTRONE * and again the
recommended dosage is 12 mg/m2 daily x 5.
Combination Therapy for Leukemia
NOVANTRONE *. together with cytosine arabinoside, has been used successfully for
the treatment of both first line and second line patients with acute non-lymphocytic
leukemia.
For induction, the recommended dosage is 10-12 mg/m2 of NOVANTRONE * for 3
days and 100 m g/m2 of cytosine arabinoside for 7 days (the latter given as a continu
ous 24 hour infusion).
If a second course is indicated, then the second course is recommended with the
same combination at the same daily dosage levels but with NOVANTRONE * give for
only 2 days and cytosine arabinoside for only 5 days.
If severe or life-threatening non-hematological toxicity is observed during the first
induction course, the second induction course should be withheld until the toxicity
clears.
Note regarding pediatric usage: Experience in pediatric patients is limited; how
ever, complete remissions have been observed with NOVANTRONE * as single agent
therapy at a dosage of 8 mg/m2 daily for 5 days.
ADMINISTRATION OF SOLUTION
NOVANTRONE* solution should be diluted to at least 50 mL with either Sodium
Chloride for Injection (USP) or 5% Dextrose for Injection (USP). This solution should
be introduced slowly into the tubing of a freely-running intravenous infusion of
Sodium Chloride for Injection (USP) or 5% Dextrose for Injection (USP) administered
over not less than three to five minutes intravenously. If extravasation occurs, the
administration should be stopped immediately and restarted in another vein. The
nonvesicant properties of NOVANTRONE minimize the possibility of severe reactions
following extravasation, however, tissue necrosis has been reported rarely.
NOVANTRONE should be administered by individuals experienced in the use of
anti neoplastic therapy.
Caution in the handling and preparation of NOVANTRONE solutions must be
exercised and the use of protective eyeglasses, gloves and other protective clothing
is recommended. (See "GUIDELINES FOR SAFE USE BY HOSPITAL PERSON
NEL" section.)
STORAGE DIRECTIONS
NOVANTRONE should be stored at room tem perature-D O NOT FREEZE With
recommended storage, NOVANTRONE remains stable for two (2) years.
Following preparation ot the infusion, the diluted solution should be stored at room
temperature and used within 24 hours. Any original solution which remains in the vial
should be discarded. NOTE: LIKE THE ORIGINAL SOLUTIONS, THE DILUTIONS
SHOULD ALSO NOT BE FROZEN.
DRUG COMPATIBILITY
NOVANTRONE* should not be administered concommitantly with heparin since a
precipitate may form. Until specific compatibility data are available, it is recom
mended that NOVANTRONE * not be mixed in the same infusion with other drugs.
GUIDELINES FOR SAFE USE BY HOSPITAL PERSONNEL-CONSULT THE
PACKAGE INSERT.
CHEMISTRY
Composition
NOVANTRONE* mitoxantrone hydrochloride, a synthetic anthracenedione, is a
potent antineoplastic agent. Its molecular formula is C ^ H ^ N jO ^ H C I and its molec
ular weight is 517 4. It is a hygroscopic dark blue solid supplied as a sterile, aqueous
solution containing mitoxantrone hydrochloride equivalent to 2 m g/m L mitoxantrone
free base, with sodium chloride, sodium acetate, and acetic acid as inactive ingredi
ents. The product does not contain antibacterial preservatives. Its structural formula
appears below.
H
H

Molecular Formula: C?2H28N40 6.2 HCI
Molecular Weight: 517 4
Chemical Name: 1.4-Dihydroxy-5,8 bis[[2 ((2-hydroxyethyl)aminol-ethyl]amino)9,10-anthracenedione dihydrochloride
AVAILABILITY
NOVANTRONE mitoxantrone hydrochloride injection is supplied as a sterile aqueous
solution at a concentration equivalent to 2 mg mitoxantrone free base per mL, and is
available in the following vial sizes:
10 mL/vial (20 mg) Product C o d e .....................................................................9393-34
12.5 mL/vial (25 mg) Product C ode................................................................... 9393-72
Identification
Glass vials containing 10 and 12.5 mL of a clear, dark blue solution
REFERENCES:

1 Cowan J D. A randomized trial of doxorubicin, mitoxantrone and bisantrene in
advanced breast cancer (A South West Oncology Group Study). Investigational New
Drugs 3:149-152,1985.
2. Submission: United States Food and Drug Administration, Sept. 1985.
3. Neidhart J A. Comparable efficacy of Novantrone and Adriamycin in breast can
cer. The Current Status of Novantrone (Symposium), Scottsdale, Arizona March
1985.
4 Posner LE et al. Mitoxantrone: an overview of safety and toxicity. Investigational
New Drugs 3 (2): 133-137,1985.
‘ Registered User Cyanamid Canada Inc. Product Monograph available upon request.
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A Microcomputer System
for the Practising Cardiac Surgeon
The authors present a computer program
designed for the practising cardiac sur
geon who wishes to computerize patient
data. The program is efficient, versatile
and can be adapted to individual needs.
It can be used with any IBM PCcompatible machine and requires little
knowledge of computer science. More
than 250 items on 30 000 patients can
be stored and all this information ana
lysed simultaneously. The program can
chart a patient's profile and tabulate the
information of the entire registry. It can
generate lists of patients with their sur
geons, cardiologists, diagnoses, opera
tions and dates of intervention. It can
also be used for mailing purposes.

who underwent cardiac operations.1
Unfortunately, such expertise is not
always immediately available to the prac
tising surgeon who wants to keep track
o f his own data and compare his findings
with those from other institutions. Every
surgeon wishes to know the characteris
tics o f his patients and maintain a basic
knowledge o f his results, both o f which
are possible with computers. There is a
large communications gap between the
professional programmer and the practis
ing surgeon in regard to ways by which
data can be collected and used on a dayto-day basis.
For these reasons we developed a sim

ple computer program that can be used
daily by practising surgeons who have
limited resources and little knowledge o f
computer science.

Development
First we developed an open-heart data
form (Fig. 1) on which most o f the data
pertinent to patients suffering from com
mon adult cardiac diseases can be
recorded. We focused on the most com 
mon issues o f interest to surgeons and
those that are usually reported in the sur
gical literature.
Common, easily recognizable abbrevi-

O PEN -H EART DATA FORM

Un programme informatise developpe
specifiquement pour les chirurgiens cardiaques est prdsentd. II permet de suivre
les charactdristiques des patients qu'ils
op&rent. Ce programme est puissant et
peut s'adapter aux besoins individuels.
Le programme fonctionne sur tout ordinateur compatible avec un IBM PC et
n'exige pas de grandes connaissances en
informatique. II peut emmagasiner 250
donnees individuelles pour 30 000
patients et analyser toutes ces donnees
simultanement. Les rdsultats peuvent
etre obtenus pour tous les patients inscrits au registre ou pour un petit nombre
de patients specifiques. Des listes de
patients avec leur chirurgien, cardiologue, diagnostique, intervention chirurgicale et date d'opdration, sont facilement
disponsibies. Ces listes peuvent etre
transformees en Etiquette de courrier.

Many reports in the literature have used
multivariate analysis done by professional
statisticians on large numbers o f patients
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FIG . 1— Open-heart data form.
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nent only to a specific institution. In our
institution “ max” and “ min” represent
the maximum and minimum septal tem
perature recorded by direct insertion of
a thermal probe in the septum during aor
tic cross-clamping (Fig. 5).
For valvular heart disease, the type and
size of valve inserted are recorded, fol
lowed by operative findings and opera
tive and postoperative complications.
To gain uniformity in reporting we
used standard official references for defi
nitions of terms and measurements.2'3
The meaning of the abbreviations is
usually self-explanatory, as in the opera
tive complications LOS = low output
syndrome and MOR = mortality. A dic
tionary explaining the meaning of each
abbreviation is readily available to all per
sonnel.

ations were used. On the form a positive
finding is circled, as in Fig. 2 — a patient
with a history of diabetes mellitus (DBM)
and a previous myocardial infarction
(MI). The present status at time of oper
ation is then recorded, as shown in Fig.
3 for a 62-year-old man with stable angina
class III and a normal electrocardiogram
who is taking Inderal and nitroglycerin.
As we progressed to recording numer
ical data such as age or ejection fraction,
we added a blank next to the abbrevia
tion, and if we wanted an evaluation of
the parameter at rest or with exercise we
added a divided blank. For example, a
patient with an ejection fraction of 40%
and a pulmonary wedge pressure of 15
mm Hg rising to 25 mm Hg after exer
cise is recorded as EJF 40, PW P 15/25
(Fig. 4). Some observations can be perti
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FIG. 3—Example o f cardiac status at time of operation recorded on data form.
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FIG. 4— Example of heart catheterization findings recorded on form.
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FIG. 5- -Recording of minimum and maximum septal temperatures during aortic crossclamping.
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The program runs on any IBM PCcompatible computer using M S-DOS
(Micro Soft-disc operating system). It has
the following features: 256 Kb internal
memory (RAM), two 360 Kb disk drives,
one 10 Mb hard disk and an Epson FX
100 printer (Epson America Inc., Tor
rance, Calif.).
The 10 Mb hard disk has enough
space to record the data of approximately
10 000 patients. When full, other hard
disks can be added in parallel. The data
base program uses only 128 Kb o f inter
nal memory (RAM).
The limit of the entire system is approx
imately 30 000 patients. The 256-Kb inter
nal memory can manipulate all the data
of 30 000 patients simultaneously. The
cost of this computer system is approxi
mately $7000., excluding the program
software.
Software

FIG. 2—Example of positive findings recorded on history portion of form.
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FIG. 6—Example o f six criteria used to select specific group of patients.

SMK

Once we had designed the open-heart
data form we asked professional com
puter programmers to design a program
that would meet the following criteria: (a)
store all information on every patient
being operated upon; (b) have the flexi
bility to add new items if required; (c)
tabulate the total of all the information
in the registry with standard deviation
when necessary; (d) tabulate data on a
specific population, choosing up to five
simultaneous selection criteria.
The program was written in compiled
basic language called GENIA, a data-base
program developed by Micro Diffusion
of Montreal. The main features are as
follows:
• A large number of items can be
stored for each patient.
• Patients are identified by their hospi
tal unit number to avoid any error in iden
tification.
• Tabulation of the data in the regis
try can be for all patients entered.
• Tabulation of data on selected
groups of patients can be obtained.
• Specific patient groups can be iden
tified by choosing many simultaneous
selection criteria.
As an example, with this program we
can tabulate the anginal status, age, sex
and coronarographic findings of all
patients in the registry. We can also
choose to report the information on only
the patients who fulfil the following
criteria: male, over 70 years of age, hav
ing diabetes, unstable angina, class III
preinfarction, and undergoing emergency
operation (Fig. 6).
As new information is obtained on
follow-up it can be entered by simply
recalling the patient unit number. Correc
tion of errors can be made at will. The
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program dictionary indicates precisely the
way to enter the selection criteria in order
to retrieve the information. New items
can be added when necessary; for exam
ple, myopathy in the diagnosis section
and heart transplant in the surgical data.
Items that are never recorded can be
changed or replaced by ones that will be
more useful.
Use of the System

We have not inserted limits to measure
ments as they are often very wide and
would have required too much space in
the program. We rely on the competence
of individuals manipulating the data to
obtain good information.
This system is valuable in studying
patients with common types of cardiac
disease and those suffering from coronary
artery or valvular heart disease. It is not
very useful for unusual conditions such
as left atrial myxoma, since few such
patients are operated upon each year. It
is also not useful for analysing the impact
of medication, since the field changes
rapidly and new modes and combinations
are constantly being introduced.

For the system to work, people
knowledgeable in the field of clinical
cardiac diseases must participate in
recording the data. The surgeon is asked
to fill out the open-heart data form upon
completion o f the operation, at which
time all the information is available. This
data recording usually takes no more than
7 minutes. During hospitalization or at
time of discharge the surgeon completes
the information on the postoperative
course. If a third party fills out the form
it is the surgeon’s responsibility to ensure
the completeness and reliability of the
entries. The entry of the data into the
computer is done by a secretary with ade
quate knowledge in the field of cardiac
disease, to avoid errors in understanding
the data. To enter a cross-clamp time of
6.0 minutes instead of 60 minutes for a
triple-vessel coronary artery bypass would
be a gross error, difficult to locate but not
to correct.

We anticipate improving the retrieval
system by displaying it in graph form,
with regression lines.4 In addition, when
hospital data such as heart catheteriza
tions are computerized, they could be
entered directly into our registry. Since we
are using this program we plan to concen
trate on the main adult cardiac issues of
coronary artery and valvular heart dis
ease. There is little advantage in keeping
data on unusual cases in this manner,
aside from simply allowing the surgeon
to keep an accurate and easily accessible
list of his case load and characteristics,
referral practice and so on.

Limitations

Discussion

Although this system is very efficient
it would not have stayed simple if we
covered all possibilities. Thus, we elected
to maintain simplicity at the expense of
every imaginable eventuality. The entry
of the data depends on many people who
supply the information to the surgeon.

Future Improvements

Practising surgeons fully realize that
computer technology can greatly assist in
recording and analysing patient data.5'7
Unfortunately, most surgeons in clinical
practice have limited knowledge in com
puter science and limited access to a com
puter, which is why, as practising sur

Table 1-Comparison of 36 Patients With and 244 Patients Without Left
Main Coronary Artery Disease (LMD), 1984
Findings

With LMD, no. (%)

History
Cerebrovascular disease
Peripheral vascular disease
Diabetes mellitus
Hypertension
Hyperlipidemia
Congestive heart failure
Myocardial infarction
Smoker
Family history of cardiac disease
Angina
Stable
Unstable
Preinfarction
Postinfarction
Class 1*

II
III
IV
American Society of Anesthesia-emergency
‘ Canadian Cardiovascular Society classification.3
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Without LMD, no. (%|

geons, we developed a system that is easy
to use.
The output of the data is versatile and
can be used in many ways. The data can
be retrieved for the entire cardiac surgery
service or for one specific surgeon or
cardiologist. All patients can be listed
with their surgeon, cardiologist, date of
operation and procedures. Individual sur
geons in our unit can have an up-to-date
list of all patients they have operated on
for a given period. The list will include
the name of the referring cardiologist, the
diagnosis, the operation and date per
formed and the number of follow-up
visits. Patients’ names and addresses can
be printed on labels for mailing purposes.
The profiles of different groups of
patients can be compared for analysis.
Recently we wished to compare the data
from 36 patients who had a left main
coronary artery lesion with 244 patients
who did not suffer from this lesion. All
were operated on during 1984. Table I
sets forth the data tabulated for these two
groups of patients. In addition we were
able to compare our own data with those
of reports in the literature.8
We chose to use an IBM PC computer
as it was the most popular machine, with
the best reputation for versatility and ease
of maintenance. The computer can also
be used with many other programs, for
either billing or word processing. The
Hayes modem (Hayes Microcomputer
Products, Inc., Norcross, Ga.) allows us
to communicate with other computer
centres.
Most items such as patient age and sex
are objective and precise, but a number
of assessments in cardiac diseases are sub
jective and vary with interpretation.
Thus, all cardiac surgery units must
define their measurements.
This recording system has given a good
global evaluation of the work done in our
unit and can answer accurately most ques
tions asked of it.
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The La-z-boy Position and Muscle Blood Flow
in the Lower Limbs
Patients are encouraged to sit upright in
bed after surgery in order to reduce the
risk of pulmonary complications. Adjust
ing the hospital bed to place the patient
in the la-z-boy position minimizes the
work of nursing staff in maintaining the
patient in an upright position.
This study was designed to answer
concerns that the la-z-boy position might
impair muscle blood flow in the lower
limbs and thereby predispose patients to
venous thrombosis. In 11 healthy volun
teers the authors measured and com
pared blood flow from the gastrocnemius
muscle in the la-z-boy position and in the
more conventional straight-leg position.
There was no clinically or statistically
significant difference in blood flow in the
two positions.

position (Fig. 1A compromises muscle
blood flow in the lower limbs.
We use the la-z-boy posture to main
tain the patient in an upright position in
bed after surgery because we believe that
the risk of pulmonary complications is
reduced when the chest is kept in an
upright position. Both posture1 and
abdominal surgery2 affect the functional
residual capacity of the lungs. In healthy
people this capacity decreases in passing
from the erect to the supine position.
Although functional residual capacity in
both positions is reduced after thoracic
and abdominal surgery, the advantage of
the upright over the supine position is
maintained.3 The importance of func
tional residual capacity lies in its relation
to the closing capacity — the volume

Afin de reduire les risques de complica
tions pulmonaires, on encourage les
patients h s'asseoir droits dans leur lit.
L'ajustement du lit d'hdpital pour placer
le malade dans la position d'une chaise
de detente (la-z-boy) reduit le travail
requis du personnel infirmier pour maintenir le patient en position assise.
Cette etude a et6 mise sur pied pour
repondre aux craintes que la position de
la chaise de detente puisse reduire la cir
culation sanguine musculaire dans les
membres interieurs et predisposer ainsi le
patient aux thromboses veineuses. Les
auteurs ont mesure et compart chez 11
volontaires sains la circulation sanguine
dans le gastrocnemien alors qu'ils 6taient
en position de chaise de detente ou dans
la position plus conventionnelle avec
jambes Gtendues. Entre les deux posi
tions, on n'a observe aucune difference
cliniquement ou statistiquement significa
tive de la circulation sanguine.

Methods

The aim of this study was to determine
whether nursing patients in the la-z-boy
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below which small airways close in the
dependent areas of the lung. If the sum
of the functional residual capacity and
tidal volume is less than the closing capac
ity, the affected alveoli are not ventilated,
so they tend to become atelectatic. In the
ory, the risk of postoperative atelectasis
should be reduced by maintaining a high
resting lung volume.
Obese patients, who are particularly
susceptible to atelectasis postoperatively,
should benefit the most by being nursed
upright. To keep these patients propped
up against pillows is difficult and neces
sitates frequent attention. The workload
of nursing staff can be reduced if the
hospital bed is used to its full advantage.
Most beds can be adjusted to the so-called
la-z-boy position. Once “ stabilized” in
this position, the patient cannot slide
down the bed into a supine postion.
We undertook the present study be
cause some colleagues were concerned
that flexing the hips and knees in the laz-boy position would interfere with the
venous return from the lower limbs and
predispose patients to venous thrombo
sis. We therefore wished to determine
whether the venous blood flow in the legs
of subjects in the la-z-boy position
differed from that of the same subjects
in the conventional straight-leg position
(Fig. IB). In isolated muscle prepara
tions4 and intact muscle in man5'6 there
is a linear relation between blood flow in
limb muscles measured by xenon washout
and total limb venous blood flow meas
ured directly o r by plethysmography.

C
FIG. 1—Muscle blood flow measured in
la-z-boy position (A), straight-leg position
(B) and leg-down position (C).

We measured blood flow in the lateral
head of the right gastrocnemius muscle
in 11 healthy medical students ranging in
age from 25 to 30 years. Measurements
were made with the students in three
different positions: the la-z-boy with the
back at 45° (Fig. 1A), the straight-leg po
sition with the back at 45° (Fig. IB) and
the leg-down position, with the subject
sitting on the edge of the bed (Fig. 1C).
The leg-down position was used so that
we might assess the sensitivity of the
method to detect changes in blood flow
with change? in posture. We anticipated
that there would be a substantial reduc-
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tion in blood flow when the lower limb
was moved from a horizontal to an up
right position. Muscle blood flow was
measured by the xenon clearance tech
nique of Lassen.7 The only modification
that we made was to replace xenon 133
with xenon 127. The higher energy
gamma rays (145 to 375 keV) of 127Xe
eliminate the problem of tissue absorp
tion of the low-energy (80 keV) 133Xe
gamma rays.
After the students had rested for 30
minutes we injected 60 to 70 gCi of 127Xe
dissolved in 0.05 to 0.1 ml normal saline
into the right gastrocnemius at a level 10
cm below the tibial tubercle. The injec
tion was made with a five-eighths-inch
30-gauge needle. The count rate from the
injection site was measured in one-second
intervals with a straight-bore collimator,
sodium iodide detector system interfaced
to a PDP 11 03 computer (Digital Equip
ment Corp., Maynard, Mass.). The rate
of disappearance of l27Xe from the mus
cle is proportional to muscle blood flow.
We measured the disappearance rate dur
ing 5-minute intervals in the la-z-boy,
straight-leg then leg-down position in five
students and straight-leg, la-z-boy then
leg-down position in the other six. The
T 1/5 of the slope of the 127Xe clearance
curve during each 5-minute measurement
period was calculated with a log-fit least
squares program on our digital computer.
Muscle blood flow (Qm) was calculated
from the equation Qm = k X 100
ml/min-100-1 g where k is the rate cons
tant for the disappearance of 127Xe from
the muscle and Xis the blood/muscle par
tition coefficient of xenon. The rate cons
tant k is calculated from the equation k
= 0.693 h- T%. We used a Xvalue of 0.7. ~1
Analysis of the results was by the twotailed Student’s f-test for paired data.
Results
The difference between muscle blood
flow in the legs of students in the la-z-boy
position and in the straight-leg position

Student no.
1
2
3
4
5
B
7
8
9
10
11
Mean ± SO
'Measured first.
368

was neither clinically nor statistically sig
nificant (p = 0.74) (Table I). (If subject
11, whose values differ greatly from those
of the other subjects, is excluded from the
analysis, this difference remains insignifi
cant [p = 0.45].)
Muscle blood flow in the la-z-boy posi
tion was approximately three times
greater than flow in the leg-down posi
tion (p = 0.0075).
Discussion
We have shown that the xenon clear
ance method is sensitive in detecting
changes of blood flow associated with
changes in posture insofar as a threefold
reduction in muscle blood flow was
demonstrated on moving the limb from
the la-z-boy to the leg-down position. Our
results show that there is no change in
calf-muscle blood flow with change from
the traditional straight-leg to the la-z-boy
position.
The xenon clearance technique has
been used to measure blood flow in a var
iety of organs including muscle,7 skin8
and brain.9 The two major criticisms of
the technique are that the partition coeffi
cient may change in a disease process and
that xenon clearance may be diffusionlimited and not just blood-flow limited.4
This would make the technique unrelia
ble at high rates of blood flow. Neither
c f these problems arose in our study. We
studied healthy volunteers over a short
period so a change in the flow rate (X) was
highly unlikely. We also measured mus
cle blood flow at rest when the mean flow
was 3.9 ml/min-100~1g. The problem of
diffusion limitation only becomes impor
tant at high flow (30 to 40 ml/min-100
g) such as occurs during exercise.
The reduction in muscle blood flow in
the leg-down position has been reported
by others.10 It might be explained by the
effect of gravity on venous hydrostatic
pressure or by increased sympathetic drive
either regionally or through an increase
in systemic catecholamines. Blood flow

Table 1—Blood Flow in the Gastrocnemius Muscle of Students
in the Leg-Down, Straight-Leg and La-z-hoy Positions
Blood flow, ml/min - 100*1 g
Leg-down
Straight-leg
1.6
4.4*
0.6
2.6*
0.6
3.2
0.4
2.6
2.4
4.7
3.1
2.0
0.2
1.9*
3.9
7.4*
0.7
2.4*
1.8
9.9*
1.4
1.8
1.5 ± 1.2
3.9 ± 2.6

La-z-boy
2.9
2.4
3.6*
2.7*
5.3*
2.3*
2.8
5.0
2.3
6.1
11.3*
4.2 ± 2.7

to muscle is intimately related to muscle
contractile activity. It is possible that the
gastrocnemius muscle is more relaxed in
the leg-down position than in the la-z-boy
or straight-leg position. This would
explain the reduced muscle blood flow in
the leg-down position. However, Amery
and associates10 have also reported
reduced anterior tibial muscle blood flow
on moving from the supine to the stand
ing position, during which the tone of the
anterior tibial muscle is increased, not
decreased.
In the la-z-boy position venous blood
has to overcome gravity to flow up to the
bent knee and this might be expected to
reduce venous blood flow as happened in
the leg-down position. However, the
gravitational pressure opposing flow of
the blood in the upward segment (calf) is
exactly counterbalanced by the gravita
tional increase in pressure and flow in the
downward segment (thigh). This is the
siphon principle and unless there is
venous collapse in the thigh it should
maintain venous blood flow unchanged
from the straight-leg position.11
Although our study was carried out in
young healthy volunteers we believe that
the results are applicable to the patient
population. We are not aware of any
pathophysiologic state that would have an
effect on venous blood flow in the la-zboy position different from that on blood
flow in the straight-leg position. We
recommend the use of the la-z-boy posi
tion following surgery as a convenient,
safe and effective means of maintaining
the patient in a chest-upright position.
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Small-Bowel Obstruction
After Conservative Treatment of Gastric Bezoar
Gastric bezoar is an uncommon compli
cation of gastric procedures. Increasingly
it is managed by pharmacologic or
endoscopic manipulations. The risk of
intestinal obstruction after nonsurgical
therapy is illustrated by two cases that
were successfully managed without
resorting to enterotomy.
Le bezoard de I'estomac est une compli
cation peu courante des interventions
gastriques. De plus en plus, on le traite
par manipulation pharmacologique ou
endoscopique. Les risques d'une obstruc
tion intestinale consecutive a un traitement nonchirurgical sont illustres par
deux cas qu'on a pu traiter avec succes
sans recourir a une enterotomie.

Conservative treatment o f postgastrec
tomy bezoars includes manual attempts
at external disruption, suction, lavage,
and endoscopic internal fragmentation
with biopsy forceps and polypectomy
snares.1’2 In addition to physical disrup
tion, chemical treatment with papaine and
acetylcysteine has been tried with moder
ate success.3,4 Many gastroenterologists
favour these nonsurgical methods of
relieving gastric outlet obstruction.
However, one possible complication of
these treatments is dislodgement of a
piece o f the bezoar with subsequent
blockage of the small bowel, necessitat
ing exploratory laparotomy. Conservative
treatment of small-bowel obstruction due
to a bezoar almost always fails.5’7 It is
therefore imperative to monitor closely all
patients who have had conservative dis
ruption o f gastric bezoars by either chem
ical or physical methods.
We present two cases in which smallbowel obstruction developed after conser-

vative treatment o f gastric bezoars. Both
patients required exploratory laparotomy
to relieve their obstruction.

then easily manipulated through the ileocecal
valve into the large bowel. Postoperatively the
patient did well and left the hospital in satis
factory condition.

Case Reports

Case 2

Case 1
A 25-year-old man, with a history of vagot
omy and pyloroplasty for bleeding duodenal
ulcer, was admitted with gastric outlet obstruc
tion secondary to a phytobezoar. He was
treated conservatively with metoclopramide
and pineapple juice and discharged in satisfac
tory condition. Several days later he was read
mitted with signs and symptoms of bowel
obstruction. Laboratory values were within the
normal range and two views of the abdomen
were consistent with small-bowel obstruction.
A contrast upper gastrointestinal series demon
strated a bezoar in the stomach and dilated
fluid-filled bowel loops with a filling defect in
the distal ileum, consistent with a bezoar caus
ing blockage of the small bowel (Fig. 1). Ini
tial conservative management failed to relieve
the bowel obstruction. Flat plate of the abdo
men demonstrated no barium entering the large
bowel on hospital day 5. The patient was taken
to the operating room where the bezoars in the
terminal ileum and the stomach were manu
ally broken up without opening bowel or
stomach. The bezoar in the terminal ileum was

A 45-year-old woman had suffered recurrent
bouts of epigastric pain for 3 days. The pain
increased in severity on the day of admission
and each attack lasted approximately 1 minute.
The pain occasionally radiated to the back. She
vomited twice on the day of admission. She had
previously u ndergone v ag o to m y and
pyloroplasty. Findings on physical examination
were generally negative except for some epigas
tric tenderness. The patient was kept on
nasogastric suction and in trav enously
administered fluids. Endoscopic examination
after gastric lavage revealed a gastric bezoar,
which was fragm ented. A fter this she
experienced crampy abdominal pain, abdomi
nal distension, tympany and tenderness. An
upper gastrointestinal series demonstrated
complete small-bowel obstruction (Fig. 2). At
laparotomy there was a large bezoar in the mid
ileum causing obstruction. P art o f the origi
nal bezoar remained in stomach. The bezoars
were manually disimpacted and fragmented
without opening the gastrointestinal tract and
the pieces o f ileal bezoar were then milked into
the cecum. Postoperatively, the patient did
well.

FIG. 1—Upper gastrointestinal series show
ing nasogastric tube positioned with its tip in
duodenum, part o f gastric bezoar and, in
pelvis, loop of ileum obstructed by another
bezoar.

FIG. 2—Upper gastrointestinal series show
ing small-bowel obstruction. Barium has not
reached point o f obstruction, therefore bezoar
is not seen.
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(^Mefoxin
(sterile cefoxitin sodium, Frosst Std.)

ANTIBIOTIC
ACTION
In v itro stu d ie s d e m o n s tra te th a t th e
bactericidal action of cefoxitin, a cephamycin
derived from cephamycin C, results from the
in h ib itio n of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
th e 7 a p o s itio n is re s p o n s ib le fo r the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREA TM EN T

The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia m arcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
s h o u ld be perform ed to d e term in e the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rg a n is m s p a rtic u la rly a p p ro p ria te fo r
therapy with MEFOXIN* are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)

E. coli
K le b s ie lla s p e c ie s ( in c lu d i n g
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

K.

Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
w h o are a ls o re c e iv in g c a r b e n ic illin ,
gentam icin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable fo r
p a t ie n t s w ith b a c te re m ia , b a c te r ia l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
fro m su c h d e b ilita tin g c o n d itio n s as
m alnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
p o sto p e ra tive ly) to patients undergoing
vaginal or abdominal hysterectom y and
abdominal surgery when there is a significant
risk of postoperative infection or where the
o ccu rre n ce of postoperative in fe ctio n is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
a d m in is tra tio n of any a n tib io tic beyond
*®Trademark

24 hours fo llow ing surgery increases the
possibility of adverse reactions but, in the
majority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens fo r culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hypers e n s it iv it y r e a c tio n s to M E F O X IN *,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c ro s s -a lle rg e n ic ity betw een
cepham ycins and the oth er beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta -la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is im portant to co n sid e r a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. While studies indicate that a toxin
produced by C lostridium d iffic ile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in is tra tio n o f th e d ru g s h o u ld be
d is c o n tin u e d . S e rio u s h y p e rs e n s itiv ity
re a ctio n s may re q u ire tre a tm e n t w ith
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
h ig h and p ro lo n g e d serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling's solutions
but not w ith the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum m ay o c c u r if serum
concentrations of cefoxitin exceed 100/vg/mL.
Serum samples from patients treated with
MEFOXIN* sh o u ld not be analyzed fo r
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m inistration of
c e p h a lo s p o r in s a nd a m in o g ly c o s id e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tr a tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100m g/kg/day and
above) have been a sso cia te d w ith an
increased incidence of eosinophilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a c tio n s ra re ly re q u ire d cessation of
treatment and usually have been mild and
transient.
Local Reactions

T h r o m b o p h le b itis has o c c u rre d w ith
intravenous administration. Some degree of
pain and tenderness is usually experienced
after intramuscular injections using water.
Induration has occasionally been reported.
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Allergic

M aculopapular rash, u rtica ria , p ru ritu s,
eosinophilia, fever and other allergic reactions
have been noted.

1 * r

Gastrointestinal

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.

A. —

<^

Blood

T ra n s ie n t e o s in o p h ilia , le u k o p e n ia ,
neutropenia, hemolytic anemia, and thromboc y to p e n ia have been re p o rte d . Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN*.

t -

Liver Function

Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
*

Kidney

Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been re p o rte d ra re ly. The ro le of
MEFOXIN* in changes in renal function tests
is d i f f ic u lt to a ssess, s in c e fa c to rs
predisposing to prerenal azotemia or to
im paired renal function have often been
present.

1
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TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN* may be adm inistered in tra 
venously or intramuscularly when required.
(See complete monograph for full details on
ADMINISTRATION and RECONSTITUTION.)
TREATMENT DOSAGE
Adults

The usual adult dosage is 1 g or 2g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
T y p e of
o f infection

D aily
D osage

« *

Frequency
and Route
1 g every 6 -8 h
I.V. o r I.M .

U nc om plica te d
form s* o f in
fections such as
pneum onia,
urinary tract
infection, soft
tissue infection

3 -4 g

M oderately
severe o r severe
infections

6 -8 g

1 g every 4 h
or
2 g every 6 -8 h I.V.

Infections
c om m only
needing a n ti
biotics in higher
dosage (e.g. gas
g angrene)
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2 g every 4 h
or
3 g every 6 h I.V.

‘ In c lu d in g p a tie n ts
a b s e n t o r u n lik e ly

in w h o m

4

*

4

+

4.

•

■» A
A*

V«
b a c t e r e m ia

is

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infectionsshould be maintained
for at least 10 days to guard against the risk of
rheumatic fever or glom erulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.
Adults with Impaired Renal Function

MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage

■~c-

should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
A fte r a lo a d in g do se , th e fo llo w in g
recommendations for maintenance dosage
may be used as a guide:
RENAL
FUNCTION

Mild
im pairm ent
Moderate
im pairm ent
Severe
im pairm ent
Essentially
no function

CREATININE
CLEARANCE
m L /m in

DO S E

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

FREQUENCY

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
Above 1500 g
20-40 mg/kg every 12 h I V.
Neonates
01 week of 20-40
age mg/kg every 12 h I V.
1-4 weeks of age
20-40 mg/kg every 8 h I.V
Infants
1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recommended for the ther
apy of meningitis. If meningitis is suspected,
an appropriate antibiotic should be used.
At present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function "However, if the
administration of MEFOXIN" is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g a d m in is te re d in tr a m u s c u la r ly or
in tra v e n o u s ly ju s t p r io r to s u rg e ry
(approximately one-half to one hour before
initial incision).
The second and third 2g doses should be
administered at 2-6hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* (sterile cefoxitin sodium, Frosst
Std.) is supplied as sterile powder in boxes of
10 vials:
No. 3356 1 g cefoxitin as sodium salt
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

Discussion
Gastric bezoars seen after partial gas
tric resection cause serious clinical
problems.8 " Most of them are concre
tions of food and fibre and may be
associated with symptoms ranging from
a sensation of fullness in the upper abdo
men to epigastric pain. More than 45
different foodstuffs have been recorded
in the literature as obstructing factors.
The major culprits have been the fibrous
pulp of pithy fruits or vegetables and their
skins.12
Obstruction of the small bowel by
bezoars is usually in the distal ileum and
can occur at any time after operation.13
Hypochlorhydria, diminished antral
motility and incomplete mastication seem
to be the main predisposing factors.
Recently the H2 receptor antagonist
cimetidine has also been causally linked
to phytobezoar formation.14 Rumley and
colleagues15 described a case of smallbowel obstruction after incomplete chem
ical dissolution of gastric bezoar. Our two
cases reflect problems seen after other
conservative treatm ents of gastric
bezoars. Small-bowel obstruction secon
dary to spontaneous passage of bezoars
into the small intestine has also been
reported.16' 18
The clinical signs and symptoms of
bezoar obstruction are similar to those of
other types of small-bowel obstruction.
Dehydration and electrolyte imbalance
are not prominent features. A history of
gastric surgery and recent conservative
treatment of the gastric bezoars is help
ful in diagnosis. It must be remembered
that patients are probably equally at risk
after a vagotomy and drainage as after
a partial gastrectomy. Contrast studies of
the small bowel are diagnostic.
At exploration it is important to exa
mine the entire length of small bowel to
exclude the presence o f additional
bezoars. The gastric remnant should also
be examined even when it is difficult to
do so because of adhesions from previ
ous surgery. Closed fragmentation of the
bezoars and milking of the small frag
ments down into the cecum by gentle
m anipulation is usually successful.
Enterotomy to remove an impacted
bezoar should rarely be necessary.
Prophylactic measures to prevent
bezoar formation following gastric sur
gery include giving advice about slow eat
ing and careful chewing, improving den
tition, avoiding pulpy fibrous fruits and
vegetables and the use of metoclopramide
in delayed gastric em ptying.2" 4" 9-20
Bezoars may form after any gastric oper
ation — not just gastrectomy.
Conclusions
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Increased use of physical disruption
and chemical dissolution of gastric

bezoars has saved many patients from
surgery. Small-bowel obstruction may
occur after these conservative approaches
to gastric bezoars as described in our
cases. It is recommended that if conser
vative treatment is used, the possibility of
partial or complete small-bowel obstruc
tion must be kept in mind and these
patients kept under close observation. If
surgical exploration for small-bowel
obstruction is required, most patients can
be successfully managed without resort
ing to enterotomy or gastrotomy.
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Methods for Detecting Locally Recurrent
and Contralateral Second Primary Breast Cancer
The author has studied the roles of ther
mography, mammography and breast
self-examination in detecting recurrent
primary cancer or a second primary in
the contralateral breast. Of 273 patients
whose primary cancer was treated by
lumpectomy, recurrence developed in 52
(1 9 % ); 51 were detected on clinical
examination and 1 by mammography
alone. None were detected by thermog
raphy alone. Of the 51 patients with a
local recurrence detected clinically, 35
had undergone repeat mammography
before biopsy. A change suggestive of a
malignant condition was noted in only
15 (4 3 % ). Thirty-seven had adequately
stable postoperative thermograms for
review. Only 9 (2 5 % ) of these thermo
grams showed a change in pattern
before or at the time the recurrence was
detected. Similar results were found in
the detection of a secondary primary in
the contralateral breast in these patients
and also in a further 193 women whose
primary cancers were treated by total
mastectomy during the same period.
Close clinical supervision is the most
efficient method of detecting local recur
rence and contralateral second primary
breast cancer.
L'auteur a etudie le role respectif de la
thermographie, de la mammographie et
de Tauto-examen des seins dans la
detection des r£cidives de cancers primitifs ou de I'apparition d'un second can
cer primitif dans le sein contralateral. Sur
273 patientes dont le cancer primitif fut
traite par tumorectomie, une recidive est
apparue chez 52 (1 9 % ); 51 ont 6t6
decelees a I'examen clinique et 1 a la
mammographie seulement. Aucune n'a
ete deceive par thermographie seule
ment. Sur les 51 patientes dont la reci
dive locale avait ete deceiee cliniquement, 35 avaient subies une
mammographie de contrfile avant la biop-
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sie. Un changement indicatif d'un cancer
fut observe dans seulement 15 cas
(4 3 % ). Trente-sept possedaient des ther
mographies postoperatoires suffisamment stables pour §tre etudiees. Seule
ment 9 (2 5 % ) de ces thermographies
presentaient des changements caracteristiques avant ou juste au moment ou la
recidive fut deceiee. Des resultats similaires furent obtenus chez ces patientes en
ce qui concerne la detection d'un
deuxieme cancer primitif dans le sein
contralateral et chez 193 autres femmes
dont les cancers primitifs furent traites
par mastectomie totale au cours de la
m§me periode. Une surveillance clinique
etroite constitue la methode la plus efficace de detection des recidives locales
et des seconds cancers primitifs du sein
contralateral.

Local recurrence in the breast occurs
in 25% o f women after lumpectomy
for primary surgical treatment o f breast
cancer. This rate can be reduced with
adjuvant radiotherapy to the breast
postop eratively.1’2 In this study I
assessed the roles o f thermography, mam
mography and breast self-examination in
detecting such local recurrences over a
10-year period. A similar study was car
ried out on patients in whom a con
tralateral second primary breast cancer
developed after either lumpectomy or
total mastectomy as primary surgical
treatment.

Methods
All women whose primary breast
cancer was treated by lumpectomy were
kept under rigid clinical supervision —
every 3 months for the first year, every
4 months for the second year, every 6
months to the fifth year and annually
thereafter. All were instructed in breast
self-examination and their technique was

reviewed by the surgeon at each clinical
visit. All who were 40 years or older
underwent mammography preoperatively
and every 2 years postoperatively. If a
local recurrence was detected clinically
less than 1 year after operation, mam
mography was not repeated before
biopsy. If the tumour was detected clini
cally 1 year or more postoperatively,
mammography was repeated before
biopsy unless a repeat mammogram had
been obtained within the previous 6
months. All patients underwent thermog
raphy preoperatively and a baseline ther
mogram was obtained postoperatively,
usually at 1 year and annually there
after. If a local recurrence was suspected
clinically, thermography was repeated
before biopsy. Increased heat at the lum
pectomy site persists for some months
postoperatively and stable baseline ther
mograms are usually not obtainable for
6 to 12 months after operation. If the
patient has had adjuvant radiotherapy to
the breast after lumpectomy, markedly
increased heat emission may persist for
years.
Women whose primary breast cancers
were treated by total mastectomy were
closely monitored clinically and their
technique of breast self-examination was
reviewed in the same manner as those
treated by lumpectomy. Thermograms of
the remaining breast were obtained annu
ally and mammograms every 2 years. If
a new primary in the remaining breast was
suspected clinically, thermography was
repeated before biopsy. Mammography
Table 11-Method of Detecting Contralateral
Primary Breast Cancer in 17 Women
Method

No.

%

Clinical examination
Mammography
Thermography

17
7
3

100
41
18

Table I—Method of Detecting Local Recurrences
Method
Clinical examination
Mammography
Thermography

No./total no.

%

51*152
16/364
9/371

98
44
24

*1 patient had a clinically occult local recurrence detected by mammography only.
t2 6 patients did not undergo repeat mammography at the time of biopsy.
425 patients did not have stable postoperative baseline thermograms for comparison at the time of biopsy.
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was also repeated before biopsy if more
than 6 months had elapsed since the previ
ous study.
Results (Table I)
From July 1972 to October 1983, 273
lumpectomies were performed as primary
treatment for breast cancers. By Dec. 31,
1983, 52 (19%) of the women had a local
recurrence. One was detected by routine
mammography although findings on clin
ical examination and thermography were
normal. The remaining 51 lesions were ajl
palpable; 16 (31%) of these were detected
by the patient as a result of selfexamination, 4 (8%) accidentally by the
patient and 31 (61%) by the surgeon at
follow-up.
Adequately stable baseline thermo
grams were available postoperatively for
37 of the 51 patients with clinical local
recurrence. Only 9 (25%) of them showed
a change in thermographic pattern before
or at the time the local recurrence was
detected.
Repeat mammography was performed
before biopsy in 35 of the 51 local recur
rences. A change suggestive of a malig
nant condition was noted in 15.
During the same 10-year period, 193
women underwent total mastectomy for
primary breast cancer. Of the total 466

(273 lumpectomies and 193 total mastec
tomies) patients under supervision, 17
(4%) subsequently had a contralateral
second primary breast cancer. All had
adequately stable baseline thermograms
postoperatively and all underwent repeat
mammography before biopsy. Three
(18%) showed a change in thermographic
pattern at the time of or before detection
of the second primary. Seven (41%)
showed mammographic changes (Table
II).
Discussion
It is surprising that only one-third of
the women detected their local recurrence
by breast self-examination. Although all
were quite efficient in its practice they
tended to neglect it because they were
being checked clinically every 3 months
by someone they perceived to be more
skilled (their surgeon).
Currently, no data are available on the
ability of mammography or thermogra
phy to detect local recurrence after lum
pectomy. Although mammography iden
tified 88% of clinically detected primary
breast cancers in women aged 50 to 59
years and 79% of those in women aged
40 to 49 years in the Breast Cancer Detec
tion Demonstration Project,3 it identi
fied only 75% of new contralateral

primary breast cancer in women under
supervision after mastectomy.4 The fact
that mammography was able to detect less
than half of our local recurrences after
lumpectomy is probably due in part to age
(20% of our patients were under 40 years)
and in part to the quarterly clinical exami
nations that are incorporated into our
program of postoperative supervision.
Conclusions
Close clinical supervision is the most
efficient method of detecting local recur
rence after lumpectomy for treatment of
primary breast cancer. Thermographic
changes were present in less than 25% ,
mammographic changes in less than 50%.
Similar results were found in the con
tralateral second primary breast cancers
detected.
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THE 12TH INTERNATIONAL CONFERENCE ON

HOFFMANN® EXTERNAL FIXATION
WILL BE HELD IN
GARMISCH PARTENKIRCHEN,
WEST GERMANY
FROM OCTOBER 9 -1 1 , 1 9 8 6
Topics Will Include:
Basic B io m echan ics of External Fixation .
E x p e rim e n ta l, C lin ica l and Th eo retica l
R esearch.
Ela stic Extern al Fixation.
''Biocom pression'.'

1965
1972
1973
1975
1976
1977
1978
1980
1981
1982
1983
1985

T h i s Congress has earned itself a great inte rnation al reputation over the last 20 years for
reflecting the cur re nt state of the art a n d for lo oking forward into the future of external
skeletal fixation technology. As always, the mo st e m i n e n t international speakers will be
present as well as participants from the five co n ti n e n ts of the world, re porti ng on their
varied experiences.
T h e official languages will be Ger man, E ngli s h an d Fr en ch with simultaneous translation.

A p p lic a tio n of E xtern al Fixation in case of:
In tra -a rtic u la r fractures
Lower and up p e r e xtrem ity
fractures
Pelvic fractures
Spine
War injurie s
C h ild ren 's fractures
M axillo-facial fractures
Infected fractures
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Percutaneous Catheter Drainage
of Abdominal Abscesses
This paper presents a study of 45
patients who had percutaneous catheter
drainage of 52 intra-abdominal
abscesses. In 37 patients this was the
only treatment necessary; the other 8
needed further surgery to correct the
cause of the abscess or treat concurrent
surgical disease. The catheter complica
tion rate was 3.8%.
Cet article est consacre a une etude portant sur 45 patients qui ont subi le drai
nage par catheter percutane de 52 abces
intra-abdominaux. Pour 37 patients, ce
fut la le seul traitement necessaire; les 8
autres ont du subir d'autres interventions
chirurgicales pour corriger la cause de
I'abcds ou pour traiter une maladie concomitante operable. Le taux de complica
tions dues au catheter fut de 3.8% .

In 1908 Barnard1 reported that the death
rate associated with intra-abdominal
abscesses decreased from 100% to 47%
with surgical drainage. Thirty years later
Ochsner and DeBakey2 described the
ideal drainage procedure as one “ charac
terized by its directness, simplicity and,
above all, avoidance of unnecessary con
tamination of uninvolved areas” . This
surgical doctrine and the advent of antibi
otics have further reduced the death rate
to around 20% in most series.3 With
cross-sectional imaging, antibiotics and
adherence to surgical principles, many
series quote success rates of up to 90%
after percutaneous catheter drainage and
death rates ranging from 0% to 15%.4-7
Patients and Method
During a 4-year period ending in
December 1984, 23 men and 22 women,
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ranging in age from 16 to 101 years (mean
45 years) underwent 52 catheter drainage
procedures for collections of intra
abdominal fluid at the Ottawa Civic
Hospital. When clinical suggestion or
plain-film evidence indicated an abscess,
the patient underwent enhanced com
puterized tomography of the abdomen
and pelvis. The radiology and surgical
staff collaborated on the selection of
patients and routes for percutaneous
catheter drainage.8
Seldinger catheters or trocars were
used, under fluoroscopic control, to intu
bate the abscess.9"11 Aspirates were sent
for microbiologic studies. All patients
received parenterally administered antibi
otics. Gravity drainage was instituted
after fixation of the tube.
Subsequent radiologic investigation,
such as repeat scanning or sinography,
was indicated by clinical response (dimi
nution of fever and drainage) and leuko
cyte count. If drainage was inadequate,
a larger bore catheter was inserted. If pus
was too viscid or contained substantial
debris, irrigation was instituted with
saline or antibiotic solution. New, recur
rent or loculated abscesses required addi
tional catheters.
Criteria for removal of the catheter
included cessation of drainage and clear
return of irrigants, followed by 48 hours
of clinical well-being and radiologic evi
dence of cavity resolution.
Findings
Follow-up ranged from 5 to 38 months.
Duration of drainage ranged from 0 to
105 days (mean 20 days).
Primary abscesses (22%) are those that

presented de novo (Table I). The majority
(78%) were secondary or postoperative in
nature (Table II).
The location of the abscesses is outlined
in Table III. They occurred most fre
quently in the subphrenic spaces (48%).
The apparent prevalence of pancreatic
abscesses in men was due to two patients
who had undergone pancreatic debride
ment for sepsis and had either multiple
or recurrent collections requiring repeated
drainage.
There were two ipsilateral thoracic
empyemas after drainage of subphrenic
abscesses, for a catheter complication rate
of 3.8%.
Percutaneous catheter drainage was the
only method of treatment in 37 of 45
patients for a success rate of 82%. One
patient died of multiple organ failure 60
days after drainage. At autopsy there was
no evidence of a residual intra-abdominal
abscess.
Eight (18%) patients required further
surgery after initial drainage of the
abscess. Subphrenic abscess developed in
two after multiple surgical procedures on
the stomach. The abscesses communi
cated with the gastric remnant and were
presumably due to leakage at the suture
lines. A third patient had a fecal fistula
after injury to the colon at left nephrec
tomy. The fistula closed with conserva
tive treatment but 6 months later a para
colic abscess developed that required
percutaneous drainage. Sinography again
demonstrated a fistula to the colon, so a
diverting colostomy was performed. One
patient had percutaneous drainage of a
subhepatic abscess after cholecystectomy
for a gangrenous gallbladder. This man
subsequently required lysis of small-bowel

Table 1—Origin of Primary Abscess in 10 Patients
Origin
Men
Hepatic
2
—
Appendiceal
—
Perinephric
—
Subphrenic from perforated duodenal ulcer
Diverticular
1
—
Cholecystic
Subhepatic from colonic carcinoma
1
Totals
4

Women
_

2
1
1
1
1
6
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adhesions secondary to a previous gas
trectomy. At operation, his drainage
catheter was removed and a larger bore
tube inserted. Another man had per
cutaneous drainage o f a pancreatic
abscess. Contrast films showed commu
nication with the pancreatic duct. His
abscess resolved and the catheter was
removed. Six months later, however, a
pseudocyst of the pancreas developed and
he required cystogastrostomy. A sixth
patient underwent total gastrectomy with
splenectomy for carcinoma of the
stomach. In the postoperative period, he
had percutaneous drainage o f a loculated
collection beneath the left diaphragm. His
symptoms resolved but 1 month later, a
recurrent collection in the area could not
be drained effectively by a percutaneous
catheter. At laparotomy the loculated col
lection was found to be necrotic tumour
and not pus. The seventh patient had a
subhepatic collection after cholecystec
tomy. This was drained by a percutane
ous catheter, but continued to drain bile
for 2 months. At laparotomy, the bile was
leaking from an anomalous right hepatic
duct that had been injured during previ
ous surgery. This was treated by
hepaticojejunostomy. The last patient
was a 101-year-old woman who, because
o f her age, had an empyema o f the gall
bladder treated by percutaneous drainage.
Cholangiography showed a stone within
the common bile duct that was asympto
matic. The patient did not want to go
home with a drainage catheter so it was
removed. Three weeks later her symptoms
recurred and a m ore perm anent
cholecystostomy was carried out under
general anesthesia. Subsequent cholan-

Table 11-Type of Surgery Resulting
in Secondary Abscess in 35 Patients
Women
Men
Type of surgery
4
3
Gastric
1
Splenic
3
2
Hepatic
0
4
Biliary tract
3
4
2
Pancreatic
1
1
Appendiceal
4
Other
3
16
Totals
19

giography again revealed the commonbile-duct stone. Sphincterotomy was per
formed endoscopically, and with irriga
tion through the catheter in the gallblad
der the stone was eventually washed out
o f the common bile duct. The cholecystomy tube was then removed and the
patient remained well until her death
several months later from an unrelated
cause.

Discussion
Our failures demonstrate a variety of
circumstances in which percutaneous
catheter drainage, although able to con
trol the initial abscess, was not curative
because o f the underlying cause. Drainage
was, however, useful in demonstrating
fistulous abscesses.
The procedure is safe. If abscesses are
multilocular, multiple catheters may be
required. The surgeon and radiologist
should collaborate in the decision and
method o f drainage.
In most cases drainage is the only treat
ment required. In 18% o f our cases, fur
ther surgery was necessary to correct the
cause o f the abscess or concurrent surgi
cal disease. Catheter drainage cannot
carry out debridement as may be required
in pancreatic abscesses and infected pseu
docysts,10,12 so it may not be the proce
dure o f choice in these circumstances.
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-
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BOOKS REVIEWS
continued from page 332
SURGICAL PATHOLOGY OF THE HEAD
AND NECK (in two volumes). Edited by
Leon Barnes. 1866 pp. Iilust. Marcel Dekker, Inc., New York, 1985. Price not stated.
ISBN 0-8247-7216-4 (v. 1); ISBN 0-82477269-5.

The first chapter of this tome discusses
the relation of the head and neck surgeon
to the pathologist and provides a thought
ful discussion of the need for and benefit of
close collaboration between them. The tech
niques of frozen section, immunoperoxidase
techniques and electron microscopy are dealt
with in three successive chapters. Volume 1
covers diseases of the larynx and hypopharynx
and esophagus, followed by chapters on
the oral cavity, nose and paranasal sinuses,
nasopharynx, external auditory canal and mid
dle ear, salivary glands and tumours of the ner
vous system, mid-facial destructive lesions and
tumours and tumour-like lesions of soft tissues.
Volume 2 commences with general chapters
on diseases of the bone and joints, hematologic
disorders and occult primary tumours and then
deals with cysts, odontogenic tumours, diseases
of the thyroid, parathyroid, selected skin
lesions and pathologic conditions of the eye
and finishes with chapters on infectious dis
eases and miscellaneous disorders of the head
and neck.
Since there is little general pathology in the
sense of a discussion of disease processes in this
text it complements, but does not replace,
works on general pathology.
The chapters vary enormously in length,
detail and number of references. For example,
the chapter on diseases of the larynx,
hypopharynx and esophagus is 85 pages long
and contains 341 references on diseases of the
larynx and an additional 166 on the
hypopharynx and esophagus. The chapter on
diseases of the bone and joints covers 162 pages
and lists no fewer than 930 references. By con
trast, nasopharyngeal carcinoma rates only 13
pages and 28 references although it is proba
bly the most extensively studied and writtenabout pharyngeal lesion. In the longer chap
ters, references are broken down by subsection
and form an excellent source of reference
material. There is no ready answer as to the
optimum amount of bibliographic material that
should be presented in a handbook; if the
material crosses disciplinary boundaries I
favour extensive references, otherwise only key
references should be used. Inevitably in a book
of this size, which was 5 years in publication,
the bibliographic material is dated. However,
it is more than adequate to underpin recent
references that may be obtained through com
puter retrieval services.
The book is well illustrated with high-quality
photomicrographs and electron micrographs.
It inevitably reflects US opinions and the clin
ical biases of the institutions from which it
comes. For example, the suggestion that the
only treatment for verrucous carcinoma of the
larynx is surgery and that radiotherapy con
verts 30% of these lesions to anaplastic carci
nomas is not acceptable at our centre, but it
a widely held US misconception. On the other
hand, the discussion about carcinoma of the
larynx is excellent.
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Esophageal Obstruction Secondary
to a Mediastinal Pancreatic Pseudocyst
The authors report a rare complication of
pancreatic pseudocyst. A 47-year-old
man suffered rapidly progressing dyspha
gia and complete esophageal obstruction
secondary to extrinsic compression by
mediastinal extension of a pancreatic
pseudocyst. Ultrasonography and espe
cially computerized tomography were
instrumental in diagnosis and in the plan
ning of the operation. A posterior cystogastrostomy successfully drained the
pseudocyst and relieved the esophageal
obstruction.
Les auteurs decrivent une complication
rare d'un pseudokyste pancreatique.
Chez un homme de 47 ans, sont apparues une dysphagie rapidement evolutive
et une obstruction oesophagienne totale
secondaire a une compression extrins§que par extension mediastinale d'une
pseudokyste pancreatique. L'echographie et, tout particulibrement, la tomographie par ordinateur ont servi a diagnostiquer la maladie et £ planifier
I'operation. Une cystogastrostomie posterieure a permis de drainer le pseu
dokyste et de soulager ('obstruction
oesophagienne.

Pancreatic pseudocysts are common
sequelae o f pancreatitis. They are collec
tions o f pancreatic enzymes, blood and
necrotic debris limited by a fibrous wall
and are usually confined to the pancreas,
lesser sac or anterior pararenal space.1"3
More unusual spread has been described
into splenic parenchyma, neck and scro
tum.4-7 Very rarely they may extend into
the m ediastinum by way o f the
esophageal or aortic hiatus.4-8"14 Medi
astinal pseudocysts rarely cause dyspha-
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gia but radiologic evidence o f esophageal
displacement is not uncommon.4'14 To
our knowledge complete esophageal
obstruction from such cysts has not been
reported. We report such a case. A defini
tive diagnosis is essential as symptomatic
relief follows pseudocyst drainage which
should be done through an abdominal
rather than a thoracic approach.4,8 This
case emphasizes the importance of
thorough radiologic investigation, espe
cially computerized tomography, in
reaching the diagnosis, documenting the
anatomic location and extent of the lesion
and in planning the appropriate surgical
approach.

lesser sac and esophageal hiatus into the medi
astinum. The anteromedial portion of the right
hemidiaphragm was bulging inferiorly, secon
dary to pressure from the mediastinal compo
nent of the pseudocyst. The cyst was aspirated
through the posterior wall of the stomach. It
contained sterile, dark brown, murky fluid
which had an amylase concentration of 14 250
U /L. A posterior cystogastrostomy completely
decompressed the cyst. There was free commu
nication between the mediastinal and abdomi
nal portions.
Six months after operation the patient was
able to swallow normally and was well. The
pleural effusion had resolved. A follow-up
computerized tomogram documented complete
resolution o f the pseudocyst.

Case Report
A 47-year-old man had suffered from lower
esophageal dysphagia for 5 days; it had rapidly
progressed to the point at which he could not
swallow liquids and regurgitated saliva. His
only other complaint was of constant mild
epigastric pain. He denied any history of pan
creatitis but did admit that he had long been
a heavy drinker. He also had severe peripheral
vascular disease and had undergone multiple
vascular reconstructive procedures.
Findings on examination were unremarka
ble apart from his obvious dysphagia and signs
of a right pleural effusion. This effusion had
previously been tapped and found to be a
benign exudate, but had not been analysed for
the presence of amylase.
Chest films showed a right pleural effusion
and an ill-defined retrocardiac mass. Radiologic findings from barium swallow demon
strated anterolateral displacement and obstruc
tion of the lower esophagus of an extrinsic
nature. Endoscopy confirm ed complete
obstruction o f the esophagus at 32 cm with no
evidence of an intrinsic mucosal lesion or for
eign body.
Ultrasonography demonstrated the presence
o f a posterior mediastinal cystic mass with
extension into the abdominal cavity. A
thoracoabdominal computerized tomogram
confirmed the presence of a large pseudocyst
arising from the pancreatic bed and extending
cephalad into the mediastinum to obstruct the
esophagus (Fig. 1). It also demonstrated signs
of chronic inflammation in the body and tail
of the pancreas.
At laparotomy, a large cyst was found aris
ing from the middle part of the body of the
pancreas. It extended cephalad through the

Fig. lb
FIG. 1—(a) Cross-section o f thorax 18 cm
below sternal notch clearly demonstrates
posterior mediastinal extension of pseudocyst
(P) behind heart (H). Note also right pleural
effusion (F) and descending thoracic aorta (A),
(b) Reformatted sagittal view displays large
pancreatic pseudocyst (P) originating in pan
creatic bed and extending cephalad into medi
astinum and obstructing barium filled esopha
gus (E).
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Discussion
Mediastinal extension of pancreatic
pseudocysts is rare, approximately 30
cases having been reported.4,8"14 These
patients usually present with cardi
orespiratory symptoms due to local pres
sure or secondary to concomitant pleural
effusions.4,8' 14 Our patient had no cardi
orespiratory symptoms, despite a chronic
right pleural effusion; dysphagia, secon
dary to esophageal obstruction was the
presenting symptom. Dysphagia has
previously been noted in conjunction with
mediastinal pseudocysts but has usually
been a minor complaint.4,8,11 The acute
onset and rapid progression to esophageal
obstruction in our case suggests acute
expansion into the mediastinum or
enlargement of the mediastinal compo
nent of the pseudocyst.
Ultrasonography and computerized
tomography have been valuable adjuncts
to the investigation of many types of
thoracic and abdominal conditions.1,3,11
In this case, computerized tomography in
particular was instrumental in making the
definitive diagnosis and anatomically
documenting the extent of the pseudocyst.
The reformatted sagittal computerized

tomogram (Fig. lb) clearly demonstrated
the large pseudocyst with mediastinal
extension, which was compressing and
obstructing the lower esophagus.
Laparotomy and cystogastrostomy or
cystoenterostomy are the procedures of
choice for draining mediastinal pseu
docysts.4,8 The success of such an
approach depends upon the presence of
an abdominal component of the pseu
docyst that freely communicates with the
mediastinum. Banks and colleagues8
reported the only case in which an
abdominal component to a mediastinal
pseudocyst was not found. However, this
pseudocyst was successfully drained at
laparotom y by a cystoenterostom y
through the diaphragm.
The diagnosis of these rare mediastinal
extensions of pancreatic pseudocysts
should be suspected clinically in patients
with persistent cardiorespiratory com
plaints following pancreatitis, especially
when associated with a persistent pleural
effusion or retrocardiac mass. Dysphagia
is an uncommon complaint but mediasti
nal pseudocysts can produce esophageal
obstruction. As in our case, mediastinal
pseudocysts should be drained by lapa

H arold P. D rutz ,
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rotomy and cystogastrostomy or cystoen
terostomy.
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Prophylactic Use of Antibiotics in Combined
Abdominovaginal Marlex Sling Procedures for
Correction of Recurrent Urinary Stress Incontinence
The charts of 75 patients who under
went a combined abdominovaginal
Marlex sling procedure to correct urinary
incontinence were analysed to assess
the value of antibiotic prophylaxis. Six
patients who received antibiotics
preoperatively for underlying medical
problems were excluded from the study.
Eighteen patients operated on before
1980 did not receive antibiotic
prophylaxis and of these only 1 suffered
a superficial abdominal wound infection.
Fifty-one consecutive patients received

From the Gynecological Urology and Urodynamic Investigative Unit, Mount Sinai
Hospital and the Department o f Obstetrics
and Gynecology, University o f Toronto,
Toronto, Ont.
Accepted for publication Mar. 25, 1986
Reprint requests to: Dr. Harold P. Drutz,
Ste. 1221, Mount Sinai Hospital, 600
University Ave., Toronto, Ont. M5G 1X5

antibiotics prophylactically; of this group
again only 1 had a superficial abdominal
wound infection. These findings suggest
that antibiotic prophylaxis may not be
necessary with this operation. Neverthe
less, the authors believe a prospective,
randomized, double-blind study to
include a placebo is warranted, and such
a study will be undertaken in their unit.
Les dossiers m6dicaux de 75 patientes
qui ont 6t6 operees pour la pose de bandelettes abdominovaginales de toile Mar
lex pour corriger une incontinence urinaire ont 6t6 analyses dans le but
d’6valuer I'interet d'une antibiotherapie
preventive dans ce genre d'intervention.
Six patientes qui avaient recu des antibiotiques en pr£op£ratoire pour des probl£mes medicaux sous-jacents ont 6t£
exclues de l'6tude. Dix-huit patientes
operees avant 1980 n'ont pas repue
d'antibiotherapie preventive; de celles-ci.

une seule a contracts une infection de
plaie superficielle. Cinquante-et-une
patientes ont par la suite recu des antibiotiques £ titre prophylactique; encore ie
une seule a eu une infection superficielle
de la plaie abdominale. Ces resultats
indiquent que I'antibiotherapie preventive
n'est peut-etre pas n6cessaire dans cette
operation. Les auteurs croient neanmoins qu'il y a lieu de mener une etude
prospective, randomisee et & double insu
contre placebo. Une telle etude sera
entreprise dans leur service.

There is evidence that antibiotics given
prophylactically are effective in prevent
ing postoperative infections and reducing
“ febrile morbidity” in vaginal hysterec
tom y.1,2 To date there have been no
studies on the effect o f antibiotic
prophylaxis in combined abdominovagi
nal surgery for recurrent urinary stress
incontinence, especially when a foreign
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body like Marlex (polypropylene) mesh
(Davol Rubber Co., Providence, R[) is
used for reconstruction. We carried out
a retrospective study to ascertain the need
for prophylaxis against postoperative
wound infections in women who under
went combined abdominovaginal Marlex
sling operations to correct recurrent uri
nary stress incontinence.

Cefazolin (1 g intravenously 1 hour
before operation, then 1 g at 6 and 12
hours after surgery) was used in 6 cases,
cefoxitin (2 g intravenously 1 hour before
operation, then 2 g 4 to 6 hours and 8 to
12 hours after) was given to 41 patients
and metronidazole (500 mg intravenously
before operation then 500 mg 8 and 16
hours after) was given to 4 patients
allergic to penicillin or cephalosporins.

Patients and Method
The charts of 75 women who had com
bined abdominovaginal Marlex sling
procedures at the Mount Sinai Hospital
in Toronto, between 1978 and 1984, were
reviewed. All were operated upon vaginally by the same gynecologist and
abdominally by the same urologist with
the assistance of resident staff.
We noted the type of antibiotics used,
the presence o f febrile m orbidity
postoperatively and wound, urinary tract
and other infections. The length of hospi
tal stay was also documented. In addition
to the routine blood and sputum cultures,
vaginal swab and catheter urine cultures
were done in patients with elevated tem
peratures.
Febrile morbidity was defined as an
elevated temperature, higher than 38.0°
C, on two or more occasions taken 6
hours apart and at least 24 hours after the
operation.
Findings
Six patients who received antibiotics
preoperatively were removed from the
study because of inadequate information
or prophylactic use of an antibiotic for
other indications such as endocarditis.
Eighteen patients operated on before 1980
were not given antibiotics prophylactically. This left as the study population 51
patients who did receive antibiotic
prophylaxis. They were given cefazolin
(Ancef; Smith, Kline and French Canada
L td., Mississauga, O nt.), cefoxitin
(Mefoxin; Frosst, Dorval, PQ), or
metronidazole (Flagyl; Rhone-Poulenc
Pharm a Inc., Montreal, PQ), depending
on a history of allergy to penicillin. The
majority of patients were at minimal risk
of infection. Six patients were obese and
one had diabetes. Age ranged from 31 to
85 years (mean 42 years). No patient had
received antibiotics within 2 weeks of
admission.

Complication
Wound infection
Urinary infection
Febrile morbidity
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become infected. The abdominal wound
infection was treated simply by opening
the abdominal incision and changing the
dressing daily. There was no deep infec
tion. She was hospitalized for 21 days.
Nine patients suffered febrile morbidity;
in two of these /3-hemolytic streptococcus;
was cultured from the vaginal vault. Ten
of the 18 patients received a Martius pedi
cle graft. The average hospital stay for
this group was 9 days.

Complications (Table I)
One patient who received cefoxitin
suffered an abdominal wound infection
that grew Escherichia coli and Proteus
mirabilis, both sensitive to cefoxitin. In
addition she had a urinary tract infection
(colony count more than 105) due to
Streptococcus faecalis. This patient had
received a Martius3 pedicle graft but
there was no evidence of infection at the
graft site.
Seven patients had bacteria isolated
from their catheter urine at the time the
suprapubic catheter was removed and
four of these-had an elevated tempera
ture. Five of the isolates were S. faecalis,
three from patients who received cefoxi
tin prophylaxis, and two from patients
who received cefazolin prophylaxis. The
remaining isolates, E. coli and group B
hemolytic streptococcus, were from
patients with metronidazole prophylaxis,
both of whom had an elevated temper
ature.
Sixteen of the 51 patients had febrile
morbidity: 12 of these had received cefox
itin, 2 cefazolin and 2 metronidazole. The
remaining patients had no obvious source
of infection. One of the cefoxitin group
had a vaginal vault culture which grew
(3-hemolytic streptococcus.
Nine patients received a Martius graft
— seven in the cefoxitin group and two
in the cefazolin group. The average hospi
tal stay for patients who received antibi
otics prophylactically was 9 days. The
patient with the wound infection was
hospitalized for 20 days.
Of the 18 patients who did not receive
antibiotic prophylaxis, 2 had urinary tract
infection, due to E. coli in one and S.
faecalis in the other. One patient had an
abdominal wound infection that grew
Staphylococcus aureus and S. faecalis.
She was obese. She also received a Mar
tius fibrofatty pedicle graft as part of her
vaginal operation, but this did not

Table I— Complications of Operation in the 51 Patients
Who Received Antibiotic Prophylaxis________
Type of antibiotic
Cefazolin
Cefoxitin
(n-6)
In-41)
1
2
2

Surgeons have been reluctant to use
foreign-material prostheses because of the
fear of infection and rejection. Many
sling procedures have been devised to
treat recurrent urinary stress inconti
nence, but because of the problems with
foreign materials most surgeons prefer
homologous materials, such as fascia lata,
rectus fascia, round ligament and tendon
of the palmaris longus.4 In the past, for
eign materials used included Mersilene
gauze, EXVS (epiurethral suprapubic
vaginal suspension) and Teflon tape.5-7
Complications reported with these
materials include suprapubic abscess and
urethral fistula. In 1970 M organ8
introduced Marlex mesh to treat recurrent
stress urinary incontinence. Usher9 used
the material in the treatment of hernias
and reported a 10% incidence of wound
infection. Bryans10 reported four wound
infections in his series of 69 patients with
Marlex mesh slings, but unfortunately he
did not mention antibiotic prophylaxis.
Although w ound infection in our
experience is low in patients not receiv
ing antibiotics prophylactically, we found
that febrile morbidity was substantially
less (16 of 51, 31%) in those who received
antibiotics prophylactically than in those
who did not (9 of 18, 50%) (p = 0.17,
X2 test). Morgan did not report any
wound infection in his first series of 20
patients8 nor in his second series of 118
patients.11 He did not use antibiotic
prophylaxis.
In our 75 patients there were only two
wound infections, one in the 51 patients
with and one in the 18 patients without
antibiotic prophylaxis. Both infections
were superficial and were treated easily
with simple wound cleansing. There was
no abscess formation and no complica
tions associated with the antibiotic
administration.
Conclusions

Metronidazole
(n-4)

—

3
12

Discussion

2
2

This study suggests that even though
the potential of a serious wound infection
exists due to the use of a foreign substance
in a highly contaminated area, prophylac
tic antibiotics may not make a difference
to the frequency of infection. Although
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this retrospective study may be considered
to have an inadequate control group, it
has prompted us to embark on a double
blind, prospective study on the use of
antibiotics prophylactically in surgery for
urinary stress incontinence using the
Marlex sling procedure.
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Hepatic Artery Infusion Chemotherapy
With the Infusaid Pump: a Canadian Experience
Hepatic artery infusion of
5-fluoro-2'-deoxyuridine !FUDR), utilizing
the implantable "Infusaid pum p", was
used to treat 16 patients with diffuse
hepatic metastases from colorectal carci
noma. Pump implantation was associated
with minimal morbidity and no deaths.
The pumps have now been in use for
190 treatment-months without serious
complication. Six patients died of cancer
between 3 and 26 months (mean 13
months) after insertion of the pump. Five
died with recurrent disease outside the
liver. Ten patients were alive 6 to 17
months (mean 12 months) after pump
implantation. Follow-up ultrasonography
in 13 patients documented regression of
hepatic lesions in 7, no change in 4 and
progression in 2.
Regional perfusion chemotherapy can
be instituted safely and treatment carries
acceptable morbidity. Survival is
prolonged relative to historic controls.
Death ultimately occurs because of dis
tant metastases. True assessment of the
efficacy of this therapy demands
prospective randomized trials of regional
perfusion versus conventional therapy,
with care to incorporate objective means
of assessing quality of life during
treatment.
La perfusion de 5-fluoro-2'-desoxyuridine (FUDR) dans I’artEre hepatique,
a I'aide d'une pompe implantable
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"Infusaid", a servi au traitement de 16
patients presentant des metastases
hepatiques diffuses d'un cancer colorec
tal. Une morbidite minimale a ete associee a I'implantation de la pompe; il n'y
eut aucun deces. Les pompes ont maintenant ete en utilisation sans complica
tions serieuses pendant I'equivalent de
190 mois de traitement. Six patients
sont decedes de cancer de 3 a 26 mois
(moyenne 13 mois) apres I'insertion de la
pompe. Cinq sont dEcEdEs de rEcidives
extra-hepatiques. Dix patients vivent
encore de 6 a 17 mois (moyenne 12
mois) apres I'implantation de la pompe.
Des Echographies de controle prises chez
13 patients ont demontre une regression
des lEsions hepatiques dans 7 cas,
aucun changement dans 4 et 1'evolution
de la maladie dans 2.
La chimiothErapie rEgionale par perfu
sion peut etre instaurEe sans risque et le
traitement entraine une morbiditE accep
table. Par comparaison retrospective
avec un groupe tEmoin, la survie est prolongEe. Finalement, le dEces survient des
suites de mEtastases E distance. L'Evaluation veritable de I'efficacitE de ce trai
tement exige la rEalisation d'essais thErapeutiques prospectifs et randomisEs
comparant la perfusion rEgionale et le
traitement classique. On devra prendre
soin d'y incorporer des moyens objectifs
d'Evaluer la qualitE de la vie durant le
traitement.

Colorectal cancers commonly metastasize
to the liver.1-3 O f patients who undergo
resection o f primary carcinomas, 10% to
20% will have evidence o f hepatic
involvement, which will develop in an
additional 30% to 45% during the ensu
ing 24 months.3'5 Liver metastases are a

major determinant o f long-term sur
vival.1-5 Patients with untreated hepatic
disease survive 4 to 6 m onths.1-3 Wagner
and a sso cia tes1 and Bengtsson and
colleagues2 have shown that survival
depends on the extent o f hepatic involve
ment. Patients with unilateral disease can
survive longer than those with diffuse
disease.
Therapeutic options for these patients
range from palliative care through aggres
sive surgical resection and combination
radiotherapy and chemotherapy.6-8 The
limited response to intravenous systemic
chemotherapy led to attempts at regional
arterial infusion.6,9 This technique was
initially fraught with technical and phar
macologic problems. However, with the
development o f the implantable Infusaid
pump (Infusaid Corp., Norwood, Mass.),
a continuous drug-delivery system, and
newer chemotherapy agents, hepatic
artery infusion chemotherapy has become
a feasible treatment alternative.10-15 We
report our experience with hepatic arterial
infusion o f 5-fluoro-2'-deoxyuridine
(FUDR) over the past 36 months at
Queen’s University in Kingston, Ont.

Patients and Methods
Sixteen patients (11 men, 5 women)
with hepatic metastases from colorectal
carcinoma, discovered either at original
resection or on follow-up, underwent
Infusaid pump placement for regional
perfusion chemotherapy. They ranged in
age from 47 to 72 years (mean 60 years).
Only patients with unresectable metastatic
disease confined to the liver, were consi
dered for pump implantation and all had
the Infusaid pump1 implanted in a sub
cutaneous pouch in the right lower quad
rant. The infusion catheter was tunnelled
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through the abdominal wall and inserted
through the lesser sac in the gastroduo
denal artery, where the tip was positioned
at the junction with the common hepatic
artery before being fixed in place. In two
patients preoperative arteriography
showed aberrant arterial supply of the left
hepatic lobe via a branch o f the left gas
tric artery; this necessitated insertion of
two catheters in each case. Total hepatic
perfusion was assessed by intraoperative
fluroescein dye injection. The gallbladder
was removed at the time of pump implan
tation.
Following implantation, patients were
examined every 2 weeks in the outpatient
clinic. On alternate visits the pump was
loaded with either 500 mg of FUDR or
sterile water, each in combination with
10 000 units of heparin. Patients had
hematologic and biochemical testing
monthly and ultrasonography every 6
months.
Any clinical or biochemical evidence of
drug-induced hepatic toxicity was treated
by removing the medication from the
pump or reducing the dose of FUDR.
Findings
Seven patients had liver involvement at
the time of original resection, and in the
remainder it was discovered at an aver
age of 14 months (range from 7 to 32
months) after. Hepatic involvement was
bilateral and diffuse in 14, but large cen
tral masses were present in 2.
All patients had the pump inserted at
laparotomy other than the original resec
tion. There were no deaths related to
pump insertion. The average hospital stay
postoperatively was 10 days (range from
7 to 30 days). Fever secondary to atelec
tasis developed in three patients and per
sistent pump pouch seromas requiring
extended drainage for their resolution in
two.
Collectively, the pumps have now been
in use for 190 treatment-months. Only
one technical problem occurred — an
air lock which was corrected by flushing
the pump. There have been no infections
of pump fluid or microbiologic evidence
of contamination. Three patients have
their pumps serviced by family doctors,
and one patient travelled to the United
States for an extended period while con
tinuing therapy.
Twelve patients experienced nausea and
occasional vomiting during treatment
cycles, but this persisted only in 2. The
problem was controlled by decreasing the
dose of FUDR. There were two episodes
of chemical hepatitis requiring hospital
admission; both resolved when FUDR
was removed from the pump.
Six patients died of cancer a mean of
13 months (range from 3 to 26 months)
after pump implantation. Five had evi
dence of either pulmonary or skeletal
metastases. Ten patients were alive 6 to
380

17 months (mean 12 months) after pump
implantation, but 5 showed evidence of
pulmonary involvement.
Follow-up ultrasonography was per
formed in the 13 patients who survived
6 months or longer; regression of hepatic
lesions was demonstrated in 7, no change
in 4 and progression in 2.
Discussion
There is no doubt that patients with
diffuse hepatic metastases have a short
survival.1' 5 Conventional systemic single
or combination chemotherapy produces
response in 15% to 30% of patients.6’7,10
The results of our study and those of
o th ers,11-15 although uncontrolled,
demonstrated improved survival over that
noted in historic controls. There are the
oretical reasons why hepatic artery infu
sion therapy should be more efficacious
in the treatment of locally advanced
hepatic metastases.
First, various techniques have shown
that hepatic metastases derive 90% to
95% of their blood supply from arterial
flow.10'16'17 In contrast, normal hepatic
parenchyma derives 65% to 70% of its
blood supply from the portal circulation.
Thus, there is an ideal vascular bed
through which regional arterial perfusion
should result in selective delivery of the
chemotherapeutic agent to the tumour.
Second, several aspects of drug therapy
make regional perfusion attractive. The
principal agents used to treat colorectal
cancers are 5-fluorouracil and FUDR.
Both have a low-slope therapeutic index
and are not particularly cell-cycle specific,
making it advantageous to deliver high
concentrations to the tumour by continu
ous infusion for maximal effect.17 They
also have a short half-life and rapid clear
ance. This favours regional concentration
— hepatic extraction of FUDR on first
pass through the liver has been shown to
be between 70% and 90% ,17 reflecting
an increase in drug concentration in the
liver of 200 to 300 times that achieved by
intravenous administration.
This study confirms earlier reports that
the Infusaid pump system can be
implanted for hepatic arterial infusion
chemotherapy with minimal morbidity,
even in patients with diffuse hepatic dis
ease.11' 15 Furthermore, chemotherapy
can continue on a long-term basis with
minimal inconvenience. The majority of
our patients continued to lead normal
lives and one was able to take an extended
vacation in the United States, thanks to
the number of centres that are familiar
with the system and were willing to load
the pumps.
Our group of patients survived longer
than anticipated, relative to historic con
trols.1-5 The mean survival of 12 to 13
months is in keeping with other uncon

trolled studies.10"15 The ultrasonographic
documentation of a response rate of
approximately 53% is also in keeping
with those of previous reports.10'15
Five of the six patients in our study who
died of their disease did so with evidence
of distant metastases. As already men
tioned pulmonary or bony disease deve
loped in several of our survivors and this
has been the experience of many other
groups.10-15 A lthough we shall not
influence the death rate from this disease
with regional perfusion therapy, this tech
nique does appear to prolong survival
with limited morbidity and preservation
of good quality life. The results of this
and other uncontrolled studies are
encouraging and warrant prospective ran
domized trials to test the true efficacy of
this mode of therapy. Such studies are
now under way in multicentre trials in the
United States.10
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Recidive d’infection de prothese vasculaire:
traitement par pontage a partir de I’aorte thoracique basse
abordee par voie abdominale
Les auteurs rapportent le cas d'une
patiente de 72 ans qui avait eu un pon
tage axillobif6moral apres exerese d'une
prothese aortobif6morale infect6e.
L'echec par recidive infectieuse a pose le
probldme d'une nouvelle revascularisa
tion, associee a I'ablation du pontage
infects.
L'intervention a consiste en un pon
tage entre I'aorte thoracique basse et les
femorales superficielles distales, en pas
sant par le trou obturateur. L'abord de
I'aorte thoracique basse a ete effectue
par une voie strictemeht abdominale, ce
qui diminue la lourdeur d'un tel geste. Le
resultat obtenu, avec un recul de 18
mois, a ete satisfaisant sur le plan vas
culaire et infectieux.
Two years before admission a 72-yearold woman received an aortobifemoral
bypass graft. When the graft became
infected it was replaced by an axillofemoral bypass graft. This also became
infected. In another attempt at revascu
larization, a bypass was installed be
tween the lower part of the thoracic
aorta and the two distal parts of the
superficial femoral arteries, passing
through the obturator foramen. Access
to the lower part of the thoracic aorta
was made through an abdominal inci
sion, lowering the risk factors associated
with such an intervention. At 18-month
follow-up, the results were satisfactory;
the graft was patent and not infected.

L’infection d’une prothese aortobifemorale reste une des complications les plus
graves de la chirurgie v.asculaire. La mor
tality varie de 14% a 75%; le taux
d’amputation peut atteindre 50% .1-6 Le
Du service de chirurgie, Hopital SainlFrangois d ’A ssise, Quebec, Qui.
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traitement anti-infectieux est efficace si la
prothese infectee est enlevee. Un nouveau
pontage dans la meme seance operatoire
est le plus souvent necessaire pour revasculariser les membres. Malgre [’amelio
ration des resultats obtenus en utilisant
les pontages extra-anatomiques,5’6 le
traitement peut aboutir a un echec6,7 par
thrombose ou recidive infectieuse.
La decision d’une reintervention est
difficile dans ces circonstances et le choix
de la methode, primordial pour la vie et
les membres du patient.
Nous rapportons le cas d’une patiente
qui resume ce genre de situation. Elle a
ete traitee avec succes par une technique
qui n’est pas courante dans ce type d e d i
cation, mais qui nous a permis un resul
tat a moyen terme satisfaisant.
Cas Clinique
La patiente est agee de 70 ans lorsqu’une
prothese aortobifemorale est placee en juin
1982. Dix mois plus tard, une infection de toute
la prothese est diagnostiquee. En juillet 1983,
il est pratique un pontage entre l’axillaire droite
et les deux femorales superficielles proximales, ainsi que I’ablation de la prothese aorto
bifemorale. L ’aorte sous-renale est suturee.
Une recidive infectieuse apparait au lOeme jour
postoperatoire sur le trajet du nouveau pon
tage, mais respectant les anastomoses. Des traitements successifs a visee locale ont peu d ’effet.
La patiente est suivie regulierement.
En juillet 1984, l’apparition d’un ecoulement
sanguinolent au niveau de la cicatrice axillaire
fait craindre une hemorragie brutale.
La reintervention est decidee et, au debut
d ’aout 1984, nous effectuons un pontage entre
I’aorte thoracique basse et les femorales super
ficielles en passant par le trou obturateur. La
prothese axillo-bifemorale est enlevee. Les sui
tes operatoires sont simples sur le plan gene
ral, vasculaire et infectieux. Un petit epanchement pleural droit, spontanement resolutif,
resume les complications.
La patiente va bien avec un recul de 18 mois.
11 n’y a pas de signe de recidive infectieuse. Les
pouls peripheriques tibial posterieur et pedieux
sont peryus des deux cotes.

Technique operatoire

La technique employee est celle decrite

par Bacourt8,9 et Cormier et collaborateurs.10 L’abord de I’aorte thoracique
basse a necessity une laparotomie mediane
depassant l’ombilic vers le bas.
Le ligament triangulaire doit etre sectionne permettant de recliner le lobe gau
che du foie vers la droite. Le petit epi
ploon est ouvert sur presque toute sa
hauteur. L’oesophage est entoure sur un
lac et recline vers la gauche.
II est important de reperer le tronc coeliaque et son origine aortique avant de
secdonner le ligament arque et le tissu
musculaire separant l’orifice aortique et
l’orifice oesophagien. Suivant l’anatomie,
cette partie a sectionner est variable. Chez
notre patiente et dans 80% des cas c’est
le faisceau profond du pilier droit du
diaphragme qui passe en avant de l’aorte
de bas en haut, de droite a gauche, avant
de contourner le bord gauche de
l’oesophage. Ailleurs c’est le faisceau
superficiel ne du pilier gauche qui masque
I’aorte.
Les culs-de-sac pleuraux doivent etre
refoules et la face anterieure de I’aorte
thoracique basse apparait degagee sur 10
a 12 cm (fig. 1). Sous clampage lateral une
prothese en GORE-TEX no. 8 a ete
implantee a ce niveau, puis passee en
arriere du pancreas et du 4eme
duodenum.
Une bifurcation par anastomose avec
une autre prothese GORE-TEX no. 8 a
permis de revasculariser les deux
femorales superficielles en passant par les
trous obturateurs (fig. 2).
Les femorales superficielles ont ete
abordees par voie sus et mediocrurale,11
a la partie moyenne de la cuisse, en restant a distance des foyers infectieux
inguinaux (fig. 3).
La femorale superficielle est facile a
trouver entre le vaste interne et le coutu
rier. Par cette voie, on accede egalement
a la femorale profonde plus externe et
plus posterieure, dans Tangle forme par
le vaste interne et le moyen adducteur.
La revascularisation terminee, les plaies
operatoires ont ete soigneusement isolees
avant le temps septique d’ablation de la
prothese axillobifemorale. II a ete neces-
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saire de fermer Paxillaire et les deux
femorales superficielles proximales par
des patchs. La paroi de l’artere iliaque
primitive droite, endarteriectomisee et
prelevee lors du temps abdominal, a
permis ces angioplasties, en evitant un
prelevement veineux (fig. 2).
Discussion
Pour esperer le succes dans une infec
tion de prothese aortobifemorale, il faut
adopter une attitude agressive comprenant l’ablation de la prothese et un
pontage extra-anatomique dans le meme
temps operatoire, si la vascularisation des
membres est trop precaire par les collaterales. Seul les pontages dont l’infection
respecte les anastomoses peuvent etre
traites par des therapeutiques a visee
exclusivement locale. Cette strategic a
permis d ’ameliorer les resultats,6,7 mais
cette complication reste neanmoins redoutable, menagant la vie et les membres des
patients qui en sont atteints.
L’eventualite d ’un echec d ’une deriva
tion extra-anatomique, par thrombose ou
recidive infectieuse, peut se poser.4'6,7 Le
taux d ’amputation secondaire est egalement leve dans ces cas.5'6 On peut alors
opter pour une nouvelle revascularisation
extra-anatomique, mais la remise en place
d ’une prothese aortique est une solution
adoptee par plusieurs auteurs, avec de
bons resultats.4-7'12
La technique d ’un nouveau pontage
aortique varie suivant les circonstances et
les equipes. L’anastomose superieure peut
se situer: a) sur l’aorte sous-renale si le
moignon aortique est suffisant, mais la
dissection peut etre laborieuse avec risque
de blessure intestinale; b) sur l’aorte
ascendante,13 mais il y a un risque de
mediastinite important;4 et c) sur l’aorte
thoracique basse pouvant etre abordee
par thoracotomie,14 voie thoraco-abdominale,7 ou voie abdominale pure.8-10
Les pontages a partir de l’aorte thora
cique ont tous l’avantage de s’implanter

FIG. 1—Dans 80% des cas c’est le faisceau
profond du pilier droit du diaphragme qui
passe en avant de I’aorte. II doit etre secfionne
en totalite ainsi que le ligament arque, pour
avoir correctement acces a la face anterieure
de I’aorte.
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sur une zone tres souvent epargnee par
l’atherosclerose et par les chirurgies
anterieures. L’approche abdominale pure
nous parait moins lourde qu’une voie
thoracique (thoracotomie ou sternotomie)
associee a une laparotomie, ou qu’un
abord thoraco-abdominal.
La revascularisation des membres et
des arteres viscerales, digestives et renales,
par cette technique, a ete surtout rapportee par des auteurs franpais.8-10 A notre
connaissance, elle n’a pas ete utilisee apres
infection de prothese. La remise en place
d’une prothese aortique apres infection
necessite la guerison du foyer
retroperitoneal initial. Il n ’y a pas de
methode permettant de prevoir avec cer
titude cette guerison. Neanmoins des
delais minima de 2 mois ont permis des
revascularisations avec succes.6 11 semble
que 6 mois soit un delai suffisant et
securitaire.7
Le succes d ’une revascularisation en cas
d ’infection active necessite egalement
deux autres conditions; la separation
constante des gestes septiques et aseptiques en per- et postoperatoire jusqu’a
cicatrisation complete des plaies, et un
nouveau pontage devant passer a distance
des zones septiques.
Le passage par le trou obturateur est
une solution connue depuis longtemps
pour eviter le triangle de scarpa.15’16
L’anastomose peut se faire sur la poplitee, voire meme plus haut sur la femorale
superficielle ou la femorale profonde. La

FIG. 2—Le Irajet du pontage est schematise,
depuis son origine sur I'aorte jusqu'aux femo
rales superficielles en passant par les trous
obturateurs. Une portion de I’artere iliaque pri
mitive droite a ete prelevee pour la confection
des patchs effectues apres ablation de la pro
these infectee.

voie d’abord mediocruiale est egalement
tres utilisee dans les infections de pro
these. Elle laisse le choix entre la superfi
cielle et la profonde distales pour l’anastomose inferieure tout en gardant une
distance securitaire vis-a-vis des infections
inguinales.
La guerison des zones infectees se fait
en general rapidement, apres ablation de
la prothese. L’antibiotherapie locale et
generate est importante, mais celle ne doit
pas etre necessairement prolongee.7 Dans
notre cas, nous avons maintenu la patiente 1 mois sous traitement antibiotique.
Conclusions
L ’utilisation des pontages extraanatomiques associee a l’ablation de la
prothese est une methode qui a permis
d ’ameliorer le pronostic des infections de
protheses aortiques.
Neanmoins un certain nombre d’echecs
posent a nouveau le probleme de la revas
cularisation. Dans ces circonstances la
remise en place d ’une prothese partir de
I’aorte semble etre une methode de trai
tement plus definitive, avec un risque
acceptable.6,710 La technique que nous
avons employee nous a semble la plus
facile et la moins lourde des techniques
proposees.6'7'12-14
Le resultat 18 mois, que nous avons
obtenu permet d ’affirmer que cette

FIG. 3—L’incision cutance de la voie
d ’abord mediocrurale se situe sur une ligne
joignant I'epine iliaque antero-superieure et le
bord interne de la rotule.
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methode, outre de nombreuses autres
indications, a sa place dans l’arsenal therapeutique utilise dans les recidives
d’infections prothetiques.
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Trendelenburg Pulmonary Embolectomy
for Cardiac Arrest Secondary
to Massive Pulmonary Embolism
Cardiac arrest secondary to massive pul
monary embolism is rarely reversible by
nonsurgical measures. A patient sus
tained refractory cardiac arrest and was
resuscitated by Trendelenburg pulmonary
embolectomy without cardiopulmonary
bypass. This report describes the diagno
sis and treatment of this 37-year-old
man and provides a review of the litera
ture on pulmonary embolectomy for
patients in whom cardiac arrest has
occurred. Awareness of the feasibility of
salvaging patients with cardiac arrest
secondary to massive pulmonary
embolism may lead to wider application
of pulmonary embolectomy when con
ventional resuscitation is unsuccessful.
II est rare de pouvoir inverser un arret
cardiaque secondaire a une embolie pulmonaire massive par des moyens non
chirurgicaux. Un patient ayant subi un
arret cardiaque resistant a pu etre reanimd par une embolectomie pulmonaire
de Trendelenburg sans circulation extracorporelle. Cet article decrit le diagnostic
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et le traitement chez cet homme de 37
ans et offre une revue des publications
medicales relatives a I'embolectomie pul
monaire chez les patients qui ont subi un
arret cardiaque. En faisant connaitre qu'il
est possible de rescaper les patients victimes d'arrets cardiaques secondaires a
des embolies pulmonaires massives, on
souhaite voir s’etendre le recours b
I'embolectomie pulmonaire devant
I'echec des moyens de reanimation traditionnels.

When a patient experiences cardiac arrest
from massive pulmonary embolism the
only way to avoid rapid death is to per
form pulmonary embolectomy, with or
without cardiopulmonary bypass. We
report our experience in which this tech
nique was used successfully. We also
review the literature on the outcome o f
pulmonary embolectomy in patients who
have sustained a cardiac arrest.

Case Report
A 37-year-old obese white man was admit
ted to The Methodist Hospital in Houston for
evaluation of unstable angina pectoris. He had
no history of myocardial infarction or other
cardiac problems.
His blood pressure was 130/80 mm Hg,
respiratory rate 18/min and pulse rate 78
beats/min. Physical findings were otherwise
unremarkable.
The electrocardiogram showed small Q

waves and ST elevation in the anterior leads,
consistent with an anterior wall myocardial
infarction of indeterminate age. Laboratory
values were normal.
Cardiac catheterization with selective coro
nary arteriograms showed proximal high-grade
stenoses in the right, left anterior descending,
circumflex and obtuse marginal coronary arter
ies. The ejection fraction was 45%.
Two days after admission the patient under
went coronary artery bypass grafting of the left
anterior descending, obtuse marginal and dis
tal circumflex coronary arteries. His early
postoperative course was uncomplicated and
he was transferred from the intensive care unit
on postoperative day 2. While plans were being
made for his discharge 5 days later, he
experienced shortness of breath which became
progressively worse during the day. A porta
ble chest film showed marked absence of lung
vascularity and a clinical diagnosis of pulmo
nary embolism was made. He was started on
heparin intravenously with a bolus of 10 000
units followed by continuous infusion of 1300
units/h.
Because of increasing dyspnea he was
returned to the intensive care unit where,
shortly after arrival he suffered respiratory and
cardiac arrest. Endotracheal intubation was
performed and external cardiac massage begun,
but with little effect. He was taken immediately
to the operating room, where, because no per
fusionist was immediately available, pulmo
nary embolectomy was performed without
cardiopulmonary bypass.
The previous median sternotomy incision
was opened. Stay sutures were placed in the
pulmonary artery. The ascending aorta and
superior and inferior venae cavae were
clamped. A short longitudinal incision was
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made in the main pulmonary artery. With
sponge holding forceps, a large amount of
thromboembolic material was extracted from
the pulmonary artery bifurcation and both
main branches. The pulmonary artery incision
was closed and the aortic and vena caval
clamps were removed. The total occlusion time
was three minutes. After a brief period of
cardiac massage normal cardiac function
resumed and the patient required support with
only low-dose dopamine. A right, transverse
flank incision was made and the inferior vena
cava exposed retroperitoneally. It was throm
bosed to the level of the testicular veins. A
Miles vena caval clip was placed inferior to the
renal veins. The incisions were closed and the
patient returned to the intensive care unit with
stable cardiopulmonary function.
His postoperative course was complicated by
a pulmonary infarction of the right lower lobe
leading to lung abscess, bronchopleural fistula
and empyema. The fistula was successfully
managed with tube thoracostomy. He had sus
tained some hypoxic cerebral injury from his
cardiac arrest, but at the time of discharge from
hospital almost 10 weeks after operation he was
fully ambulant, oriented and talking coher
ently. Because the period of inflow occlusion
was so short, the cerebral ischemia he
experienced was attributed to the severe
preoperative hypotension which was unrespon
sive to cardiopulmonary resuscitation.
A t follow-up 26 months postoperatively the
patient was free of angina and the lung com
plication had resolved. His cortical function
continued to improve and currently his only
deficits are some impairment of short-term
memory and minor personality changes.

Discussion
The first pulmonary embolectomy was
performed by Friedrich Trendelenburg in
1908.1 In his initial report he described
three patients, none of whom survived
longer than 37 hours. The first success
ful pulmonary embolectomy was per
formed by Kirschner,2 a student of Tren
delenburg, in 1924. Following a report by
Churchill3 in 1934 of 10 consecutive
unsuccessful embolectomies, the proce
dure fell into disfavour. In 1965
Vosschulte4 presented a review of 43
Trendelenburg embolectomies with only
7 survivors, which did not increase
enthusiasm for this approach.
Cooley and colleagues5 in 1961 and
Sharp6 in 1962 independently described
the use of extracorporeal circulation to
support the patient during pulmonary
embolectomy. These reports led to a
resurgence of interest in the procedure.
Operative death rates for pulmonary
embolectom y with cardiopulmonary
bypass have ranged from 10% to
75% ,7-15 depending on the technique and
the condition of the patient before sur
gery. G lassford and colleagues16
reported a 60% overall survival (12 of 20)
after pulmonary embolectomy with cardi
opulmonary bypass. In their series 5 of
10 patients who had cardiac arrest before
surgery survived. Bottzauw and col
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cardiopulmonary bypass. Case report. A nn Surg 1962;
leagues17 reported a 74% survival in a
156: 1-4
group of 23 patients who underwent pul
7. KlENY R, E isenmann B, JEANBLANC B, et al: Chirurgische Behandlung der massiven Lungenembolie. Bericht
monary embolectomy with cardiopulmo
liber 45 erfolgreiche Operationen, hiervon 10 Engriffe
nary bypass. Tschirkov and associates18
nach Trendelenburg. Thoraxchir Vask Chir 1978; 26:
259-265
reported a series of 29 patients who
8. Miller GAH, H all RJC, P an eth M: Pulmonary
underwent pulmonary embolectomy with
embolectomy, heparin, and streptokinase: their place in
cardiopulmonary bypass in which there
the treatment of acute massive pulmonary embolism. A m
Heart J 1977; 93: 568-574
was a 29% overall operative death rate.
9. SCHULTE HD: Lungenarterienembolie — chirurgische
None of the patients in this series had
Aspekte. Dtsch Arzt 1979; 2: 85
cardiac arrest before arriving in the oper 10. Satter P: Pulmonary embolectomy with the aid of
extracorporeal circulation. Thorac Cardiovasc Surg 1982;
ating room. Mattox and colleagues19
30: 31-35
11. BEALL AC JR, Cooley DA: Current status of embolec
reported a 50% survival for emergency
tomy for acute massive pulmonary embolism. Am J Car
pulmonary embolectomy performed on
diol 1965; 16: 828-833
39 patients. These patients were all in
12. BERGER RL: Pulmonary embolectomy with preoperative
circulatory support. Ann Thorac Surg 1973; 16: 217-227
extremis and a portable cardiopulmonary
13. PANETH M: Pulmonary embolectomy. An analysis of 12
bypass pump was used for resuscitation
cases. J Thorac Cardiovasc Surg 1967; 53: 77-83
14. SAUTTER RD: Massive pulmonary thromboembolism.
and embolectomy.
Experience with 12 pulmonary embolectomies. JAM A
Not all hospitals have cardiopulmonary
1965; 194: 336-338
15. Scannell JG: The surgical management of acute mas
bypass available and in those that do it
sive pulmonary embolism. Prog Cardiovasc Dis 1967; 9:
may occasionally not be immediately
488-494
available, as in our case. Clarke20 16. G lassford DM jr , A lford w c j r , Burrus GR, et
al: Pulmonary embolectomy. A nn Thorac Surg 1981; 32:
described 42 patients who underwent
28-32
emergency pulmonary embolectomy with
17. Bottzauw j , Vejlsted H, A lbrechtsen O: Pulmo
nary embolectomy using extracorporeal circulation. Tho
normothermic venous inflow occlusion.
rac Cardiovasc Surg 1981; 29: 320-322
O f 26 patients who had not suffered
18. T schirkov a , Krause E, E lert O, et al: Surgical
management of massive pulmonary embolism. J Thorac
cardiac arrest before surgery, 25 survived
Cardiovasc Surg 1978; 75: 730-733
the operation; 7 died later. Of 16 patients
19. Mattox KL, Feldtman RW, Beall AC JR, et al: Pul
who had sustained a cardiac arrest before
monary embolectomy for acute massive pulmonary embo
lism. Ann Surg 1982; 195: 726-731
operation only 1 survived. Our patient
20. C larke DB: Pulmonary embolectomy re-evaluated. Ann
falls into the latter category, thus his sur
R Coll Surg Engl 1981; 63: 18-24
vival represents a rare occurrence. Pulmo 21. HECKER BR, LYNCH C: Intraoperative diagnosis and
treatment of massive pulmonary embolism complicating
nary embolectomy without bypass has
surgery on the abdominal aorta. Br J Anaesth 1983; 55:
689-691
also been perform ed successfully
22. G reenfield LJ, z o c c o JJ: Intraluminal management
intraoperatively during an unrelated
o f acute massive pulmonary thromboembolism. J Tho
procedure.21 However, as the previously
rac Cardiovasc Surg 1979; 77: 402-410
23. GREENFIELD LJ: Intraluminal techniques for vena caval
quoted statistics indicate, the use of car
interruption and pulmonary embolectomy. World J Surg
diopulmonary bypass is desirable.22'23
1978; 2: 45-59
More recently Greenfield has advo 24. Stew art JR, G reenfield LJ: Transvenous vena caval
filtration and pulmonary embolectomy. Surg Clin North
cated the use of a percutaneous suctionA m 1982; 62: 411-430
tipped catheter for pulmonary embolec
tomy. In a series of 25 patients the “ oper BOOK REVIEW S
ative” death rate was 32%.24
continued from page 375
Neither this procedure nor thrombo
The greatest weakness of this text lies in its
lytic therapy, which is now available, can index which is deplorable; there is, for exam
be effectively employed in the patient who ple, no mention of acquired immune deficiency
has sustained a cardiac arrest from pul syndrome (AIDS) although it is mentioned in
monary embolism. When there is no alter the text. Amyloidosis of the larynx, also men
tioned in the text, is not indexed, and, in
native we recom m end pulm onary
embolectomy for such patients. As this general, a 17-page index for an 1800-page book
report and the report of Clarke20 indi dealing with minutiae is inadequate.
I admire Barnes for taking on the task of
cate, lack of available cardiopulmonary putting together such a large work and I recog
bypass should not prevent an attempt at nize the difficulties of such an undertaking. He
pulm onary embolectomy when the
deserves success and I believe this tome will
patient is in extremis.
find a ready place on the shelves of most
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Fatal Fat Embolism
During Cemented Total Knee Arthroplasty:
a Case Report
Evidence is accumulating that emboliza
tion of bone marrow contents to the
lungs can cause the hypotension, hypox
emia, cardiac arrest and death reported
after total hip arthroplasty and that the
embolism results from high intramedul
lary pressures exerted during implanta
tion of the prosthesis. The authors
describe such an occurrence in an
80-year-old man who had a cemented
long-stem total knee prosthesis inserted.
Autopsy revealed numerous pulmonary
fat emboli that were distributed
predominantly in arterioles and capil
laries. The possibility of pulmonary fat
microembolism occurring during
cemented total knee arthroplasty should
be recognized, particularly when
prostheses with long intramedullary
stems are used. Preventive or prophylac
tic measures that should be considered
to avoid fat embolism during implanta
tion include venting the intramedullary
canal and meticulous lavage to clear
away intramedullary debris. Increasing
the inspired oxygen concentration as the
prosthesis is inserted and monitoring of
cardiopulmonary status to avoid simul
taneous hypotension and hypoxemia may
help to prevent the cardiopulmonary
changes associated with pulmonary fat
microembolism.
Les preuves s'accumulent a I'effet que,
suite d une arthroplastie totale de la
hanche. I'embolisation de tissu provenant de la moelle dans les poumons peut
causer hypotension, hypoxemie, arret
cardiaque, puis la mort et que cette
embolie resulte des fortes pressions
intramedullaires qui sont exercees durant
I'implantation de la proth&se. Les auteurs
d£crivent ce qui est survenu chez un
homme de 80 ans au moment de I'insertion de la longue tige d'une prothese
totale du genou. L'autopsie a revele de
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nombreuses embolies graisseuses du
poumon, distributes surtout dans les
arterioles et les capillaires. On doit garder a I'esprit la possibilite que survienne
une embolie graisseuse microscopique du
poumon pendant une arthroplastie totale
du genou, en particulier quand la prothese du tige intramedullaire longue. Les
mesures preventives ou prophylactiques
auxquelles on devrait penser pour tviter
les embolies graisseuses durant I'implan
tation sont les suivantes: ventilation du
canal mtdullaire et lavage mtticuleux
pour chasser les debris intramedullaires.
Augmentation de la concentration d'o xygene inspiree au moment de I'insertion
de la prothtse et monitorage des fonctions cardiopulmonaires pour tviter une
hypotension et une hypoxtmie simultanees peut contribuer a prevenir les
modifications cardiopulmonaires relives
aux embolies graisseuses microscopiques.

H ypotension,1-3 hypoxemia,3-6 cardiac
arrest1,2 and sudden death2 have all been
documented during cemented total hip
arthroplasty. Evidence is accumulating
that these changes are caused by emboli
zation o f bone-marrow content to the
lungs due to the high intramedullary pres
sures generated during insertion o f the
cement and prosthesis.2-10 Only two case
reports appear in the literature o f deaths
fo llo w in g
cem ented
total knee
arthroplasty.11,12 Although both describe
pulmonary fat microemboli, one death
was attributed to methylmethacrylate tox
icity.11 We report a patient whose death
was caused by multiple fat microemboli
in the lungs during cemented total knee
arthroplasty.

density in the middle of the right lung. No
active process was identified and the appear
ance was unchanged from a film taken 3
months previously. An electrocardiogram
showed sinus bradycardia with sinus arrhyth
mia and left axis deviation.
Under general anesthesia, with endotracheal
intubation, a cemented Guepar II total knee
arthroplasty was inserted. A tourniquet was
used. Anesthesia was maintained with isoflurane at an inspired concentration of 1% to 2%
in a nitrous oxide and oxygen mixture (50:50).
The intramedullary canal was irrigated before
the prosthesis was inserted and regular bone
cement was used with no intramedullary plug
or venting procedure. The surgeon (R.R.R.)
noticed an especially tight fit of the prosthesis
into both the femoral and tibial medullary
canals.
The patient’s pulse rate, arterial blood pres
sure and skin colour remained unchanged
throughout the procedure. The tourniquet was
released before closing the wound and within
seconds the blood pressure fell to 100/40 mm
Hg. The total tourniquet time was 76 minutes,
and the tourniquet was released 22 minutes
after cement insertion. The patient rapidly
became cyanotic. All anesthesia was discon
tinued. There was a progressive fall in blood
pressure and pulse rate during the next 2
minutes to a systolic pressure of 40 mm Hg and
a pulse rate of 40 beats/min. Intravenous fluids
and sympathomimetic drugs were given
without improvement in blood pressure, pulse
rate or skin colour. External cardiac massage
was started and a cardiovascular surgeon con-

Case Report
An 80-year-old man was admitted to hospi
tal for left total knee arthroplasty. He had a
35° varus deformity of his left knee due to
severe osteoarthritis (Fig. 1). There was a his
tory of recurrent pulmonary infection 3 years
previously, a resolved cerebrovascular accident
and prostatic carcinoma. Preoperatively the
patient was well, with no cardiorespiratory
symptoms. His arterial blood pressure was
140/90 mm Hg, pulse rate 56 beats/min and
respiratory rate 16/min. A chest film showed
linear scarring at the left base and a nodular

FIG. 1—Anteroposterior view of patient’s
left knee. There are extensive osteoarthritic
changes.
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suited. Arterial blood-gas measurements rev
ealed profound hypoxemia and mild metabolic
acidosis, pH 7.28, arterial tension of carbon
dioxide was 46 mm Hg and of oxygen 32 mm
Hg on 100% oxygen.
The patient was put on femorofemoral cardi
opulmonary bypass with marked improvement
in hemodynamic status and oxygenation. Mas
sive pulmonary embolism was ruled out by
intraoperative pulmonary angiography, using
an image intensifier and a catheter passed from
the right basilic vein into the right ventricle.
The angiogram could not, however, rule out
pulmonary microemboli. Attempts were made
to insert an intra-aortic balloon pump, but it
could not be passed up either common iliac
artery due to severe atherosclerosis. It was not
possible to wean the patient off cardiopulmo
nary bypass and eventually resuscitation was
discontinued 3 hours after tourniquet release.

Autopsy Findings
The major findings were limited to the
lungs and heart. The lungs were edema
tous and congested (weight of the right
lung 825 g and left lung 710 g). The heart
weighed 410 g and was of normal size and
configuration, but severe atherosclerotic
changes were identified in the coronary
c._ dation with 100% occlusion of the
circumflex artery and 70% occlusion of
the left anterior descending artery.
Histologically, the lungs contained
numerous fat emboli (Fig. 2) that were
distributed predominantly in arterioles
and capillaries (Fig. 3). No emboli were
identified in the major vessels. Examina
tion of the heart revealed focal scarring
of the myocardium and fibre hyper
trophy.

using a prosthesis with a long intramedul
lary stem, differs from cemented total hip
arthroplasty: the bone cement is inserted
into two long medullary canals as
opposed to one during total hip
arthroplasty, and a tourniquet is gener
ally used during total knee arthroplasty.
Samii and associates13 demonstrated
increased pulmonary vascular resistance
and transient systemic hypotension dur
ing cemented total knee arthroplasty
when a tourniquet was not used. The use
of a tourniquet delayed the onset of
increased pulmonary vascular resistance
and no change in arterial pressure was
observed.14 The use of noncemented
total knee protheses did not produce any
significant hemodynamic alterations.14
Adams and associates11 and H arris12
each reported a death following cemented
total knee arthroplasty. While pulmonary
fat microemboli were found at autopsy
in both cases, Adams and colleagues
attributed their patient’s death to cerebral
ischemia produced by hypotension secon
dary to methylmethacrylate toxicity. We
report a third case, death being due to
multiple pulmonary fat microemboli
associated with cemented total knee
arthroplasty. We believe that high
intramedullary pressures were produced
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Discussion
A number of cardiorespiratory changes
have been documented during cemented
total hip arthroplasty. Hypotension
occurs in approxim ately 80% of
patients.1 Hypoxemia frequently occurs,
although arterial oxygen tension is not
routinely monitored during this proce
dure.3'56 Occasionally cardiac arrest and
sudden death have been reported.1,2 Our
case demonstrates that these complica
tions, although less well known, may
occur during cemented to tal knee
arthroplasty.
Experimental studies have demon
strated that cemented implants generate
high intramedullary pressures4,8'9 with
many pulmonary microemboli.7"9 Nota
ble cardiopulmonary changes, including
increased pulmonary arterial pressure,
decreased arterial oxygen tension and
increased intrapulmonary shunt fraction,
are associated with cement and implant
insertion,9,10 suggesting that these pul
monary microemboli are physiologically
important and may be responsible for the
cardiopulmonary changes seen during
total hip arthroplasty.3,4,8-10
Cemented total knee arthroplasty,
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by the long stem and tight fit of the
prosthesis, causing embolization of fat
and marrow content into the venous sys
tem. When the tourniquet was released,
multiple pulmonary microemboli were
produced. We speculate that our patient
had a decreased cardiopulmonary reserve
and that the microemboli produced severe
hypoxemia, arterial hypotension and
acute right heart failure, leading to death.
A number of preventive or prophylac
tic measures have been advocated for
cemented hip arthroplasty. Kallos and
associates8 recommended increasing the
inspired oxygen concentration when the
cement and prosthesis are inserted,
appropriate monitoring of cardiopulmo
nary parameters such as blood-gas meas
urement and maintaining adequate
intravascular volume to avoid simultane
ous hypotension and hypoxemia. Venting
the intram edullary canal2,4,5,7,8 and
eliminating intramedullary debris by
meticulous lavage before inserting the
cement and prosthesis help to prevent the
cardiopulmonary changes observed dur
ing cemented procedures.10 These meas
ures should be considered during inser
tion of cemented total knee prostheses
with long intramedullary stems since fatal
pulmonary fat microembolization can
occur following tourniquet release.

FIG. 2—Pulmonary fat emboli (osmium
tetroxide, initial magnification x 25).

FIG. 3—Distribution o f pulmonary fat
emboli by vessel size.
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SESAP V Critique
ITEM 228
Small- or moderate-sized aneurysms of the ascending aorta are often not apparent on a chest roentgenogram. The
aneurysm remains beneath the sternum and is not visible in the PA projection until it is larger than 8 to 10 cm in diameter.
A high incidence of coexisting atherosclerotic aneurysms has been observed among patients with descending thoracic
aneurysms treated surgically (47% in one series of 112 patients). These may require surgical therapy concomitantly or
early after treatment of the descending aneurysm. Cystic medial degeneration is the most common cause of aneurysms
of the ascending aorta, and atherosclerosis is the most common cause of aneurysms of the descending aorta. Among patients
with thoracic aneurysms treated nonoperatively, pain was a symptom in fewer than 50% of patients in two large series.
Rupture of the aneurysm is the most common cause of death among patients who are not operated on, accounting for
30% to 40% of all deaths.
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GROUPE DE RECHERCHE EN NEUROPSYCHOLOGIE DU QUEBEC - (GRNQ, the Quebec
neuropsychology group) sponsored by the LouisH. Lafontaine Hospital, affiliated to the Universi
ty of Montreal: Second Conference on Neuropsy
chology of Subcortical Disturbances, Normal and
Pathological Aging, Epilepsy and Head Injury
(simultaneous translation); November 7th and 8th,
1986 at the Louis-H. Lafontaine Hospital, Teach
ing Department, 2nd Bourget, Suite 2055, 7401
Hochelaga St., Montreal, Quebec H1N 3M 5. For
more information call; (514) 253-8200 extension
219 or 210.
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MICROSURGICAL COURSE: - The Department
of Surgery, M cM aster University is now offering
one week, on-going courses in microsurgery, us
ing animal facilities and videotapes. These courses
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structions. The laboratory is organized to guide
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tant on a one-to-one basis. Please call: Dr. A. Thoma at (416) 52 3 -0 0 1 9 for further information.
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tidisciplinary program w ith an integrated trans
plant service w hich will perform 80 kidney
transplants, 50 heart transplants, and 40 liver
transplants in 1986. Training includes the op
portunity fo r research. Candidates must have
their LMCC's and general licensure in Ontario.
Completion o f an accredited residency pro
gram in anesthesia, internal medicine or gener
al surgery preferred, but not essential. Address
correspondence to: Dr. David Grant, Room
8-OP18, University Hospital, PO Box 5339,
Postal Station 'A ', London, ON N6A 5A5.
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VASCULAR SURGEON: — The Division of Vascu
lar Surgery at the Wellesley Hospital has an open
ing for a third vascular surgeon. The appointment
w ill be full tim e, will carry a university rank, and
the successful applicant will be expected to car
ry out teaching and research in addition to clini
cal activities. The division is accredited by the
Royal College o f Physicians and Surgeons of
Canada for post-graduate vascular training. The
Wellesley Hospital is a fully affiliated teaching
hospital of the University of Toronto w ith 565 ac
tive beds and a full range of medical and surgical
services. Applications should be sent by October
30, 1986 to: Dr. John Provan, Surgeon-in-Chief,
Chief, Division o f Vascular Surgery, 160 Welles
ley St. East, Ste. 217, E.K. Jones Building, Toron
to, ON M4Y 1J3.
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Faculty of Medicine
Memorial University of Newfoundland
The Faculty o f Medicine, M em orial U n ive rsity o f N ew 
foundland, is inviting applications fo r th e position o f
Professor and Director of Orthopedics. This w ill involve
a jo in t appointm ent as C hief o f O rthopedics at The
General Hospital w ithin the Health Sciences Centre, and
academ ic leadership in other a ffiliated hospitals.
The appointee w ill have o p p o rtu n ity to re cru it tw o fu ll
tim e fa cu lty members, to expand teaching and research
program s and to re-establish a full and independent
M em orial U niversity residency training program .
The candidate w ill have, or be eligible fo r, Royal Col
lege o f Physicians & Surgeons o f Canada ce rtifica tio n
in the specialty and w ill be eligible fo r licensure in the
Province o f N ewfoundland.
A ll qualified individuals are encouraged to apply but
preference w ill be given to Canadian citizens and per
manent residents in accordance w ith Canadian immigra
tion requirements.
Send application w ith curriculum vitae and names and
addresses o f three referees to:
Dr. A .M . House,
Associate Dean, Professional Affairs,
Faculty of Medicine.
Memorial University of Newfoundland,
Health Sciences Centre,
St. John's, Nfld. A1B 3 V 6
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